supp.fit

Vitamin D: study protocols

2,526 study groups say how much Vitamin D participants took a day. These are the doses the studies gave. They are not a recommendation.

Vitamin D: what the research found →

Dose per serving from products

10,203 products in our catalogue print how much Vitamin D a serving holds.

Most common: 10 mcg to 25 mcg, 35% of 10,203 products.

Dose per servingProducts
1 mcg or less
434
1 mcg to 2.5 mcg
364
2.5 mcg to 5 mcg
666
5 mcg to 10 mcg
1,944
10 mcg to 25 mcg
3,536
25 mcg to 50 mcg
1,524
50 mcg to 100 mcg
704
100 mcg to 250 mcg
756
over 250 mcg
275

Dose per serving from research

1,864 study groups in 1,164 studies say how much Vitamin D participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 IU to 1,000 IU, 29% of 1,864 study groups.

Daily doseStudy groups
250 IU or less
76
250 IU to 500 IU
304
500 IU to 1,000 IU
534
1,000 IU to 2,500 IU
338
2,500 IU to 5,000 IU
285
5,000 IU to 10,000 IU
209
10,000 IU to 25,000 IU
20
25,000 IU to 50,000 IU
25
over 50,000 IU
73

Commonly used together

875 of 2,526 study groups took Vitamin D with something else. Shown: what 3 or more different studies gave. The 10 most common of 33.

What was given together, not what works together.

Taken withStudy groups
Calcium
697
Omega-3 Fatty Acids
32
Vitamin K
29
Vitamin B12
26
Zinc
22
Iron
19
Folic Acid
17
Multivitamin
17
Whey Protein
17
Fish Oil
16

2,526 study groups

Study
Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial
2023 · calcifediol · Adults receiving ChAdOx1 nCoV-19 vaccine; age range and sex not specified
50 mcg26 weeks262
A 2-Year Follow-Up After a 2-Year RCT with Vitamin D and Exercise: Effects on Falls, Injurious Falls and Physical Functioning Among Older Women
2017 · D+ Ex− (vitamin D without exercise) · Home-dwelling women aged 70–80 years
20 mcg2 years102
A 2-Year Follow-Up After a 2-Year RCT with Vitamin D and Exercise: Effects on Falls, Injurious Falls and Physical Functioning Among Older Women
2017 · D+ Ex+ (vitamin D with exercise) · Home-dwelling women aged 70–80 years
20 mcg2 years102
Improved Healing of Diabetic Foot Ulcers After High-dose Vitamin D: A Randomized Double-blinded Clinical Trial
2023 · high-dose vitamin D3 · People with diabetes and one or more foot ulcers lasting more than 6 weeks
170 mcg48 weeks24
Improved Healing of Diabetic Foot Ulcers After High-dose Vitamin D: A Randomized Double-blinded Clinical Trial
2023 · low-dose vitamin D3 · People with diabetes and one or more foot ulcers lasting more than 6 weeks
20 mcg48 weeks24
Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial
2006 · D(+) group · Patients with congestive heart failure; age and sex not specified
50 mcg270 days—
Effects of Vitamin D on Cardiac Function in Patients With Chronic HF: The VINDICATE Study
2016 · Vitamin D · Adults with vitamin D-deficient chronic heart failure due to left ventricular systolic dysfunction; stable NYHA class II or III symptoms
100 mcg1 year80
Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients
2004 · 100 mcg (4000 IU)/day · Adults attending an endocrinology clinic with low serum 25(OH)D; age and sex varied
100 mcg1 year66
Vitamin D Status and Physical Activity during Wintertime in Forensic Inpatients-A Randomized Clinical Trial
2021 · Intervention group (vitamin D) · Male forensic inpatients; age range 31–81 years in the analysed sample
40 mcg135 days43
A 12-week double-blind randomized clinical trial of vitamin D₃ supplementation on body fat mass in healthy overweight and obese women
2012 · vitamin D group · Women aged 18–50 with BMI ≥25 kg/m², apparently healthy and overweight or obese
25 mcg90 days42
Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial
2017 · calcitriol · Patients with non-alcoholic fatty liver disease (NAFLD) following an energy-restricted weight-loss program; age and sex not stated
25 mcg12 weeks37
Effects of vitamin D supplementation on depressive symptoms in type 2 diabetes mellitus patients: Randomized placebo-controlled double-blind clinical trial
2019 · Vitamin D group · Adults with type 2 diabetes mellitus and mild to moderate depressive symptoms
100 mcg12 weeks32
A randomized, double-blinded, placebo-controlled, parallel trial of vitamin D(3) supplementation in adult patients with migraine
2019 · D3-Vitamin · Adults aged 18–65 with migraine
100 mcg24 weeks24
A 12-week double-blind randomised controlled trial investigating the effect of dietary supplementation with 125 μg/d vitamin D in adults with asthma
2024 · vitamin D group · Adults aged 20–62 with mild to moderate asthma
125 mcg12 weeks13
Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers
2009 · vitamin D group · Healthy overweight adults with mean baseline 25(OH)D concentration of 30 nmol/L (12 ng/mL); age and sex distribution not stated
83 mcg1 year—
Bone Microstructure in Response to Vitamin D3 Supplementation: A Randomized Placebo-Controlled Trial
2019 · Vitamin D3 supplementation · Healthy postmenopausal women with low 25(OH)D at screening; age range not reported
70 mcg90 days—
Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial
2024 · Vitamin D · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses
2,000 IU1936 days12,927
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
2025 · Vitamin D · Men aged 50 years or older and women aged 55 years or older, without type 2 diabetes at baseline; older US adults
2,000 IU1935 days11,062
Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial
2011 · Vitamin D group · Indian term infants with birth weight 1.8–2.5 kg, enrolled before 48 hours of age
5 mcg26 weeks1,039
Vitamin D supplementation and incidence of major depressive disorder - A randomized clinical trial
2026 · 3200 IU/day vitamin D3 · Adults with a mean age of 68.2 years; 42.5% of the overall trial population were women. No specific condition was required.
3,200 IU5 years817
Vitamin D supplementation and incidence of major depressive disorder - A randomized clinical trial
2026 · 1600 IU/day vitamin D3 · Adults with a mean age of 68.2 years; 42.5% of the overall trial population were women. No specific condition was required.
1,600 IU5 years814
Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population
2022 · Eldecalcitol group · Adults aged 30–78 years, men and women, with impaired glucose tolerance in Japan
0.75 mcg3 years630
Active vitamin D treatment in the prevention of sarcopenia in adults with prediabetes (DPVD ancillary study): a randomised controlled trial
2024 · eldecalcitol group · Adults with prediabetes; mean age 60.8 years; both sexes
0.75 mcg1059 days548
Does antenatal cholecalciferol supplementation affect the mode or timing of delivery? Post hoc analyses of the MAVIDOS randomized controlled trial
2023 · Cholecalciferol · Pregnant women aged over 18 years with singleton pregnancies and baseline 25(OH)D of 25–100 nmol/l
1,000 IU—479
The Association of Prenatal Vitamin D Sufficiency With Aeroallergen Sensitization and Allergic Rhinitis in Early Childhood
2021 · high-dose vitamin D · Pregnant women aged 18–39 years at 10–18 weeks of gestation, nonsmoking, with a personal or partner history of asthma or atopy
4,400 IU—440
Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial
2019 · vitamin D alone · Adults aged 45–75 with at least one adenomatous polyp detected and removed within the preceding 4 months
1,000 IU5 years420
Early pregnancy vitamin D status and risk of preeclampsia
2016 · treatment group · Pregnant women; age and condition beyond pregnancy not reported
4,400 IU—408
Early pregnancy vitamin D status and risk of preeclampsia
2016 · control group · Pregnant women; age and condition beyond pregnancy not reported
400 IU—408
Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial
2022 · Cholecalciferol (1000 IU daily) · Pregnant women aged over 18 years with a singleton pregnancy under 17 weeks’ gestation and baseline serum 25(OH)D of 25–100 nmol/L
1,000 IU—352
High-dose vitamin D3 supplementation in pregnancy and risk of neurodevelopmental disorders in the children at age 10: A randomized clinical trial
2024 · high-dose · Pregnant women; the abstract does not give an age range or report a diagnosed condition
2,800 IU—315
High-dose vitamin D3 supplementation in pregnancy and risk of neurodevelopmental disorders in the children at age 10: A randomized clinical trial
2024 · standard dose · Pregnant women; the abstract does not give an age range or report a diagnosed condition
400 IU—308
Vitamin D3 Supplementation at 5000 IU Daily for the Prevention of Influenza-like Illness in Healthcare Workers: A Pragmatic Randomized Clinical Trial
2022 · vitamin D3 supplementation intervention group · Healthcare workers aged 18 years or older; no specific diagnosis or deficiency required
5,000 IU270 days299
Fish Oil and Vitamin D Supplementations in Pregnancy Protect Against Childhood Croup
2023 · High-dose vitamin D group · Pregnant women in the Danish population-based Copenhagen Prospective Studies on Asthma in Childhood 2010 mother-child cohort
2,800 IU32 weeks295
Fish Oil and Vitamin D Supplementations in Pregnancy Protect Against Childhood Croup
2023 · Standard-dose vitamin D group · Pregnant women in the Danish population-based Copenhagen Prospective Studies on Asthma in Childhood 2010 mother-child cohort
400 IU32 weeks286
Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial
2019 · vitamin D supplements · Adults aged 30 to 90 with stage I to III digestive tract cancer who underwent curative surgery
2,000 IU—251
Reduced Relapse-Free Survival in Colorectal Cancer Patients with Elevated Soluble CD40 Ligand Levels Improved by Vitamin D Supplementation
2023 · vitamin D group · Adults aged 30–90 years with resected stage I–III epithelial cancer of the digestive tract, including colorectal cancer
2,000 IU1205 days251
Effect of Vitamin D Supplements on Relapse or Death in a p53-Immunoreactive Subgroup With Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial
2023 · Vitamin D group · Adults aged 35–90 with stage I–III digestive tract cancer after curative surgery; the p53-immunoreactive subgroup had serum p53-Ab positivity and p53-IHC [3+] cancer cells
2,000 IU—241
Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren
2010 · vitamin D(3) group · schoolchildren
1,200 IU120 days167
Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial
2022 · Vitamin D group (VDG) · Frontline healthcare workers caring for hospitalized patients with COVID-19, SARS-CoV-2-free at enrollment; adults, both sexes
4,000 IU30 days160
Effect of Vitamin D Supplementation on Recurrent Wheezing in Black Infants Who Were Born Preterm: The D-Wheeze Randomized Clinical Trial
2018 · sustained supplementation group · Black infants born at 28 to 36 weeks’ gestation
400 IU—153
Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial
2014 · Vitamin D and gargling · University students aged 17 years or older; both sexes; no specific diagnosed condition stated
1,429 IU8 weeks150
Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial
2014 · Vitamin D and no gargling · University students aged 17 years or older; both sexes; no specific diagnosed condition stated
1,429 IU8 weeks150
Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial
2011 · 17.5 mg risedronate once a week · Older women with Parkinson's disease
1,000 IU2 years136
Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial
2011 · Placebo · Older women with Parkinson's disease
1,000 IU2 years136
Maternal vitamin D intakes during pregnancy and child health outcome
2023 · 2000 IU/day · Pregnant women receiving vitamin D during pregnancy; age and condition beyond pregnancy not reported.
2,000 IU—121
Maternal vitamin D intakes during pregnancy and child health outcome
2023 · 4000 IU/day · Pregnant women receiving vitamin D during pregnancy; age and condition beyond pregnancy not reported.
4,000 IU—120
Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease
2019 · Vitamin D group · Adults aged 18–80 with ulcerative colitis or Crohn’s disease in stable condition
500 IU26 weeks119
Maternal vitamin D intakes during pregnancy and child health outcome
2023 · 600 IU/day · Pregnant women receiving vitamin D during pregnancy; age and condition beyond pregnancy not reported.
600 IU—119
Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial
2025 · study group - vitamin D intake · Adult women aged 18–74 with primary breast cancer receiving neoadjuvant systemic therapy
7,143 IU—114
Treatment of vitamin D deficiency is an effective method in the elimination of asymptomatic bacterial vaginosis: A placebo-controlled randomized clinical trial
2015 · intervention group · Women aged 18–35 with vitamin D deficiency and asymptomatic bacterial vaginosis
2,000 IU15 weeks103
In "High-Risk" Infants with Sufficient Vitamin D Status at Birth, Infant Vitamin D Supplementation Had No Effect on Allergy Outcomes: A Randomized Controlled Trial
2020 · vitamin D group · Term infants with sufficient maternal vitamin D status late in pregnancy and a family history of allergic disease in at least one parent or sibling; infants were followed for allergy outcomes
400 IU26 weeks97
The effects of vitamin D supplementation on postoperative atrial fibrillation after coronary artery bypass grafting in patients with vitamin D deficiency
2022 · Group B · Patients with vitamin D insufficiency undergoing coronary artery bypass grafting
600,000 IU1 day93
Effect of isolated vitamin D supplementation on the rate of falls and postural balance in postmenopausal women fallers: a randomized, double-blind, placebo-controlled trial
2016 · VITD group · Brazilian postmenopausal women aged 50–65 years with at least 12 months of amenorrhea and a history of falls in the previous 12 months
1,000 IU274 days80
Vitamin D supplementation improves the metabolic syndrome risk profile in postmenopausal women
2020 · VD group · Postmenopausal women aged 50–65 years with vitamin D deficiency
1,000 IU274 days80
Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
2018 · vitamin D · Patients with non-small cell lung cancer (NSCLC) after operation; age and sex not specified
1,200 IU1 year77
Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial
2015 · vitD3 · Adults aged 18 years or older, male and female, with newly diagnosed sputum smear-positive pulmonary tuberculosis; most had deficient or insufficient vitamin D status
5,000 IU8 weeks72
Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial
2015 · PBA+vitD3 · Adults aged 18 years or older, male and female, with newly diagnosed sputum smear-positive pulmonary tuberculosis; most had deficient or insufficient vitamin D status
5,000 IU8 weeks72
High-dose preoperative cholecalciferol to prevent post-thyroidectomy hypocalcaemia: A randomized, double-blinded placebo-controlled trial
2019 · cholecalciferol · Patients undergoing thyroidectomy for Graves' disease, malignancy or goitre
300,000 IU1 day72
Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical Cancer
2025 · Treatment group · Adults with advanced-stage cervical cancer, FIGO stages IIB–IVA, eligible for radiotherapy; sex and age range not stated
10,000 IU19 weeks69
Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)
2019 · cholecalciferol group · Adults aged 18–65 with relapsing-remitting multiple sclerosis, low serum 25OHD, and receiving interferon beta-1a
50,000 IU96 weeks64
Vitamin D supplementation to patients with frequent respiratory tract infections: a post hoc analysis of a randomized and placebo-controlled trial
2015 · vitamin D group · Adults aged 18–75 with primary immunodeficiency or increased susceptibility to respiratory tract infections
4,000 IU1 year62
Vitamin D supplementation reduces the risk of acute otitis media in otitis-prone children
2013 · VD group · Children with a history of recurrent acute otitis media
1,000 IU120 days58
Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe COVID-19 Patients: A Randomized Clinical Trial
2022 · Group 1 (low-dose vitamin D) · Adults aged 18 years or older hospitalized with moderate-to-severe COVID-19 and hyperinflammation
1 mcg—58
The effect of vitamin D on recurrence of uterine fibroids: A randomized, double-blind, placebo-controlled pilot study
2022 · vitamin D · Women who had undergone hysteroscopic myomectomy; mean age 37.9 ± 6.5 years
1,000 IU1 year55
Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial
2013 · paricalcitol · Incident kidney transplant recipients
2 mcg1 year50
"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study"
2020 · Group receiving Calcifediol · Adults hospitalized with confirmed COVID-19; women and men, aged 18 years or older, with acute respiratory infection and viral pneumonia
532 mcg—50
Randomized trial of activated vitamin D for acute kidney injury prevention in critically ill patients
2025 · calcitriol group · Critically ill adults aged 18 years or older in an ICU, at high risk of moderate-to-severe acute kidney injury within 7 days or with mild AKI at enrollment
4 mcg5 days50
Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study
2010 · vitamin D3 · Patients with Crohn's disease in remission
1,200 IU1 year46
Vitamin D Intake May Reduce SARS-CoV-2 Infection Morbidity in Health Care Workers
2022 · Group II · Health care workers aged 18–65 years, women and men, with negative SARS-CoV-2 PCR and occupational exposure to infected patients
2,000 IU90 days46
A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD
2014 · calcitriol · Patients with stages 3–4 CKD and PTH >120 pg/ml
0.25 mcg24 weeks45
A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD
2014 · paricalcitol · Patients with stages 3–4 CKD and PTH >120 pg/ml
1 mcg24 weeks45
Association of vitamin D with functional cure in chronic hepatitis B: Insights from a retrospective cohort study and an intervention study
2024 · VD group · Patients with chronic hepatitis B and baseline vitamin D insufficiency
800 IU—45
The effect of standard-dose wintertime vitamin D supplementation on influenza infection in immunized nursing home elderly residents
2021 · experimental group · Adults aged 65 years or older who were frail residents of nursing homes and had received influenza vaccination
800 IU90 days41
Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial
2025 · VD group · Women aged ≥45 years with breast cancer eligible for neoadjuvant chemotherapy
2,000 IU26 weeks40
Vitamin D supplementation to persistent carriers of MRSA-a randomized and placebo-controlled clinical trial
2018 · Vitamin D · Men and women aged 18–75 with persistent MRSA carriage and serum 25OHD below 75 nmol/L
4,000 IU1 year32
Comparison of 300,000 and 600,000 IU Oral Vitamin-D Bolus for Vitamin-D Deficiency in Young Children
2017 · 600,000 IU group · Children aged 3 months to 3 years with vitamin-D deficiency
600,000 IU1 day30
Comparison of 300,000 and 600,000 IU Oral Vitamin-D Bolus for Vitamin-D Deficiency in Young Children
2017 · 300,000 IU group · Children aged 3 months to 3 years with vitamin-D deficiency
300,000 IU1 day30
Calcitriol supplementation accelerates the recovery of patients with tuberculosis who have vitamin D deficiency: a randomized, single-blind, controlled clinical trial
2022 · Low-25(OH)D-Calcitriol group · Adults aged 18–70 with tuberculosis and serum 25(OH)D below 75 nmol/L
0.5 mcg24 weeks30
Long-Term Vitamin D Supplementation and the Effects on Recurrence and Metabolic Status of Cervical Intraepithelial Neoplasia Grade 2 or 3: A Randomized, Double-Blind, Placebo-Controlled Trial
2018 · vitamin D group · Women diagnosed with cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3)
25,000 IU26 weeks29
A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study
2007 · 200 IU group · Nursing home residents; average age 89; sex not specified
200 IU150 days26
A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study
2007 · 400 IU group · Nursing home residents; average age 89; sex not specified
400 IU150 days25
A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study
2007 · 600 IU group · Nursing home residents; average age 89; sex not specified
600 IU150 days25
A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study
2007 · 800 IU group · Nursing home residents; average age 89; sex not specified
800 IU150 days23
Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients
2012 · Treatment group · Adults with chronic hepatitis C virus genotype 2–3, ages 48 ± 14 years; 65% male
2,000 IU24 weeks20
Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females
2013 · Maxmarvil group · Postmenopausal Korean females aged 50–70 with osteoporosis
0.5 mcg2 weeks20
Randomized Controlled Trial Assessing Vitamin D's Role in Reducing BPPV Recurrence in Older Adults
2025 · Group A · Adults aged 50 and above with vitamin D <30 ng/mL and idiopathic BPPV
2,000 IU26 weeks19
Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial
2013 · treatment group (cases) · Patients aged 20–40 years with optic neuritis and serum 25 (OH) D levels below 30 ng/ml
7,143 IU1 year15
Exploring the synergistic effects of vitamin D and synbiotics on cytokines profile, and treatment response in breast cancer: a pilot randomized clinical trial
2024 · Vitamin D group (VitD) · Adult women with histologically confirmed, non-metastatic primary invasive breast cancer who were candidates for neoadjuvant therapy
1,000 IU18 weeks15
Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily
2004 · Alfacalcidol · Community-dwelling elderly men and women; the abstract does not give an age range
1 mcg36 weeks—
Prospective study of vitamin D supplementation and rickets in China
1992 · 100 IU/day group · Term infants during the first 6 months of life
100 IU26 weeks—
Prospective study of vitamin D supplementation and rickets in China
1992 · 200 IU/day group · Term infants during the first 6 months of life
200 IU26 weeks—
Prospective study of vitamin D supplementation and rickets in China
1992 · 400 IU/day group · Term infants during the first 6 months of life
400 IU26 weeks—
Falls are associated with decreased renal function and insufficient calcitriol production by the kidney
2007 · calcitriol · Women aged 65–77 years; generally healthy, with some analyses focused on women with creatinine clearance below 60 ml/min
0.5 mcg3 years—
Falls are associated with decreased renal function and insufficient calcitriol production by the kidney
2007 · calcitriol + estrogen · Women aged 65–77 years; generally healthy, with some analyses focused on women with creatinine clearance below 60 ml/min
0.5 mcg3 years—
Treatment of postmenopausal osteoporosis with calcitriol or calcium
1992 · calcitriol · Postmenopausal women with osteoporosis and one or more vertebral compression fractures
0.5 mcg3 years—
Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial
2010 · Cholecalciferol 2000 IU/d · Patients aged 65 years or older recovering from acute hip fracture; 79.2% were women
2,000 IU1 year—
Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial
2010 · Cholecalciferol 800 IU/d · Patients aged 65 years or older recovering from acute hip fracture; 79.2% were women
800 IU1 year—
Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial
2012 · vitamin D group · Mongolian school-age children
800 IU26 weeks—
Low-dose calcitriol versus calcium in established postmenopausal osteoporosis
1990 · calcitriol · Women under 80 with at least 3 years of postmenopausal osteoporosis
0.5 mcg3 years—
Comprehensive Safety Monitoring of 12-Month Daily 7000-IU Vitamin D3 Supplementation in Human Immunodeficiency Virus-Infected Children and Young Adults
2016 · 7000-IU/d vitD3 · HIV-infected children and young adults aged 9–24.9 years
7,000 IU1 year—
Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial
2017 · Vitamin D3 · Adults aged 45–75 with at least one large-bowel adenoma removed before enrollment
1,000 IU1376 days—
Vitamin D supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal Asthma Reduction Trial
2017 · 4400 international units/d vitamin D · Pregnant women at risk of having children with asthma; race-specific age range not reported
4,400 IU——
Vitamin D supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal Asthma Reduction Trial
2017 · Placebo plus 400 international units/d vitamin D · Pregnant women at risk of having children with asthma; race-specific age range not reported
400 IU——
Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial
2017 · 800 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American
800 IU1 year—
Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial
2017 · 1600 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American
1,600 IU1 year—
Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial
2017 · 2400 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American
2,400 IU1 year—
Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial
2017 · 3200 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American
3,200 IU1 year—
Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial
2017 · 4000 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American
4,000 IU1 year—
Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial
2017 · 4800 IU/day vitamin D3 group · Postmenopausal women aged 57–90 with vitamin D insufficiency (baseline serum 25OHD ≤20 ng/mL); Caucasian or African American
4,800 IU1 year—
Vitamin D-supplemented yogurt drink reduces Candida infections in a paediatric intensive care unit: a randomised, placebo-controlled clinical trial
2019 · VD group · Children aged 12 months to 5 years admitted to a paediatric intensive care unit and receiving broad-spectrum antibiotic therapy
300 IU2 weeks—
Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure
2020 · vitamin D group · older adults; mean age 67.1 years, 50.6% women; no condition specified
2,000 IU1935 days—
Effect of Vitamin D on Relapse-Free Survival in a Subgroup of Patients with p53 Protein-Positive Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Trial
2020 · vitamin D group · Patients with p53-positive digestive tract cancer
2,000 IU——
Effect of early and late prenatal vitamin D and maternal asthma status on offspring asthma or recurrent wheeze
2021 · intervention · Pregnant women aged 18–39 years at 10–18 weeks’ gestation, at increased risk of offspring asthma or atopy due to their own or their partner’s history of asthma or atopy
4,400 IU——
Risk of keratinocyte carcinomas with vitamin D and calcium supplementation: a secondary analysis of a randomized clinical trial
2020 · Vitamin D3 · Men and women aged 45–75 recently diagnosed with a colorectal adenoma
1,000 IU5 years—
Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial
2020 · Vitamin D3 active · Men aged 50 years or older and women aged 55 years or older without cancer or cardiovascular disease at study entry
2,000 IU1937 days—
The effects of vitamin D supplementation on types of falls
2021 · 200 IU/d control · Community-dwelling adults aged 70 years or older with elevated fall risk and serum 25-hydroxyvitamin D of 10–29 ng/mL; men and women
200 IU2 years—
The effects of vitamin D supplementation on types of falls
2021 · 1000 IU/d group · Community-dwelling adults aged 70 years or older with elevated fall risk and serum 25-hydroxyvitamin D of 10–29 ng/mL; men and women
1,000 IU2 years—
The effects of vitamin D supplementation on types of falls
2021 · 2000 IU/d group · Community-dwelling adults aged 70 years or older with elevated fall risk and serum 25-hydroxyvitamin D of 10–29 ng/mL; men and women
2,000 IU2 years—
The effects of vitamin D supplementation on types of falls
2021 · 4000 IU/d group · Community-dwelling adults aged 70 years or older with elevated fall risk and serum 25-hydroxyvitamin D of 10–29 ng/mL; men and women
4,000 IU2 years—
Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial
2021 · Vitamin D arm · Adults aged 75 years or younger with recently resected stage II cutaneous malignant melanoma
2,000 IU3 years—
Short-Term Hypocalcemia Prophylaxis With Calcitriol Before Thyroidectomy
2021 · intervention group · Patients about to undergo total thyroidectomy for thyroid disease
1 mcg3 days—
Effects of early vitamin D supplementation on the prevention of bronchopulmonary dysplasia in preterm infants
2022 · vitamin D supplementation (VD) group · Preterm infants; age range and sex not reported.
800 IU4 weeks—
Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial
2022 · Vitamin D active/omega 3 placebo · Men aged 50 years or older and women aged 55 years or older; general older-adult population, not selected for vitamin D deficiency
2,000 IU5 years—
Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial
2022 · Vitamin D supplementation (with or without omega-3 supplementation; exercise assignment varied) · Community-dwelling adults aged 70 years and older, generally healthy and active, without major health events in the prior 5 years
2,000 IU3 years—
Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization
2022 · vitamin D3 group · Adults enrolled in VITAL; mean age 67.1 years, 50.6% women, with and without type 2 diabetes
2,000 IU1935 days—
Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial
2023 · Vitamin D3 · Adults with a recently diagnosed colorectal adenoma and no remaining polyps after complete colonoscopy; the analyzed subgroup consisted of non-Hispanic White participants
1,000 IU5 years—
Effect of intratrial mean 25(OH)D concentration on diabetes risk, by race and weight: an ancillary analysis in the D2d study
2023 · vitamin D3 group · people with prediabetes
4,000 IU913 days—
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes
2023 · vitamin D3 supplementation group · Men aged 50 years or older and women aged 55 years or older, free of known cardiovascular disease or cancer, from the general US population
2,000 IU1935 days—
Maternal Vitamin D Supplementation and Infantile Rickets: Secondary Analysis of a Randomized Trial
2024 · vitamin D 4200 IU/week · Pregnant women in Bangladesh
600 IU——
Maternal Vitamin D Supplementation and Infantile Rickets: Secondary Analysis of a Randomized Trial
2024 · vitamin D 16 800 IU/week · Pregnant women in Bangladesh
2,400 IU——
Maternal Vitamin D Supplementation and Infantile Rickets: Secondary Analysis of a Randomized Trial
2024 · vitamin D 28 000 IU/week, prenatal · Pregnant women in Bangladesh
4,000 IU——
Maternal Vitamin D Supplementation and Infantile Rickets: Secondary Analysis of a Randomized Trial
2024 · vitamin D 28 000 IU/week, prenatal and postpartum · Pregnant women in Bangladesh, continuing supplementation postpartum
4,000 IU——
Early Vitamin D Supplementation in Infants Born Extremely Preterm and Fed Human Milk: A Randomized Controlled Trial
2025 · intervention · Infants born at 28 weeks of gestation or less and fed human milk
800 IU2 weeks—
Effect of prenatal high-dose vitamin D on childhood atopic dermatitis is modified by maternal cotinine metabolome: A secondary analysis of a randomized clinical trial
2026 · high-dose · Pregnant women starting supplementation at pregnancy week 24; maternal tobacco exposure was assessed, with no restriction to a specific exposure group stated
2,800 IU——
Effect of prenatal high-dose vitamin D on childhood atopic dermatitis is modified by maternal cotinine metabolome: A secondary analysis of a randomized clinical trial
2026 · standard-dose · Pregnant women starting supplementation at pregnancy week 24; maternal tobacco exposure was assessed, with no restriction to a specific exposure group stated
400 IU——
Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients
2004 · 15 mcg (600 IU)/day · Adults attending an endocrinology clinic with low serum 25(OH)D; age and sex varied
13.6 mcg1 year65
Effect of calcifediol and cholecalciferol on muscle function in postmenopausal women: a randomized controlled trial
2025 · Calcifediol · Postmenopausal women aged 50–70 with osteopenia or osteoporosis and serum 25(OH)D <30 ng/mL
20 mcg26 weeks49
The acute effects of milk intake on calcium homeostasis and cardiovascular outcome: A randomized crossover trial in postmenopausal women
2022 · 500 ml water with added cholecalciferol · Postmenopausal women aged 60–80 years with vitamin D insufficiency at screening
200 mcg1 day20
Calcifediol versus vitamin D3 effects on gait speed and trunk sway in young postmenopausal women: a double-blind randomized controlled trial
2015 · calcifediol group · Postmenopausal women, mean age 61.5 years, with low average 25(OH)D levels
20 mcg120 days10
Calcifediol versus vitamin D3 effects on gait speed and trunk sway in young postmenopausal women: a double-blind randomized controlled trial
2015 · vitamin D3 group · Postmenopausal women, mean age 61.5 years, with low average 25(OH)D levels
20 mcg120 days10
Winter vitamin D(3) supplementation does not increase muscle strength, but modulates the IGF-axis in young children
2019 · 20 µg/day vitamin D3 · Healthy children aged 4–8 years
20 mcg20 weeks—
Effects of vitamin D supplementation on acute respiratory tract infections in 6-8-year-old children: a randomized clinical trial
2025 · vitamin D group · Healthy children aged 6–8 years
20 mcg24 weeks—
Changes in bone density and microarchitecture following treatment of Graves' disease and the effects of vitamin D supplementation. A randomized clinical trial
2024 · vitamin D group · Adults aged 18–80 with newly diagnosed Graves’ disease thyrotoxicosis
70 mcg270 days44
Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial
2012 · cholecalciferol group · Adults with hypertension in Denmark; mean age 61 ± 10 years. A subgroup had baseline vitamin D insufficiency.
75 mcg20 weeks—
Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements
2011 · CaD group · Postmenopausal women aged 50–79 years
400 IU7 years18,176
Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study
2013 · Calcium plus vitamin D (CaD) group · Postmenopausal women aged 50–79 years
400 IU7 years18,176
A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast
2021 · calcium plus vitamin D · Postmenopausal women aged 50–79 years at enrollment
400 IU2592 days18,176
Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation
2017 · active treatment · older women; median age 63 years
400 IU7 years18,141
Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women's health initiative
2015 · intervention group · Postmenopausal women aged 50–79 years, free of heart failure at baseline, with and without pre-existing cardiovascular risk conditions
400 IU2577 days18,023
Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study
2004 · Calcium and Vitamin D Program · Community-dwelling residents aged 66 years and older
400 IU3 years4,957
Efficacy of vitamin D(3) supplementation for the prevention of pulmonary tuberculosis and mortality in HIV: a randomised, double-blind, placebo-controlled trial
2020 · vitamin D3 supplementation group · Tanzanian adults aged 18 years or older living with HIV, initiating ART, with serum 25(OH)D below 30 ng/mL
9,143 IU1 year2,001
Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial
2017 · vitamin D3 + calcium group · Healthy postmenopausal women aged 55 years or older
2,000 IU1461 days1,156
Zoledronic acid and clinical fractures and mortality after hip fracture
2007 · zoledronic acid group · Men and women aged 50 years or older after surgical repair of a recent minimal-trauma hip fracture
800 IU1826 days1,065
Zoledronic acid and clinical fractures and mortality after hip fracture
2007 · placebo group · Men and women aged 50 years or older after surgical repair of a recent minimal-trauma hip fracture
800 IU1826 days1,062
Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study
2015 · supplement group — women · Women aged 40–69 with esophageal squamous dysplasia (ESD) in Linxian, China
20 mcg6 years927
Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study
2015 · supplement group — men · Men aged 40–69 with esophageal squamous dysplasia (ESD) in Linxian, China
20 mcg6 years726
A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study
2011 · Eldecalcitol · Osteoporotic patients aged 46 to 92 years; patients with serum 25-hydroxyvitamin D below 50 nmol/L also received vitamin D3
0.75 mcg3 years528
Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis
2013 · Eldecalcitol group · Japanese adults aged 46–92 with osteoporosis; predominantly women; patients with low baseline serum 25(OH)D also received vitamin D3
0.75 mcg3 years528
A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study
2011 · Alfacalcidol · Osteoporotic patients aged 46 to 92 years; patients with serum 25-hydroxyvitamin D below 50 nmol/L also received vitamin D3
1 mcg3 years526
Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis
2013 · Alfacalcidol group · Japanese adults aged 46–92 with osteoporosis; predominantly women; patients with low baseline serum 25(OH)D also received vitamin D3
1 mcg3 years526
Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: A randomized trial
2020 · intervention · Patients with confirmed benign paroxysmal positional vertigo (BPPV); supplementation was given when serum vitamin D was below 20 ng/mL
800 IU1 year518
The Association of Prenatal Vitamin D Sufficiency With Aeroallergen Sensitization and Allergic Rhinitis in Early Childhood
2021 · placebo multivitamin with low-dose vitamin D · Pregnant women aged 18–39 years at 10–18 weeks of gestation, nonsmoking, with a personal or partner history of asthma or atopy
400 IU—441
Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial
2019 · calcium and vitamin D · Adults aged 45–75 with at least one adenomatous polyp detected and removed within the preceding 4 months
1,000 IU5 years421
Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction
2020 · vitamin D group · Pregnant women aged 18–39 years with a personal history of asthma, eczema, or allergic rhinitis, or a partner with one of these conditions
4,400 IU—405
Effect of Vitamin D3 Supplementation During Pregnancy on Risk of Persistent Wheeze in the Offspring: A Randomized Clinical Trial
2016 · Vitamin D3 group · Pregnant women enrolled at 24 weeks of pregnancy
2,400 IU—315
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
2000 · 200-IU salmon calcitonin group · Postmenopausal women with established osteoporosis
400 IU5 years287
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
2000 · Placebo group · Postmenopausal women with established osteoporosis
400 IU5 years270
Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial
2014 · vitamin D3 group · Adults aged 18 years or older with symptomatic asthma and serum 25-hydroxyvitamin D below 30 ng/mL
4,000 IU28 weeks201
Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study
2009 · Risedronate group · Men with primary or secondary osteoporosis
800 IU2 years158
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Placebo (Ca-D group) · Postmenopausal women with osteoporosis and vertebral fractures
800 IU2 years146
Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial
2025 · active placebo group · Children aged 3–18 years with a documented history of recurrent respiratory tract infections
10 mcg90 days113
Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial
2025 · active group · Children aged 3–18 years with a documented history of recurrent respiratory tract infections
10 mcg90 days104
Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients
2021 · A VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 71 years, predominantly women
0.5 mcg1 year99
Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients
2021 · NA VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 71 years, predominantly women
800 IU1 year98
Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients
2021 · P-A VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 72 years, predominantly women
0.5 mcg1 year98
Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients
2021 · P-NA VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 70 years, predominantly women
800 IU1 year97
Reduced primary care respiratory infection visits following pregnancy and infancy vitamin D supplementation: a randomised controlled trial
2015 · lower-dose vitamin D3 (1000 IU/400 IU) · Pregnant women from 27 weeks' gestation to birth and their infants from birth to age 6 months
1,400 IU—87
Reduced primary care respiratory infection visits following pregnancy and infancy vitamin D supplementation: a randomised controlled trial
2015 · higher-dose vitamin D3 (2000 IU/800 IU) · Pregnant women from 27 weeks' gestation to birth and their infants from birth to age 6 months
2,800 IU—86
Randomized clinical trial of intraoperative parathyroid gland angiography with indocyanine green fluorescence predicting parathyroid function after thyroid surgery
2018 · Control group · Adults undergoing total or completion thyroidectomy with at least one well-perfused parathyroid gland identified by indocyanine green angiography; men and women; thyroid disease requiring surgery
1,600 IU15 days73
Perioperative versus postoperative calcium and vitamin D supplementation to prevent symptomatic hypocalcemia after total thyroidectomy: a randomized placebo controlled trial
2023 · Perioperative supplementation group · Adults older than 18 years undergoing total or completion thyroidectomy
1 mcg17 days68
Perioperative versus postoperative calcium and vitamin D supplementation to prevent symptomatic hypocalcemia after total thyroidectomy: a randomized placebo controlled trial
2023 · Postoperative supplementation group · Adults older than 18 years undergoing total or completion thyroidectomy
1 mcg2 weeks66
A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nutraceutical, as preventive treatment in children with allergic rhinoconjunctivitis: phase II
2019 · Lertal® Group (LG) · Children aged 6–12 years with allergic rhinoconjunctivitis and sensitization to house dust mites or pollens
5 mcg12 weeks64
Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial
2003 · Cal+D-group · Elderly women aged 63–99 years in long-stay geriatric care
800 IU12 weeks62
Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study
2020 · experiment group · Men and women aged 80–93 years with osteopenia living independently
125 IU548 days62
Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study
2020 · control group · Men and women aged 80–93 years with osteopenia living independently
125 IU548 days61
Prevention of postoperative hypocalcemia with routine oral calcium and vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection
2009 · Group A · Patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection; age and sex not specified
1 mg—49
Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy
2006 · oral calcium/vitamin D group · patients who underwent total thyroidectomy; age and sex not specified
1 g2 weeks45
Vitamin D Intake May Reduce SARS-CoV-2 Infection Morbidity in Health Care Workers
2022 · Group I · Health care workers aged 18–65 years, women and men, with negative SARS-CoV-2 PCR and occupational exposure to infected patients
12,143 IU90 days45
Does Preoperative Calcium and Calcitriol Decrease Rates of Post-Thyroidectomy Hypocalcemia? A Randomized Clinical Trial
2021 · Control group · Patients undergoing total thyroidectomy; age and sex not reported
0.5 mcg—44
[Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia]
2014 · VD group · Men with idiopathic oligoasthenozoospermia
200 IU90 days43
Does Preoperative Calcium and Calcitriol Decrease Rates of Post-Thyroidectomy Hypocalcemia? A Randomized Clinical Trial
2021 · Intervention group · Patients undergoing total thyroidectomy; age and sex not reported
0.5 mcg—38
Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?
2006 · Vitamin D plus calcium · Institutionalized women aged 65–97
800 IU90 days33
Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis
2012 · Cholecalciferol group · Postmenopausal women with osteoporosis
300,800 IU7 days30
Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis
2012 · Placebo group with shared supplementation · Postmenopausal women with osteoporosis
800 IU7 days30
Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial
2020 · juice-based TMN · Patients with non-small-cell lung cancer receiving first-line chemotherapy, with weight loss or low BMI
20 mcg12 weeks26
The efficacy of oral vitamin D supplements on fusion outcome in patients receiving elective lumbar spinal fusion-a randomized control trial
2022 · Experimental group · Adults aged 20–80 undergoing elective lumbar spinal fusion for spinal stenosis or degenerative spondylolisthesis
800 IU90 days21
Exploring the synergistic effects of vitamin D and synbiotics on cytokines profile, and treatment response in breast cancer: a pilot randomized clinical trial
2024 · Vitamin D + synbiotic group (VitD + Pro) · Adult women with histologically confirmed, non-metastatic primary invasive breast cancer who were candidates for neoadjuvant therapy
1,000 IU18 weeks18
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
2000 · risedronate 2.5 mg/day group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis
500 IU2 years—
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
2000 · risedronate 5 mg/day group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis
500 IU3 years—
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
2000 · placebo group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis
500 IU3 years—
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
2000 · 100-IU salmon calcitonin group · Postmenopausal women with established osteoporosis
400 IU5 years—
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
2000 · 400-IU salmon calcitonin group · Postmenopausal women with established osteoporosis
400 IU5 years—
The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial
2005 · risedronate group · Elderly women with Alzheimer disease and baseline 25-hydroxyvitamin D deficiency
1,000 IU548 days—
The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial
2005 · control group · Elderly women with Alzheimer disease and baseline 25-hydroxyvitamin D deficiency
1,000 IU548 days—
Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial
2006 · cholecalciferol-calcium · Ambulatory, community-dwelling men and women aged 65 years or older
700 IU3 years—
Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial
2007 · Ca + D · Healthy postmenopausal women aged over 55 years
1,100 IU4 years—
Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial
2008 · calcium plus vitamin-D supplementation · Women in the Women's Health Initiative; age and specific health conditions are not stated in the abstract
400 IU——
Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women
2008 · ergocalciferol group · Community-dwelling women aged 70–90 with serum 25-hydroxyvitamin D below 24.0 ng/mL and a history of falling in the previous year
1,000 IU1 year—
Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women
2008 · vitamin D3 plus calcium · Community-dwelling, healthy ambulatory men and women aged 65 years or older
700 IU3 years—
Calcium and vitamin d supplementation decreases incidence of stress fractures in female navy recruits
2008 · calcium and vitamin D group · female Navy recruits undergoing basic training
800 IU8 weeks—
Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals
2009 · calcium plus vitamin D · Community-dwelling women and men, mean age 77 years, with serum 25-hydroxyvitamin D below 78 nmol/l
800 IU1 year—
Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study
2009 · Control group without previous vertebral fractures · Men with primary or secondary osteoporosis without previous vertebral fractures
800 IU2 years—
Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial
2009 · CaD supplementation · Postmenopausal women aged 51–82 years
400 IU2557 days—
Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial
2011 · CaD (calcium plus vitamin D) · Postmenopausal women aged 50 to 79 years enrolled in the Women's Health Initiative calcium/vitamin D trial
400 IU7 years—
Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set
2011 · Calcium and vitamin D (CaD) · Community-dwelling postmenopausal women
400 IU2557 days—
Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy
2014 · Active CaD + active hormone therapy · Postmenopausal women aged 50–79; not selected for low bone density or osteoporosis
400 IU2628 days—
Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy
2014 · Active CaD + placebo hormone therapy · Postmenopausal women aged 50–79; not selected for low bone density or osteoporosis
400 IU2628 days—
Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D
2014 · 1000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ
1,000 IU90 days—
Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D
2014 · 2000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ
2,000 IU90 days—
Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D
2014 · 4000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ
4,000 IU90 days—
The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. From the Women's Health Initiative Randomized Controlled Trial
2015 · calcium and vitamin D group · Postmenopausal women aged 50–79 years
400 IU7 years—
Effect of Calcium β-Hydroxy-β-Methylbutyrate (CaHMB), Vitamin D, and Protein Supplementation on Postoperative Immobilization in Malnourished Older Adult Patients With Hip Fracture: A Randomized Controlled Study
2016 · CaHMB/vitamin D/protein group · Older female patients with malnutrition and hip fracture
1,000 IU30 days—
Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials
2017 · Ca/D intervention · Postmenopausal women aged 50–79 with an intact uterus, included in the analytical sample by self-reported age of natural menopause
400 IU——
Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials
2017 · HT + Ca/D intervention · Postmenopausal women aged 50–79 with an intact uterus, included in the analytical sample by self-reported age of natural menopause
400 IU——
Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial
2017 · Vitamin D3 plus calcium · Adults aged 45–75 with at least one large-bowel adenoma removed before enrollment
1,000 IU1376 days—
The influence of genetic susceptibility and calcium plus vitamin D supplementation on fracture risk
2017 · calcium plus vitamin D group · White postmenopausal women
400 IU339 weeks—
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
2019 · n-3 fatty acids plus vitamin D group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial
2,000 IU1936 days—
Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease
2019 · CaD-supplement group · Postmenopausal women in the Women's Health Initiative who entered the calcium and vitamin D trial after one year in a menopausal hormone therapy trial
400 IU2264 days—
Risk of keratinocyte carcinomas with vitamin D and calcium supplementation: a secondary analysis of a randomized clinical trial
2020 · Vitamin D3 plus calcium carbonate · Men and women aged 45–75 recently diagnosed with a colorectal adenoma
1,000 IU5 years—
Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial
2020 · Vitamin D3 and marine omega-3 fatty acids active · Men aged 50 years or older and women aged 55 years or older without cancer or cardiovascular disease at study entry
2,000 IU1937 days—
Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial
2022 · Vitamin D active/omega 3 active · Men aged 50 years or older and women aged 55 years or older; general older-adult population, not selected for vitamin D deficiency
2,000 IU5 years—
Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial
2022 · Vitamin D plus marine omega-3 supplementation (exercise assignment varied) · Community-dwelling adults aged 70 years and older, generally healthy and active, without major health events in the prior 5 years
2,000 IU3 years—
Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial
2023 · Vitamin D3 and calcium · Adults with a recently diagnosed colorectal adenoma and no remaining polyps after complete colonoscopy; the analyzed subgroup consisted of non-Hispanic White participants
1,000 IU5 years—
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes
2023 · combination supplementation group · Men aged 50 years or older and women aged 55 years or older, free of known cardiovascular disease or cancer, from the general US population
2,000 IU1935 days—
Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial
2024 · Vitamin D and n-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses
2,000 IU1936 days—
Long-Term Effect of Randomization to Calcium and Vitamin D Supplementation on Health in Older Women : Postintervention Follow-up of a Randomized Clinical Trial
2024 · CaD · Postmenopausal women with no history of breast or colorectal cancer
400 IU7 years—
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
2025 · Vitamin D plus marine omega-3 · Men aged 50 years or older and women aged 55 years or older, without type 2 diabetes at baseline; older US adults
2,000 IU1935 days—
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Sodium fluoride · Postmenopausal women with osteoporosis and vertebral fractures
800 IU2 years—
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Monofluorophosphate, 200 mg/day · Postmenopausal women with osteoporosis and vertebral fractures
800 IU2 years—
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Monofluorophosphate, 150 mg/day · Postmenopausal women with osteoporosis and vertebral fractures
800 IU2 years—
A randomized clinical trial of omega-3 fatty acid and vitamin D supplementation on electrocardiographic risk profiles
2023 · Vitamin D3 active treatment · Men aged 50 years or older and women aged 55 years or older in the VITAL ECG substudy; no specific disease required
2,000 IU2 years446
Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial
2016 · 400 IU/d vitamin D group · Pregnant women aged 18–39 years, 10–18 weeks’ gestation, with a personal or partner history of asthma, eczema, or allergic rhinitis
400 IU—436
Efficacy of High-Dose Supplementation With Oral Vitamin D3 on Depressive Symptoms in Dialysis Patients With Vitamin D3 Insufficiency: A Prospective, Randomized, Double-Blind Study
2016 · test group · Dialysis patients with depression and vitamin D3 insufficiency; age and sex not specified
7,143 IU52 weeks362
High-Dose Vitamin D Supplementation in Pregnancy and Neurodevelopment in Childhood: A Prespecified Secondary Analysis of a Randomized Clinical Trial
2020 · high-dose vitamin D3 group · pregnant Danish women recruited at 24 weeks of pregnancy
2,800 IU—315
High-Dose Vitamin D Supplementation in Pregnancy and Neurodevelopment in Childhood: A Prespecified Secondary Analysis of a Randomized Clinical Trial
2020 · standard-dose vitamin D3 group · pregnant Danish women recruited at 24 weeks of pregnancy
400 IU—308
Prevention of urinary tract infections with vitamin D supplementation 20,000 IU per week for five years. Results from an RCT including 511 subjects
2016 · vitamin D group · People with prediabetes; age and sex not specified
2,857 IU5 years256
Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial
2010 · vitamin D3 · Children aged 1–36 months with non-severe or severe pneumonia
100,000 IU1 day224
Effect of Vitamin D3 Supplementation in the First 2 Years of Life on Psychiatric Symptoms at Ages 6 to 8 Years: A Randomized Clinical Trial
2023 · 1200-IU vitamin D group · Infants randomized at about 2 weeks of age; healthy infants of Northern European ancestry
1,200 IU2 years177
Effect of Vitamin D3 Supplementation in the First 2 Years of Life on Psychiatric Symptoms at Ages 6 to 8 Years: A Randomized Clinical Trial
2023 · 400-IU vitamin D group · Infants randomized at about 2 weeks of age; healthy infants of Northern European ancestry
400 IU2 years169
Vitamin D Supplementation for Treatment and Prevention of Pneumonia in Under-five Children: A Randomized Double-blind Placebo Controlled Trial
2016 · vitamin D group · Children aged 6 months to 5 years with WHO-defined severe pneumonia
100,000 IU1 day162
Impact of vitamin D supplementation on the clinical outcomes of COVID-19 pneumonia patients: a single-center randomized controlled trial
2024 · intervention group · Adults aged 18 years or older with COVID-19 pneumonia
2 mcg—147
Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia
2012 · vitamin D group · Mongolian schoolchildren with vitamin D deficiency
300 IU90 days143
Once-weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency
2010 · 8400 IU vitamin D(3) group · Adults aged 70 years or older with vitamin D insufficiency
1,200 IU—114
Repletion of vitamin D associated with deterioration of sleep quality among postmenopausal women
2016 · Vitamin D · Overweight or obese postmenopausal women aged 50–75 years with insufficient serum 25(OH)D (≥10 and <32 ng/mL)
2,000 IU1 year109
A parallel group double-blind RCT of vitamin D3 assessing physical function: is the biochemical response to treatment affected by overweight and obesity?
2014 · 400 I.U. vitamin D3 · Healthy postmenopausal women aged 60–70 years, BMI 18–45 kg/m²
400 IU1 year102
A parallel group double-blind RCT of vitamin D3 assessing physical function: is the biochemical response to treatment affected by overweight and obesity?
2014 · 1,000 I.U. vitamin D3 · Healthy postmenopausal women aged 60–70 years, BMI 18–45 kg/m²
1,000 IU1 year101
Efficacy and Safety of High-Dose Vitamin D Supplementation vs Solifenacin or Standard Urotherapy for Overactive Bladder Dry in Children: A Randomized Clinical Trial
2024 · VDS + SU group · Children with dry overactive bladder; median age 82.0 months
2,400 IU8 weeks100
Role of vitamin D supplementation and vitamin D receptor in drug-resistant epilepsy: A double-blind placebo-controlled trial conducted in India
2025 · Vitamin D group · Adults with drug-resistant epilepsy, serum vitamin D below 30 ng/mL, and at least 2 seizures per month
8,571 IU26 weeks99
Vitamin D Supplementation Improves Cognitive Function Through Reducing Oxidative Stress Regulated by Telomere Length in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized Controlled Trial
2020 · intervention group · Chinese adults aged 65 years and older with mild cognitive impairment
800 IU1 year93
Increased food allergy and vitamin D: randomized, double-blind, placebo-controlled trial
2014 · vitamin D3 supplements · Breastfeeding mothers of infants with facial eczema at the 1-month check-up
800 IU6 weeks82
Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study
2015 · Alfacalcidol · Adults with clinically definite multiple sclerosis and significant fatigue; mean age 41.1 years, 118 of 158 participants were female
1 mcg26 weeks80
Effect of vitamin D supplementation alone on muscle function in postmenopausal women: a randomized, double-blind, placebo-controlled clinical trial
2015 · VITD group · Postmenopausal women aged 50–65 years with a history of falls in the previous 12 months
1,000 IU39 weeks80
Vitamin D supplementation improves anxiety but not depression symptoms in patients with vitamin D deficiency
2020 · intervention group · Adults aged 18–60 with major depressive disorder and serum 25(OH)D ≤75 nmol/L
1,600 IU26 weeks79
A randomized controlled trial of vitamin D supplementation on perinatal depression: in Iranian pregnant mothers
2016 · vitamin D group · Pregnant women aged 18 years or older, at 26–28 weeks of gestation, without a history of mental illness or specified internal diseases and with baseline EPDS scores of 0–13
2,000 IU8 weeks75
Muscle Cramps Do Not Improve With Correction of Vitamin D Insufficiency
2017 · low-dose vitamin D · Postmenopausal women aged 60 years or younger than 75 years, with baseline 25(OH)D levels of 14 to 27 ng/mL
800 IU1 year75
Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial
2022 · Higher dose of vitamin D3 · Women aged 21 and older with type 2 diabetes, significant depressive symptoms, and serum 25(OH)D below 32 ng/mL
7,143 IU26 weeks65
Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial
2022 · Lower dose of vitamin D3 · Women aged 21 and older with type 2 diabetes, significant depressive symptoms, and serum 25(OH)D below 32 ng/mL
714 IU26 weeks64
Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease
2013 · vitamin D3 supplements · Patients with Parkinson disease; age and sex not reported
1,200 IU1 year56
Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial
2018 · Group 1 · Adolescents aged 14–18 years with irritable bowel syndrome and vitamin D deficiency
2,000 IU26 weeks56
Effect of vitamin D deficiency on depressive symptoms in child and adolescent psychiatric patients: results of a randomized controlled trial
2020 · Verum group (VG) · Children and adolescents aged 11.0–18.9 years with vitamin D deficiency and at least mild depressive symptoms receiving psychiatric inpatient or daycare treatment
2,640 IU4 weeks56
Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial
2021 · intervention group · Adults with asthma and serum 25-hydroxyvitamin D3 below 30 ng/mL
2,286 IU26 weeks56
Improved control of childhood asthma with low-dose, short-term vitamin D supplementation: a randomized, double-blind, placebo-controlled trial
2016 · vitamin D group · Japanese schoolchildren with asthma; age and sex not specified
800 IU60 days54
Efficacy of vitamin D supplementation in reducing body mass index and lipid profile in healthy young adults in Colombia: a pilot randomised controlled clinical trial
2023 · 200 IU group · Healthy young adults from the SIMBA cohort in Colombia; mean age 22.6 years; men and women
200 IU15 weeks54
Effects of vitamin D and/or calcium intervention on sleep quality in individuals with prediabetes: a post hoc analysis of a randomized controlled trial
2024 · vitamin D group · Chinese individuals with prediabetes; age and sex not specified
1,600 IU24 weeks54
Protein-enriched diet, with the use of lean red meat, combined with progressive resistance training enhances lean tissue mass and muscle strength and reduces circulating IL-6 concentrations in elderly women: a cluster randomized controlled trial
2014 · resistance training plus lean red meat (RT+Meat) group · Women aged 60–90 years residing in retirement villages
1,000 IU120 days53
Effect of calcifediol and cholecalciferol on muscle function in postmenopausal women: a randomized controlled trial
2025 · Vitamin D3 · Postmenopausal women aged 50–70 with osteopenia or osteoporosis and serum 25(OH)D <30 ng/mL
3,200 IU26 weeks52
Effect of Vitamin D Supplementation on Body Composition and Physical Fitness in Healthy Adults: A Double-Blind, Randomized Controlled Trial
2019 · vitamin D group · healthy adults; age range and sex not specified
420 IU1 year48
Protein-enriched diet, with the use of lean red meat, combined with progressive resistance training enhances lean tissue mass and muscle strength and reduces circulating IL-6 concentrations in elderly women: a cluster randomized controlled trial
2014 · control resistance training (CRT) group · Women aged 60–90 years residing in retirement villages
1,000 IU120 days47
Efficacy of vitamin D supplementation in reducing body mass index and lipid profile in healthy young adults in Colombia: a pilot randomised controlled clinical trial
2023 · 1000 IU group · Healthy young adults from the SIMBA cohort in Colombia; mean age 22.6 years; men and women
1,000 IU15 weeks47
Oral vitamin D(3) supplementation for femtosecond LASIK-associated dry eye vitamin D for LASIK dry eye syndrome
2022 · experimental group · Patients with dry-eye symptoms one month after femtosecond LASIK surgery; ages and sex not reported
2,000 IU12 weeks45
The effect of vitamin D on urgent urinary incontinence in postmenopausal women
2023 · vitamin D group · Postmenopausal women with vitamin D deficiency and urge urinary incontinence or nocturia more than once at night
7,143 IU8 weeks45
Paricalcitol and endothelial function in chronic kidney disease trial
2014 · paricalcitol · Patients with stage 3 to 4 chronic kidney disease and parathormone >65 pg/mL
2 mcg12 weeks44
Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients
2016 · PCT · Adults with stage G3–4 chronic kidney disease; age and sex not specified
2 mcg12 weeks44
The impact of vitamin D supplementation as an adjuvant therapy on clinical outcomes in patients with severe atopic dermatitis: A randomized controlled trial
2020 · Treatment group · Children aged 5–16 years with severe atopic dermatitis
1,600 IU90 days44
Effect of alfacalcidol on the pulmonary function of adult asthmatic patients: A randomized trial
2017 · Alfacalcidol plus standard asthma treatment · Adults with asthma
1 mcg120 days43
The impact of exercise and vitamin D supplementation on physical function in community-dwelling elderly individuals: A randomized trial
2018 · exercise and vitamin D group · Community-dwelling adults aged 60 years or older who were not taking osteoporosis medications
1,000 IU24 weeks43
The effects of Vitamin D3 supplementation on Spermatogram and endocrine factors in asthenozoospermia infertile men: a randomized, triple blind, placebo-controlled clinical trial
2021 · Vitamin D3 group · Infertile men with asthenozoospermia and vitamin D3 levels below 30 ng/ml; mean age approximately 35 years
4,000 IU90 days43
The impact of exercise and vitamin D supplementation on physical function in community-dwelling elderly individuals: A randomized trial
2018 · vitamin D group · Community-dwelling adults aged 60 years or older who were not taking osteoporosis medications
1,000 IU24 weeks42
Efficacy of high-dose vs. low-dose vitamin D₃ supplementation in children with chronic tic disorders: a randomized controlled trial
2025 · low-dose vitamin D₃ supplementation group · Children aged 4–15 years with chronic tic disorders
1,000 IU90 days42
Efficacy of high-dose vs. low-dose vitamin D₃ supplementation in children with chronic tic disorders: a randomized controlled trial
2025 · high-dose vitamin D₃ supplementation group · Children aged 4–15 years with chronic tic disorders
5,000 IU90 days41
Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial
2020 · vitamin D3 supplemented group · Adults with episodic migraine; age and sex not stated
2,000 IU12 weeks40
The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial
2020 · Vitamin D group · Adults aged 18–45 with episodic migraine
2,000 IU12 weeks40
Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial
2024 · Vitamin D group · Patients with post-COVID fatigue or neuropsychiatric symptoms
8,571 IU8 weeks40
Effects of cholecalciferol supplementation on depressive symptoms, C-peptide, serotonin, and neurotrophin-3 in type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial
2024 · cholecalciferol · Adults with type 2 diabetes mellitus and mild to moderate depressive symptoms; mean age about 54 years; both sexes
4,000 IU12 weeks40
Effect of vitamin D as Nutrition Supplement on Patients with Prolonged Ventilation due to Ventilator Associated Pneumonia and Sepsis Followed Severe Traumatic Lung Contusion: A Randomized Controlled Trial
2026 · Group B · Adult ICU patients with severe traumatic lung contusion who remained mechanically ventilated for 10 consecutive days and subsequently developed ventilator-associated pneumonia and sepsis
100,000 IU2 weeks40
Vitamin D in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After COVID-19 or Vaccination: A Randomized Controlled Trial
2026 · Control group · Adults aged 18 years or older with ME/CFS following COVID-19 infection or vaccination and vitamin D insufficiency or deficiency
1 mcg24 weeks39
Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial
2017 · calcium carbonate + calcitriol · Patients with non-alcoholic fatty liver disease (NAFLD) following an energy-restricted weight-loss program; age and sex not stated
25 mcg12 weeks37
The effect of hormonal contraceptives combined with vitamin D3 supplements on sexual dysfunction in women with polycystic ovary syndrome: a randomized double-blind placebo-controlled trial
2025 · OCP-treated · Women aged 18–40 with PCOS, vitamin D3 deficiency (<20 ng/ml), and sexual dysfunction
7,143 IU90 days35
The effect of hormonal contraceptives combined with vitamin D3 supplements on sexual dysfunction in women with polycystic ovary syndrome: a randomized double-blind placebo-controlled trial
2025 · Placebo · Women aged 18–40 with PCOS, vitamin D3 deficiency (<20 ng/ml), and sexual dysfunction
7,143 IU90 days35
The Effect of Vitamin D Supplementation on Quality of Life in Stage II-III Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy: A Single-Blind, Randomized Controlled Trial
2024 · vitamin D · Adults with stage II–III colorectal cancer undergoing adjuvant chemotherapy; age and sex not specified
10,000 IU26 weeks34
A randomised controlled trial evaluating the impact of targeted vitamin D supplementation on endothelial function in type 2 diabetes mellitus: The DIMENSION trial
2016 · vitamin D group · Adults with type 2 diabetes and hypovitaminosis D; mean age 53.5 years, 52% male
4,000 IU16 weeks33
Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study
2012 · Group D · Patients with atopic dermatitis; age and sex not reported
1,600 IU60 days30
The effect of vitamin D on primary dysmenorrhea with vitamin D deficiency: a randomized double-blind controlled clinical trial
2016 · treatment group · Women with primary dysmenorrhea and vitamin D deficiency; age range not stated
7,143 IU8 weeks30
Androgens and hirsutism score of overweight women with polycystic ovary syndrome improved after vitamin D treatment: A randomized placebo controlled clinical trial
2021 · treatment group · Overweight Jordanian females aged 18–49 years with vitamin D deficiency and PCOS
7,143 IU12 weeks30
Significant improvement of facial actinic keratoses after blue light photodynamic therapy with oral vitamin D pretreatment: An interventional cohort-controlled trial
2022 · Group 2 (VDAK) · Adults aged 18 years or older, male and nonpregnant female patients with at least 10 actinic keratoses on the face or scalp
10,000 IU2 weeks29
Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial
2015 · simvastatin plus vitamin D · Adults aged 18 or older with episodic migraine for at least 3 years and at least 4 migraine days per month
2,000 IU24 weeks28
Effect of physical activity and vitamin D compared with vitamin D alone on muscle strength, back flexibility and aerobic activity in patients with chronic kidney disease: A comparative study from Pakistan
2021 · VDPA arm · Patients with CKD stage 2–4 and vitamin D deficiency (<20 ng/mL); age and sex not reported
4,000 IU90 days28
Online positive-oriented counseling, taking vitamin D3 tablet, online lifestyle modification training on premenstrual syndrome: a 3-armed randomized clinical trial
2023 · vitamin D3 tablet group · Women aged 20–40 with premenstrual syndrome and serum 25-hydroxyvitamin D3 below 30 ng/ml
7,143 IU6 weeks28
Effects of Vitamin D Supplementation on Central Hemodynamic Parameters and Autonomic Nervous System in Obese or Overweight Individuals
2024 · Vitamin D group (VD) · Adults aged 40–70, both sexes, with overweight or obesity (BMI 25.0–39.9 kg/m²) and serum 25(OH)D below 30 ng/mL
7,000 IU8 weeks28
Randomized study of the effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammation, and SIRT1 in obese women with mild to moderate depressive symptoms
2022 · vitamin D group · Obese women with mild to moderate depressive symptoms
7,143 IU8 weeks27
Vitamin D supplementation and exercise for improving physical function, body composition and metabolic health in overweight or obese older adults with vitamin D deficiency: a pilot randomized, double-blind, placebo-controlled trial
2023 · Vitamin D · Adults aged 50–80 years with vitamin D deficiency who were overweight or obese
4,000 IU24 weeks26
Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis: an open-label randomized controlled study
2016 · eldecalcitol group · Postmenopausal women, mean age 74 years, with osteoporosis treated with bisphosphonate
0.75 mcg26 weeks25
The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial
2024 · group 2: vitamin D supplementation (VitD) · Women aged 28–64 with newly diagnosed stage II or III breast cancer, before first chemotherapy treatment
7,143 IU9 weeks24
Baduanjin Exercise, With or Without Vitamin D, Outperforms Vitamin D Alone in Reducing Frailty Among Institutionalized Older Adults: A Cluster-Based Randomized Controlled Trial
2025 · Combined group · Adults aged 65 years or older living in long-term care facilities who could walk and perform activities independently; frailty was assessed, and vitamin D dosing was based on baseline levels and medical needs.
800 IU90 days24
Efficacy of ultraviolet B radiation versus vitamin D(3) on postural control and cognitive functions in relapsing-remitting multiple sclerosis: A randomized controlled study
2023 · vitamin D 3 group · Patients of both genders with relapsing-remitting multiple sclerosis (RRMS)
7,143 IU12 weeks23
Vitamin D(3) supplementation using an oral spray solution resolves deficiency but has no effect on VO(2) max in Gaelic footballers: results from a randomised, double-blind, placebo-controlled trial
2017 · Vitamin D (VD) group · Apparently healthy male and female Gaelic footballers over age 18
3,000 IU12 weeks22
Efficacy of oral cholecalciferol on rhododendrol-induced vitiligo: A blinded randomized clinical trial
2018 · vitamin D (VD)-intervention group · female patients with rhododendrol-induced vitiligo
5,000 IU150 days22
Effects of vitamin D supplementation on metabolic parameters, serum irisin and obesity values in women with subclinical hypothyroidism: a double-blind randomized controlled trial
2023 · vitamin D supplement group · Women aged 20–65 with subclinical hypothyroidism (TSH 5–10 µIU/mL), normal fT4, and BMI 25–37 kg/m²
7,143 IU12 weeks22
Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties
2013 · low dose group · Adults aged 18 or older with relapsing-remitting multiple sclerosis, low 25-OH-D, and flu-like symptoms during interferon-beta treatment
800 IU1 year21
Prevalence of vitamin D deficiency and the effect of vitamin D3 supplementation on response to anti-tuberculosis therapy in patients with extrapulmonary tuberculosis
2024 · Vitamin D group · Adults aged 18 years or older with vitamin D deficiency and extrapulmonary tuberculosis
7,143 IU1 year21
Comparison of Vitamin D Levels in Patients with and without Acne: A Case-Control Study Combined with a Randomized Controlled Trial
2016 · Vitamin D group · Patients with acne and vitamin D deficiency; age and sex range not specified
1,000 IU60 days20
Correcting Vitamin D Insufficiency Improves Some But Not All Aspects of Physical Performance During Winter Training in Taekwondo Athletes
2018 · vitamin D group · Collegiate male and female taekwondo athletes aged 19–22 years with low serum 25(OH)D concentration
5,000 IU4 weeks20
The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial
2022 · Group 3 (vitamin D: 10–30 ng/ml + vitamin D supplementation), subgroup with baseline 25(OH)D 20–30 ng/ml · Adults with diabetic macular edema and vitamin D insufficiency, baseline 25(OH)D 20–30 ng/ml
800 IU39 weeks20
High- vs. routine-dose vitamin D3 in severe lupus on pulse methylprednisolone: a randomized, double-blind, placebo-controlled clinical trial
2025 · routine-dose (RD) · Inpatients with severe systemic lupus erythematosus receiving intravenous pulse methylprednisolone; age and sex not stated
1,000 IU24 weeks20
Comparative evaluation of the effects of diclofenac sodium and vitamin D supplementation on symptoms in individuals with myofascial pain and vitamin D deficiency: a randomized controlled clinical trial
2025 · Group B · Adults aged 18–40 with myofascial pain, bruxism, and vitamin D deficiency (25(OH)D below 20)
10,000 IU8 weeks20
Impact of Vitamin D Supplementation on Gross Motor Development of Healthy Term Infants: A Randomized Dose-Response Trial
2016 · 400 IU group · Healthy, term, breastfed infants; ages at motor assessments were 3 and 6 months
400 IU—19
A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder
2019 · VID · Children aged 2.5–8 years with autism spectrum disorder
2,000 IU1 year19
The role of vitamin D in amelioration of oral lichen planus and its effect on salivary and tissue IFN-γ level: a randomized clinical trial
2024 · Group A · Middle-aged men and women with symptomatic oral lichen planus and vitamin D deficiency or insufficiency (serum vitamin D ≤30 ng/mL)
8,571 IU30 days19
Supplemental vitamin D and physical performance in COPD: a pilot randomized trial
2013 · vitamin D supplementation arm · Caucasian men with severe COPD, age 50 years or older; mean age 68 years
2,000 IU6 weeks18
Impact of Vitamin D Supplementation on Gross Motor Development of Healthy Term Infants: A Randomized Dose-Response Trial
2016 · 800 IU group · Healthy, term, breastfed infants; ages at motor assessments were 3 and 6 months
800 IU—18
Impact of Vitamin D Supplementation on Gross Motor Development of Healthy Term Infants: A Randomized Dose-Response Trial
2016 · 1,200 IU group · Healthy, term, breastfed infants; ages at motor assessments were 3 and 6 months
1,200 IU—18
Effect of physical activity and vitamin D compared with vitamin D alone on muscle strength, back flexibility and aerobic activity in patients with chronic kidney disease: A comparative study from Pakistan
2021 · VD arm · Patients with CKD stage 2–4 and vitamin D deficiency (<20 ng/mL); age and sex not reported
4,000 IU90 days18
Effectiveness of Vitamin D along with Splint therapy in the Vit D deficient patients with Temporomandibular disorder-A Randomized, double-blind, placebo-controlled clinical trial
2022 · Group S + D · Adults aged 18–45 with temporomandibular disorder and vitamin D levels below 30 ng/ml
8,571 IU8 weeks18
Baduanjin Exercise, With or Without Vitamin D, Outperforms Vitamin D Alone in Reducing Frailty Among Institutionalized Older Adults: A Cluster-Based Randomized Controlled Trial
2025 · Vitamin D group · Adults aged 65 years or older living in long-term care facilities who could walk and perform activities independently; frailty was assessed, and supplementation was adjusted according to baseline vitamin D levels and medical needs.
800 IU90 days17
Effect of vitamin D supplementation and isokinetic training on muscle strength, explosive strength, lean body mass and gait in severely burned children: A randomized controlled trial
2017 · VD group · Children aged 10–16 years with circumferential lower-extremity burns covering 40–55% of total body surface area
1,000 IU12 weeks15
Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study(‡)
2020 · vitamin D (VID) · Children aged 2.5–8 years with autism spectrum disorder
2,000 IU1 year15
Efficacy of Vitamin D Supplementation in Addition to Aerobic Exercise Training in Obese Women with Perceived Myalgia: A Single-Blinded Randomized Controlled Clinical Trial
2021 · Group A · Women aged 30–40 with class I obesity, vitamin D deficiency, and nonspecific muscle pain
7,143 IU12 weeks15
Efficacy of Vitamin D Supplementation in Addition to Aerobic Exercise Training in Obese Women with Perceived Myalgia: A Single-Blinded Randomized Controlled Clinical Trial
2021 · Group B · Women aged 30–40 with class I obesity, vitamin D deficiency, and nonspecific muscle pain
7,143 IU12 weeks15
The role of rehabilitation and vitamin D supplementation on motor and psychological outcomes in poststroke patients
2021 · experimental group (EG) · Adults with ischemic or hemorrhagic stroke 30–60 days before enrollment, undergoing intensive neurorehabilitation
2,000 IU12 weeks15
Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients
2024 · Group I · Female patients with systemic lupus erythematosus (SLE); age not reported
1,200 IU90 days15
Impact of vitamin D3 supplementation on motor functionality and the immune response in Parkinson's disease patients with vitamin D deficiency
2025 · VitD3 group · Adults aged 45–80 with Parkinson’s disease and low vitamin D; mean age 73.4 years; men and women
1,000 IU90 days15
Supplementary zinc and vitamin D in management of symptomatic oral lichen planus: a three-arm randomized clinical trial
2025 · Group III (TA + VIT D) · Adults with symptomatic atrophic, erosive, or bullous oral lichen planus; age and sex ranges not specified
400 IU8 weeks14
Effects of six months of vitamin D supplementation in patients with heart failure: a randomized double-blind controlled trial
2014 · cholecalciferol · Elderly patients with chronic heart failure and plasma vitamin D levels below 30 ng/mL; mean age 74 years
4,000 IU26 weeks13
Vitamin D₃ Supplementation Reduces the Symptoms of Upper Respiratory Tract Infection during Winter Training in Vitamin D-Insufficient Taekwondo Athletes: A Randomized Controlled Trial
2018 · vitamin D group · Male collegiate taekwondo athletes aged 19–22 with vitamin D insufficiency
5,000 IU4 weeks13
Effect of vitamin D supplementation on microvascular reactivity in obese adolescents: A randomized controlled trial
2021 · fruit juice with vitamin D · obese adolescents
4,000 IU90 days13
Vitamin D Supplementation on Carotid Remodeling and Stiffness in Obese Adolescents
2022 · OS (with vitamin D supplementation) · Adolescents aged 12–17 with severe obesity
4,000 IU90 days13
Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis
2011 · group D · Patients with atopic dermatitis; age and sex not specified
1,600 IU60 days12
Insulin-sensitizing effects of vitamin D repletion mediated by adipocyte vitamin D receptor: Studies in humans and mice
2020 · vitamin D group · Overweight or obese adults with insulin resistance and vitamin D deficiency; age range and sex not specified
5,444 IU26 weeks11
Oral vitamin D versus acitretin in congenital non-syndromic ichthyosis: double blinded, randomized controlled trial
2022 · group A · Patients with congenital non-syndromic ichthyosis; age and sex not specified
2,000 IU24 weeks11
Serum and gene expression profile of cytokines following combination of yoga training and vitamin D supplementation in breast cancer survivors: a randomized controlled trial
2022 · HVD · Breast cancer survivors aged 47.90 ± 7.95 years on average, with stage 0 to IIA disease
4,000 IU12 weeks10
Serum and gene expression profile of cytokines following combination of yoga training and vitamin D supplementation in breast cancer survivors: a randomized controlled trial
2022 · Y-HVD · Breast cancer survivors aged 47.90 ± 7.95 years on average, with stage 0 to IIA disease
4,000 IU12 weeks10
Serum and gene expression profile of cytokines following combination of yoga training and vitamin D supplementation in breast cancer survivors: a randomized controlled trial
2022 · Y-LVD · Breast cancer survivors aged 47.90 ± 7.95 years on average, with stage 0 to IIA disease
2,000 IU12 weeks10
Effect of Vitamin D Supplementation on Obesity-Induced Insulin Resistance: A Double-Blind, Randomized, Placebo-Controlled Trial
2018 · vitamin D group · Men and women aged 18–70 years with obesity (BMI ≥30 kg/m²) and vitamin D deficiency, enrolled in a weight-loss program
3,571 IU90 days9
The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial
2022 · Group 3 (vitamin D: 10–30 ng/ml + vitamin D supplementation), subgroup with baseline 25(OH)D 10–20 ng/ml · Adults with diabetic macular edema and vitamin D levels of 10–20 ng/ml
7,143 IU8 weeks8
Maturation of primary and permanent teeth in preterm infants
2000 · 500 IU/day vitamin D; unsupplemented breast milk · Preterm infants
500 IU——
Maturation of primary and permanent teeth in preterm infants
2000 · 1000 IU/day vitamin D; unsupplemented breast milk · Preterm infants
1,000 IU——
Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial
2006 · Low-dose vitamin D · Girls aged 10–17 years; vitamin D deficiency status and other conditions not specified
200 IU1 year—
Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial
2006 · High-dose vitamin D · Girls aged 10–17 years; vitamin D deficiency status and other conditions not specified
2,000 IU1 year—
An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment
2007 · calcitriol · Women aged 65–77 years; generally healthy, ambulatory older women
0.5 mcg3 years—
An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment
2007 · calcitriol + ET/HT · Women aged 65–77 years; generally healthy, ambulatory older women
0.5 mcg3 years—
Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial
2008 · 20,000 IU vitamin D per week · Overweight and obese adults aged 21–70 years, both sexes
2,857 IU1 year—
Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial
2008 · 40,000 IU vitamin D per week · Overweight and obese adults aged 21–70 years, both sexes
5,714 IU1 year—
Vitamin C provision improves mood in acutely hospitalized patients
2011 · Vitamin D · Acutely hospitalized patients with hypovitaminosis D
2,000 IU——
Changes in balance, functional performance and fall risk following whole body vibration training and vitamin D supplementation in institutionalized elderly women. A 6 month randomized controlled trial
2011 · WBV training with conventional-dose vitamin D · Institutionalized women, mean age 79.6 years
880 IU26 weeks—
Changes in balance, functional performance and fall risk following whole body vibration training and vitamin D supplementation in institutionalized elderly women. A 6 month randomized controlled trial
2011 · WBV training with high-dose vitamin D · Institutionalized women, mean age 79.6 years
1,600 IU26 weeks—
Changes in balance, functional performance and fall risk following whole body vibration training and vitamin D supplementation in institutionalized elderly women. A 6 month randomized controlled trial
2011 · No-training group with conventional-dose vitamin D · Institutionalized women, mean age 79.6 years
880 IU26 weeks—
Changes in balance, functional performance and fall risk following whole body vibration training and vitamin D supplementation in institutionalized elderly women. A 6 month randomized controlled trial
2011 · No-training group with high-dose vitamin D · Institutionalized women, mean age 79.6 years
1,600 IU26 weeks—
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial
2011 · Stratum A high-dose vitamin D2 group · Women with early breast cancer and aromatase inhibitor-induced musculoskeletal symptoms, receiving adjuvant anastrozole, with baseline 25-hydroxy vitamin D of 20–29 ng/ml
7,143 IU26 weeks—
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial
2011 · Stratum B high-dose vitamin D2 group · Women with early breast cancer and aromatase inhibitor-induced musculoskeletal symptoms, receiving adjuvant anastrozole, with baseline 25-hydroxy vitamin D of 10–19 ng/ml
7,143 IU26 weeks—
Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial
2011 · Vitamin D group · Adults at high risk of type 2 diabetes; mean age 57 years
2,000 IU16 weeks—
Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality
2011 · Vitamin D · Women aged 50–60 years who refused hormonal therapy; postmenopausal women with climacteric symptoms
400 IU1 year—
Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder
2013 · vitamin D3 plus fluoxetine · Patients with major depressive disorder diagnosed using DSM-IV criteria; age and sex not reported
1,500 IU8 weeks—
Vitamin D supplementation for nonspecific musculoskeletal pain in non-Western immigrants: a randomized controlled trial
2012 · Vitamin D group (baseline allocation) · Vitamin D-deficient non-Western immigrants with nonspecific persistent musculoskeletal pain
150,000 IU6 weeks—
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease
2012 · paricalcitol group · Adults with chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved ejection fraction
2 mcg48 weeks—
The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial
2013 · oral cholecalciferol 2000 IU/day · Patients with systemic lupus erythematosus; age and sex not reported
2,000 IU1 year—
Anti-inflammatory effect of vitamin D on gingivitis: a dose-response randomised control trial
2013 · Group A · People with gingivitis; age and sex not reported
2,000 IU90 days—
Anti-inflammatory effect of vitamin D on gingivitis: a dose-response randomised control trial
2013 · Group B · People with gingivitis; age and sex not reported
1,000 IU90 days—
Anti-inflammatory effect of vitamin D on gingivitis: a dose-response randomised control trial
2013 · Group C · People with gingivitis; age and sex not reported
500 IU90 days—
Effects of vitamin C and vitamin D administration on mood and distress in acutely hospitalized patients
2013 · high-dose vitamin D · Acutely hospitalized patients with a high prevalence of hypovitaminosis C and D
5,000 IU8 days—
Maternal vitamin D3 supplementation during the third trimester of pregnancy: effects on infant growth in a longitudinal follow-up study in Bangladesh
2013 · maternal vitamin D3 · Pregnant women in Bangladesh receiving supplementation during the third trimester; age and specific condition not stated
5,000 IU——
Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial
2013 · vitamin D(3) · Adults aged 45–75 in good health, with a history of colorectal adenoma and serum 25-hydroxyvitamin D ≥12 ng/mL
1,000 IU——
Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: a randomized study
2014 · High-dose vitamin D3 group · People with chronic urticaria; age and sex not specified
4,000 IU12 weeks—
Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: a randomized study
2014 · Low-dose vitamin D3 group · People with chronic urticaria; age and sex not specified
600 IU12 weeks—
Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial
2014 · weight loss + 2000 IU oral vitamin D3/d · Overweight or obese postmenopausal women aged 50–75 years with serum 25(OH)D ≥10 ng/mL but <32 ng/mL
2,000 IU1 year—
Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children
2014 · oral cholecalciferol · Mongolian children aged 2–17 years with winter-related atopic dermatitis
1,000 IU30 days—
Effects of Calcium Plus Vitamin D Supplementation on Anthropometric Measurements and Blood Pressure in Vitamin D Insufficient People with Type 2 Diabetes: A Randomized Controlled Clinical Trial
2015 · 50,000 IU/wk vitamin D3 plus calcium placebo · People with type 2 diabetes and vitamin D insufficiency
7,143 IU8 weeks—
A randomized double-blind placebo-controlled study adding high dose vitamin D to analgesic regimens in patients with musculoskeletal pain
2015 · vitamin D group · patients with musculoskeletal pain; age and sex not reported
4,000 IU90 days—
A systems-based investigation into vitamin D and skeletal muscle repair, regeneration, and hypertrophy
2015 · vitamin D3 · males with insufficient serum 25(OH)D
4,000 IU6 weeks—
Acute Effects of Vitamin D3 Supplementation on Muscle Strength in Judoka Athletes: A Randomized Placebo-Controlled, Double-Blind Trial
2016 · treatment · adult male white national-level judoka athletes involved in full-time training; described as vitamin D insufficient
150,000 IU8 days—
The Effects of Oral Vitamin D Supplement on Atopic Dermatitis: A Clinical Trial with Staphylococcus aureus Colonization Determination
2015 · Vitamin D group · Patients with atopic dermatitis
2,000 IU4 weeks—
The clinical effect of vitamin D supplementation combined with grass-specific sublingual immunotherapy in children with allergic rhinitis
2016 · vitamin D group · Children aged 5–12 years with grass-pollen sensitivity and allergic rhinitis; some had concomitant asthma
1,000 IU152 days—
Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Increase Muscle Strength and Function in Frail Elderly Adults in a Randomized Controlled Trial
2016 · LD + MCT · Frail elderly nursing home residents; mean age 86.6 years; 11 men and 27 women enrolled across the study
20 mcg90 days—
Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Increase Muscle Strength and Function in Frail Elderly Adults in a Randomized Controlled Trial
2016 · LD + LCT · Frail elderly nursing home residents; mean age 86.6 years; 11 men and 27 women enrolled across the study
20 mcg90 days—
Effect of Lactobacillus rhamnosus GG and vitamin D supplementation on the immunologic effectiveness of grass-specific sublingual immunotherapy in children with allergy
2016 · SLIT-vitamin D group · Children aged 5–12 years with grass-pollen sensitivity and allergic rhinitis
1,000 IU150 days—
Three doses of vitamin D, bone mineral density, and geometry in older women during modest weight control in a 1-year randomized controlled trial
2017 · 600 IU group · Postmenopausal women, mean age 58 ± 6 years, with overweight or obesity, undergoing weight control
600 IU1 year—
Three doses of vitamin D, bone mineral density, and geometry in older women during modest weight control in a 1-year randomized controlled trial
2017 · 2000 IU group · Postmenopausal women, mean age 58 ± 6 years, with overweight or obesity, undergoing weight control
2,000 IU1 year—
Three doses of vitamin D, bone mineral density, and geometry in older women during modest weight control in a 1-year randomized controlled trial
2017 · 4000 IU group · Postmenopausal women, mean age 58 ± 6 years, with overweight or obesity, undergoing weight control
4,000 IU1 year—
High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial
2016 · vitamin D group · people with relapsing-remitting multiple sclerosis (RRMS)
10,000 IU90 days—
Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial
2018 · Vitamin D group · Children aged 5–12 years with ADHD
2,000 IU8 weeks—
Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Benefit Cognition in Frail Elderly Adults: A Randomized Controlled Trial
2017 · LD+MCT · Frail elderly nursing-home residents; mean age 86.6 years; sex not stated
20 mcg90 days—
Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Benefit Cognition in Frail Elderly Adults: A Randomized Controlled Trial
2017 · LD+LCT · Frail elderly nursing-home residents; mean age 86.6 years; sex not stated
20 mcg90 days—
Winter vitamin D(3) supplementation does not increase muscle strength, but modulates the IGF-axis in young children
2019 · 10 µg/day vitamin D3 · Healthy children aged 4–8 years
10 mcg20 weeks—
Effect of vitamin D and omega-3 on nocturnal enuresis of 7-15-year-old children
2018 · Group A · Children aged 7–15 with nocturnal enuresis
1,000 IU60 days—
Effect of vitamin D treatment in children with attention-deficit hyperactivity disorder
2019 · vitamin D group · Children aged 2–18 years with ADHD
7,143 IU6 weeks—
Changes in Dietary Intake and Adherence to the NU-AGE Diet Following a One-Year Dietary Intervention among European Older Adults-Results of the NU-AGE Randomized Trial
2018 · NU-AGE diet group · apparently healthy men and women aged 65–80 years
10 mcg1 year—
Effects of vitamin D supplementation on cognitive function and blood Aβ-related biomarkers in older adults with Alzheimer's disease: a randomised, double-blind, placebo-controlled trial
2019 · vitamin D group · Older adults with Alzheimer's disease
800 IU1 year—
Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial
2019 · vitamin D3 group · Adults at high risk of diabetes or with newly diagnosed type 2 diabetes
5,000 IU26 weeks—
Oral Nano Vitamin D Supplementation Reduces Disease Activity in Ulcerative Colitis: A Double-Blind Randomized Parallel Group Placebo-controlled Trial
2019 · oral nano vitamin D · Patients with active ulcerative colitis and vitamin D <40 ng/mL
60,000 IU8 days—
Effects of zinc, vitamin D, and their co-supplementation on mood, serum cortisol, and brain-derived neurotrophic factor in patients with obesity and mild to moderate depressive symptoms: A phase II, 12-wk, 2 × 2 factorial design, double-blind, randomized, placebo-controlled trial
2020 · Vitamin D group · Overweight or obese adults with depressive symptoms and BDI-II score ≥10; mean age 38.35 years
2,000 IU12 weeks—
Effect of High-Dose vs Standard-Dose Vitamin D Supplementation in Pregnancy on Bone Mineralization in Offspring Until Age 6 Years: A Prespecified Secondary Analysis of a Double-Blinded, Randomized Clinical Trial
2020 · High-dose vitamin D · Pregnant women; offspring were followed through age 6 years
2,800 IU——
Effect of High-Dose vs Standard-Dose Vitamin D Supplementation in Pregnancy on Bone Mineralization in Offspring Until Age 6 Years: A Prespecified Secondary Analysis of a Double-Blinded, Randomized Clinical Trial
2020 · Standard-dose vitamin D · Pregnant women; offspring were followed through age 6 years
400 IU——
Effect of eldecalcitol on muscle function and fall prevention in Japanese postmenopausal women: A randomized controlled trial
2021 · Eldecalcitol group · Japanese postmenopausal women with osteoporosis
0.75 mcg24 weeks—
Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 - A Randomized Clinical Trial
2020 · intervention group · Adults aged 18–65 with diarrhea-predominant irritable bowel syndrome and vitamin D deficiency and/or insufficiency
7,143 IU9 weeks—
Vitamin D Supplementation Improves Health-Related Quality of Life and Physical Performance in Children with Sickle Cell Disease and in Healthy Children
2020 · HbSS, 4000 IU/day · African American children aged 5–20 years with HbSS sickle cell disease
4,000 IU12 weeks—
Vitamin D Supplementation Improves Health-Related Quality of Life and Physical Performance in Children with Sickle Cell Disease and in Healthy Children
2020 · HbSS, 7000 IU/day · African American children aged 5–20 years with HbSS sickle cell disease
7,000 IU12 weeks—
Vitamin D Supplementation Improves Health-Related Quality of Life and Physical Performance in Children with Sickle Cell Disease and in Healthy Children
2020 · Healthy, 4000 IU/day · Healthy African American children aged 5–20 years without HbSS
4,000 IU12 weeks—
Vitamin D Supplementation Improves Health-Related Quality of Life and Physical Performance in Children with Sickle Cell Disease and in Healthy Children
2020 · Healthy, 7000 IU/day · Healthy African American children aged 5–20 years without HbSS
7,000 IU12 weeks—
The effect of multistrain synbiotic and vitamin D3 supplements on the severity of atopic dermatitis among infants under 1 year of age: a double-blind, randomized clinical trial study
2022 · Vitamin D3 group · Infants under 1 year of age with atopic dermatitis
1,000 IU60 days—
Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis
2020 · ELD group · Women aged 65 or over with osteoporosis
0.75 mcg24 weeks—
The effect of vitamin D add-on therapy on the improvement of quality of life and clinical symptoms of patients with chronic spontaneous urticaria
2023 · low (group 1) · Adults with chronic spontaneous urticaria; age range and sex not specified
600 IU12 weeks—
The effect of vitamin D add-on therapy on the improvement of quality of life and clinical symptoms of patients with chronic spontaneous urticaria
2023 · high (group 2) · Adults with chronic spontaneous urticaria; age range and sex not specified
4,000 IU12 weeks—
The Effects of 6-Month Vitamin D Supplementation during the Non-Surgical Treatment of Periodontitis in Vitamin-D-Deficient Patients: A Randomized Double-Blind Placebo-Controlled Study
2020 · Vitamin D group · Adults aged 30 years or older with generalized chronic periodontitis and serum 25(OH)D below 30 ng/mL
3,571 IU26 weeks—
Vitamin D in Children With Inflammatory Bowel Disease: A Randomized Controlled Clinical Trial
2021 · Vitamin D group · Children with inflammatory bowel disease and hypovitaminosis D
2,000 IU26 weeks—
Intake of 25-Hydroxyvitamin D(3) May Reduce the Severity of Upper Respiratory Tract Infection: Post hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study
2020 · 25OHD group · Japanese men and women with insufficient or deficient blood 25-hydroxyvitamin D levels (≤75 nmol/L)
10 mcg——
Vitamin D Supplementation Improves the Effects of the Rehabilitation Program on Balance and Pressure Distribution in Patients after Anterior Cervical Interbody Fusion-Randomized Control Trial
2020 · vitamin D supplemented (D3) group · Adults aged 31–68 with cervical spinal stenosis or degenerative disc disease undergoing anterior cervical interbody fusion
3,200 IU5 weeks—
Daily intake of yogurt drink fortified either with vitamin D alone or in combination with added calcium causes a thyroid-independent increase of resting metabolic rate in adults with type 2 diabetes: a randomized, double-blind, clinical trial
2021 · D-fortified yogurt drink (DY) · Adults with type 2 diabetes
1,000 IU12 weeks—
Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial
2021 · 5000 IU group · Adults aged 20–75 with mild to moderate, RT-PCR-confirmed COVID-19 and sub-optimal vitamin D status
5,000 IU2 weeks—
Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial
2021 · 1000 IU group · Adults aged 20–75 with mild to moderate, RT-PCR-confirmed COVID-19 and sub-optimal vitamin D status
1,000 IU2 weeks—
Vitamin D3 Supplementation Effects on Spermatogram and Oxidative Stress Biomarkers in Asthenozoospermia Infertile Men: a Randomized, Triple-Blind, Placebo-Controlled Clinical Trial
2022 · Group A · Men with asthenozoospermia, infertility, and serum 25-OH-D3 <30 ng/ml
4,000 IU90 days—
Vitamin D supplementation and gross motor development: A 3-year follow-up of a randomized trial
2022 · 400 IU/day (standard-of-care) · Healthy infants receiving supplementation from 1 to 12 months of age
400 IU330 days—
Vitamin D supplementation and gross motor development: A 3-year follow-up of a randomized trial
2022 · 800 IU/day · Healthy infants receiving supplementation from 1 to 12 months of age
800 IU330 days—
Vitamin D supplementation and gross motor development: A 3-year follow-up of a randomized trial
2022 · 1200 IU/day · Healthy infants receiving supplementation from 1 to 12 months of age
1,200 IU330 days—
Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial
2023 · vitamin D plus placebo · Men aged 50 and older without clinically apparent cardiovascular disease or cancer; this analysis excluded men with multiple sclerosis or Parkinson’s disease at baseline
2,000 IU1935 days—
A randomized controlled trial of Vitamin D supplementation in Iranian patients with schizophrenia: Effects on serum levels of glycogen synthase kinase-3β and symptom severity
2023 · vitamin D treatment group · adult men with chronic schizophrenia and vitamin D deficiency (≤20 ng/mL)
2,000 IU8 weeks—
Vitamin D and Child Neurodevelopment-A Post Hoc Analysis
2023 · 400 IU/day vitamin D3 group · Pregnant women with singleton pregnancies and no preexisting chronic diseases; good general health; recruited at 12–16 weeks of gestation
400 IU——
Vitamin D and Child Neurodevelopment-A Post Hoc Analysis
2023 · 2000 IU/day vitamin D3 group · Pregnant women with singleton pregnancies and no preexisting chronic diseases; good general health; recruited at 12–16 weeks of gestation
2,000 IU——
Vitamin D and Child Neurodevelopment-A Post Hoc Analysis
2023 · 4000 IU/day vitamin D3 group · Pregnant women with singleton pregnancies and no preexisting chronic diseases; good general health; recruited at 12–16 weeks of gestation
4,000 IU——
Effect of vitamin D supplementation on symptoms severity in vitamin D insufficient women with premenstrual syndrome: A randomized controlled trial
2024 · vitamin D group · Vitamin D-insufficient women with premenstrual syndrome; age range not reported
3,571 IU16 weeks—
Effect of Calcium and Vitamin D Supplementation (Dairy vs. Pharmacological) on Bone Health of Underprivileged Indian Children and Youth with Type-1 Diabetes: A Randomized Controlled Trial
2024 · Milk (group A) · Underprivileged Indian children and youth aged 5–23 years with type-1 diabetes mellitus; both sexes
1,000 IU1 year—
Effect of dairy products fortified with vitamin d(3) on restless legs syndrome in women with premenstrual syndrome, abdominal obesity and vitamin d deficiency: a pilot study
2024 · Fortified low-fat milk · Women aged 30–50 with premenstrual syndrome, abdominal obesity and vitamin D deficiency
1,500 IU10 weeks—
Effect of dairy products fortified with vitamin d(3) on restless legs syndrome in women with premenstrual syndrome, abdominal obesity and vitamin d deficiency: a pilot study
2024 · Fortified low-fat yogurt · Women aged 30–50 with premenstrual syndrome, abdominal obesity and vitamin D deficiency
1,500 IU10 weeks—
Weekly Vitamin D Supplementation to Prevent Acute Respiratory Infections in Young Children at Different Latitudes: A Randomized Controlled Trial
2024 · low-dose · Children aged 1.5–3.5 years without a stated condition
800 IU26 weeks—
Weekly Vitamin D Supplementation to Prevent Acute Respiratory Infections in Young Children at Different Latitudes: A Randomized Controlled Trial
2024 · high-dose · Children aged 1.5–3.5 years without a stated condition
1,600 IU26 weeks—
Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial
2025 · Vitamin D3, without omega-3s · Generally healthy, community-dwelling adults aged 70 years or older; men and women
2,000 IU3 years—
Rickets in very-low-birth-weight infants born at Baragwanath Hospital
1994 · Breast-milk only · Very-low-birth-weight neonates weighing less than 1,200 g at birth
800 IU18 weeks—
No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects
1997 · calcitriol · healthy male subjects; age not reported
1.5 mcg7 days—
Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60
2000 · 25OH vitamin D3 · Men and women over age 60; elderly volunteers
15 mcg4 years—
Effects of vitamin D and high dairy protein intake on bone mineralization and linear growth in 6- to 8-year-old children: the D-pro randomized trial
2021 · Vitamin D3 plus high-protein yogurt · Healthy Danish children aged 6–8 years with light skin
20 mcg24 weeks—
Effects of vitamin D and high dairy protein intake on bone mineralization and linear growth in 6- to 8-year-old children: the D-pro randomized trial
2021 · Vitamin D3 plus normal-protein yogurt · Healthy Danish children aged 6–8 years with light skin
20 mcg24 weeks—
Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study
2023 · intervention group · Adults aged 18 years or older hospitalized with PCR-confirmed COVID-19 who required more than 48 hours of admission
0.75 mcg—78
The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial
2020 · Study group · Women undergoing ICSI
50 mcg26 weeks50
Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial
2018 · TMN · Adults aged 50 years or older with moderate-to-severe COPD and pre-cachexia or cachexia
20 mcg12 weeks22
Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren
2003 · multimicronutrient supplementation · Schoolchildren in Nyanza Province, Kenya; age and sex not specified
5 mcg335 days—
Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal
2003 · Multiple micronutrients · Pregnant women in rural Nepal
10 mcg——
Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial
2016 · 4400 IU/d vitamin D group · Pregnant women aged 18–39 years, 10–18 weeks’ gestation, with a personal or partner history of asthma, eczema, or allergic rhinitis
4,400 IU—440
Daily adjunctive therapy with vitamin D(3) and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia
2018 · vitamin D3 + PBA · HIV-negative adults over 18 with newly diagnosed pulmonary tuberculosis
5,000 IU16 weeks175
Effects of Enhanced Exercise and Combined Vitamin D and Calcium Supplementation on Muscle Strength and Fracture Risk in Postmenopausal Chinese Women
2017 · group D · Postmenopausal women at high risk of osteoporosis
0.25 mcg2 years131
An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial
2016 · Active · Adults aged 65 years or older who had undergone hip fracture surgery; men and women with a recent surgically repaired hip fracture
800 IU26 weeks111
Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial
2025 · vitamin K2/D3 arm · Adults aged 18 years or older with at least two moderate-intensity long COVID symptoms persisting for at least three months after COVID-19 infection
2,000 IU24 weeks98
Role of Lactobacillus rhamnosus (FloraActive™) 19070-2 and Lactobacillus reuteri (FloraActive™) 12246 in Infant Colic: A Randomized Dietary Study
2018 · probiotic group · Exclusively breastfed infants aged 4–12 weeks with infant colic
5 mcg4 weeks86
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
2016 · denosumab 60 mg Q6M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate
400 IU1 year85
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
2016 · denosumab 60 mg Q2M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate
400 IU1 year85
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
2016 · denosumab 60 mg Q3M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate
400 IU1 year82
Vitamin D Attenuates Left Atrial Volume Changes in African American Males with Obesity and Prediabetes
2016 · vitamin D group · African American male veterans aged 35–85 with obesity, prediabetes and vitamin D deficiency
7,143 IU1 year81
Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial
2017 · Placebo arm · Women with stage I–III breast cancer starting adjuvant letrozole, with 25(OH)D level ≤40 ng/ml; median age 61
600 IU24 weeks80
Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial
2017 · Vitamin D3 arm · Women with stage I–III breast cancer starting adjuvant letrozole, with 25(OH)D level ≤40 ng/ml; median age 61
4,886 IU24 weeks80
Improving rehabilitation in sarcopenia: a randomized-controlled trial utilizing a muscle-targeted food for special medical purposes
2020 · Experimental formula · Adults aged 65 years or older with sarcopenia admitted for inpatient rehabilitation
1,600 IU8 weeks70
High-intensity aquatic exercises (HydrOS) improve physical function and reduce falls among postmenopausal women
2013 · aquatic exercise group (AEG) · Postmenopausal women, mean age 58.8 years
1,000 IU24 weeks64
Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial
2011 · Vitamin D group · Patients with treatment-naive early rheumatoid arthritis
500 IU90 days59
Effects of vitamin D and/or calcium intervention on sleep quality in individuals with prediabetes: a post hoc analysis of a randomized controlled trial
2024 · vitamin D + calcium group · Chinese individuals with prediabetes; age and sex not specified
1,600 IU24 weeks53
Combination of alfacalcidol and calcium improved handgrip strength and mobility among Indonesian older women: A randomized controlled trial
2018 · Alfacalcidol group · Indonesian older women with handgrip strength ≤22 kg
0.5 mcg90 days47
Vitamin D(3) supplementation does not enhance the effects of resistance training in older adults
2021 · Vitamin D3 arm · Men and women aged 56–77 years, older adults with normal lung function or moderate COPD; some had indications of sarcopenia
12,000 IU25 weeks46
Vitamin D in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After COVID-19 or Vaccination: A Randomized Controlled Trial
2026 · Intervention group · Adults aged 18 years or older with ME/CFS following COVID-19 infection or vaccination and vitamin D insufficiency or deficiency
26 mcg24 weeks46
High-intensity aquatic exercises (HydrOS) improve physical function and reduce falls among postmenopausal women
2013 · control group (CG) · Postmenopausal women, mean age 58.8 years
1,000 IU24 weeks44
A Nutritionally Complete Oral Nutritional Supplement Powder Improved Nutritional Outcomes in Free-Living Adults at Risk of Malnutrition: A Randomized Controlled Trial
2022 · nutrition supplement (intervention group) · Chinese men and women aged 18 years or older, all classified as at risk of malnutrition; mean age 66.5 years, range 41–89
8 mcg12 weeks44
Effect of vitamin D(3) and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV
2020 · Low VitD group · Postmenopausal African American or Hispanic women aged 40–70 living with HIV, with serum 25-OHD of 10–32 ng/ml and stable antiretroviral therapy
1,000 IU1 year41
Effect of vitamin D(3) and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV
2020 · Moderate VitD group · Postmenopausal African American or Hispanic women aged 40–70 living with HIV, with serum 25-OHD of 10–32 ng/ml and stable antiretroviral therapy
3,000 IU1 year41
[Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women]
2010 · Group B · Perimenopausal or postmenopausal women with low bone mineral density or osteoporosis
0.5 mcg48 weeks40
Changes in body composition following a dietary and lifestyle intervention trial: the postmenopausal health study
2009 · dietary intervention group (DG) · Healthy postmenopausal women
7.5 mcg1 year39
[Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women]
2010 · Group A · Perimenopausal or postmenopausal women with low bone mineral density or osteoporosis
0.5 mcg48 weeks36
Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial
2014 · combined calcium and vitamin D treatment · Multi-ethnic men and women aged 18 years or older, vitamin D-deficient and at risk of type 2 diabetes; BMI 25–40 kg/m²
2,000 IU26 weeks35
Co-administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double-blinded randomized controlled trial
2024 · Probiotic group · Adults aged 18–65 with schizophrenia
400 IU12 weeks35
[Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women]
2010 · Group C · Perimenopausal or postmenopausal women with low bone mineral density or osteoporosis
0.5 mcg48 weeks33
A Novel Fortified Dairy Product and Sarcopenia Measures in Sarcopenic Older Adults: A Double-Blind Randomized Controlled Trial
2021 · intervention group · Community-recruited older adults with sarcopenia
1,000 IU12 weeks33
The effect of vitamin D and magnesium supplementation on the mental health status of attention-deficit hyperactive children: a randomized controlled trial
2021 · Intervention group · Children aged 6–12 years with ADHD and low serum 25-hydroxyvitamin D and magnesium levels
7,143 IU8 weeks33
A randomized controlled trial of high dose vitamin D3 in patients with heart failure
2013 · Vitamin D3 group · Adults aged 50 years or older with heart failure (NYHA class II–IV) and serum 25OHD ≤37.5 ng/ml
7,143 IU26 weeks32
Effects of progesterone and vitamin D on outcome of patients with acute traumatic spinal cord injury; a randomized, double-blind, placebo controlled study
2016 · progesterone and vitamin D · Adults with acute traumatic spinal cord injury
0.01 mg/kg5 days32
Calcium Plus Vitamin D Supplementation During the Third Trimester of Pregnancy in Adolescents Accustomed to Low Calcium Diets Does Not Affect Infant Bone Mass at Early Lactation in a Randomized Controlled Trial
2015 · calcium plus vitamin D supplementation · Brazilian adolescent mothers consuming low-calcium diets, from 26 weeks of gestation until parturition
200 IU—30
Long-term Effects of Calcium β-Hydroxy-β-Methylbutyrate and Vitamin D3 Supplementation on Muscular Function in Older Adults With and Without Resistance Training: A Randomized, Double-blind, Controlled Study
2020 · HMB+D + exercise · Men and women aged 60 years or older with insufficient, but not clinically deficient, 25-hydroxyvitamin D levels (15–30 ng/mL)
2,000 IU1 year30
The Effect of Branched Chain Amino Acids-Enriched Nutritional Supplements on Activities of Daily Living and Muscle Mass in Inpatients with Gait Impairments: A Randomized Controlled Trial
2019 · RJ group · Adult inpatients aged 20 years or older with gait impairments admitted to acute and convalescent rehabilitation wards
40 mcg58 days29
Long-term Effects of Calcium β-Hydroxy-β-Methylbutyrate and Vitamin D3 Supplementation on Muscular Function in Older Adults With and Without Resistance Training: A Randomized, Double-blind, Controlled Study
2020 · HMB+D + no exercise · Men and women aged 60 years or older with insufficient, but not clinically deficient, 25-hydroxyvitamin D levels (15–30 ng/mL)
2,000 IU1 year27
Randomized study of the effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammation, and SIRT1 in obese women with mild to moderate depressive symptoms
2022 · co-supplementation group · Obese women with mild to moderate depressive symptoms
7,143 IU8 weeks27
Calcium plus vitamin D3 supplementation facilitated fat loss in overweight and obese college students with very-low calcium consumption: a randomized controlled trial
2013 · calcium+D group · Generally healthy overweight or obese college students aged 18–25 years with daily calcium intake below 600 mg; predominantly female
125 IU12 weeks26
The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial
2024 · group 3: both omega-3 and vitamin D supplementation (ω3+VitD) · Women aged 28–64 with newly diagnosed stage II or III breast cancer, before first chemotherapy treatment
7,143 IU9 weeks24
The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study
2009 · Group 1 · Infertile women with polycystic ovary syndrome (PCOS); age not stated
400 IU90 days20
The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study
2009 · Group 2 · Infertile women with polycystic ovary syndrome (PCOS); age not stated
400 IU90 days20
Effects of Vitamin D and Calcium Fortified Yogurts on Gait, Cognitive Performances, and Serum 25-Hydroxyvitamin D Concentrations in Older Community-Dwelling Females: Results from the GAit, MEmory, Dietary and Vitamin D (GAME-D2) Randomized Controlled Trial
2019 · intervention group (fortified yogurt) · Females aged 65 years or older with hypovitaminosis D (serum 25OHD <75 nmol/L), living independently at home or in an autonomous residence
400 IU90 days20
The acute effects of milk intake on calcium homeostasis and cardiovascular outcome: A randomized crossover trial in postmenopausal women
2022 · 500 ml semi-skimmed milk with added cholecalciferol · Postmenopausal women aged 60–80 years with vitamin D insufficiency at screening
200 mcg1 day20
High- vs. routine-dose vitamin D3 in severe lupus on pulse methylprednisolone: a randomized, double-blind, placebo-controlled clinical trial
2025 · high-dose (HD) · Inpatients with severe systemic lupus erythematosus receiving intravenous pulse methylprednisolone; age and sex not stated
1,000 IU24 weeks20
Falls and physical function in older patients with Benign Paroxysmal Positional Vertigo (BPPV): findings from a placebo controlled, double blinded randomized control trial (RCT) investigating efficacy of vitamin D treatment in lowering the recurrence rate of BPPV
2025 · Group A · Adults aged 50 years or older with idiopathic BPPV and depleted baseline vitamin D
3,000 IU26 weeks19
Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial
2021 · Group B (vitamin D supplementation group) · Adults aged 20 years or older with decompensated cirrhosis, receiving oral branched-chain amino acid preparations for at least 6 months; serum 25(OH)D below 30 ng/mL
2,000 IU1 year16
A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder
2019 · VIDOM · Children aged 2.5–8 years with autism spectrum disorder
2,000 IU1 year15
Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study(‡)
2020 · vitamin D and omega-3 LCPUFA (VIDOM) · Children aged 2.5–8 years with autism spectrum disorder
2,000 IU1 year15
Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients
2024 · Group III · Female patients with systemic lupus erythematosus (SLE); age not reported
1,200 IU90 days15
Muscle-Related Effect of Whey Protein and Vitamin D(3) Supplementation Provided before or after Bedtime in Males Undergoing Resistance Training
2022 · before bedtime (BB) · Males aged 18–24 years with vitamin D deficiency, healthy and untrained, undergoing resistance training
4,000 IU6 weeks14
Muscle-Related Effect of Whey Protein and Vitamin D(3) Supplementation Provided before or after Bedtime in Males Undergoing Resistance Training
2022 · after sleeping (AS) · Males aged 18–24 years with vitamin D deficiency, healthy and untrained, undergoing resistance training
4,000 IU6 weeks14
Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis
2011 · group DE · Patients with atopic dermatitis; age and sex not specified
1,600 IU60 days11
Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study
2012 · Group B (calcium and calcitriol; PTH <5) · Adults aged 18–82 undergoing completion or total thyroidectomy, with POD1 PTH <5
1 mcg15 days7
Maturation of primary and permanent teeth in preterm infants
2000 · 500 IU/day vitamin D; calcium- and phosphorus-supplemented breast milk · Preterm infants
500 IU——
Maturation of primary and permanent teeth in preterm infants
2000 · 1000 IU/day vitamin D; calcium- and phosphorus-supplemented breast milk · Preterm infants
1,000 IU——
Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy?
2002 · group C · Patients who underwent total thyroidectomy
1 mg26 weeks—
Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects
2006 · resistance training plus vitamin D and calcium · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects
400 IU270 days—
Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects
2006 · control (no resistance training) plus vitamin D and calcium · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects
400 IU270 days—
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
2007 · RE+ (reinforcement) · Postmenopausal women aged 65–80 with osteoporosis or a low-trauma fracture
400 IU1 year—
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
2007 · RE− (no reinforcement) · Postmenopausal women aged 65–80 with osteoporosis or a low-trauma fracture
400 IU1 year—
Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain
2007 · calcium plus cholecalciferol · Postmenopausal women aged 50 to 79 years
400 IU7 years—
Predictors of adherence in the Women's Health Initiative Calcium and Vitamin D Trial
2009 · active treatment · Postmenopausal women aged 50–79 years
400 IU——
Calcium plus vitamin D supplementation and fat mass loss in female very low-calcium consumers: potential link with a calcium-specific appetite control
2009 · calcium+D supplementation · Overweight or obese women, mean age 43 years, with daily calcium intake below 800 mg
10 mcg15 weeks—
A comparison between the efficacy of dydrogesterone and calcium plus vitamin D in improving women's general health
2010 · calcium plus vitamin D · Young women who were students at Shiraz University
400 mg——
A randomized controlled trial of the effects of vitamin D on muscle strength and mobility in older women with vitamin D insufficiency
2010 · Vitamin D group · Women aged 70 to 90 with vitamin D insufficiency, living in the community
1,000 IU1 year—
Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial
2011 · Vitamin D and calcium group · Adults at high risk of type 2 diabetes; mean age 57 years
2,000 IU16 weeks—
Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults
2012 · Calcium and vitamin D-fortified regular orange juice · Overweight and obese adults; mean age 40.0 ± 12.9 years; sex not stated
300 IU16 weeks—
Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults
2012 · Calcium and vitamin D-fortified lite orange juice · Overweight and obese adults; mean age 40.0 ± 12.9 years; sex not stated
300 IU16 weeks—
The effect of vitamin D on calcium absorption in older women
2012 · 400 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency
400 IU1 year—
The effect of vitamin D on calcium absorption in older women
2012 · 800 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency
800 IU1 year—
The effect of vitamin D on calcium absorption in older women
2012 · 1600 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency
1,600 IU1 year—
The effect of vitamin D on calcium absorption in older women
2012 · 2400 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency
2,400 IU1 year—
The effect of vitamin D on calcium absorption in older women
2012 · 3200 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency
3,200 IU1 year—
The effect of vitamin D on calcium absorption in older women
2012 · 4000 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency
4,000 IU1 year—
The effect of vitamin D on calcium absorption in older women
2012 · 4800 IU/d vitamin D3 · Postmenopausal Caucasian women with vitamin D insufficiency
4,800 IU1 year—
High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: results of a randomized double blind pilot study
2012 · High-dose vitamin D group · Children and adolescents aged 7–21 years with sickle cell disease, including participants with and without chronic pain
200 IU26 weeks—
Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial
2013 · vitamin D(3) plus calcium · Adults aged 45–75 in good health, with a history of colorectal adenoma and serum 25-hydroxyvitamin D ≥12 ng/mL
1,000 IU——
Complementary treatment of obesity and overweight with salacia reticulata and vitamin d
2013 · Group B · Healthy, physically active adults aged 30–60 years with BMI 25–45 and overweight or obesity
4.8 mcg4 weeks—
Effects of Calcium Plus Vitamin D Supplementation on Anthropometric Measurements and Blood Pressure in Vitamin D Insufficient People with Type 2 Diabetes: A Randomized Controlled Clinical Trial
2015 · 50,000 IU/wk vitamin D3 plus 1000 mg/d calcium · People with type 2 diabetes and vitamin D insufficiency
7,143 IU8 weeks—
A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods
2015 · VDCa group · Adult male and female volunteers aged 50 years or older
800 IU26 weeks—
Effects of Calcium-Vitamin D and Calcium-Alone on Pain Intensity and Menstrual Blood Loss in Women with Primary Dysmenorrhea: A Randomized Controlled Trial
2017 · calcium-vitamin D group · Women students with moderate or severe primary dysmenorrhea
5,000 IU——
Calcium plus vitamin D supplementation and height loss: findings from the Women's Health Initiative Calcium and Vitamin D clinical trial
2016 · CaD group · Postmenopausal women aged 50–79, generally healthy
400 IU8 years—
High dose vitamin D may improve lower urinary tract symptoms in postmenopausal women
2017 · standard dose group · Postmenopausal women with low bone mineral density
800 IU1 year—
Supplementing Breakfast with a Vitamin D and Leucine-Enriched Whey Protein Medical Nutrition Drink Enhances Postprandial Muscle Protein Synthesis and Muscle Mass in Healthy Older Men
2017 · test group · Healthy older men; mean age 71 ± 4 years
800 IU6 weeks—
Effect of vitamin D and omega-3 on nocturnal enuresis of 7-15-year-old children
2018 · Group C · Children aged 7–15 with nocturnal enuresis
1,000 IU60 days—
Vitamin D supplementation may improve back pain disability in vitamin D deficient and overweight or obese adults
2019 · Vitamin D group · Overweight or obese adults with vitamin D deficiency; otherwise healthy
4,000 IU16 weeks—
A high weekly dose of cholecalciferol and calcium supplement enhances weight loss and improves health biomarkers in obese women
2018 · vitamin D3 plus Ca (Diet/Ca/D) · Obese women with vitamin D deficiency
7,143 IU90 days—
Low-Dose Omega-3 Fatty Acid and Vitamin D for Anthropometric, Biochemical Blood Indices and Respiratory Function. Does it work?
2020 · experimental group · Office workers aged 40–60 years; sex and health condition not stated
5 mcg16 weeks—
Effects of zinc, vitamin D, and their co-supplementation on mood, serum cortisol, and brain-derived neurotrophic factor in patients with obesity and mild to moderate depressive symptoms: A phase II, 12-wk, 2 × 2 factorial design, double-blind, randomized, placebo-controlled trial
2020 · Vitamin D plus zinc group · Overweight or obese adults with depressive symptoms and BDI-II score ≥10; mean age 38.35 years
2,000 IU12 weeks—
Effects of High-Dose Vitamin D Supplementation on Phase Angle and Physical Function in Patients with Prostate Cancer on ADT
2021 · low-dose vitamin D · Men aged 60 years or older with stage I–IV prostate cancer receiving ADT and suboptimal vitamin D levels (<32 ng/ml)
600 IU24 weeks—
Randomized Study of the Effects of Vitamin D and Magnesium Co-Supplementation on Muscle Strength and Function, Body Composition, and Inflammation in Vitamin D-Deficient Middle-Aged Women
2021 · intervention · Women aged 40–55 years with vitamin D deficiency
7,143 IU8 weeks—
Vitamin D and Calcium Milk Fortification in Pregnant Women with Periodontitis: A Feasibility Trial
2020 · Group 1—fortified milk and early therapy · Pregnant women aged 18 years or older with low-risk pregnancy and periodontitis
1,000 IU——
Vitamin D and Calcium Milk Fortification in Pregnant Women with Periodontitis: A Feasibility Trial
2020 · Group 3—fortified milk and late therapy · Pregnant women aged 18 years or older with low-risk pregnancy and periodontitis
1,000 IU——
Calcium Carbonate Attenuates Withdrawal and Reduces Craving: A Randomized Controlled Trial in Alcohol-Dependent Patients
2021 · calcium carbonate group · Alcohol-dependent patients undergoing inpatient alcohol-withdrawal treatment; age and sex not specified
5 mcg2 weeks—
Exploratory Efficacy of Calcium-Vitamin D Milk Fortification and Periodontal Therapy on Maternal Oral Health and Metabolic and Inflammatory Profile
2021 · Fortified sachet and powdered milk plus periodontal treatment during pregnancy (early PT + fortification) · Adult pregnant women with periodontitis; age over 18 years, enrolled by up to 20 weeks’ gestation
1,000 IU——
Exploratory Efficacy of Calcium-Vitamin D Milk Fortification and Periodontal Therapy on Maternal Oral Health and Metabolic and Inflammatory Profile
2021 · Fortified sachet and powdered milk plus periodontal treatment after delivery (late PT + fortification) · Adult pregnant women with periodontitis; age over 18 years, enrolled by up to 20 weeks’ gestation
1,000 IU——
Daily intake of yogurt drink fortified either with vitamin D alone or in combination with added calcium causes a thyroid-independent increase of resting metabolic rate in adults with type 2 diabetes: a randomized, double-blind, clinical trial
2021 · Ca-D-fortified yogurt drink (CDY) · Adults with type 2 diabetes
1,000 IU12 weeks—
Functional improvements to 6 months of physical activity are not related to changes in size or density of multiple lower-extremity muscles in mobility-limited older individuals
2022 · nutritional supplement · Community-dwelling mobility-limited older men and women; mean age 77 ± 5 years
800 IU26 weeks—
Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial
2023 · vitamin D plus omega-3 fatty acids · Men aged 50 and older without clinically apparent cardiovascular disease or cancer; this analysis excluded men with multiple sclerosis or Parkinson’s disease at baseline
2,000 IU1935 days—
Vitamin D Supplementation Has No Impact on Cardiorespiratory Fitness, but Improves Inflammatory Status in Vitamin D Deficient Young Men Engaged in Resistance Training
2022 · Vitamin D supplemented (VD) group · Vitamin-D-deficient young men, mean age 23.7 years, without chronic disease, participating in resistance training
8,000 IU12 weeks—
Effects of vitamin D on sex steroids, luteinizing hormone, and testosterone to luteinizing hormone ratio in 307 infertile men
2024 · active group · infertile men
301,400 IU150 days—
Effect of Calcium and Vitamin D Supplementation (Dairy vs. Pharmacological) on Bone Health of Underprivileged Indian Children and Youth with Type-1 Diabetes: A Randomized Controlled Trial
2024 · Calcium supplement (group B) · Underprivileged Indian children and youth aged 5–23 years with type-1 diabetes mellitus; both sexes
1,000 IU1 year—
Alcohol use disorder and muscle weakness: Original study of the effect of vitamin D supplementation in ambulatory participants with alcohol use disorder
2024 · CAU (care as usual) · Community-dwelling adults with alcohol use disorder; ages and sex by arm not reported. The reported outcome subgroup had vitamin D concentrations below 50 nmol/L.
800 IU1 year—
Effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor, interleukin-6, and insulin-like growth factor-1 in monocyte in pre-frail older adults: A randomized double-blind placebo-controlled trial
2024 · cholecalciferol group · pre-frail older adults
4,000 IU12 weeks—
Evaluation of efficacy of cholecalciferol and silymarin in improving lower urinary tract symptoms of benign prostatic hyperplasia: A double-blind, randomized, controlled trial
2024 · Cholecalciferol and Silymarin combination · Men aged 50–80 with benign prostatic hyperplasia and lower urinary tract symptoms, with serum 25-(OH) vitamin D below 20 ng/ml
7,143 IU90 days—
The relationship between serum vitamin D, testosterone, and oxidative stress levels in women with sexual dysfunction: A case-controlled study
2024 · intervention group · Women aged 18–45 with female sexual dysfunction and low serum vitamin D
7,143 IU4 weeks—
The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial
2025 · ω3+VitD group · Women newly diagnosed with breast cancer receiving chemotherapy; age range not reported
7,143 IU9 weeks—
Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial
2025 · Vitamin D3 and omega-3s, without SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women
2,000 IU3 years—
Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial
2025 · Vitamin D3 and omega-3s with SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women
2,000 IU3 years—
Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial
2025 · D12 · Premenopausal women aged 18 or older with PCOS and serum 25(OH)D of 10–30 ng/mL
4,286 IU12 weeks—
Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial
2025 · D24 · Premenopausal women aged 18 or older with PCOS and serum 25(OH)D of 10–30 ng/mL
4,286 IU24 weeks—
Rickets in very-low-birth-weight infants born at Baragwanath Hospital
1994 · Breast-milk and premature formula · Very-low-birth-weight neonates weighing less than 1,200 g at birth
800 IU18 weeks—
Effect of vitamin D supplementation on glucose control in mid-late gestation: A randomized controlled trial
2023 · 400 IU/d vitamin D3 · Pregnant women recruited at 24–28 weeks’ gestation
400 IU60 days862
Effect of vitamin D supplementation on glucose control in mid-late gestation: A randomized controlled trial
2023 · 1600 IU/d vitamin D3 · Pregnant women recruited at 24–28 weeks’ gestation
1,600 IU60 days858
Vitamin D supplementation for cardiometabolic risk markers in pregnant women based on the gestational diabetes mellitus or obesity status : a randomized clinical trial
2024 · control group · Pregnant women at 24–28 weeks' gestation with serum 25(OH)D <75 nmol/L; included women with or without GDM or overweight/obesity
400 IU60 days771
Vitamin D supplementation for cardiometabolic risk markers in pregnant women based on the gestational diabetes mellitus or obesity status : a randomized clinical trial
2024 · intervention group · Pregnant women at 24–28 weeks' gestation with serum 25(OH)D <75 nmol/L; included women with or without GDM or overweight/obesity
1,600 IU60 days766
A Mediterranean-like dietary pattern with vitamin D3 (10 µg/d) supplements reduced the rate of bone loss in older Europeans with osteoporosis at baseline: results of a 1-y randomized controlled trial
2018 · Mediterranean-like dietary intervention · Men and women aged 65–79 years; free-living older adults, including a subgroup with osteoporosis at baseline
10 mcg1 year632
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density
2007 · alendronate 10 mg/calcium-placebo · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day
400 IU2 years280
Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis
2014 · ALN/D group · Postmenopausal women with osteoporosis; mean age 73 years
800 IU1 year257
The effect of high-dose vitamin D(3) supplementation on bone mineral density in subjects with prediabetes
2018 · vitamin D · Prediabetic adults; the abstract does not specify their age or sex distribution. The reported significant femoral-neck result was in males.
2,857 IU5 years256
Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial
1995 · vitamin D group · Women aged 70 years and older
400 IU2 years177
Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
2018 · ALN/D5600 group · Chinese postmenopausal women older than 55 with osteoporosis
800 IU1 year111
Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis
2015 · ALN + ELD group · Japanese men and women aged 60–90 with primary osteoporosis or osteopenia and at least one vertebral fracture
0.75 mcg48 weeks110
Adverse Effects of High-Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males
2020 · 400 IU daily vitamin D3 · Healthy vitamin D-sufficient adults aged 55–70 years; males and females
400 IU3 years109
Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
2018 · calcitriol group · Chinese postmenopausal women older than 55 with osteoporosis
0.25 mcg1 year108
Adverse Effects of High-Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males
2020 · 10,000 IU daily vitamin D3 · Healthy vitamin D-sufficient adults aged 55–70 years; males and females
10,000 IU3 years102
Adverse Effects of High-Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males
2020 · 4000 IU daily vitamin D3 · Healthy vitamin D-sufficient adults aged 55–70 years; males and females
4,000 IU3 years100
A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis
2006 · Placebo tablets and vitamin D group · Children and adolescents aged 6–18 years with juvenile rheumatoid arthritis who had not taken corticosteroids for at least 3 months
400 IU2 years95
Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults
1995 · Vitamin D supplementation · Men and women aged 63–76 years (mean age 70), recruited from general practitioner age-sex registers in Cambridge, UK; no stated condition
2.5 mg5 weeks95
Cholecalciferol Supplementation Attenuates Bone Loss in Incident Kidney Transplant Recipients: A Prespecified Secondary Endpoint Analysis of a Randomized Controlled Trial
2022 · cholecalciferol · Adults aged 20–80 years, 1 month after living kidney transplantation; most had vitamin D deficiency
4,000 IU330 days92
Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis
2006 · alfacalcidol group · Postmenopausal Caucasian patients with osteoporosis and normal vitamin D serum levels
1 mcg547 days76
Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis
1999 · alfacalcidol · Patients with diseases requiring long-term high-dose corticosteroid treatment who were steroid naive at study entry
1 mcg1 year74
Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: a randomized placebo-controlled trial
2014 · vitamin D supplementation group · Chinese patients with grades I-II essential hypertension
2,000 IU26 weeks63
Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease
1999 · treatment group · Elderly patients with Parkinson's disease; mean age 70.6 years
1 mcg548 days43
Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial
2015 · group 1 · Women with endometrial cancer after treatment and surgery
1 mcg2 years39
Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial
2015 · group 2 · Women with endometrial cancer after treatment and surgery
1 mcg2 years37
Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study
2016 · alfacalcidol plus alendronate · Adult women with systemic connective tissue diseases starting high-dose glucocorticoid therapy (prednisolone-equivalent dose at least 20 mg/day)
1 mcg1 year36
The effect of season and vitamin D supplementation on bone mineral density in healthy women: a double-masked crossover study
2001 · Group 1 (vitamin D; crossover) · Healthy women aged 24–70 years (mean age 47.2 years)
800 IU1 year35
Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D
1999 · vitamin D3 group · Elderly patients with hemiplegia after stroke and hypovitaminosis D
1 mcg1 year34
Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study
2016 · alfacalcidol · Adult women with systemic connective tissue diseases starting high-dose glucocorticoid therapy (prednisolone-equivalent dose at least 20 mg/day)
1 mcg1 year33
Combination of Calcitriol and Zoledronic Acid on PINP and β-CTX in Postoperative Patients with Diabetic Osteoporosis: A Randomized Controlled Trial
2022 · control group · Adults aged 40–78 with diabetic osteoporosis and surgically treated posterior cruciate ligament tibial avulsion fractures
0.25 mcg1 year30
Combination of Calcitriol and Zoledronic Acid on PINP and β-CTX in Postoperative Patients with Diabetic Osteoporosis: A Randomized Controlled Trial
2022 · observation group · Adults aged 43–78 with diabetic osteoporosis and surgically treated posterior cruciate ligament tibial avulsion fractures
0.25 mcg1 year30
Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis
2000 · D group · Postmenopausal women aged 55–81 years with osteoporosis, more than 5 years after menopause
0.75 mcg2 years29
Effects of 12 Weeks of Whole-Body Vibration Training and Vitamin D Supplementation on Bone Density and Muscle Quality in the Aged with Osteosarcopenia: A Randomized Controlled Trial
2025 · WBVT group · Older adults with osteosarcopenia; age range and sex not specified
0.25 mcg90 days24
Effects of calcium and vitamin D supplementation on blood pressure and serum lipids and carotenoids: a randomized, double-blind, placebo-controlled, clinical trial
2013 · vitamin D3 · Adults aged 30–75 with at least one pathology-confirmed adenomatous colorectal polyp in the previous 36 months
800 IU26 weeks23
Effect of Calcitriol Supplementation on Blood Pressure in Older Adults
2016 · calcitriol group · Older adults with hypertension; mean age 71.7 ± 10 years
1,000 IU6 weeks22
Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome
2010 · risedronate + alfacalcidol group · Patients with minimal-change nephrotic syndrome receiving prednisolone
0.25 mcg1 year20
Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome
2010 · alfacalcidol-alone group · Patients with minimal-change nephrotic syndrome receiving prednisolone
0.25 mcg1 year20
Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss
1993 · Group 3 · Women with postmenopausal bone loss
2 mcg1 year20
Bone mineral metabolism in full-term infants fed human milk, cow milk-based, and soy-based formulas
1992 · human milk-fed group · Normal, healthy, full-term infants
400 IU120 days17
Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol
2008 · group 3 (alendronate + alfacalcidol) · Kidney transplant recipients with low bone mineral density; 22 women and 42 men were recruited overall, but the arm's sex and age distribution are not reported.
0.5 mcg1 year17
Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol
2008 · alfacalcidol group · Japanese women with systemic autoimmune disease excluding rheumatoid arthritis, receiving glucocorticoids of at least 5 mg/day prednisolone equivalent for more than 6 months
1 mcg2 years16
Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine
2004 · vitamin D3 alone (group D) · Patients with chronic glomerulonephritis receiving prednisolone; age and sex distribution for this arm not reported
0.5 mcg8 weeks15
Treatment of osteopenia and osteoporosis in renal transplant children and adolescents
2004 · group 2 · Children and adolescents who had undergone renal transplantation at age 17 years or younger and had osteopenia or osteoporosis
0.25 mcg1 year15
A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents
2004 · group 2 · Children and adolescents with low bone mineral density after renal transplantation
0.25 mcg1 year15
Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure
1995 · calcitriol group · 13 patients in the predialysis phase of chronic renal failure
0.25 mcg1 year13
Randomised controlled trial of vitamin D supplementation on bone density and biochemical indices in preterm infants
1999 · Vitamin D 960 IU/day · Preterm infants born before 33 weeks of gestational age
960 IU90 days—
Calcitriol for bone loss in patients with primary biliary cirrhosis
1999 · calcitriol · Women with primary biliary cirrhosis
1 mg187 weeks—
Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3
1999 · 1alpha(OH)D3-treated group · Japanese women within 5 years of menopause
1 mcg2 years—
Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3
1999 · Combination-treated group (conjugated estrogens + 1alpha(OH)D3) · Japanese women within 5 years of menopause
1 mcg2 years—
Calcitriol for bone disease in patients with cirrhosis of the liver
1999 · calcitriol group · Men and women with cirrhosis of the liver
1 mg——
The long-term effect of early mineral, vitamin D, and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely
1999 · 500 IU/day vitamin D; unsupplemented breast milk · Preterm infants; sex and exact age range not stated
500 IU——
The long-term effect of early mineral, vitamin D, and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely
1999 · 1000 IU/day vitamin D; unsupplemented breast milk · Preterm infants; sex and exact age range not stated
1,000 IU——
Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate
2000 · group A · Heart transplant recipients; age and sex not specified
0.5 mcg548 days—
Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation
2001 · calcitriol · Patients undergoing cardiac or lung transplantation; age and sex not specified
0.5 mcg26 weeks—
Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss
2001 · calcitriol · Women aged 65–77 with normal bone density for their age
0.5 mcg3 years—
Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss
2001 · hormone replacement therapy/estrogen replacement therapy plus calcitriol · Women aged 65–77 with normal bone density for their age
0.5 mcg3 years—
Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study
2001 · calcitriol group · men with primary osteoporosis and at least one baseline fragility fracture
0.5 mcg2 years—
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation
2004 · calcitriol · Cardiac transplant patients; age and sex not specified
0.5 mcg1 year—
Preventing wintertime bone loss: effects of vitamin D supplementation in healthy postmenopausal women
1992 · Vitamin D supplementation · Healthy postmenopausal women with low vitamin D intakes
500 IU1 year—
Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss
2006 · HRT/D group · Postmenopausal women aged 60 years or older with low lumbar bone mineral density (T-score less than -1)
1 mcg2 years—
A positive dose-response effect of vitamin D supplementation on site-specific bone mineral augmentation in adolescent girls: a double-blinded randomized placebo-controlled 1-year intervention
2006 · 5 microg vitamin D3 group · Adolescent girls, mean age 11.4 ± 0.4 years, with adequate dietary calcium intake
5 mcg1 year—
A positive dose-response effect of vitamin D supplementation on site-specific bone mineral augmentation in adolescent girls: a double-blinded randomized placebo-controlled 1-year intervention
2006 · 10 microg vitamin D3 group · Adolescent girls, mean age 11.4 ± 0.4 years, with adequate dietary calcium intake
10 mcg1 year—
Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone
2006 · Low-dose vitamin D, adults · Adults aged 18 to 54 years on long-term antiepileptic drug therapy
400 IU1 year—
Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone
2006 · High-dose vitamin D, adults · Adults aged 18 to 54 years on long-term antiepileptic drug therapy
4,000 IU1 year—
Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone
2006 · Low-dose vitamin D, children and adolescents · Children and adolescents aged 10 to 18 years on long-term antiepileptic drug therapy
400 IU1 year—
Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone
2006 · High-dose vitamin D, children and adolescents · Children and adolescents aged 10 to 18 years on long-term antiepileptic drug therapy
2,000 IU1 year—
ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects
2007 · 0.5 microg/day ED-71 group · Osteoporotic subjects
0.5 mcg1 year—
ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects
2007 · 0.75 microg/day ED-71 group · Osteoporotic subjects
0.75 mcg1 year—
ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects
2007 · 1.0 microg/day ED-71 group · Osteoporotic subjects
1 mcg1 year—
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial
2007 · ALN 70 mg once a week plus calcitriol (1,25D3) 0.5 microg daily · Women aged 60 and older with osteoporosis, vitamin D insufficiency, and secondary hyperparathyroidism
0.5 mcg1 year—
Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial
2008 · placebo group · Children aged 6–18 years with juvenile rheumatoid arthritis, without systemic corticosteroid therapy in the 3 months before enrollment
400 IU2 years—
Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis
2009 · alfacalcidol · Patients with ulcerative colitis receiving glucocorticoids
1 mcg1 year—
What is needed to keep persons with multiple sclerosis vitamin D-sufficient throughout the year?
2013 · vitamin D(3) intervention group · Patients with multiple sclerosis; age and sex not reported
2,857 IU96 weeks—
Skeletal effects of vitamin D supplementation in postmenopausal black women
2012 · vitamin D · Postmenopausal Black women with serum 25(OH)D levels below 20 ng/mL
1,000 IU2 years—
Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women
2013 · 400 IU vitamin D group · White postmenopausal women aged 60–70 years
400 IU1 year—
Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women
2013 · 1000 IU vitamin D group · White postmenopausal women aged 60–70 years
1,000 IU1 year—
The effect of vitamin D supplementation on blood pressure in patients with elevated blood pressure and vitamin D deficiency: a randomized, double-blind, placebo-controlled trial
2015 · vitamin D-supplemented group (VDG) · Patients with elevated blood pressure and vitamin D deficiency; age and sex not specified
7,143 IU8 weeks—
25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial
2018 · vitamin D 400 IU/d · Postmenopausal women; age range and baseline vitamin D status not specified
400 IU1 year—
25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial
2018 · vitamin D 1000 IU/d · Postmenopausal women; age range and baseline vitamin D status not specified
1,000 IU1 year—
Alendronate/Vitamin D for attenuating bone mineral density loss during antiretroviral initiation: a pilot randomized controlled trial
2019 · concomitant treatment arm (CTA) · Treatment-naïve HIV-positive adults initiating antiretroviral therapy
800 IU24 weeks—
Alendronate/Vitamin D for attenuating bone mineral density loss during antiretroviral initiation: a pilot randomized controlled trial
2019 · delayed treatment arm (DTA) · Treatment-naïve HIV-positive adults initiating antiretroviral therapy
800 IU24 weeks—
Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA)
2020 · eldecalcitol · Patients with glucocorticoid-induced osteoporosis
0.75 mcg2 years—
Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA)
2020 · alfacalcidol · Patients with glucocorticoid-induced osteoporosis
1 mcg2 years—
The effects of vitamin D and curcuminoids supplementation on anthropometric measurements and blood pressure in type 2 diabetic patients with coexisting hypovitaminosis D: A double-blind, placebo-controlled randomized clinical trial
2020 · vitamin D3 · Adults with type 2 diabetes and insufficient vitamin D status
7,143 IU12 weeks—
Pregnancy vitamin D supplementation and offspring bone mineral density in childhood follow-up of a randomized controlled trial
2024 · Cholecalciferol · Pregnant adults aged 18 years or older with a singleton pregnancy and serum 25(OH)D of 25–100 nmol/L
1,000 IU——
Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients
2025 · eldecalcitol add-on therapy · Postmenopausal women with hormone receptor-positive early-stage breast cancer (TNM stage 0–3A), treated with aromatase inhibitors and risedronate for more than 12 months
0.75 mcg2 years—
Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3
1995 · B, Vitamin D3 · Postmenopausal women
300 IU1 year—
Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3
1995 · C, Climen+Vitamin D3 · Postmenopausal women
300 IU1 year—
Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss
1994 · placebo · Healthy white women 3 to 6 years after spontaneous menopause
400 IU1059 days—
Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation
1995 · vitamin D supplement · Out-patients aged 16–77 with Crohn's disease
1,000 IU1 year—
Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study
1997 · D group · Healthy postmenopausal women
300 IU913 days—
Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study
1997 · HRT+D group · Healthy postmenopausal women
300 IU913 days—
The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype
1997 · vitamin D group · Women aged 70 years and over participating in a trial of vitamin D supplementation
400 IU2 years—
Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids)
2024 · vitamin D arm · Schoolchildren aged 6–11 years in Cape Town, South Africa; children with chronic illness other than asthma and clinical evidence of rickets were excluded.
35.7 mcg3 years829
Vitamin D substrate-product relationship in idiopathic hypercalciuria
2009 · Controls receiving 25OHD · Age- and sex-matched controls; mean age 61.5 years
25 mcg2 weeks57
Vitamin D substrate-product relationship in idiopathic hypercalciuria
2009 · AH subjects receiving 25OHD · Adults with absorptive hypercalciuria; mean age 60.9 years
25 mcg2 weeks52
Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial
2013 · group receiving vitamin D2 · Healthy volunteers; age range and sex not reported.
50 mcg8 weeks46
Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial
2020 · Intervention group · Male forensic inpatients aged 31–81 with varied mental health and substance-use diagnoses
40 mcg135 days43
Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial
2013 · vitamin D3 group · Healthy volunteers; age range and sex not reported.
50 mcg8 weeks42
Effect of vitamin D fortified foods on bone markers and muscle strength in women of Pakistani and Danish origin living in Denmark: a randomised controlled trial
2019 · Pakistani fortified-food group · Pakistani-origin women aged 18–50 at risk of vitamin D deficiency
29 mcg90 days33
Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status over the winter months
2013 · vitamin D3 · Healthy adults aged 18–50 years
25 mcg25 weeks32
Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status over the winter months
2013 · vitamin D2 · Healthy adults aged 18–50 years
25 mcg25 weeks31
Vitamin D receptor Cdx-2-dependent response of central obesity to vitamin D intake in the subjects with type 2 diabetes: a randomised clinical trial
2015 · Vitamin D3-fortified doogh (FD) · Adults with type 2 diabetes
25 mcg12 weeks31
Effect of vitamin D fortified foods on bone markers and muscle strength in women of Pakistani and Danish origin living in Denmark: a randomised controlled trial
2019 · Danish fortified-food group · Danish-origin women aged 18–50 at risk of vitamin D deficiency
29 mcg90 days31
Vitamin D-Fortified Bread Is as Effective as Supplement in Improving Vitamin D Status: A Randomized Clinical Trial
2016 · fortified bread (FP) · Healthy adults aged 20–60 years
25 mcg8 weeks30
Vitamin D-Fortified Bread Is as Effective as Supplement in Improving Vitamin D Status: A Randomized Clinical Trial
2016 · supplement (SP) · Healthy adults aged 20–60 years
25 mcg8 weeks30
Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study
2024 · calcifediol group · People with multiple sclerosis; age and sex not reported
50 mcg—25
Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study
2024 · cholecalciferol group · People with multiple sclerosis; age and sex not reported
50 mcg—25
Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level
2001 · 25 microg vitamin D3/d group · Healthy men and women aged 41 +/- 9 years
25 mcg152 days—
Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level
2001 · 100 microg vitamin D3/d group · Healthy men and women aged 41 +/- 9 years
100 mcg152 days—
Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol
2003 · 25 micro g cholecalciferol · Healthy men living in Omaha; age not reported
25 mcg20 weeks—
Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol
2003 · 125 micro g cholecalciferol · Healthy men living in Omaha; age not reported
125 mcg20 weeks—
Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration
2008 · vitamin D3 supplementation · Adults; age range, sex, and health status not specified
86 mcg26 weeks—
High-dose vitamin d intervention in infants--effects on vitamin d status, calcium homeostasis, and bone strength
2012 · 30 μg group · Infants receiving supplementation from age 2 weeks to 3 months
30 mcg10 weeks—
High-dose vitamin d intervention in infants--effects on vitamin d status, calcium homeostasis, and bone strength
2012 · 40 μg group · Infants receiving supplementation from age 2 weeks to 3 months
40 mcg10 weeks—
A 250 μg/week dose of vitamin D was as effective as a 50 μg/d dose in healthy adults, but a regimen of four weekly followed by monthly doses of 1250 μg raised the risk of hypercalciuria
2013 · 50 μg/d · Healthy adults
50 mcg90 days—
A 250 μg/week dose of vitamin D was as effective as a 50 μg/d dose in healthy adults, but a regimen of four weekly followed by monthly doses of 1250 μg raised the risk of hypercalciuria
2013 · 250 μg/week · Healthy adults
35.7 mcg90 days—
Vitamin D supplementation in elderly nursing home residents increases 25(OH)D but not 1,25(OH)2D
1990 · Vitamin D group · Elderly nursing home residents
50 mcg6 weeks—
Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial
2014 · cholecalciferol group · Adults aged 29–77 with primary hyperparathyroidism; 76% of the enrolled participants were women
70 mcg52 weeks—
Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease
2014 · 30 µg MR calcifediol group · Adults with chronic kidney disease, vitamin D insufficiency and elevated intact parathyroid hormone
30 mcg6 weeks—
Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease
2014 · 60 µg MR calcifediol group · Adults with chronic kidney disease, vitamin D insufficiency and elevated intact parathyroid hormone
60 mcg6 weeks—
Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease
2014 · 90 µg MR calcifediol group · Adults with chronic kidney disease, vitamin D insufficiency and elevated intact parathyroid hormone
90 mcg6 weeks—
Maternal vitamin D₃ supplementation at 50 μg/d protects against low serum 25-hydroxyvitamin D in infants at 8 wk of age: a randomized controlled trial of 3 doses of vitamin D beginning in gestation and continued in lactation
2015 · 25 μg vitamin D₃/d group · Pregnant women, supplementation begun during gestation and continued through 8 weeks postpartum; breastfed infants received no supplementation
25 mcg——
Maternal vitamin D₃ supplementation at 50 μg/d protects against low serum 25-hydroxyvitamin D in infants at 8 wk of age: a randomized controlled trial of 3 doses of vitamin D beginning in gestation and continued in lactation
2015 · 50 μg vitamin D₃/d group · Pregnant women, supplementation begun during gestation and continued through 8 weeks postpartum; breastfed infants received no supplementation
50 mcg——
Oral High-Dose Vitamin D Dissolved in Oil Raised Serum 25-Hydroxy-Vitamin D to Physiological Levels in Obese Patients After Sleeve Gastrectomy-A Double-Blind, Randomized, and Placebo-Controlled Trial
2016 · Vitamin D3 in oil · Morbidly obese patients after sleeve gastrectomy
80 mcg12 weeks—
Effects of vitamin D2-fortified bread v. supplementation with vitamin D2 or D3 on serum 25-hydroxyvitamin D metabolites: an 8-week randomised-controlled trial in young adult Finnish women
2016 · D2 supplement and regular bread · Healthy women aged 20–37 years
25 mcg8 weeks—
Effects of vitamin D2-fortified bread v. supplementation with vitamin D2 or D3 on serum 25-hydroxyvitamin D metabolites: an 8-week randomised-controlled trial in young adult Finnish women
2016 · D3 supplement and regular bread · Healthy women aged 20–37 years
25 mcg8 weeks—
Effects of vitamin D2-fortified bread v. supplementation with vitamin D2 or D3 on serum 25-hydroxyvitamin D metabolites: an 8-week randomised-controlled trial in young adult Finnish women
2016 · Placebo pill and D2-biofortified bread · Healthy women aged 20–37 years
25 mcg8 weeks—
Obese young adults exhibit lower total and lower free serum 25-hydroxycholecalciferol in a randomized vitamin D intervention
2016 · cholecalciferol group · Young people aged 15–25 years, including participants with severe childhood-onset obesity and normal-weight participants
50 mcg12 weeks—
Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease
2016 · ER calcifediol 30 µg · Adults with stage 3 or 4 chronic kidney disease, secondary hyperparathyroidism and vitamin D insufficiency
30 mcg26 weeks—
Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease
2016 · ER calcifediol 60 µg · Adults with stage 3 or 4 chronic kidney disease, secondary hyperparathyroidism and vitamin D insufficiency
60 mcg26 weeks—
Increased vitamin D intake differentiated according to skin color is needed to meet requirements in young Swedish children during winter: a double-blind randomized clinical trial
2017 · 25 μg/d vitamin D3 group · Children aged 5–7 years in Sweden with fair or dark skin
25 mcg90 days—
Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens
2017 · 40 μg/day · Postmenopausal women aged 55 years or older with vitamin D inadequacy
40 mcg90 days—
Genetic Variation of the Vitamin D Binding Protein Affects Vitamin D Status and Response to Supplementation in Infants
2019 · 30 μg/d vitamin D3 group · Healthy term infants
30 mcg716 days—
Effectiveness of vitamin D supplementation in Swedish children may be negatively impacted by BMI and serum fructose
2020 · 25 μg vitamin D group · children aged 5–7 years in northern and southern Sweden; no condition stated
25 mcg90 days—
Efficiency of Vitamin D Supplementation in Healthy Adults is Associated with Body Mass Index and Baseline Serum 25-Hydroxyvitamin D Level
2020 · Group A: capsules with starch-adsorbed vitamin D · Adults aged 18–65 with suboptimal serum 25-OH-vitamin D levels (30–50 nmol/L)
25 mcg8 weeks—
Efficiency of Vitamin D Supplementation in Healthy Adults is Associated with Body Mass Index and Baseline Serum 25-Hydroxyvitamin D Level
2020 · Group B: oil-based Valens vitamin D oral spray · Adults aged 18–65 with suboptimal serum 25-OH-vitamin D levels (30–50 nmol/L)
25 mcg8 weeks—
Efficiency of Vitamin D Supplementation in Healthy Adults is Associated with Body Mass Index and Baseline Serum 25-Hydroxyvitamin D Level
2020 · Group C: water-based Valens vitamin D oral spray · Adults aged 18–65 with suboptimal serum 25-OH-vitamin D levels (30–50 nmol/L)
25 mcg8 weeks—
Effects of High-Dose Vitamin D Supplementation on Placental Vitamin D Metabolism and Neonatal Vitamin D Status
2024 · 90 µg vitamin D group · Pregnant women enrolled at gestational weeks 11–16; no specific pregnancy complication required
90 mcg26 weeks—
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men
1998 · vitamin D3 25 micrograms/day · healthy men, mean age 28 years
25 mcg8 weeks—
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men
1998 · 25(OH)D3 50 micrograms/day · healthy men, mean age 28 years
50 mcg4 weeks—
The impact of supplemental n-3 long chain polyunsaturated fatty acids and dietary antioxidants on physical performance in postmenopausal women
2013 · n-3 LCPUFA group · Postmenopausal women over age 65 without the listed bone, cancer or liver diseases; most were prefrail or frail.
1,000 IU180 days85
Melatonin, vitamins and minerals supplements for the treatment of Covid-19 and Covid-like illness: A prospective, randomized, double-blind multicenter study
2024 · Treatment group · Adults younger than 60 years with COVID-19 or COVID-like illness, no previous medical history, and not hospitalized
2.5 mcg—82
Effects of a 6-Month Multifaceted Diet and Exercise Intervention on Cognition in Older Adults at Risk of Cognitive Decline: The PONDER Double-Blind, Placebo-Controlled Randomized Trial
2022 · Multimodal exercise program with daily supplement · Community-dwelling older adults with subjective memory impairment; mean age 70.2 years, 70% female
1,000 IU26 weeks73
Effect of zinc plus multivitamin supplementation on growth in school children
2016 · Chelated zinc plus multivitamins · Healthy Thai schoolchildren aged 4–13 years
200 IU26 weeks70
Leucine-Enriched Protein Supplementation Increases Lean Body Mass in Healthy Korean Adults Aged 50 Years and Older: A Randomized, Double-Blind, Placebo-Controlled Trial
2020 · protein mixture powder (intervention group) · Healthy Korean adults aged 50–80 years, men and women, without sarcopenia
1,600 IU12 weeks54
The effect of 12-weeks Nutritional supplementation on Nutritional Intake and Status among Indonesian Older Outpatients with Malnutrition Risk, the Prolansia study: a randomized controlled trial
2025 · intervention group (standard care plus NDD) · Men and women aged 60 years and older with malnutrition or at risk of malnutrition, attending outpatient clinics in Indonesia
800 IU12 weeks54
Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study
2015 · GCQID group · Japanese women and men aged 40–74 years with knee pain
5 mcg16 weeks50
Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferolin Discogenic Sciatica in Young People: A Randomized Clinical Trial
2023 · Supplement group (SG) · Adults aged 18–45 with acute sciatica due to lumbar disc herniation and low-back pain NRS 5–7
800 IU30 days41
Effects of Low-Dose Dairy Protein Plus Micronutrient Supplementation during Resistance Exercise on Muscle Mass and Physical Performance in Older Adults: A Randomized, Controlled Trial
2018 · ExPM (resistance exercise plus low-dose dairy protein and micronutrient supplementation) · Adults aged 65–80 years, non-disabled and not exercising regularly
5 mcg12 weeks40
A novel oral nutritional supplement improves gait speed and mitochondrial functioning compared to standard care in older adults with (or at risk of) undernutrition: results from a randomized controlled trial
2021 · Novel supplement · Adults aged 65 years and older with or at risk of undernutrition
10.8 mcg12 weeks40
Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial
2024 · combo group · Men aged 70 years or older with low-normal to low testosterone and mobility impairment
38 mcg16 weeks36
Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial
2024 · training group · Men aged 70 years or older with low-normal to low testosterone and mobility impairment
38 mcg16 weeks36
Magnesium-Zinc-Calcium-Vitamin D Co-supplementation Improves Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial
2018 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS); age not reported
400 IU12 weeks30
The efficacy of Sarcomeal® oral supplementation plus vitamin D3 on muscle parameters, metabolic factors, and quality of life in diabetic sarcopenia: a randomized controlled clinical trial
2025 · Intervention group · Adults aged 50–75 years with type 2 diabetes and sarcopenia
1,000 IU12 weeks30
Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children
2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis
5 mcg120 days26
A whey protein-based multi-ingredient nutritional supplement stimulates gains in lean body mass and strength in healthy older men: A randomized controlled trial
2017 · SUPP (multi-ingredient nutritional supplement) · Healthy men aged 60 years or older
1,000 IU20 weeks25
A Five-Ingredient Nutritional Supplement and Home-Based Resistance Exercise Improve Lean Mass and Strength in Free-Living Elderly
2020 · Muscle5 (M5) · Sedentary or low-active, free-living men aged 65 years or older, with normal to class 1/low-risk obesity and varying degrees of age-related muscle loss
1,000 IU12 weeks22
A prospective randomized comparative trial evaluating postoperative nutritional intervention in patients with oral cancer
2022 · Intervention group · Adults with oral cancer after surgery; ages 18 and older, both sexes
2,857 IU26 weeks22
Supportive treatment of vascular dysfunction in pediatric subjects with obesity: the OBELIX study
2022 · Treatment group · Children aged 6–17 years with obesity (BMI above the 95th percentile for age)
25 mcg26 weeks16
Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management
2024 · Muscle 5 (M5) · Men aged 66–91 years; older, sedentary or low-active participants, with the subgroup analysis including overweight or obese men with at least one additional metabolic-syndrome risk factor
1,000 IU12 weeks16
Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up
2019 · AMD-M group · Adults with intermediate age-related macular degeneration; 9 male and 21 female enrolled overall, mean age 69.32 years
800 IU26 weeks15
The Effect of a Multi-ingredient Supplement on Resistance Training-induced Adaptations
2021 · SUPP group · Healthy young adults, male and female, mean age 22 ± 2 years, undertaking resistance exercise training
2,000 IU10 weeks13
Impact of vitamin D supplementation during a resistance training intervention on body composition, muscle function, and glucose tolerance in overweight and obese adults
2013 · VitD group · Overweight and obese adults, women and men, participating in resistance training; no metabolic disease or diabetes
4,000 IU12 weeks10
The Effect of Fish Oil, Vitamin D and Protein on URTI Incidence in Young Active People
2015 · supplementation · Young recreational athletes; age and sex not specified; healthy active population
10 mcg16 weeks—
Effects of High-Dose Vitamin D Supplementation on Phase Angle and Physical Function in Patients with Prostate Cancer on ADT
2021 · high-dose vitamin D · Men aged 60 years or older with stage I–IV prostate cancer receiving ADT and suboptimal vitamin D levels (<32 ng/ml)
7,743 IU24 weeks—
Influence of vitamin D supplementation on bone mineral content, bone turnover markers, and fracture risk in South African schoolchildren: multicenter double-blind randomized placebo-controlled trial (ViDiKids)
2024 · Vitamin D arm · Children aged 6–11 years in South African schools, without a stated chronic illness; the bone sub-study was restricted to grade 4 pupils
35.7 mcg3 years829
Phosphate Concentrations and Modifying Factors in Healthy Children From 12 to 24 Months of Age
2021 · Group30 · Healthy infants; sex not specified for this arm; no stated condition
30 mcg670 days268
Vitamin D status and cardiometabolic risk markers in young Swedish children: a double-blind randomized clinical trial comparing different doses of vitamin D supplements
2020 · 25 µg group · Healthy children aged 5–7 years, including fair- and dark-skinned children
25 mcg90 days84
Treatment With 25-Hydroxyvitamin D(3) (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
2021 · 25(OH)D3 treatment group · Adults older than 18 years hospitalized with COVID-19 and vitamin D deficiency or insufficiency (25(OH)D3 <30 ng/mL)
25 mcg60 days53
Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial
2010 · vitamin D(3) · South Asian women aged 23–68 years living in Auckland, New Zealand, who were insulin resistant and vitamin D deficient
100 mcg26 weeks42
Effect of vitamin D supplementation on testosterone levels in men
2011 · vitamin D group · Overweight men with vitamin D deficiency and low-end reference-range testosterone, participating in a weight reduction program
83 mcg1 year31
Glucose Metabolism Effects of Vitamin D in Prediabetes: The VitDmet Randomized Placebo-Controlled Supplementation Study
2015 · 40 μg/day vitamin D3 group · Adults aged 60 years or older with impaired fasting glucose or impaired glucose tolerance, overweight but not severely obese, and serum 25(OH)D3 below 75 nmol/L
40 mcg150 days24
Effects of vitamin D supplementation on circulatory YKL-40 and MCP-1 biomarkers associated with vascular diabetic complications: A randomized, placebo-controlled, double-blind clinical trial
2019 · vitamin D group · Patients with type 2 diabetes; age and sex not specified
100 mcg12 weeks24
Glucose Metabolism Effects of Vitamin D in Prediabetes: The VitDmet Randomized Placebo-Controlled Supplementation Study
2015 · 80 μg/day vitamin D3 group · Adults aged 60 years or older with impaired fasting glucose or impaired glucose tolerance, overweight but not severely obese, and serum 25(OH)D3 below 75 nmol/L
80 mcg150 days21
Effects of colon-targeted vitamins on the composition and metabolic activity of the human gut microbiome- a pilot study
2021 · Vitamin D3 · Healthy adult volunteers; age and sex range not specified
60 mcg4 weeks12
The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design
2010 · vitamin D3 plus placebo · Healthy men and women aged 20–80 years
100 mcg90 days—
Vitamin D3 and the risk of CVD in overweight and obese women: a randomised controlled trial
2012 · vitamin D group · Healthy premenopausal overweight and obese women; mean age 38 years
25 mcg12 weeks—
Calcium and vitamin d supplementation in postmenopausal women
2013 · vitamin D3 plus placebo · healthy postmenopausal white women
100 mcg26 weeks—
Prenatal vitamin D₃ supplementation suppresses LL-37 peptide expression in ex vivo activated neonatal macrophages but not their killing capacity
2014 · vitamin D group · Healthy pregnant women; gestational age 26 weeks or later
125 mcg——
Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial
2018 · vitamin D3 · Postmenopausal women with high parathyroid hormone levels and vitamin D insufficiency
70 mcg2 weeks—
Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial
2018 · valsartan plus vitamin D3 · Postmenopausal women with high parathyroid hormone levels and vitamin D insufficiency
70 mcg2 weeks—
Associations Between Change in Total and Free 25-Hydroxyvitamin D With 24,25-Dihydroxyvitamin D and Parathyroid Hormone
2018 · D3 group · Adults aged 18 years or older with 25(OH)D levels below 20 ng/mL
60 mcg16 weeks—
The effect of vitamin D3 supplementation on markers of cardiovascular health in hyperparathyroid, vitamin D insufficient women: a randomized placebo-controlled trial
2018 · vitamin D3 · Postmenopausal women with secondary hyperparathyroidism and 25-hydroxy-vitamin D levels below 50 nmol/l
70 mcg12 weeks—
Fibroblast growth factor 23 concentrations and modifying factors in children from age 12 to 24 months
2020 · 30 μg/day vitamin D3 group · Healthy infants, enrolled at approximately 2 weeks of age and followed to 24 months
30 mcg——
Low-grade inflammation from prenatal period to age 6-8 years in a Vitamin D trial
2024 · group 30 · Healthy full-term infants, from age 2 weeks to 2 years
30 mcg2 years—
Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status
2020 · placebo-treated subjects · People with primary osteoporosis; baseline vitamin D status included deficient, insufficient, and sufficient groups; age and sex not stated
400 IU2 years481
Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status
2020 · denosumab-treated subjects · People with primary osteoporosis; baseline vitamin D status included deficient, insufficient, and sufficient groups; age and sex not stated
400 IU2 years475
Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial
2014 · CaD · Postmenopausal women aged 50–79 years from the general community
400 IU—291
Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS)
2010 · supplementation group · Ambulatory postmenopausal women aged 66 to 71 years
800 IU3 years287
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density
2007 · alendronate 10 mg/elemental calcium 1000 mg · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day
400 IU2 years280
Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial
2008 · vitamin K group · Postmenopausal women with osteopenia; mean age 59 years, range 40–82
800 IU4 years217
The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease
2012 · calcium-vitamin D3 fixed combination group (Ca-D3) · Elderly institutionalized women, mean age 85 years, with moderate chronic kidney disease and severe vitamin D deficiency
800 IU2 years206
The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease
2012 · separate calcium and vitamin D3 supplements group (Ca + D3) · Elderly institutionalized women, mean age 85 years, with moderate chronic kidney disease and severe vitamin D deficiency
800 IU2 years189
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density
2007 · alendronate-placebo/calcium 1000 mg · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day
400 IU2 years140
Impact of Calcium and Two Doses of Vitamin D on Bone Metabolism in the Elderly: A Randomized Controlled Trial
2017 · Low dose group · Overweight, ambulatory adults aged 65 or older with screening serum 25OHD of 10–30 ng/ml
500 IU1 year128
Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial
2014 · Group A (alfacalcidol) · Women aged 45–75 years, postmenopausal for at least 5 years, with osteoporosis
0.5 mcg1 year118
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension
2015 · ALN/D5600 · Postmenopausal women in China aged over 55 with osteoporosis
800 IU1 year111
Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis
2015 · ALN + VitD group · Japanese men and women aged 60–90 with primary osteoporosis or osteopenia and at least one vertebral fracture
400 IU48 weeks109
Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial
2019 · 400 IU group · Healthy community-dwelling adults aged 55 to 70 years without osteoporosis, with baseline 25(OH)D of 30 to 125 nmol/L
400 IU3 years109
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension
2015 · Calcitriol · Postmenopausal women in China aged over 55 with osteoporosis
0.25 mcg1 year108
Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis
2004 · group A · Adults with established glucocorticoid-induced osteoporosis receiving long-term glucocorticoid therapy, with or without vertebral fractures; underlying conditions included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica
1 mcg3 years103
A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis
2006 · Calcium group · Children and adolescents aged 6–18 years with juvenile rheumatoid arthritis who had not taken corticosteroids for at least 3 months
400 IU2 years103
Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial
2019 · 10 000 IU group · Healthy community-dwelling adults aged 55 to 70 years without osteoporosis, with baseline 25(OH)D of 30 to 125 nmol/L
10,000 IU3 years102
Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis
2004 · group B · Adults with established glucocorticoid-induced osteoporosis receiving long-term glucocorticoid therapy, with or without vertebral fractures; underlying conditions included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica
1,000 IU3 years101
Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial
2019 · 4000 IU group · Healthy community-dwelling adults aged 55 to 70 years without osteoporosis, with baseline 25(OH)D of 30 to 125 nmol/L
4,000 IU3 years100
Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo study
2025 · All patients · Patients aged 18–60 years with early active rheumatoid arthritis and no earlier use of disease-modifying anti-rheumatic drugs
800 IU—99
Formula Milk Supplementation and Bone Acquisition in 4-6 Years Chinese Children: A 12-Month Cluster-Randomized Controlled Trial
2023 · formula milk group · Healthy Chinese children aged 4–6 years in rural Northwest China who were willing to drink milk but consumed little for economic reasons
4.5 mcg1 year96
Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation
2003 · supplementation · Ambulatory elderly women, mean age 75 years, with vitamin D insufficiency
800 IU1 year95
Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial
2015 · VitD/Cal group · HIV-infected adults initiating their first ART regimen with EFV/FTC/TDF
4,000 IU48 weeks81
Efficacy of strontium ranelate on bone mineral density in men with osteoporosis
2010 · Strontium ranelate group · Men with primary osteoporosis
800 IU1 year76
Efficacy of strontium ranelate on bone mineral density in men with osteoporosis
2010 · Alendronate group · Men with primary osteoporosis
800 IU1 year76
Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women
2001 · vitamin D(3) and calcium group · Elderly women with 25-hydroxycholecalciferol below 50 nmol/L; mean age 74 years
800 IU8 weeks74
The efficacy and safety of calcitriol and/or Caltrate D in elderly Chinese women with low bone mass
2009 · Rocaltrol+Caltrate D group · Chinese women aged over 65 years with osteopenia or osteoporosis
0.25 mcg1 year74
Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis
2006 · vitamin D plus calcium group · Postmenopausal Caucasian patients with osteoporosis and normal vitamin D serum levels
880 IU547 days72
Estimating the causal effect of milk powder supplementation on bone mineral density: a randomized controlled trial with both non-compliance and loss to follow-up
2015 · milk powder supplementation group · Healthy postmenopausal women
800 IU2 years69
The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women
2014 · Aquatic Exercise Group (AEG) · Postmenopausal women, mean age 58.8 ± 6.4 years
1,000 IU24 weeks64
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D
2011 · group B · Patients with Crohn's disease and reduced BMD (T-score < -1)
1,000 IU1278 days62
Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium
2003 · simple vitamin D (ergocalciferol) plus calcium carbonate · Females and males commencing or already taking glucocorticoids
4,286 IU2 years61
Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study
2012 · 500 mg calcium with 400 international unis (iu) vitamin D daily · Adults with β-thalassaemia and osteoporosis (BMD Z scores ≤-2·0)
400 IU1 year59
Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study
2012 · 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d · Adults with β-thalassaemia and osteoporosis (BMD Z scores ≤-2·0)
400 IU1 year59
Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients
2021 · bazedoxifene group · Postmenopausal women aged 45 years or older with rheumatoid arthritis and osteopenia, receiving low-dose glucocorticoids
800 IU56 weeks57
Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients
2021 · control group · Postmenopausal women aged 45 years or older with rheumatoid arthritis and osteopenia, receiving low-dose glucocorticoids
800 IU56 weeks57
Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study
1996 · 1 alpha(OH)D3 group · Female patients with osteoporosis; age range not reported
0.75 mcg2 years57
Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents
2019 · Ca6D group · Healthy Chinese adolescents aged 11.9–15.2 years
400 IU548 days56
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial
2015 · Risedronate group · Postmenopausal women over age 55 with hormone receptor-positive breast cancer, low bone mass, and current aromatase inhibitor treatment
200 IU2 years55
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation
2006 · Control group · Patients with orthotopic liver transplantation
0.5 mcg2 years54
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D
2011 · group C · Patients with Crohn's disease and reduced BMD (T-score < -1)
1,000 IU1278 days54
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial
2015 · Placebo group · Postmenopausal women over age 55 with hormone receptor-positive breast cancer, low bone mass, and current aromatase inhibitor treatment
200 IU2 years54
Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents
2019 · Ca9D group · Healthy Chinese adolescents aged 11.9–15.2 years
400 IU548 days54
Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients
2008 · experiment I group · Patients on maintenance dialysis with chronic renal failure, at risk of osteoporosis; age and sex not specified
0.25 mcg1 year50
Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients
2008 · experiment II group · Patients on maintenance dialysis with chronic renal failure, at risk of osteoporosis; age and sex not specified
0.25 mcg1 year50
Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride
2002 · calcium-vitamin D-placebo group · Adults with inflammatory bowel disease and osteoporosis (lumbar spine T score below -2 standard deviations), median age 35 years; normal serum 25OH vitamin D
800 IU1 year49
Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents
2019 · Ca3D group · Healthy Chinese adolescents aged 11.9–15.2 years
400 IU548 days49
Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride
2002 · calcium-vitamin D-fluoride group · Adults with inflammatory bowel disease and osteoporosis (lumbar spine T score below -2 standard deviations), median age 35 years; normal serum 25OH vitamin D
800 IU1 year45
Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation
2004 · calcitriol therapy (CT) · renal transplant recipients; age and sex not specified
0.25 mcg90 days45
Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study
2011 · Risedronate plus calcium and vitamin D3 · Patients with osteopenia or osteoporosis within the first month after liver transplantation
800 IU1 year45
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation
2006 · ALN 70 mg weekly · Patients with orthotopic liver transplantation
0.5 mcg2 years44
Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study
2011 · Calcium and vitamin D3 · Patients with osteopenia or osteoporosis within the first month after liver transplantation
800 IU1 year44
The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women
2014 · Control Group (CG) · Postmenopausal women, mean age 58.8 ± 6.4 years
1,000 IU24 weeks44
A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV
2019 · Low VitD group · Postmenopausal African American or Hispanic women aged 40–70 with HIV, serum 25-OHD 10–32 ng/mL, on stable antiretroviral therapy
1,000 IU1 year43
A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV
2019 · Moderate VitD group · Postmenopausal African American or Hispanic women aged 40–70 with HIV, serum 25-OHD 10–32 ng/mL, on stable antiretroviral therapy
3,000 IU1 year42
The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis
2004 · Calcitriol and calcium group · Post-menopausal women with osteoporosis
0.5 mcg26 weeks40
The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study
2005 · Treatment group · Men with idiopathic osteoporosis, mean age 59 ± 6 years, without vertebral fractures
400 IU548 days40
Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old
2011 · treatment group (vitamin K) · Postmenopausal Korean women over 60 years old
400 IU26 weeks40
Skeletal site-dependent response of bone mineral density and quantitative ultrasound parameters following a 12-month dietary intervention using dairy products fortified with calcium and vitamin D: the Postmenopausal Health Study
2006 · dairy group (DG) · Postmenopausal women aged 55–65 years
7.5 mcg1 year39
Changes in biochemical indexes of bone metabolism and bone mineral density after a 12-mo dietary intervention program: the Postmenopausal Health Study
2007 · dairy intervention group · postmenopausal women
7.5 mcg1 year39
Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old
2011 · control group · Postmenopausal Korean women over 60 years old
400 IU26 weeks38
Cardiometabolic Indices after Weight Loss with Calcium or Dairy Foods: Secondary Analyses from a Randomized Trial with Overweight/Obese Postmenopausal Women
2022 · Supplement group (S) · Overweight/obese, generally healthy postmenopausal women with dietary calcium intake of 800 mg/day or less
200 IU26 weeks37
Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial
2003 · Group 2 · Women aged 70 years or older with BMI ≤21 kg/m² and hip osteoporosis
800 IU1 year36
Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial
2003 · Group 1 · Women aged 70 years or older with BMI ≤21 kg/m² and hip osteoporosis
800 IU1 year35
Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial
2011 · Vitamin D3 · Adults aged 18–50 with clinically definite multiple sclerosis, fully ambulatory (EDSS ≤4.5)
2,857 IU96 weeks35
Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women
2002 · placebo · Postmenopausal African-American women aged 45–88 with osteoporosis
500 IU2 years33
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis
2006 · raloxifene group · Postmenopausal women with diagnosed osteoporosis
800 IU2 years33
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis
2006 · placebo group · Postmenopausal women with diagnosed osteoporosis
800 IU2 years33
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis
2006 · continuation of open-label alendronate group · Postmenopausal women with diagnosed osteoporosis
800 IU2 years33
Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women
2002 · alendronate group · Postmenopausal African-American women aged 45–88 with osteoporosis
500 IU2 years32
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D
2011 · group A · Patients with Crohn's disease and reduced BMD (T-score < -1)
1,000 IU1278 days32
The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study
2005 · Control group · Men with idiopathic osteoporosis, mean age 59 ± 6 years, without vertebral fractures
400 IU548 days31
Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study
2006 · PTH250 · Adults aged 52–84 years with osteoporosis
200 IU90 days31
Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial
2004 · treatment group · Healthy adults; age and sex not specified
500 IU213 days30
[Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis]
2005 · Group A · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment
1 mcg1 year30
[Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis]
2005 · Group B · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment
0.5 mcg1 year30
Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study
2006 · PTH500 · Adults aged 52–84 years with osteoporosis
200 IU90 days30
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)
2007 · group A · Adults with established postmenopausal or male osteoporosis
1 mcg2 years30
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)
2007 · group B · Adults with established postmenopausal or male osteoporosis
1,000 IU2 years30
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)
2007 · group C · Adults with established postmenopausal or male osteoporosis
1 mcg2 years30
Clodronic acid in the treatment of postmenopausal osteoporosis
2007 · clodronic acid group · Postmenopausal women aged 48–73 years with osteoporosis
400 IU3 years30
Effect of calcium plus vitamin D supplementation during pregnancy in Brazilian adolescent mothers: a randomized, placebo-controlled trial
2013 · calcium plus vitamin D · Pregnant adolescents aged 14–19 years with low-calcium diets
200 IU—30
Calcium plus vitamin D supplementation during pregnancy interacts with polymorphisms in the promoter region of the VDR gene to affect postpartum bone mass of Brazilian adolescent mothers: A randomized controlled trial
2016 · calcium plus cholecalciferol · Pregnant adolescents aged 14–19 years
200 IU—30
Reduction in Bone Loss from 5 to 20 Weeks Postpartum in Adolescents Supplemented with Calcium Plus Vitamin D during Pregnancy Is Not Sustained at 1 Year Postpartum: Follow-up Study of a Randomized Controlled Trial
2021 · supplemented group · Pregnant adolescents aged 14–19 years with habitually low calcium intake
200 IU—30
Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1 alpha-hydroxyvitamin D3 and calcium supplementation
1997 · treatment group · Patients with hemiplegia after stroke; mean duration of illness 4.8 years; age and sex not reported
1 mcg26 weeks30
Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study
2006 · PTH1000 · Adults aged 52–84 years with osteoporosis
200 IU90 days29
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial)
2008 · Control group · Adults aged 18 years or older with cystic fibrosis and low bone mass
800 IU1 year29
Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial
2015 · Resistance training (RT) · Men aged 25–60 years with low lumbar-spine or hip bone mass; apparently healthy and physically active
10 mcg1 year29
Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial
2015 · Jump training (JUMP) · Men aged 25–60 years with low lumbar-spine or hip bone mass; apparently healthy and physically active
10 mcg1 year29
Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study
2014 · B · Adults aged 61–96 years with a recent hip fracture
800 IU1 year28
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial)
2008 · Alendronate group · Adults aged 18 years or older with cystic fibrosis and low bone mass
800 IU1 year27
Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss?
2009 · Group A · Healthy, morbidly obese, premenopausal women undergoing long limb-biliopancreatic diversion
200 IU1 year26
Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss?
2009 · Group B · Healthy, morbidly obese, premenopausal women undergoing long limb-biliopancreatic diversion
200 IU1 year26
Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II
2011 · CaD group · Postmenopausal women
10 mcg1 year26
Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II
2011 · CaDK1 group · Postmenopausal women
10 mcg1 year26
Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study
2014 · BN · Adults aged 61–96 years with a recent hip fracture
800 IU26 weeks26
Two-Month Consumption of Orange Juice Enriched with Vitamin D3 and Probiotics Decreases Body Weight, Insulin Resistance, Blood Lipids, and Arterial Blood Pressure in High-Cardiometabolic-Risk Patients on a Westernized Type Diet: Results from a Randomized Clinical Trial
2024 · Intervention group · Adults aged 18–70 with BMI >25 kg/m² and high cardiometabolic risk, including hyperglycemia and/or hyperlipidemia and/or hypertension
2,000 IU8 weeks26
Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study
2014 · C · Adults aged 61–96 years with a recent hip fracture
800 IU1 year25
Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial
2017 · multispecies probiotic supplement (GeriLact) · Postmenopausal women aged 50–72 years with osteopenia
200 IU26 weeks25
Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II
2011 · CaDK2 group · Postmenopausal women
10 mcg1 year24
Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women
1998 · E + C group · Postmenopausal women with at least one non-traumatic vertebral fracture or z score < -1.5
0.5 mcg1 year24
Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome
2009 · group 1 · Premenopausal women aged 43.1 ± 7.7 years with subclinical Cushing's syndrome due to adrenal incidentaloma and osteoporosis or osteopenia
800 mg1 year23
Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome
2009 · group 2 · Premenopausal women aged 43.1 ± 7.7 years with subclinical Cushing's syndrome due to adrenal incidentaloma and osteoporosis or osteopenia
800 mg1 year23
Effects of calcium and vitamin D supplementation on blood pressure and serum lipids and carotenoids: a randomized, double-blind, placebo-controlled, clinical trial
2013 · calcium plus vitamin D3 · Adults aged 30–75 with at least one pathology-confirmed adenomatous colorectal polyp in the previous 36 months
800 IU26 weeks23
Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis
2000 · DK group · Postmenopausal women aged 55–81 years with osteoporosis, more than 5 years after menopause
0.75 mcg2 years21
Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT
2012 · Algal oil containing DHA · Individuals with osteopenia
1,000 IU1 year20
Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT
2012 · Placebo group · Individuals with osteopenia
1,000 IU1 year20
Increase of bone mineral density with sodium fluoride in patients with Crohn's disease
2000 · calcium/vitamin D/fluoride group · Patients with chronic active Crohn's disease and osteoporosis; all had received systemic high-dose steroid therapy during the previous year
1,000 IU1 year18
Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation
2000 · Control subjects · Patients with cystic fibrosis after lung transplantation
800 IU2 years18
Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation
2000 · treatment group · Long-term renal transplant recipients with serum creatinine levels less than 2.0 mg/dL
0.25 mcg1 year16
Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation
2000 · Pamidronate treatment group · Patients with cystic fibrosis after lung transplantation
800 IU2 years16
Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis
2014 · SrRan monotherapy · Postmenopausal women aged 54–73 with osteoporosis
800 IU26 weeks16
Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis
2014 · SrRan + AD3 · Postmenopausal women aged 54–73 with osteoporosis
800 IU26 weeks16
Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis
2014 · Control · Postmenopausal women aged 54–73 with osteoporosis
800 IU26 weeks16
Increase of bone mineral density with sodium fluoride in patients with Crohn's disease
2000 · calcium/vitamin D only group · Patients with chronic active Crohn's disease and osteoporosis; all had received systemic high-dose steroid therapy during the previous year
1,000 IU1 year15
Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine
2004 · vitamins D3 plus K2 (group D + K) · Patients with chronic glomerulonephritis receiving prednisolone; age and sex distribution for this arm not reported
0.5 mcg8 weeks15
Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis
2004 · calcium and vitamin D treatment group · Adults with cystic fibrosis and a BMD Z score of -1 or less in the lumbar spine, proximal femur or distal forearm
1,700 IU1 year15
Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate
1994 · treated group · Adults with asthma undergoing long-term systemic corticosteroid treatment
1,000 IU26 weeks14
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers
2000 · Vehicle group · Men aged 30–68 with idiopathic osteoporosis
400 IU548 days13
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers
2000 · PTH-(1-34) group · Men aged 30–68 with idiopathic osteoporosis
400 IU548 days10
Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial
2020 · study group · Adults aged 18–50 with HIV infection, ART-naïve at enrollment and starting TDF/FTC/EFV; mostly men
2,857 IU24 weeks9
Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients
1997 · diet plus calcium and vitamin D · Adults with newly diagnosed, untreated celiac disease; 11 of the 14 patients had osteopenia at diagnosis
4,571 IU1 year7
Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women
1990 · Calcitriol-treated group · Women over 60 years of age with osteopenia
0.5 mcg1 year4
The long-term effect of early mineral, vitamin D, and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely
1999 · 500 IU/day vitamin D; mineral-supplemented breast milk · Preterm infants; sex and exact age range not stated
500 IU——
The long-term effect of early mineral, vitamin D, and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely
1999 · 1000 IU/day vitamin D; mineral-supplemented breast milk · Preterm infants; sex and exact age range not stated
1,000 IU——
Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen
2000 · calcium and calcitriol at 0.25 microg daily · Thai postmenopausal women no more than 6 years postmenopausal
0.25 mcg2 years—
Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen
2000 · calcium and calcitriol at 0.5 microg daily · Thai postmenopausal women no more than 6 years postmenopausal
0.5 mcg2 years—
Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study
2000 · Group 1 · Premenopausal women aged 31.1 ± 6 years with systemic lupus erythematosus taking chronic steroid therapy
0.5 mcg2 years—
Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis
2001 · HEBP group · Women over 50 years old with postmenopausal osteoporosis, low BMD and lumbo-dorsal pain
0.5 mcg2 years—
Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis
2001 · Ca. D group · Women over 50 years old with postmenopausal osteoporosis, low BMD and lumbo-dorsal pain
0.5 mcg2 years—
Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study
2002 · CaD group · Adult renal transplant recipients; 65 men and 46 women, mean age 47 years
0.25 mcg26 weeks—
Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate
2003 · group A · Patients with Crohn's disease and pathological bone mineral density findings
1,000 IU821 days—
A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density
2003 · HRT/D group · Postmenopausal women aged 53–79 years with osteoporosis, at least one minimal-trauma vertebral fracture, and low lumbar bone mineral density
0.5 mcg2 years—
Preventing bone loss in renal transplant recipients with vitamin D
2003 · group 1 · adult men who were recent renal transplant recipients
0.5 mcg——
A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease
2003 · calcium and vitamin D alone · Patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip
400 IU1 year—
A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease
2003 · calcium and vitamin D with intravenous pamidronate · Patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip
400 IU1 year—
An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis
2004 · Transdermal HRT group · Postmenopausal women with primary biliary cirrhosis
0.25 mcg2 years—
An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis
2004 · Control group · Postmenopausal women with primary biliary cirrhosis
0.25 mcg2 years—
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension
2004 · alendronate 10 mg/day group · Women aged 60–86 years with low BMD who had received alendronate in FIT
250 IU3 years—
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension
2004 · alendronate 5 mg/day group · Women aged 60–86 years with low BMD who had received alendronate in FIT
250 IU3 years—
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension
2004 · placebo group · Women aged 60–86 years with low BMD who had received alendronate in FIT
250 IU3 years—
The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study
2004 · vitamin D3 plus calcium · Women aged 58–88 with a proximal humerus fracture and osteoporosis or osteopenia
800 IU12 weeks—
Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease
2005 · Etidronate group · Patients with Crohn's disease and decreased bone mineral density
400 IU2 years—
Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease
2005 · Non-etidronate group · Patients with Crohn's disease and decreased bone mineral density
400 IU2 years—
Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate
2005 · Calcium, vitamin D, and sex hormone replacement group · Adults who received an allogeneic stem cell transplant
800 IU1 year—
Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate
2005 · Calcium, vitamin D, sex hormone replacement, and pamidronate group · Adults who received an allogeneic stem cell transplant
800 IU1 year—
A prospective randomized study for prevention of postrenal transplantation bone loss
2005 · group I · adult male recent renal transplant recipients
0.5 mcg1 year—
A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial
2005 · 0.5 microg/d ED-71 · Osteoporotic patients aged 49–87 years receiving vitamin D supplementation
0.5 mcg1 year—
A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial
2005 · 0.75 microg/d ED-71 · Osteoporotic patients aged 49–87 years receiving vitamin D supplementation
0.75 mcg1 year—
A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial
2005 · 1.0 microg/d ED-71 · Osteoporotic patients aged 49–87 years receiving vitamin D supplementation
1 mcg1 year—
Effects of calcium, dairy product, and vitamin D supplementation on bone mass accrual and body composition in 10-12-y-old girls: a 2-y randomized trial
2005 · calcium (1000 mg) + vitamin D3 (200 IU) · Healthy girls aged 10–12 years at Tanner stage I–II with dietary calcium intake below 900 mg/day
200 IU2 years—
Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome
2006 · treatment group · Children with nephrotic syndrome receiving prednisolone; mean age 4.6 years, 27 boys and 13 girls across the study
400 IU60 days—
Calcium plus vitamin D supplementation and the risk of fractures
2006 · calcium plus vitamin D group · Healthy postmenopausal women aged 50 to 79 years
400 IU7 years—
Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial
2006 · calcium- and vitamin D3-fortified milk group · Men older than 50 years living in the community; mean age 61.9 years
800 IU2 years—
Long-term effects of calcium-vitamin-D3-fortified milk on bone geometry and strength in older men
2006 · milk supplementation group · men aged over 50 years; older subgroup analyses included men over 62 years
800 IU2 years—
Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations
2007 · calcium + vitamin D supplement group · Healthy overweight or obese women with daily calcium intake below 800 mg
400 IU15 weeks—
Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women
2007 · vitamin D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older
10 mcg2 years—
Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women
2007 · combined vitamins K1 and D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older
10 mcg2 years—
Bone mineral density and bone markers in patients with a recent low-energy fracture: effect of 1 y of treatment with calcium and vitamin D
2007 · calcium and vitamin D intervention group · Patients with a recent low-energy fracture of the hip, forearm, shoulder, or spine; mean age 70 ± 11 years, 84% women
1,400 IU1 year—
Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis
2007 · Raloxifene group · Postmenopausal women with osteoporosis
400 IU1 year—
Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis
2007 · Low-dose HRT group · Postmenopausal women with osteoporosis
400 IU1 year—
Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial
2008 · CaD group · Community-dwelling women aged 70–80 years
1,000 IU5 years—
The remodeling transient and the calcium economy
2008 · Ca + D group · Ambulatory postmenopausal African-American women not receiving hormone replacement therapy
20 mcg2 years—
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study
2008 · 2 mg IV ibandronate every 2 months · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis
400 IU2 years—
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study
2008 · 3 mg IV ibandronate every 3 months · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis
400 IU2 years—
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study
2008 · 2.5 mg daily oral ibandronate · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis
400 IU2 years—
Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency
2008 · Calcium plus vitamin D · Elderly women, mean age 77.2 years, with vitamin D insufficiency (serum 25(OH)D <60 nM)
1,000 IU1 year—
Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women
1991 · Vitamin D group · Healthy, ambulatory postmenopausal women with usual vitamin D intakes of 100 IU/day
400 IU1 year—
Effect of alendronate in elderly patients after low trauma hip fracture repair
2009 · Ca-Vit D group · Elderly patients after low-trauma hip fracture repair; mean age 81 ± 7 years; 79.8% women
400 IU1 year—
Effect of alendronate in elderly patients after low trauma hip fracture repair
2009 · ALN + Ca-Vit D group · Elderly patients after low-trauma hip fracture repair; mean age 81 ± 7 years; 79.8% women
400 IU1 year—
Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial
2009 · exercise + fortified milk · Men aged 50–79 years; older, well-nourished men
800 IU1 year—
Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial
2009 · fortified milk · Men aged 50–79 years; older, well-nourished men
800 IU1 year—
Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial
2008 · calcium supplementation group · Children aged 6–18 years with juvenile rheumatoid arthritis, without systemic corticosteroid therapy in the 3 months before enrollment
400 IU2 years—
Vitamin D insufficiency does not affect response of bone mineral density to alendronate
2009 · Calcium and cholecalciferol recipients · Postmenopausal women with low bone mineral density
250 IU——
Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone
2009 · DHEA group · Men and women aged 65–75 years
16 mcg2 years—
Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone
2009 · Placebo group, then open-label DHEA in year 2 · Men and women aged 65–75 years
16 mcg1 year—
Phosphate and carbonate salts of calcium support robust bone building in osteoporosis
2010 · Tricalcium phosphate group · Patients with osteoporosis treated with teriparatide and consuming less than 1000 mg phosphorus per day
1,000 IU1 year—
Phosphate and carbonate salts of calcium support robust bone building in osteoporosis
2010 · Calcium carbonate group · Patients with osteoporosis treated with teriparatide and consuming less than 1000 mg phosphorus per day
1,000 IU1 year—
The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial
2012 · standard-dose vitamin D group · Postmenopausal women aged 50–80 years with reduced bone mass (BMD T-score ≤ −2.0 in the lumbar spine or total hip)
800 IU1 year—
Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
2012 · Placebo group · Japanese postmenopausal women with osteoporosis
400 IU1 year—
Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
2012 · Denosumab 14 mg group · Japanese postmenopausal women with osteoporosis
400 IU1 year—
Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
2012 · Denosumab 60 mg group · Japanese postmenopausal women with osteoporosis
400 IU1 year—
Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
2012 · Denosumab 100 mg group · Japanese postmenopausal women with osteoporosis
400 IU1 year—
Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study
1990 · calcitriol · Postmenopausal women with vertebral fractures; age range not reported
0.62 mcg2 years—
A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation
2012 · Ibandronate group · Renal transplant recipients with early stable renal function
0.25 mcg1 year—
A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation
2012 · Placebo group · Renal transplant recipients with early stable renal function
0.25 mcg1 year—
Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis
2013 · low-dose ALN group · Chinese postmenopausal women aged 62.2 ± 7.0 years with osteopenia or osteoporosis
125 IU1 year—
Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis
2013 · standard-dose ALN group · Chinese postmenopausal women aged 62.2 ± 7.0 years with osteopenia or osteoporosis
125 IU1 year—
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study
2013 · 5-mg alendronate and 0.5-µg calcitriol (Maxmarvil®) group · Korean postmenopausal women with hormone receptor-positive early breast cancer receiving daily aromatase inhibitor
0.5 mcg24 weeks—
Effect of vitamin D supplementation on blood pressure in blacks
2013 · 1,000 IU vitamin D3 group · Black adults aged 30–80, described as healthy; vitamin D status varied
1,000 IU90 days—
Effect of vitamin D supplementation on blood pressure in blacks
2013 · 2,000 IU vitamin D3 group · Black adults aged 30–80, described as healthy; vitamin D status varied
2,000 IU90 days—
Effect of vitamin D supplementation on blood pressure in blacks
2013 · 4,000 IU vitamin D3 group · Black adults aged 30–80, described as healthy; vitamin D status varied
4,000 IU90 days—
Vitamin D supplementation after parathyroidectomy: effect on bone mineral density-a randomized double-blind study
2014 · D+ · Adults with primary hyperparathyroidism after successful parathyroidectomy; median age 60 years, range 30–80; 79% women
1,600 IU1 year—
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial
2014 · Exemestane group · Postmenopausal women with early hormone-receptor-positive breast cancer, with baseline bone mineral density T-scores of either −2.0 or greater or less than −2.0
800 IU2 years—
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial
2014 · Anastrozole group · Postmenopausal women with early hormone-receptor-positive breast cancer, with baseline bone mineral density T-scores of either −2.0 or greater or less than −2.0
800 IU2 years—
The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial
2014 · 100 g dried plum/d group · Osteopenic postmenopausal women
400 IU1 year—
The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial
2014 · 75 g dried apple/d comparative control group · Osteopenic postmenopausal women
400 IU1 year—
Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial
2014 · Low-Ca group · Girls and boys aged 12–14 years
200 IU2 years—
Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial
2014 · Mid-Ca group · Girls and boys aged 12–14 years
200 IU2 years—
Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial
2014 · High-Ca group · Girls and boys aged 12–14 years
200 IU2 years—
A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial
2015 · CC group · Postmenopausal women with osteopenia
200 IU1 year—
A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial
2015 · Control group · Postmenopausal women with osteopenia
200 IU1 year—
Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis
2016 · SrR group · Women with thalassemia major-related osteoporosis
800 IU2 years—
Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial
2016 · Group A · Postmenopausal women aged 50–65 years
800 IU2 years—
Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial
2016 · Group B · Postmenopausal women aged 50–65 years
800 IU2 years—
Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial
2016 · Group C · Postmenopausal women aged 50–65 years
800 IU2 years—
Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate
2017 · denosumab group · Men with prostate cancer and osteoporosis undergoing androgen deprivation therapy
600 IU2 years—
Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate
2017 · alendronate group · Men with prostate cancer and osteoporosis undergoing androgen deprivation therapy
600 IU2 years—
Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy
2017 · Cholecalciferol and calcium carbonate · Adults with primary hyperparathyroidism undergoing parathyroidectomy; median age 60 years, 119 women
1,600 IU1 year—
Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial
2019 · PATCH · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation alongside hormone treatment
800 IU1 year—
Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial
2019 · PILL · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation alongside combined oral contraceptive treatment
800 IU1 year—
Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial
2019 · NONE · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation and no oestrogen or progesterone
800 IU1 year—
Role of Calcium and Low-Fat Dairy Foods in Weight-Loss Outcomes Revisited: Results from the Randomized Trial of Effects on Bone and Body Composition in Overweight/Obese Postmenopausal Women
2019 · Supplement group (S) · Overweight or obese Caucasian women 2–10 years postmenopausal, generally healthy, with dietary calcium intake of 800 mg/day or less
400 IU26 weeks—
Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study
2020 · Co-supplementation group · Community-dwelling men and postmenopausal women aged 50–75 years
10 mcg1 year—
The effects of vitamin D and curcuminoids supplementation on anthropometric measurements and blood pressure in type 2 diabetic patients with coexisting hypovitaminosis D: A double-blind, placebo-controlled randomized clinical trial
2020 · vitamin D3 plus curcuminoids · Adults with type 2 diabetes and insufficient vitamin D status
7,143 IU12 weeks—
The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial
2021 · vitamin K2 (MK-7) group · Postmenopausal women with osteopenia
38 mcg1096 days—
The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial
2021 · Placebo group · Postmenopausal women with osteopenia
38 mcg1096 days—
Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial
2021 · standard-dose VitD/Ca supplementation · Adolescents aged 10–20 years with perinatally acquired HIV who were on stable cART
400 IU48 weeks—
Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial
2021 · high-dose VitD/Ca supplementation · Adolescents aged 10–20 years with perinatally acquired HIV who were on stable cART
3,257 IU48 weeks—
Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia
2022 · Group A · Postmenopausal women with osteopenia
400 IU1 year—
High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT
2024 · Arm 2 (placebo arm; daily supplements) · Men aged 60 years or older with stage I–IV prostate cancer, no bone metastases, receiving androgen deprivation therapy, and serum 25(OH)D below 32 ng/mL
800 IU24 weeks—
Impact of high-dose vitamin D and calcium carbonate supplementation on bone density in adolescents living with HIV: a randomised, placebo-controlled trial
2026 · intervention · Adolescents aged 11–19 years with perinatally acquired HIV, taking antiretroviral therapy
2,857 IU48 weeks—
Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D
1995 · 2.5 micrograms (100 IU) vitamin D/d group · Healthy ambulatory postmenopausal women
100 IU2 years—
Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D
1995 · 17.5 micrograms (700 IU) vitamin D/d group · Healthy ambulatory postmenopausal women
700 IU2 years—
Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss
1994 · calcium augmentation · Healthy white women 3 to 6 years after spontaneous menopause
400 IU1059 days—
Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss
1994 · estrogen-progesterone-calcium · Healthy white women 3 to 6 years after spontaneous menopause
400 IU1059 days—
Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial
1996 · Calcium carbonate and vitamin D3 · Patients with rheumatoid arthritis; some were receiving corticosteroids and some were not
500 IU2 years—
Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
1997 · calcium and vitamin D group · Men and women 65 years of age or older living at home
700 IU3 years—
Maternal obesity and baseline vitamin D insufficiency alter the response to vitamin D supplementation: a double-blind, randomized trial in pregnant women
2021 · 20 µg/d group · Pregnant women aged 18 years or older, from 12 gestational weeks through delivery; normal weight, overweight, and obese participants, including women with and without baseline vitamin D insufficiency.
20 mcg28 weeks121
Estimation of the maternal vitamin D intake that maintains circulating 25-hydroxyvitamin D in late gestation at a concentration sufficient to keep umbilical cord sera ≥25-30 nmol/L: a dose-response, double-blind, randomized placebo-controlled trial in pregnant women at northern latitude
2018 · 20 µg vitamin D3 group · White-skinned pregnant adults aged 21–41 years, enrolled by 18 weeks’ gestation and without a stated high-risk pregnancy
20 mcg22 weeks48
Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial
2026 · ERC group · Adults with end-stage kidney disease, advanced secondary hyperparathyroidism, and requiring regular hemodialysis; sex and age range not specified
129 mcg26 weeks33
Comparison of narrowband ultraviolet B exposure and oral vitamin D substitution on serum 25-hydroxyvitamin D concentration
2012 · oral cholecalciferol-treated · Healthy adults with serum 25(OH)D below 75 nmol/L
20 mcg4 weeks30
Influence of food matrix delivery system on the bioavailability of vitamin D(3): A randomized crossover trial in postmenopausal women
2023 · Apple juice · Postmenopausal women aged 60–80 years with vitamin D insufficiency
200 mcg1 day30
Influence of food matrix delivery system on the bioavailability of vitamin D(3): A randomized crossover trial in postmenopausal women
2023 · Semi-skim milk · Postmenopausal women aged 60–80 years with vitamin D insufficiency
200 mcg1 day30
Influence of food matrix delivery system on the bioavailability of vitamin D(3): A randomized crossover trial in postmenopausal women
2023 · Water with vitamin D3 · Postmenopausal women aged 60–80 years with vitamin D insufficiency
200 mcg1 day30
Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial
2016 · cholecalciferol · Adults with non-dialysis-dependent stage 3–5 chronic kidney disease and serum 25(OH)D below 30 ng/ml
179 mcg12 weeks22
Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial
2016 · ergocalciferol · Adults with non-dialysis-dependent stage 3–5 chronic kidney disease and serum 25(OH)D below 30 ng/ml
179 mcg12 weeks22
A 25-Hydroxycholecalciferol-Fortified Dairy Drink Is More Effective at Raising a Marker of Postprandial Vitamin D Status than Cholecalciferol in Men with Suboptimal Vitamin D Status
2017 · +HyD3 dairy drink · Men with suboptimal vitamin D status; mean age 49 years
20 mcg1 day17
A 25-Hydroxycholecalciferol-Fortified Dairy Drink Is More Effective at Raising a Marker of Postprandial Vitamin D Status than Cholecalciferol in Men with Suboptimal Vitamin D Status
2017 · +D3 dairy drink · Men with suboptimal vitamin D status; mean age 49 years
20 mcg1 day17
Serum 25-hydroxyvitamin D response to vitamin D supplementation using different lipid delivery systems in middle-aged and older adults: a randomised controlled trial
2023 · Vitamin D supplement · Healthy adults aged 50 years and older; middle-aged and older adults, men and women
20 mcg4 weeks17
Serum 25-hydroxyvitamin D response to vitamin D supplementation using different lipid delivery systems in middle-aged and older adults: a randomised controlled trial
2023 · Olive oil dairy drink · Healthy adults aged 50 years and older; middle-aged and older adults, men and women
20 mcg4 weeks15
Serum 25-hydroxyvitamin D response to vitamin D supplementation using different lipid delivery systems in middle-aged and older adults: a randomised controlled trial
2023 · Coconut oil dairy drink · Healthy adults aged 50 years and older; middle-aged and older adults, men and women
20 mcg4 weeks15
Pharmacokinetics of oral vitamin D(3) and calcifediol
2014 · daily calcifediol group · healthy females aged 50–70 years
20 mcg15 weeks5
Pharmacokinetics of oral vitamin D(3) and calcifediol
2014 · daily vitamin D(3) group · healthy females aged 50–70 years
20 mcg15 weeks5
Pharmacokinetics of oral vitamin D(3) and calcifediol
2014 · weekly calcifediol group · healthy females aged 50–70 years
20 mcg15 weeks5
Pharmacokinetics of oral vitamin D(3) and calcifediol
2014 · weekly vitamin D(3) group · healthy females aged 50–70 years
20 mcg15 weeks5
Pharmacokinetics of oral vitamin D(3) and calcifediol
2014 · single bolus calcifediol group · healthy females aged 50–70 years
140 mcg1 day5
Pharmacokinetics of oral vitamin D(3) and calcifediol
2014 · single bolus vitamin D(3) group · healthy females aged 50–70 years
140 mcg1 day5
Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3
2002 · Vitamin D3 supplementation, young men · Healthy men aged 18–35
20 mcg8 weeks—
Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3
2002 · Vitamin D3 supplementation, older men · Healthy men aged 62–79
20 mcg8 weeks—
Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol
2003 · 250 micro g cholecalciferol · Healthy men living in Omaha; age not reported
250 mcg20 weeks—
How much vitamin D3 do the elderly need?
2006 · 20 microg vitamin D3 group · Women aged 65–85 years
20 mcg12 weeks—
Wintertime vitamin D supplementation inhibits seasonal variation of calcitropic hormones and maintains bone turnover in healthy men
2009 · 20 microg (800 IU) group · Healthy white men aged 21–49 years
20 mcg26 weeks—
Estimation of the dietary requirement for vitamin D in healthy adults
2008 · 15 microg/d vitamin D3 · Men and women aged 20–40 years; healthy adults
15 mcg22 weeks—
Supplements of 20 microg/d cholecalciferol optimized serum 25-hydroxyvitamin D concentrations in 80% of premenopausal women in winter
2009 · 20 microg/d D3 group · Predominantly white premenopausal women living in Maine; mean age 22.2 ± 3.7 years
20 mcg150 days—
How much vitamin D for neonates?
1991 · 20 micrograms/d (800 IU/d) vitamin D · Neonates, including low-birth-weight and full-term well infants
20 mcg16 weeks—
Estimation of the dietary requirement for vitamin D in free-living adults >=64 y of age
2009 · 15 microg vitamin D(3)/d · men and women aged ≥64 years
15 mcg22 weeks—
Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults
2010 · Young adults, 15 microg/day · Healthy adults aged 20–40 years
15 mcg——
Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults
2010 · Elderly adults, 15 microg/day · Healthy adults aged 64 years or older
15 mcg——
Serum 25-hydroxyvitamin D concentrations of free-living subjects consuming olestra
1991 · Triglycerides (placebo) · Free-living adults; age range and sex not reported
20 mcg6 weeks—
Serum 25-hydroxyvitamin D concentrations of free-living subjects consuming olestra
1991 · Olestra · Free-living adults; age range and sex not reported
20 mcg6 weeks—
Effect of adiposity on vitamin D status and the 25-hydroxycholecalciferol response to supplementation in healthy young and older Irish adults
2012 · cholecalciferol supplementation · Healthy Irish adults aged 20–40 years and 64 years or older
15 mcg22 weeks—
Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity
2012 · HyD group · Healthy postmenopausal women, mean age 61.5 years, with a mean baseline 25(OH)D level of 13.2 ng/mL
20 mcg120 days—
Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity
2012 · vitamin D3 group · Healthy postmenopausal women, mean age 61.5 years, with a mean baseline 25(OH)D level of 13.2 ng/mL
20 mcg120 days—
Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults
2012 · 20 μg vitamin D3 group · Adults aged 50 years or older, apparently healthy
20 mcg10 weeks—
Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults
2012 · 20 μg 25-hydroxyvitamin D3 group · Adults aged 50 years or older, apparently healthy
20 mcg10 weeks—
Dietary calcium does not interact with vitamin D₃ in terms of determining the response and catabolism of serum 25-hydroxyvitamin D during winter in older adults
2014 · vitamin D₃ group · Free-living men and women aged 50 years or older, stratified by dietary calcium intake
20 mcg15 weeks—
Calcifediol improves lipid profile in osteopenicatorvastatin-treated postmenopausal women
2015 · calcifediol · Postmenopausal women aged about 59 years with low 25(OH)D, osteopenia and dyslipidemia, taking atorvastatin
20 mcg24 weeks—
Calcifediol improves lipid profile in osteopenicatorvastatin-treated postmenopausal women
2015 · cholecalciferol · Postmenopausal women aged about 59 years with low 25(OH)D, osteopenia and dyslipidemia, taking atorvastatin
20 mcg24 weeks—
Vitamin D3 supplementation: Response and predictors of vitamin D3 metabolites - A randomized controlled trial
2016 · vitamin D3 group · Adults aged 20–71 years
20 mcg12 weeks—
Estimation of the dietary requirement for vitamin D in adolescents aged 14-18 y: a dose-response, double-blind, randomized placebo-controlled trial
2016 · 20-μg/d group · White male and female adolescents aged 14–18 years in the United Kingdom during winter
20 mcg20 weeks—
Estimation of the dietary requirement for vitamin D in white children aged 4-8 y: a randomized, controlled, dose-response trial
2016 · 20 μg vitamin D3/d supplementation · White Danish children aged 4–8 years
20 mcg20 weeks—
Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone
2017 · 25D3 group · Adults aged 18 years or older with 25-hydroxyvitamin D levels below 20 ng/mL
20 mcg16 weeks—
Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults
2018 · 15 μg calcifediol group · Men and women aged 65 years or older; no condition specified
15 mcg24 weeks—
Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults
2018 · 20 μg vitamin D3 group · Men and women aged 65 years or older; no condition specified
20 mcg24 weeks—
Daily supplementation with 15 μg vitamin D(2) compared with vitamin D(3) to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial
2017 · juice supplemented with vitamin D2 · Healthy South Asian and white European women aged 20–64 years
15 mcg12 weeks—
Daily supplementation with 15 μg vitamin D(2) compared with vitamin D(3) to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial
2017 · biscuit supplemented with vitamin D2 · Healthy South Asian and white European women aged 20–64 years
15 mcg12 weeks—
Daily supplementation with 15 μg vitamin D(2) compared with vitamin D(3) to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial
2017 · juice supplemented with vitamin D3 · Healthy South Asian and white European women aged 20–64 years
15 mcg12 weeks—
Daily supplementation with 15 μg vitamin D(2) compared with vitamin D(3) to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12-wk randomized, placebo-controlled food-fortification trial
2017 · biscuit supplemented with vitamin D3 · Healthy South Asian and white European women aged 20–64 years
15 mcg12 weeks—
Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens
2017 · 20 μg/day · Postmenopausal women aged 55 years or older with vitamin D inadequacy
20 mcg90 days—
Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens
2017 · 125 μg/week · Postmenopausal women aged 55 years or older with vitamin D inadequacy
17.9 mcg90 days—
Winter Cholecalciferol Supplementation at 55°N Has No Effect on Markers of Cardiometabolic Risk in Healthy Children Aged 4-8 Years
2018 · 20 µg/d vitamin D3 group · Healthy white Danish children aged 4–8 years
20 mcg20 weeks—
Vitamin D-fortified foods improve wintertime vitamin D status in women of Danish and Pakistani origin living in Denmark: a randomized controlled trial
2020 · Danish-fortified group · Women of Danish origin living in Denmark, at risk of vitamin D deficiency
20 mcg12 weeks—
Vitamin D-fortified foods improve wintertime vitamin D status in women of Danish and Pakistani origin living in Denmark: a randomized controlled trial
2020 · Pakistani-fortified group · Women of Pakistani origin living in Denmark, at risk of vitamin D deficiency
20 mcg12 weeks—
Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults
2020 · 25(OH)D3 15 µg group · Older adults, mean age 63.3 ± 7.9 years; no specific condition stated
15 mcg26 weeks—
Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults
2020 · 25(OH)D3 20 µg group · Older adults, mean age 63.3 ± 7.9 years; no specific condition stated
20 mcg26 weeks—
Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults
2020 · D3 20 µg group · Older adults, mean age 63.3 ± 7.9 years; no specific condition stated
20 mcg26 weeks—
Vitamin D Supplementation and Sunlight Exposure on Serum Vitamin D Concentrations in 2 Parallel, Double-Blind, Randomized, Placebo-Controlled Trials
2021 · Vitamin D supplement group with UVB exposure (Brazil) · Adult women living in Brazil (16°S); mean age 31.39 ± 8.7 years; no condition stated
15 mcg12 weeks—
Vitamin D Supplementation and Sunlight Exposure on Serum Vitamin D Concentrations in 2 Parallel, Double-Blind, Randomized, Placebo-Controlled Trials
2021 · Vitamin D supplement group without UVB exposure (England) · Adult women living in England (51°N); mean age 31.39 ± 8.7 years; no condition stated
15 mcg12 weeks—
Effects of high dairy protein intake and vitamin D supplementation on body composition and cardiometabolic markers in 6-8-y-old children-the D-pro trial
2022 · high-protein yogurt plus vitamin D3 · White Danish children aged 6–8 years, described as well-nourished
20 mcg24 weeks—
Effects of high dairy protein intake and vitamin D supplementation on body composition and cardiometabolic markers in 6-8-y-old children-the D-pro trial
2022 · normal-protein yogurt plus vitamin D3 · White Danish children aged 6–8 years, described as well-nourished
20 mcg24 weeks—
Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial
2024 · calcifediol 100 µg group · Adults aged 18 years or older with vitamin D deficiency, serum 25(OH)D >10 and <20 ng/mL; males and females
14.3 mcg52 weeks—
Olestra dose response on fat-soluble and water-soluble nutrients in humans
1997 · 0 g/d olestra group · Normal healthy adults
20 mcg8 weeks—
Olestra dose response on fat-soluble and water-soluble nutrients in humans
1997 · 8 g/d olestra group · Normal healthy adults
20 mcg8 weeks—
Olestra dose response on fat-soluble and water-soluble nutrients in humans
1997 · 20 g/d olestra group · Normal healthy adults
20 mcg8 weeks—
Olestra dose response on fat-soluble and water-soluble nutrients in humans
1997 · 32 g/d olestra group · Normal healthy adults
20 mcg8 weeks—
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men
1998 · vitamin D3 250 micrograms/day · healthy men, mean age 28 years
250 mcg8 weeks—
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men
1998 · 25(OH)D3 20 micrograms/day · healthy men, mean age 28 years
20 mcg4 weeks—
Effect of vitamin D supplementation during pregnancy on mid-to-late gestational blood pressure in a randomized controlled trial in Bangladesh
2021 · 4200 IU/week vitamin D group · Pregnant women aged 18 years and older, generally healthy, enrolled at 17–24 weeks of gestation
600 IU—252
Effect of vitamin D supplementation during pregnancy on mid-to-late gestational blood pressure in a randomized controlled trial in Bangladesh
2021 · 16800 IU/week vitamin D group · Pregnant women aged 18 years and older, generally healthy, enrolled at 17–24 weeks of gestation
2,400 IU—251
[Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial]
2004 · Group 1: Vitrum Osteomag · Postmenopausal women with osteopenia; age range not reported
400 IU1 year125
A 2-Year Randomized Controlled Trial With Low-Dose B-Vitamin Supplementation Shows Benefits on Bone Mineral Density in Adults With Lower B12 Status
2022 · B-vitamin treatment · Community-dwelling adults aged 50 years or older; men and women; no specific diagnosed condition, and not currently taking B-vitamin supplements at screening
10 mcg2 years103
Calcium and vitamin D fortified milk reduces bone turnover and improves bone density in postmenopausal women over 1 year
2018 · intervention · Chinese postmenopausal women in Malaysia; mean age 59 years
15 mcg1 year61
Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study
2013 · geniVida bone blend (GBB) · Healthy postmenopausal women aged 45–55 years, 1–3 years since their last spontaneous menstrual bleeding
800 IU26 weeks31
Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation
2015 · standard PN · Children aged 6 years or older undergoing first myeloablative allogeneic hematopoietic cell transplantation; ages 6–11 or over 11, with diagnoses including leukemia
7,143 IU——
Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation
2015 · experimental PN · Children aged 6 years or older undergoing first myeloablative allogeneic hematopoietic cell transplantation; ages 6–11 or over 11, with diagnoses including leukemia
7,143 IU——
The Impact of Vitamin D, Calcium, Protein Supplementation, and Physical Exercise on Bone Metabolism After Bariatric Surgery: The BABS Study
2016 · intervention group · Women and similarly aged men with BMI >38 kg/m² after Roux-en-Y gastric bypass or sleeve gastrectomy; median age 40.7 years
6,286 IU2 years—
High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT
2024 · Arm 1 (high-dose vitamin D) · Men aged 60 years or older with stage I–IV prostate cancer, no bone metastases, receiving androgen deprivation therapy, and serum 25(OH)D below 32 ng/mL
7,943 IU24 weeks—
BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial
2006 · BXL628 group · Men aged 50 years or older with benign prostatic hyperplasia and prostate volume of at least 40 ml
150 mcg12 weeks57
The Effectiveness of Vitamin D Supplementation on Oxidative and Inflammatory Markers in Patients Suffering from End-stage Renal Disease, a Randomized Controlled Trial
2022 · vitamin D · Patients with end-stage renal disease, categorised by severity of vitamin D deficiency
250 mcg8 weeks51
Vitamin D(3) reduces risk of cardiovascular and liver diseases by lowering homocysteine levels: double-blinded, randomised, placebo-controlled trial
2021 · vitamin D · Overweight women with vitamin D deficiency
179 mcg60 days50
Effect of vitamin D(3) vs. calcifediol on VDR concentration and fiber size in skeletal muscle
2023 · HyD group · Postmenopausal women; mean age 61 ± 4 years
20 mcg26 weeks11
The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion
2006 · vitamin D group · Patients with pulmonary tuberculosis and moderately advanced pulmonary tuberculous lesions
250 mcg6 weeks—
Maintenance of wintertime vitamin D status with cholecalciferol supplementation is not associated with alterations in serum cytokine concentrations among apparently healthy younger or older adults
2011 · 15 μg/d cholecalciferol (D3) group · Apparently healthy younger adults aged 20–40 years and older adults aged ≥64 years
15 mcg22 weeks—
Associations Between Change in Total and Free 25-Hydroxyvitamin D With 24,25-Dihydroxyvitamin D and Parathyroid Hormone
2018 · 25(OH)D3 group · Adults aged 18 years or older with 25(OH)D levels below 20 ng/mL
20 mcg16 weeks—
Vitamin D3 supplementation for 8 weeks leads to improved haematological status following the consumption of an iron-fortified breakfast cereal: a double-blind randomised controlled trial in iron-deficient women
2019 · vitamin D3 group · Fe-deficient women; mean age 27.4 years
38 mcg8 weeks—
Vitamins D(2) and D(3) Have Overlapping But Different Effects on the Human Immune System Revealed Through Analysis of the Blood Transcriptome
2022 · vitamin D2 treatment group · Women aged 20–64, South Asian and white European, described as healthy
15 mcg12 weeks—
Vitamins D(2) and D(3) Have Overlapping But Different Effects on the Human Immune System Revealed Through Analysis of the Blood Transcriptome
2022 · vitamin D3 treatment group · Women aged 20–64, South Asian and white European, described as healthy
15 mcg12 weeks—
An investigation of sources of variation in calcium absorption efficiency
1995 · 25OHD pretreatment group · Healthy premenopausal women, mean age 36.4 years
20 mcg34 days—
Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study
2023 · vitamin D · Adults with prediabetes meeting at least two of three glycemic criteria and no diagnostic criteria for diabetes
4,000 IU913 days1,211
Associations of vitamin D binding protein variants with the vitamin D-induced increase in serum 25-hydroxyvitamin D
2019 · Vitamin D3 supplementation · Healthy adolescent Iranian girls
7,143 IU9 weeks619
Determinants of the Maternal 25-Hydroxyvitamin D Response to Vitamin D Supplementation During Pregnancy
2016 · 1000-IU/d cholecalciferol · Pregnant women aged over 18 years with singleton pregnancies and serum 25(OH)D of 25–100 nmol/L
1,000 IU—407
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial
2006 · ALN + D · Men and postmenopausal women with osteoporosis and serum 25OHD ≥9 ng/mL
10 mcg15 weeks360
Impact of three different daily doses of vitamin D3 supplementation in healthy schoolchildren and adolescents from North India: a single-blind prospective randomised clinical trial
2019 · Group A · Vitamin D-deficient children aged 6–16 years
600 IU26 weeks344
Impact of three different daily doses of vitamin D3 supplementation in healthy schoolchildren and adolescents from North India: a single-blind prospective randomised clinical trial
2019 · Group B · Vitamin D-deficient children aged 6–16 years
1,000 IU26 weeks341
Response to Antenatal Cholecalciferol Supplementation Is Associated With Common Vitamin D-Related Genetic Variants
2017 · Cholecalciferol 1000 IU/d · White pregnant women aged over 18 years with singleton pregnancies, enrolled before 17 weeks' gestation and with 25(OH)D of 25–100 nmol/L
1,000 IU—331
A genetic variant in the cytochrome P450 family 2 subfamily R member 1 determines response to vitamin D supplementation
2019 · Vitamin D3 supplementation · 253 healthy Iranian girls; age not reported
7,143 IU9 weeks253
Impact of vitamin D fortified milk supplementation on vitamin D status of healthy school children aged 10-14 years
2013 · Group B · Healthy school children aged 10–14 years, boys and girls
600 IU12 weeks243
Impact of vitamin D fortified milk supplementation on vitamin D status of healthy school children aged 10-14 years
2013 · Group C · Healthy school children aged 10–14 years, boys and girls
1,000 IU12 weeks233
Impact of three different daily doses of vitamin D3 supplementation in healthy schoolchildren and adolescents from North India: a single-blind prospective randomised clinical trial
2019 · Group C · Vitamin D-deficient children aged 6–16 years
2,000 IU26 weeks232
A randomized clinical trial comparing 3 different replacement regimens of vitamin D in clinically asymptomatic pediatrics and adolescents with vitamin D insufficiency
2016 · Group 1 · Children and adolescents aged 2–18 years with vitamin D below 30 ng/mL, clinically asymptomatic
400 IU1 year196
Relationship between vitamin D status and the vaginal microbiome during pregnancy
2019 · Group B: 4,400 IU/day · Pregnant women enrolled in the first trimester, with singleton pregnancies
4,400 IU—196
Vitamin D Repletion in Korean Postmenopausal Women with Osteoporosis
2016 · Vitamin D supplementation during screening · Korean postmenopausal women aged 60–90 years with osteoporosis and vitamin D deficiency (serum 25(OH)D <50 nmol/L)
2,000 IU31 days191
Relationship between vitamin D status and the vaginal microbiome during pregnancy
2019 · Group A: 400 IU vitamin D3/day—Standard dose treatment · Pregnant women enrolled in the first trimester, with singleton pregnancies
400 IU—191
Effects of different vitamin D supplementation strategies in reversing metabolic syndrome and its component risk factors in adolescents
2019 · vitamin D tablet · Saudi adolescents aged 12–18 years, boys and girls; apparently healthy
1,000 IU212 days180
Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness
2011 · 4000 IU group · Pregnant women aged 16 years or older with singleton pregnancies, enrolled before 16 weeks’ gestation
4,000 IU—169
Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness
2011 · 2000 IU group · Pregnant women aged 16 years or older with singleton pregnancies, enrolled before 16 weeks’ gestation
2,000 IU—167
Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness
2011 · 400 IU group · Pregnant women aged 16 years or older with singleton pregnancies, enrolled before 16 weeks’ gestation
400 IU—166
Vitamin D supplementation and growth in urban Mongol school children: Results from two randomized clinical trials
2017 · Vitamin D3-fortified milk group (Fortification Study) · Children aged 9–11 years in Ulaanbaatar, Mongolia; most analyzed children had serum 25(OH)D below 20 ng/ml
300 IU7 weeks138
Effects of long-term vitamin D supplementation on metabolic profile in middle-aged and elderly patients with type 2 diabetes
2023 · vitamin D group · Patients aged 50–70 years with type 2 diabetes
800 IU900 days135
The relationship between physical activity and vitamin D status in postpartum lactating and formula-feeding women
2018 · 6400 IU vitamin D3 per day · Healthy postpartum women who were lactating; age range not reported
6,400 IU213 days127
The relationship between physical activity and vitamin D status in postpartum lactating and formula-feeding women
2018 · 400 IU vitamin D3 per day (control group) · Healthy postpartum women who were lactating; age range not reported
400 IU213 days121
25-Hydroxyvitamin D in Cancer Patients Admitted to Palliative Care: A Post-Hoc Analysis of the Swedish Trial 'Palliative-D'
2022 · vitamin D3 oil drops (Detremin) · Adults with advanced or metastatic cancer in palliative care and serum 25-OHD ≤50 nmol/L
4,000 IU12 weeks121
Maternal obesity and baseline vitamin D insufficiency alter the response to vitamin D supplementation: a double-blind, randomized trial in pregnant women
2021 · 10 µg/d group · Pregnant women aged 18 years or older, from 12 gestational weeks through delivery; normal weight, overweight, and obese participants, including women with and without baseline vitamin D insufficiency.
10 mcg28 weeks119
Efficacy of Daily Supplementation of Milk Fortified With Vitamin D2 for Three Months in Healthy School Children: A Randomized Placebo Controlled Trial
2021 · Intervention group · Healthy schoolchildren aged 10–14 years with vitamin D deficiency
240 IU90 days119
Measurements of the Vitamin D Metabolome in the Calgary Vitamin D Study: Relationship of Vitamin D Metabolites to Bone Loss
2023 · 400 IU daily · Healthy males and females aged 55–70 years without vitamin D deficiency and with DXA T-scores > -2.5
400 IU1096 days109
Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care
2017 · 4000 IU/day · Men and women aged 65 years or older living in the community; not currently taking more than 400 IU/day vitamin D3
4,000 IU1 year102
Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care
2017 · 2000 IU/day · Men and women aged 65 years or older living in the community; not currently taking more than 400 IU/day vitamin D3
2,000 IU1 year102
Measurements of the Vitamin D Metabolome in the Calgary Vitamin D Study: Relationship of Vitamin D Metabolites to Bone Loss
2023 · 10,000 IU daily · Healthy males and females aged 55–70 years without vitamin D deficiency and with DXA T-scores > -2.5
10,000 IU1096 days102
Hormonal Contraceptive Use Is Associated With Higher Total but Unaltered Free 25-Hydroxyvitamin D Serum Concentrations
2018 · 800 IU vitamin D3 group · Apparently healthy women of childbearing age
800 IU8 weeks101
Hormonal Contraceptive Use Is Associated With Higher Total but Unaltered Free 25-Hydroxyvitamin D Serum Concentrations
2018 · 200 IU vitamin D3 group · Apparently healthy women of childbearing age
200 IU8 weeks100
Clinical effect of alfacalcidol in children with Henoch-Schönlein purpura: a prospective randomized controlled trial
2021 · observation group · Children with Henoch-Schönlein purpura
0.25 mcg4 weeks100
Measurements of the Vitamin D Metabolome in the Calgary Vitamin D Study: Relationship of Vitamin D Metabolites to Bone Loss
2023 · 4000 IU daily · Healthy males and females aged 55–70 years without vitamin D deficiency and with DXA T-scores > -2.5
4,000 IU1096 days100
Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: the Tromsø study
2010 · Vitamin D supplementation (40,000 IU per week) · Adults in a population-based study; age and health condition not specified
5,714 IU1 year93
Effect of vitamin D on oxidative stress and serum inflammatory factors in the patients with type 2 diabetes
2022 · Vitamin D supplement group (VitD group) · Adults with type 2 diabetes; age range and sex not specified
400 IU90 days86
A randomized trial of vitamin D supplementation in 2 community health center networks in South Carolina
2013 · 2000 IU group · Pregnant women aged 16 years or older, enrolled before 16 weeks’ gestation; diverse community health center population, many African American or Hispanic
2,000 IU26 weeks83
Safety and effectiveness of stoss therapy in children with vitamin D deficiency
2020 · stoss · Children aged 2–16 years with 25OHD <50 nmol/L
14,286 IU4 weeks83
Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial
2013 · vitamin D3 group · Pregnant women aged 18 to under 35 years, enrolled at 26 to under 30 weeks’ gestation
5,000 IU10 weeks80
Effect of isolated vitamin D supplementation on bone turnover markers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial
2018 · VD group · Women aged 50–65 years, postmenopausal for at least 12 months, with normal bone mineral density and vitamin D deficiency
1,000 IU270 days80
Isolated vitamin D supplementation improves the adipokine profile of postmenopausal women: a randomized clinical trial
2023 · vitamin D group · Postmenopausal women aged 50–65 years
1,000 IU39 weeks80
A randomized trial of vitamin D supplementation in 2 community health center networks in South Carolina
2013 · 4000 IU group · Pregnant women aged 16 years or older, enrolled before 16 weeks’ gestation; diverse community health center population, many African American or Hispanic
4,000 IU26 weeks78
Comparison between daily supplementation doses of 200 versus 400 IU of vitamin D in infants
2013 · group 1, 200 IU/day · infants; age and health status not further specified
200 IU—75
Vitamin D Metabolism Varies among Women in Different Reproductive States Consuming the Same Intakes of Vitamin D and Related Nutrients
2016 · Vitamin D intake · Healthy women of childbearing age: pregnant women at 26–29 weeks’ gestation, lactating women at 5 weeks postpartum, and nonpregnant, nonlactating controls
200 IU10 weeks75
Supplementation with Three Different Daily Doses of Vitamin D3 in Healthy Pre-pubertal School Girls: A Cluster Randomized Trial
2018 · 2000 IU group · Healthy pre-pubertal girls aged 6.1–11.8 years
2,000 IU26 weeks75
Supplementation with Three Different Daily Doses of Vitamin D3 in Healthy Pre-pubertal School Girls: A Cluster Randomized Trial
2018 · 600 IU group · Healthy pre-pubertal girls aged 6.1–11.8 years
600 IU26 weeks74
Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants: a randomized clinical trial
2011 · Capsules 800 IU · Non-western immigrant adults aged 18–65 with documented vitamin D deficiency
800 IU26 weeks72
Safety and effectiveness of stoss therapy in children with vitamin D deficiency
2020 · standard · Children aged 2–16 years with 25OHD <50 nmol/L
5,000 IU80 days68
A randomized, double-blind, placebo-controlled trial of vitamin D supplementation with or without calcium in community-dwelling vitamin D deficient subjects
2022 · Vitamin D3 · Adults aged 18 years and over, men and women, with vitamin D deficiency; apparently healthy community-dwelling UAE residents and expatriates
2,000 IU26 weeks68
Supplementation with Three Different Daily Doses of Vitamin D3 in Healthy Pre-pubertal School Girls: A Cluster Randomized Trial
2018 · 1000 IU group · Healthy pre-pubertal girls aged 6.1–11.8 years
1,000 IU26 weeks67
A randomized trial of vitamin D₃ supplementation in children: dose-response effects on vitamin D metabolites and calcium absorption
2013 · 1000 IU group · Males and females aged 9–13 years; healthy children without a stated diagnosed condition
1,000 IU12 weeks65
High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients
2008 · replenishment phase · Haemodialysis patients with vitamin D deficiency
2,857 IU39 weeks64
Comparison between daily supplementation doses of 200 versus 400 IU of vitamin D in infants
2013 · group 2, 400 IU/day · infants; age and health status not further specified
400 IU—64
A randomized trial of vitamin D₃ supplementation in children: dose-response effects on vitamin D metabolites and calcium absorption
2013 · 400 IU group · Males and females aged 9–13 years; healthy children without a stated diagnosed condition
400 IU12 weeks64
A randomized trial of vitamin D₃ supplementation in children: dose-response effects on vitamin D metabolites and calcium absorption
2013 · 2000 IU group · Males and females aged 9–13 years; healthy children without a stated diagnosed condition
2,000 IU12 weeks64
A randomized trial of vitamin D₃ supplementation in children: dose-response effects on vitamin D metabolites and calcium absorption
2013 · 4000 IU group · Males and females aged 9–13 years; healthy children without a stated diagnosed condition
4,000 IU12 weeks64
Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial
2014 · Oral cholecalciferol (D3) · Adults aged 18 years or older receiving hemodialysis for at least 2 months, with serum 25(OH)D below 25 ng/mL
7,143 IU1 year62
A randomized double-blind controlled trial comparing two regimens of vitamin D supplementation in preterm neonates
2016 · 400 IU group · Preterm neonates born at 27 to 34 weeks gestation
400 IU—60
A randomized double-blind controlled trial comparing two regimens of vitamin D supplementation in preterm neonates
2016 · 1000 IU group · Preterm neonates born at 27 to 34 weeks gestation
1,000 IU—60
Vitamin D(3) supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: Results of an open label randomized clinical trial
2017 · daily vitamin D3 group · Adults aged 18–80 with diabetes and chronic kidney disease stages 1–4
2,000 IU26 weeks60
Differences in vitamin D3 dosing regimens in a geriatric community-dwelling population
2012 · 2,000 IU vitamin D3 daily · Adults aged 65 years and older, with baseline 25(OH)D levels below or at/above 30 ng/mL
2,000 IU26 weeks59
Influence of a single oral dose of vitamin D(2) on serum 25-hydroxyvitamin D concentrations in tuberculosis patients
2009 · vitamin D(2) group, healthy adults · Healthy adults; age and sex not reported
2.5 mg1 day56
Vitamin D supplementation and growth in urban Mongol school children: Results from two randomized clinical trials
2017 · Vitamin D3 group (Supplementation Study) · Children aged 12–15 years living in Ulaanbaatar, Mongolia; all analyzed children had serum 25(OH)D below 20 ng/ml
800 IU26 weeks56
Effect of Vitamin D Supplementation on (25(OH)D) Status in Children 12-30 Months of Age: A Randomized Clinical Trial
2023 · Vitamin D2 (Ergocalciferol) 400 IU/day · Healthy children aged 12–30 months, both sexes
400 IU90 days56
Effect of Vitamin D Supplementation on (25(OH)D) Status in Children 12-30 Months of Age: A Randomized Clinical Trial
2023 · Vitamin D3 (Cholecalciferol) 1000 IU/day · Healthy children aged 12–30 months, both sexes
1,000 IU90 days56
Effect of vitamin D(3) supplementation in winter on physical performance of university students: a one-month randomized controlled trial
2023 · vitamin D group · Chinese university undergraduates; men and women, mean age 19 years; no stated diagnosed condition
1,000 IU30 days56
Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents
2008 · Vitamin D3 daily · Men and women aged 70 years or older living in nursing homes; mean age 84 years, with low vitamin D status
600 IU120 days55
[Effect of vitamin D supplementation and outdoor time on the 25(OH)D level in adolescents]
2017 · VD supplementation group · Adolescents with vitamin D deficiency at baseline; age range and sex not specified
800 IU4 weeks55
Effects of a single dose of vitamin D in septic children: a randomized, double-blinded, controlled trial
2020 · treatment group · Children aged 14 years or younger with sepsis and vitamin D deficiency
150,000 IU1 day55
Monitored Supplementation of Vitamin D in Preterm Infants: A Randomized Controlled Trial
2021 · standard vitamin D supplementation group (control group) · Preterm infants born at 24–32 weeks of gestation
500 IU52 weeks55
Effect of Vitamin D Supplementation on (25(OH)D) Status in Children 12-30 Months of Age: A Randomized Clinical Trial
2023 · Vitamin D2 (Ergocalciferol) 800 IU/day · Healthy children aged 12–30 months, both sexes
800 IU90 days55
Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2
1998 · vitamin D3 · Subjects; age, sex, and health condition not stated
4,000 IU2 weeks55
Impact of a single oral dose of 100,000 IU vitamin D3 on profiles of serum 25(OH)D3 and its metabolites 24,25(OH)2D3, 3-epi-25(OH)D3, and 1,25(OH)2D3 in adults with vitamin D insufficiency
2017 · vitamin D3 · Adults aged 20–50 with self-perceived fatigue and vitamin D insufficiency
100,000 IU1 day52
Estimations of dietary vitamin D requirements in black and white children
2016 · vitamin D-supplemented group · Healthy children aged 8–14 years, black and white; sex not specified
1,000 IU26 weeks51
The interactive effect of improvement of vitamin D status and VDR FokI variants on oxidative stress in type 2 diabetic subjects: a randomized controlled trial
2015 · vitamin D3-fortified doogh (FD) · people with type 2 diabetes; age and sex not stated
1,000 IU12 weeks50
Effect of sun exposure versus oral vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in young adults: A randomized clinical trial
2020 · oral vitamin D3 group · Young vitamin D-deficient adults in Seoul, Korea; sex and age range not stated
500 IU8 weeks50
Bioavailability and Safety of Vitamin D3 from Pizza Baked with Fortified Mozzarella Cheese: A Randomized Controlled Trial
2015 · high-dose group · Apparently healthy, ethnically diverse adults
4,000 IU8 weeks49
Randomized trial of two maintenance doses of vitamin D in children with chronic kidney disease
2022 · 1000 IU group · Children aged 9 years or older with CKD stages 3–5 or kidney transplant recipients
1,000 IU26 weeks49
Randomized trial of two maintenance doses of vitamin D in children with chronic kidney disease
2022 · 4000 IU group · Children aged 9 years or older with CKD stages 3–5 or kidney transplant recipients
4,000 IU26 weeks49
Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial
2025 · Randomized trial, denosumab group · Infertile men; mean age approximately 34 years
25 mcg160 days49
Trial of daily vitamin D supplementation in preterm infants
2014 · 800-IU group · Preterm infants born at 28 to 34 weeks' gestation
800 IU—48
Trial of daily vitamin D supplementation in preterm infants
2014 · 400-IU group · Preterm infants born at 28 to 34 weeks' gestation
400 IU—48
Estimation of the maternal vitamin D intake that maintains circulating 25-hydroxyvitamin D in late gestation at a concentration sufficient to keep umbilical cord sera ≥25-30 nmol/L: a dose-response, double-blind, randomized placebo-controlled trial in pregnant women at northern latitude
2018 · 10 µg vitamin D3 group · White-skinned pregnant adults aged 21–41 years, enrolled by 18 weeks’ gestation and without a stated high-risk pregnancy
10 mcg22 weeks48
Bioavailability and Safety of Vitamin D3 from Pizza Baked with Fortified Mozzarella Cheese: A Randomized Controlled Trial
2015 · low-dose group · Apparently healthy, ethnically diverse adults
28.6 IU8 weeks47
Evolution of Serum 25OHD in Response to Vitamin D(3)-Fortified Yogurts Consumed by Healthy Menopausal Women: A 6-Month Randomized Controlled Trial Assessing the Interactions between Doses, Baseline Vitamin D Status, and Seasonality
2018 · Gr.Suppl.5 · Healthy menopausal women aged 55–75 years; no diagnosed condition stated, with screening serum 25OHD from 25 to 75 nmol/L
5 mcg16 weeks47
Evolution of Serum 25OHD in Response to Vitamin D(3)-Fortified Yogurts Consumed by Healthy Menopausal Women: A 6-Month Randomized Controlled Trial Assessing the Interactions between Doses, Baseline Vitamin D Status, and Seasonality
2018 · Gr.Suppl.10 · Healthy menopausal women aged 55–75 years; no diagnosed condition stated, with screening serum 25OHD from 25 to 75 nmol/L
10 mcg16 weeks47
Late-onset hypogonadism: beyond testosterone
2015 · calcidiol · Men aged 34.5 ± 6.8 years with classic or subclinical hypogonadism and low 25-hydroxyvitamin D; infertility evaluation patients
571 IU90 days46
Effect of Oral Vitamin D3 Supplementation in Exclusively Breastfed Newborns: Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
2022 · vD-400 group · Exclusively breastfed term newborns, enrolled at 10 days of age; healthy infants without severe vitamin D deficiency at birth
400 IU120 days46
Long-term effects of giving nursing home residents bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving
2009 · Vitamin D- and calcium-fortified bun · Older nursing home residents; sex and age range not reported; vitamin D-deficient
125 mcg1 year45
The impact of vitamin D supplementation on VDR gene expression and body composition in monozygotic twins: randomized controlled trial
2020 · Supplemented group (SG) · Adults aged 18–45 years, women and men, without diagnosed chronic non-communicable diseases; members of monozygotic twin pairs
2,000 IU60 days45
The effect of vitamin D supplementation on glycemic status of elderly people with prediabetes: a 12-month open-label, randomized-controlled study
2022 · weekly vitamin D 3 dose of 25,000 IU · Greek adults aged 60 years or above with prediabetes
3,571 IU1 year45
Vitamin D status in full-term exclusively breastfed infants versus full-term breastfed infants receiving vitamin D supplementation in Thailand: a randomized controlled trial
2021 · Intervention group · Full-term exclusively breastfed infants aged 6–12 weeks at enrollment, without a stated health condition
400 IU120 days43
Effects of a single, high oral dose of 25-hydroxycholecalciferol on the mineral metabolism markers in hemodialysis patients
2015 · treated group · Adults with vitamin D deficiency receiving chronic hemodialysis
3 mg1 day42
Does high dose vitamin D supplementation enhance cognition?: A randomized trial in healthy adults
2017 · High Dose · Healthy adults from northern British Columbia with baseline 25(OH)D levels ≤100 nmol/L
4,000 IU18 weeks42
Vitamin D Stored in Fat Tissue During a 5-Year Intervention Affects Serum 25-Hydroxyvitamin D Levels the Following Year
2017 · vitamin D group · Adults who participated in a prevention study for type 2 diabetes; age and sex not reported
2,857 IU—42
Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial
2020 · Vitamin D group · Adults aged 25–65 with overweight or obesity and type 2 diabetes; vitamin D deficient
7,143 IU8 weeks42
Prophylactic vitamin D in healthy infants: assessing the need
2011 · Vitamin D prophylaxis · Healthy full-term infants, assigned at 1 month of age
402 IU1 year41
Reduced-fat Gouda-type cheese enriched with vitamin D(3) effectively prevents vitamin D deficiency during winter months in postmenopausal women in Greece
2017 · intervention group · Postmenopausal women aged 55–75 years
5.7 mcg8 weeks40
Does high dose vitamin D supplementation enhance cognition?: A randomized trial in healthy adults
2017 · Low Dose · Healthy adults from northern British Columbia with baseline 25(OH)D levels ≤100 nmol/L
400 IU18 weeks40
Bioequivalence Studies of Vitamin D Gummies and Tablets in Healthy Adults: Results of a Cross-Over Study
2019 · gummy vitamin D3 · Healthy adults aged 18–45 years
20,000 IU1 day40
Bioequivalence Studies of Vitamin D Gummies and Tablets in Healthy Adults: Results of a Cross-Over Study
2019 · tablet vitamin D3 · Healthy adults aged 18–45 years
20,000 IU1 day40
Effect of Vitamin D-Enriched Gouda-Type Cheese Consumption on Biochemical Markers of Bone Metabolism in Postmenopausal Women in Greece
2021 · intervention group (IG) · Postmenopausal women aged 55–75 years in Greece, including women with sufficient or insufficient vitamin D status
5.7 mcg8 weeks40
Sunlight Exposure vs Oral Vitamin D Supplementation for Prevention of Vitamin D Deficiency in Infancy: A Randomized Controlled Trial
2022 · oral vitamin D3 supplementation · Breastfed infants aged 6–8 weeks at enrollment
400 IU—40
Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial
2013 · 400 IU/d group · Healthy, term, breastfed infants enrolled at 1 month of age
400 IU335 days39
Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial
2013 · 800 IU/d group · Healthy, term, breastfed infants enrolled at 1 month of age
800 IU335 days39
Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial
2013 · 1200 IU/d group · Healthy, term, breastfed infants enrolled at 1 month of age
1,200 IU335 days38
300,000 IU or 600,000 IU of oral vitamin D3 for treatment of nutritional rickets: a randomized controlled trial
2014 · Group 1 · Children under five with clinical and radiologically confirmed nutritional rickets; median age 12 months; sex not reported
300,000 IU1 day38
300,000 IU or 600,000 IU of oral vitamin D3 for treatment of nutritional rickets: a randomized controlled trial
2014 · Group 2 · Children under five with clinical and radiologically confirmed nutritional rickets; median age 12 months; sex not reported
600,000 IU1 day38
The relationship between physical activity and vitamin D status in postpartum lactating and formula-feeding women
2018 · 2400 IU vitamin D3 per day · Healthy postpartum women who were lactating; age range not reported
2,400 IU213 days38
Colorectal cancer, Vitamin D and microbiota: A double-blind Phase II randomized trial (ColoViD) in colorectal cancer patients
2022 · Vitamin D supplementation · Adults aged 35–75 with resected stage I–III colorectal cancer after standard treatment; baseline 25(OH)D below 30 ng/ml
2,000 IU1 year38
Evaluation of the efficacy of two doses of vitamin D supplementation on glycemic, lipidemic and oxidative stress biomarkers during pregnancy: a randomized clinical trial
2020 · 1000 IU/d group · Pregnant women enrolled in the first trimester without stated clinical disease; many had vitamin D deficiency or insufficiency
1,000 IU25 weeks37
Efficacy of vitamin D supplementation among persons living with HIV/AIDS in São Paulo city, Brazil
2021 · Vitamin D (group 1; active group) · Adults with HIV-1 infection and vitamin D levels of 10–30 ng/mL; both sexes
714 IU26 weeks37
Daily Vitamin D3 Versus Stoss Vitamin D3 for Correction of 25OHD Deficiency in Children with Inflammatory Bowel Disease, a Randomised Controlled Trial
2025 · Daily vitamin D · Children aged 5–17 years with inflammatory bowel disease and vitamin D deficiency
2,000 IU1 year37
Nutritional vitamin D supplementation in dialysis: a randomized trial
2015 · 50,000 IU weekly · Adults receiving hemodialysis with 25(OH)D levels ≤32 ng/ml
7,143 IU12 weeks36
Vitamin D in newborns. A randomised controlled trial comparing daily and single oral bolus vitamin D in infants
2017 · daily dose · Newborn infants of vitamin D-deficient mothers
400 IU—36
Evaluation of the efficacy of two doses of vitamin D supplementation on glycemic, lipidemic and oxidative stress biomarkers during pregnancy: a randomized clinical trial
2020 · 2000 IU/d group · Pregnant women enrolled in the first trimester without stated clinical disease; many had vitamin D deficiency or insufficiency
2,000 IU25 weeks36
Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial
2017 · D2 daily · Healthy adults aged 18–60 years with serum 25(OH)D of 20–50 nmol/L
2,000 IU20 weeks35
Controlled randomized open label clinical study comparing the safety and efficacy of loading schedules in vitamin D deficient patients
2023 · Slower Loading Dose (SLD) · Vitamin D-deficient patients; age and sex not specified
4,286 IU14 weeks35
Loading dose vitamin D3 improves vitamin D insufficiency in adults undergoing hematopoietic stem cell transplantation: A randomized controlled trial
2023 · Control group · Adults aged 18 or older undergoing allogeneic hematopoietic stem cell transplantation
2,000 IU100 days35
A Comparison of 3 Vitamin D Dosing Regimens in Extremely Preterm Infants: A Randomized Controlled Trial
2016 · 200 IU supplement · Extremely preterm infants born at 23–27 completed weeks’ gestation
200 IU4 weeks34
Vitamin D in newborns. A randomised controlled trial comparing daily and single oral bolus vitamin D in infants
2017 · single high-dose cholecalciferol · Newborn infants of vitamin D-deficient mothers
50,000 IU1 day34
Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial
2017 · D3 daily · Healthy adults aged 18–60 years with serum 25(OH)D of 20–50 nmol/L
2,000 IU20 weeks34
Controlled randomized open label clinical study comparing the safety and efficacy of loading schedules in vitamin D deficient patients
2023 · Moderate Loading Dose (MLD) · Vitamin D-deficient patients; age and sex not specified
4,286 IU9 weeks34
Vitamin D-vitamin K interaction: effect of vitamin D supplementation on serum percentage undercarboxylated osteocalcin, a sensitive measure of vitamin K status, in Danish girls
2010 · 10 μg vitamin D3 per d · Healthy Danish girls aged 11–12 years
10 mcg1 year33
Oral vitamin D3 5000 IU/day as an adjuvant in the treatment of atopic dermatitis: a randomized control trial
2018 · vitamin D3 group · Patients with atopic dermatitis diagnosed according to Hanifin-Rajka criteria; age and sex not specified
5,000 IU90 days33
Differences in vitamin D3 dosing regimens in a geriatric community-dwelling population
2012 · 400 IU vitamin D3 daily · Adults aged 65 years and older, with baseline 25(OH)D levels below or at/above 30 ng/mL
400 IU26 weeks32
Comparison of the pharmacokinetics, safety, and tolerability of vitamin D3 in DP-R206 (150-mg ibandronate/24,000-IU vitamin D3 tablet) and as monotherapy (24,000 iu) in healthy male Korean adults
2014 · DP-R206 test drug · Healthy adult male Korean volunteers, mean age 25.8 years
24,000 IU1 day32
Evaluation of vitamin D supplementation doses during pregnancy in a population at high risk for deficiency
2014 · group 3 · Pregnant women aged 16–42 years at high risk for vitamin D deficiency
2,000 IU—32
Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens
2014 · Arm A · Children and adolescents aged 8–18 years with inflammatory bowel disease and baseline 25OHD greater than 20 ng/mL
400 IU1 year32
The effects of single high-dose or daily low-dosage oral colecalciferol treatment on vitamin D levels and muscle strength in postmenopausal women
2018 · daily dosage group · Postmenopausal women aged 50–68 with vitamin D levels below 20 ng/mL
800 IU90 days32
Evaluation of vitamin D supplementation doses during pregnancy in a population at high risk for deficiency
2014 · group 1 (control group) · Pregnant women aged 16–42 years at high risk for vitamin D deficiency
600 IU—31
Evaluation of vitamin D supplementation doses during pregnancy in a population at high risk for deficiency
2014 · group 2 · Pregnant women aged 16–42 years at high risk for vitamin D deficiency
1,200 IU—31
Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens
2014 · Arm B · Children and adolescents aged 8–18 years with inflammatory bowel disease and baseline 25OHD greater than 20 ng/mL
1,000 IU1 year31
Effects of vitamin D-fortified oil intake versus vitamin D supplementation on vitamin D status and bone turnover factors: A double blind randomized clinical trial
2022 · supplement · Healthy adults aged 18–30 years
1,000 IU12 weeks31
Pharmacokinetics of a single, large dose of cholecalciferol
2008 · cholecalciferol group · Healthy adults with limited sun exposure and milk consumption
100,000 IU1 day30
Comparative efficacy and safety of different doses of ergocalciferol supplementation in patients with metabolic syndrome
2014 · Group 2 · Patients with metabolic syndrome and vitamin D deficiency (serum 25(OH)D <20 ng/mL); age and sex not stated
2,857 IU8 weeks30
Comparative efficacy and safety of different doses of ergocalciferol supplementation in patients with metabolic syndrome
2014 · Group 3 · Patients with metabolic syndrome and vitamin D deficiency (serum 25(OH)D <20 ng/mL); age and sex not stated
5,714 IU8 weeks30
High-dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo-controlled trial
2015 · vitamin D3 supplementation · Children and young adults aged 5.0–24.9 years with perinatally acquired HIV or aged 15.0–24.9 years with behaviorally acquired HIV
7,000 IU1 year30
Vitamin D₃supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trial
2015 · 4000 IU/d group · Children and adults aged 5.0–50.9 years with HIV receiving first-line antiretroviral therapy
4,000 IU12 weeks30
Vitamin D₃supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trial
2015 · 7000 IU/d group · Children and adults aged 5.0–50.9 years with HIV receiving first-line antiretroviral therapy
7,000 IU12 weeks30
A Comparison of 3 Vitamin D Dosing Regimens in Extremely Preterm Infants: A Randomized Controlled Trial
2016 · 800 IU supplement · Extremely preterm infants born at 23–27 completed weeks’ gestation
800 IU4 weeks30
Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome
2017 · high-dose vitamin D + metformin · Women aged 18–40 with insulin-resistant PCOS
4,000 IU12 weeks30
Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome
2017 · low-dose vitamin D + metformin · Women aged 18–40 with insulin-resistant PCOS
1,000 IU12 weeks30
Determining the optimal cholecalciferol dosing regimen in children with CKD: a randomized controlled trial
2022 · Daily treatment group · Children with CKD stages 2–4 and 25OHD concentrations <30 ng/mL
3,000 IU1 year30
Investigating the Efficiency of Vitamin D Administration with Buccal Spray in the Treatment of Vitamin D Deficiency in Children and Adolescents
2021 · Group I (buccal spray) · Children and adolescents aged 3–18 years with vitamin D deficiency
2,000 IU6 weeks30
Investigating the Efficiency of Vitamin D Administration with Buccal Spray in the Treatment of Vitamin D Deficiency in Children and Adolescents
2021 · Group 2 (oral drops) · Children and adolescents aged 3–18 years with vitamin D deficiency
2,000 IU6 weeks30
The effect of vitamin D supplementation on tobacco-related disorders in individuals with a tobacco use disorder: a randomized clinical trial
2022 · vitamin D supplements · Adults who smoke cigarettes and have a tobacco use disorder; age and sex not reported
3,570 IU24 weeks30
Effects of vitamin D-fortified oil intake versus vitamin D supplementation on vitamin D status and bone turnover factors: A double blind randomized clinical trial
2022 · fortified oil · Healthy adults aged 18–30 years
1,000 IU12 weeks30
The short-term effect of high dose vitamin D3 supplementation in improving hypovitaminosis in patients with type 2 diabetes - A randomized clinical trial
2022 · vitamin D3 group · patients with type 2 diabetes and hypovitaminosis D3
7,143 IU8 weeks30
Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects
2022 · Test formulation (T), fed trial · Healthy Chinese men and women aged 18 years or older
0.75 mcg1 day30
Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects
2022 · Reference formulation (R), fed trial · Healthy Chinese men and women aged 18 years or older
0.75 mcg1 day30
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients: A Randomized Clinical Trial Study
2022 · cholecalciferol group · Females aged 18–60 years with systemic lupus erythematosus
5,000 IU12 weeks30
Concurrent effects of high-intensity interval training and vitamin D supplementation on bone metabolism among women diagnosed with osteoporosis: a randomized controlled trial
2025 · vitamin D group (VD) · Women aged 30–50 with osteoporosis; premenopausal
800 IU16 weeks30
Concurrent effects of high-intensity interval training and vitamin D supplementation on bone metabolism among women diagnosed with osteoporosis: a randomized controlled trial
2025 · concurrent group (HIIT-VD) · Women aged 30–50 with osteoporosis; premenopausal
800 IU16 weeks30
Comparison of the pharmacokinetics, safety, and tolerability of vitamin D3 in DP-R206 (150-mg ibandronate/24,000-IU vitamin D3 tablet) and as monotherapy (24,000 iu) in healthy male Korean adults
2014 · Reference drug: vitamin D3 tablet · Healthy adult male Korean volunteers, mean age 25.8 years
24,000 IU1 day29
The impact of vitamin D3 supplementation on muscle function among HIV-infected children and young adults: a randomized controlled trial
2015 · Vitamin D supplementation · HIV-infected children and young adults aged 9.6–24.9 years, with perinatally or behaviorally acquired HIV
7,000 IU1 year29
Weekly regimen of vitamin D supplementation is more efficacious than stoss regimen for treatment of vitamin D deficiency in children with chronic liver diseases
2018 · weekly regimen · Children aged 1–18 years with chronic liver disease and hypovitaminosis D
8,571 IU26 weeks28
The effects of single high-dose or daily low-dosage oral colecalciferol treatment on vitamin D levels and muscle strength in postmenopausal women
2018 · single-dose group · Postmenopausal women aged 50–68 with vitamin D levels below 20 ng/mL
300,000 IU90 days28
Genetic Variations in VDR could Modulate the Efficacy of Vitamin D3 Supplementation on Inflammatory Markers and Total Antioxidant Capacity among Breast Cancer Women: A Randomized Double Blind Controlled Trial
2019 · Vitamin D3 · Women with breast cancer, mean age 47 years; participants were undergoing chemotherapy
7,143 IU8 weeks28
Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects
2022 · Test formulation (T), fasting trial · Healthy Chinese men and women aged 18 years or older
0.75 mcg1 day28
Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects
2022 · Reference formulation (R), fasting trial · Healthy Chinese men and women aged 18 years or older
0.75 mcg1 day28
Effects of vitamin D supplementation on metabolic parameters in women with polycystic ovary syndrome: a randomized controlled trial
2024 · vitamin D group · Women aged 21–34 years with PCOS and vitamin D deficiency or insufficiency
2,000 IU12 weeks28
Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial
2016 · 4000 IU/day vitamin D3 group · Adults older than 65 years who were clinically stable long-term nursing-home residents without sun exposure
4,000 IU16 weeks27
Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule
2019 · Group 1 (KIPOS) · Healthy adults aged 18–45 years, men and women; vitamin D deficient at baseline
100,000 IU1 day27
Seven-month wintertime supplementation of 1200 IU vitamin D has no effect on hand grip strength in young, physically active males: A randomized, controlled study
2022 · intervention group · Young male military conscripts aged 19–27 years; physically active, with no stated diagnosed condition
1,200 IU30 weeks27
The change in plasma 25-hydroxyvitamin D did not differ between breast-fed infants that received a daily supplement of ergocalciferol or cholecalciferol for 3 months
2013 · D2 group · Healthy, breast-fed term newborns, enrolled at about 1 month of age
10 mcg90 days26
The change in plasma 25-hydroxyvitamin D did not differ between breast-fed infants that received a daily supplement of ergocalciferol or cholecalciferol for 3 months
2013 · D3 group · Healthy, breast-fed term newborns, enrolled at about 1 month of age
10 mcg90 days26
Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule
2019 · Group 2 (UVEDOSE) · Healthy adults aged 18–45 years, men and women; vitamin D deficient at baseline
100,000 IU1 day26
No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes
2010 · open safety study · Adults aged 18–39 with recent-onset type 1 diabetes
0.25 mcg39 weeks25
A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness
2010 · experimental group · Black boys and girls, mean age 16.3 ± 1.4 years, normotensive, with vitamin D insufficiency/deficiency commonly observed in this population
2,000 IU16 weeks25
Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis
2012 · cholecalciferol · Adults receiving hemodialysis for stage 5D chronic kidney disease; most had vitamin D insufficiency or deficiency
28,571 IU3 weeks25
Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D
2012 · Cholecalciferol group · Haemodialysis and non-haemodialysis patients with chronic kidney disease and 25-OHD <50 nmol/L at screening
5,714 IU8 weeks25
The effects of vitamin D supplementation on lipid profiles and oxidative indices among diabetic nephropathy patients with marginal vitamin D status
2019 · Intervention group · Patients with diabetic nephropathy and marginal serum vitamin D status
7,143 IU8 weeks25
The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status
2019 · low dose group · Adults over 18 with vitamin D deficiency and active mild to moderate ulcerative colitis
1,000 IU12 weeks25
Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study
2020 · Group B · Healthy vitamin D-deficient Caucasian men and women aged 18–60 years
7,143 IU12 weeks25
Pharmacodynamics of Oral Cholecalciferol in Healthy Individuals with Vitamin D Deficiency: A Randomized Open-Label Study
2021 · Group B · Caucasian healthy males and females aged 18–60 years with 25OHD below 20 ng/mL
7,143 IU12 weeks25
Assessment of the effect of routine-dose vitamin D3 supplementation in Chinese women of childbearing age with vitamin D insufficiency
2025 · 800 IU/day vitamin D3 group · Women aged 18–50 with vitamin D insufficiency (serum total 25(OH)D <20 ng/mL)
800 IU26 weeks25
A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness
2010 · control group · Black boys and girls, mean age 16.3 ± 1.4 years, normotensive, with vitamin D insufficiency/deficiency commonly observed in this population
400 IU16 weeks24
Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency
2013 · vitamin D · Women aged 20–40 with polycystic ovary syndrome and vitamin D deficiency
2,500 IU60 days24
Placental vitamin D metabolism and its associations with circulating vitamin D metabolites in pregnant women
2017 · single vitamin D intake · Healthy pregnant women at 26–29 weeks of gestation
511 IU10 weeks24
The interaction of vitamin D supplementation with Omentin-1 gene polymorphism on metabolic biomarkers, omentin-1 levels and anthropometric measures in women with prediabetes: A double-blind randomized controlled trial
2025 · Vitamin D intervention, AT genotype · Women aged 18–65 with prediabetes and the Omentin-1 AT genotype
3,571 IU12 weeks24
The interaction of vitamin D supplementation with Omentin-1 gene polymorphism on metabolic biomarkers, omentin-1 levels and anthropometric measures in women with prediabetes: A double-blind randomized controlled trial
2025 · Vitamin D intervention, TT genotype · Women aged 18–65 with prediabetes and the Omentin-1 TT genotype
3,571 IU12 weeks24
Vitamin D intervention by pharmacists in geriatric outpatients
2008 · educational intervention · Geriatric outpatients aged 65 to 89 years with insufficient vitamin D (12–31 ng/mL)
1,200 IU12 weeks23
Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial
2024 · vitamin D group · Adults aged 20–60 with MASLD and NASH
4,000 IU12 weeks23
The Effect of High Dose Cholecalciferol on Arterial Stiffness and Peripheral and Central Blood Pressure in Healthy Humans: A Randomized Controlled Trial
2016 · Cholecalciferol group · Healthy adults older than 18 years with serum 25-OH vitamin D ≤50 nmol/L
3,000 IU16 weeks22
Response to vitamin D replacement therapy in obese children and adolescents with vitamin D deficiency: a randomized controlled trial
2023 · Group 1 · Children and adolescents aged 12–18 years with obesity and vitamin D deficiency
6,000 IU12 weeks22
Effects of vitamin D supplementation on metabolic parameters, serum irisin and obesity values in women with subclinical hypothyroidism: a double-blind randomized controlled trial
2023 · vitamin D supplement group · Women aged 20–65 with subclinical hypothyroidism (TSH 5–10 µIU/mL), normal fT4, and BMI 25–37 kg/m²
7,143 IU12 weeks22
A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: no advantage of loading doses over daily supplementation
2011 · Placebo bolus · Men and women over age 50 with an acute fragility hip fracture
1,000 IU90 days21
Effects of vitamin D3 and calcium supplementation on serum levels of tocopherols, retinol, and specific vitamin D metabolites
2012 · vitamin D3 · Adults aged 30–75 in general health with a history of at least one pathology-confirmed adenomatous colorectal polyp within the previous 36 months
800 IU26 weeks21
The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis
2013 · low-dose group · Patients with multiple sclerosis treated with IFN-β; age and sex not specified
800 IU1 year21
Vitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial
2024 · Cohort F (part 2, standard of care) · Children aged 6 to under 18 with physician-diagnosed asthma, BMI at or above the 85th percentile, and screening serum 25(OH)D of 10–30 ng/mL
600 IU16 weeks21
Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults
2024 · vitamin D group · Healthy adults aged 18–53 years, with no underlying health conditions
4,000 IU12 weeks21
The bioavailability of vitamin D from fortified cheeses and supplements is equivalent in adults
2008 · fortified cheddar cheese (DC) · Adults; age range, sex, and health condition not specified
4,000 IU8 weeks20
The bioavailability of vitamin D from fortified cheeses and supplements is equivalent in adults
2008 · liquid vitamin D supplement taken with food (DS+) · Adults; age range, sex, and health condition not specified
4,000 IU8 weeks20
Maternal vitamin D supplementation to improve the vitamin D status of breast-fed infants: a randomized controlled trial
2013 · single dose group · Healthy lactating women aged 18 years or older, exclusively breastfeeding a healthy infant aged 1–6 months
150,000 IU4 weeks20
Maternal vitamin D supplementation to improve the vitamin D status of breast-fed infants: a randomized controlled trial
2013 · daily dose group · Healthy lactating women aged 18 years or older, exclusively breastfeeding a healthy infant aged 1–6 months
5,000 IU4 weeks20
Pharmacokinetics of daily versus monthly vitamin D3 supplementation in non-lactating women
2014 · 150,000 IU group · Healthy non-pregnant, non-lactating women aged 18–40 years
150,000 IU4 weeks20
The efficacy of vitamin D supplementation during a prolonged submarine patrol
2014 · 1,000 IU/day · Submariners on a prolonged submarine patrol; adult age and sex not specified
1,000 IU90 days20
Late-onset hypogonadism: beyond testosterone
2015 · cholecalciferol · Men aged 34.5 ± 6.8 years with classic or subclinical hypogonadism and low 25-hydroxyvitamin D; infertility evaluation patients
714 IU90 days20
Effect of vitamin D3 supplementation and influence of BsmI polymorphism of the VDR gene of the inflammatory profile and oxidative stress in elderly women with vitamin D insufficiency: Vitamin D3 megadose reduces inflammatory markers
2015 · supplementation group (SG) · Elderly women aged 68±6 years with vitamin D insufficiency
200,000 IU4 weeks20
Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial
2016 · juvenile-onset SLE-VitD · juvenile-onset systemic lupus erythematosus patients; ages and sex not stated
7,143 IU24 weeks20
Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial
2016 · 800 IU/day vitamin D3 group · Adults older than 65 years who were clinically stable long-term nursing-home residents without sun exposure
800 IU16 weeks20
Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial
2016 · 2000 IU/day vitamin D3 group · Adults older than 65 years who were clinically stable long-term nursing-home residents without sun exposure
2,000 IU16 weeks20
Comparison of the effect of daily versus bolus dose maternal vitamin D(3) supplementation on the 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) ratio
2018 · daily-dose group · Lactating females aged 24–40 years with a singleton infant aged 1–6 months
5,000 IU4 weeks20
Vitamin D Daily versus Monthly Administration: Bone Turnover and Adipose Tissue Influences
2018 · daily dose group · Men and women aged 77 ± 8 years with hypovitaminosis D (serum 25(OH) vitamin D3 between 10 and 30 ng/mL)
1,750 IU26 weeks20
Comparison of two vitamin D supplementation strategies in children with sickle cell disease: a randomized controlled trial
2021 · Placebo bolus group (daily vitamin D3 prescription) · Children aged 5–17 years with sickle cell disease, all genotypes; the study notes many children with SCD were vitamin D-deficient
1,000 IU90 days20
Effect of Daily Vitamin D Supplementation on Serum Vitamin D Levels in Children with Epilepsy Receiving Sodium Valproate Monotherapy: A Randomized, Controlled Trial
2023 · intervention group · Children aged 2–12 years with newly diagnosed epilepsy, vitamin D-sufficient status, receiving sodium valproate monotherapy
600 IU90 days20
Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma
2023 · Cohort F · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL
600 IU16 weeks20
Vitamin D supplementation during Antarctic winter
2009 · 1000 IU/d group · Adults with limited ultraviolet B exposure wintering at McMurdo Station in Antarctica
1,000 IU150 days19
The effects of season-long vitamin D supplementation on collegiate swimmers and divers
2013 · VIT D · Men and women collegiate NCAA Division I swimmers and divers, generally healthy and aged 18 or older
4,000 IU26 weeks19
The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis
2013 · high-dose group · Patients with multiple sclerosis treated with IFN-β; age and sex not specified
4,370 IU1 year19
Pharmacokinetics of daily versus monthly vitamin D3 supplementation in non-lactating women
2014 · daily group · Healthy non-pregnant, non-lactating women aged 18–40 years
5,000 IU4 weeks19
The Effect of Vitamin D Supplementation on Metabolic Phenotypes in Thais with Prediabetes
2015 · vitamin D₂ · Thai adults with impaired fasting glucose and/or impaired glucose tolerance
2,857 IU90 days19
A single mega dose of vitamin D(3) improves selected physical variables in vitamin D-deficient young amateur soccer players: a randomized controlled trial
2020 · single dose · Vitamin D-deficient, mildly trained recreational soccer-playing boys; age not stated
200,000 IU12 weeks19
Improving Vitamin D Status in Preterm Newborns: A Randomized Trial of 800 vs. 400 IU/Day
2025 · 400 IU/day group · Preterm newborns with gestational age ≤32 weeks or birth weight ≤1500 g
400 IU6 weeks19
Improving Vitamin D Status in Preterm Newborns: A Randomized Trial of 800 vs. 400 IU/Day
2025 · 800 IU/day group · Preterm newborns with gestational age ≤32 weeks or birth weight ≤1500 g
800 IU6 weeks19
Vitamin D supplementation during Antarctic winter
2009 · 2000 IU/d group · Adults with limited ultraviolet B exposure wintering at McMurdo Station in Antarctica
2,000 IU150 days18
Vitamin D supplementation during Antarctic winter
2009 · 400 IU/d group · Adults with limited ultraviolet B exposure wintering at McMurdo Station in Antarctica
400 IU150 days18
Effects of Vitamin D Supplementation on Serum 25-Hydroxyvitamin D Concentrations in Cirrhotic Patients: A Randomized Controlled Trial
2016 · Vitamin D group · Adults aged 18–75 with compensated cirrhosis and serum 25(OH)D below 30 ng/mL
2,800 IU8 weeks18
Impact of High-Dose Vitamin D3 Supplementation in Patients with Crohn's Disease in Remission: A Pilot Randomized Double-Blind Controlled Study
2017 · High-dose vitamin D3 · Patients with Crohn's disease in remission; age and sex not stated
10,000 IU1 year18
Effects of Vitamin D Supplementation on Haematological Values and Muscle Recovery in Elite Male Traditional Rowers
2018 · Group treated with 3000 IU/day of vitamin D3 (VD3G) · Elite male rowers, mean age 27 ± 6 years, without disease
3,000 IU8 weeks18
Four weeks of vitamin D supplementation improves nitric oxide-mediated microvascular function in college-aged African Americans
2020 · vitamin D supplementation · Healthy college-aged adults, 21 ± 2 years; African American and European American men and women
2,000 IU4 weeks18
Changes of 25(OH)D Concentration, Bone Resorption Markers and Physical Performance as an Effect of Sun Exposure, Supplementation of Vitamin D and Lockdown among Young Soccer Players during a One-Year Training Season
2022 · supplemented group (GS) · Male young elite soccer players, mean age 17.2 years, competing in the Polish Central Junior League
5,000 IU8 weeks18
Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study
2008 · cholecalciferol treatment group · Adults aged 18–85 with stage 3 or 4 chronic kidney disease, serum 25(OH)D concentrations of 30 ng/mL or less, and PTH levels greater than 70 pg/mL
7,143 IU12 weeks17
The response of elderly veterans to daily vitamin D3 supplementation of 2,000 IU: a pilot efficacy study
2011 · cholecalciferol group · Veterans aged 70 and older
2,000 IU26 weeks17
The efficacy of vitamin D supplementation during a prolonged submarine patrol
2014 · 2,000 IU/day · Submariners on a prolonged submarine patrol; adult age and sex not specified
2,000 IU90 days17
Supplemental vitamin D increases serum cytokines in those with initially low 25-hydroxyvitamin D: a randomized, double blind, placebo-controlled study
2015 · 8000 IU vitamin D group · Healthy adults, mean age 32 years; both sexes, with varying baseline vitamin D status
8,000 IU5 weeks17
Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2
1998 · vitamin D2 · Subjects; age, sex, and health condition not stated
4,000 IU2 weeks17
Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study
2013 · cholecalciferol · Haemodialysis patients with end-stage renal disease and low baseline serum 25(OH)D
1,785 IU1 year16
Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial
2013 · 1600 IU/d group · Healthy, term, breastfed infants enrolled at 1 month of age
1,600 IU—16
Impact of High-Dose Vitamin D3 Supplementation in Patients with Crohn's Disease in Remission: A Pilot Randomized Double-Blind Controlled Study
2017 · Low-dose vitamin D3 · Patients with Crohn's disease in remission; age and sex not stated
1,000 IU1 year16
Randomized trial of two doses of vitamin D3 in preterm infants <32 weeks: Dose impact on achieving desired serum 25(OH)D3 in a NICU population
2017 · 400 IU group · Preterm infants born at less than 32 weeks’ gestational age
400 IU8 weeks16
Randomized trial of two doses of vitamin D3 in preterm infants <32 weeks: Dose impact on achieving desired serum 25(OH)D3 in a NICU population
2017 · 800 IU group · Preterm infants born at less than 32 weeks’ gestational age
800 IU8 weeks16
A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption
2021 · vitamin D3 · Healthy adults with differing BMI and adults with intestinal malabsorption
900 mcg1 day16
A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption
2021 · 25(OH)D3 · Healthy adults with differing BMI and adults with intestinal malabsorption
900 mcg1 day16
Comparative Bioavailability Study of a New Vitamin D3 Orodispersible Film Versus a Marketed Oral Solution in Healthy Volunteers
2022 · Test_fast (vitamin D3 ODF under fasting conditions) · Healthy male and female volunteers aged 40–70 years
25,000 IU1 day16
Comparative Bioavailability Study of a New Vitamin D3 Orodispersible Film Versus a Marketed Oral Solution in Healthy Volunteers
2022 · Test_fed (vitamin D3 ODF under fed conditions) · Healthy male and female volunteers aged 40–70 years
25,000 IU1 day16
Comparative Bioavailability Study of a New Vitamin D3 Orodispersible Film Versus a Marketed Oral Solution in Healthy Volunteers
2022 · Reference_fed (vitamin D3 oral solution under fed conditions) · Healthy male and female volunteers aged 40–70 years
25,000 IU1 day16
Direct Effects of Vitamin D Supplementation on Ultramarathon-Induced Changes in Kynurenine Metabolism
2022 · experimental (supplementation, S) · Adult male amateur ultramarathon runners with no reported known disease; mean age 42.40 ± 7.59 years
150,000 IU1 day16
Effect of oral cholecalciferol 2,000 versus 5,000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency
2013 · 2,000-IU group · Vitamin D-deficient patients with serum 25OHD ≤ 50 nmol/L
2,000 IU90 days15
Effect of oral cholecalciferol 2,000 versus 5,000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency
2013 · 5,000-IU group · Vitamin D-deficient patients with serum 25OHD ≤ 50 nmol/L
5,000 IU90 days15
Vitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial
2024 · Cohort D (part 1, standard of care) · Children aged 6 to under 18 with physician-diagnosed asthma, BMI at or above the 85th percentile, and screening serum 25(OH)D of 10–30 ng/mL
600 IU16 weeks15
Assessment of the effect of routine-dose vitamin D3 supplementation in Chinese women of childbearing age with vitamin D insufficiency
2025 · 400 IU/day vitamin D3 group · Women aged 18–50 with vitamin D insufficiency (serum total 25(OH)D <20 ng/mL)
400 IU26 weeks15
Fortification of orange juice with vitamin D: a novel approach for enhancing vitamin D nutritional health
2003 · Vitamin D-fortified orange juice · Adults; age range and sex not reported
1,000 IU12 weeks14
Pharmacokinetics of high-dose weekly oral vitamin D3 supplementation during the third trimester of pregnancy in Dhaka, Bangladesh
2013 · PL (pregnant, lower dose) · Pregnant women aged 18 to under 35 years, enrolled at 27 to under 31 weeks of gestation in Bangladesh
2,000 IU—14
Vitamin D deficiency, serum leptin and osteoprotegerin levels in older diabetic patients: an input to new research avenues
2014 · Vitamin D3 · Patients aged 60 years or older with type 2 diabetes mellitus and diabetic foot complications
300,000 IU1 day14
Supplemental vitamin D increases serum cytokines in those with initially low 25-hydroxyvitamin D: a randomized, double blind, placebo-controlled study
2015 · 4000 IU vitamin D group · Healthy adults, mean age 32 years; both sexes, with varying baseline vitamin D status
4,000 IU5 weeks14
Vitamin D supplementation in nursing home patients: randomized controlled trial of standard daily dose versus individualized loading dose regimen
2015 · Daily dose regimen (DD) · Nursing home patients with severe 25-hydroxyvitamin D deficiency
800 IU26 weeks14
Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial
2016 · 50,000 IU/week vitamin D3 group · Adults older than 65 years who were clinically stable long-term nursing-home residents without sun exposure
7,143 IU16 weeks14
Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women
2006 · 125 microg/day vitamin D(2) group · Postmenopausal women with osteopenia or osteoporosis; median age 61.5 years
125 mcg90 days13
The effect of high-dose vitamin D supplementation on serum vitamin D levels and milk calcium concentration in lactating women and their infants
2006 · 4000 IU/day vitamin D group · Fully breastfeeding mothers, randomized at 1 month postpartum; age not reported
4,000 IU90 days13
[Is daily supplementation with vitamin D2 equivalent to daily supplementation with vitamin D3 in the elderly?]
2012 · GD2 · Ambulatory postmenopausal women, mean age 77.1 years; most had deficient baseline 25OHD levels
800 IU45 days13
Impact of Vitamin D Replacement on Markers of Glucose Metabolism and Cardio-Metabolic Risk in Women with Former Gestational Diabetes--A Double-Blind, Randomized Controlled Trial
2015 · vitamin D group · Malaysian women with former gestational diabetes, 6–48 months postpartum, and plasma 25(OH)D of 15–50 nmol/L without overt diabetes
4,000 IU26 weeks13
A randomized two way cross over study for comparison of absorption of vitamin D3 buccal spray and soft gelatin capsule formulation in healthy subjects and in patients with intestinal malabsorption
2015 · Healthy subjects—soft gelatin capsule formulation · Adults aged 18–65, healthy subjects, either sex
1,000 IU30 days13
A randomized two way cross over study for comparison of absorption of vitamin D3 buccal spray and soft gelatin capsule formulation in healthy subjects and in patients with intestinal malabsorption
2015 · Patients with malabsorption syndrome—soft gelatin capsule formulation · Adults aged 18–65 with ulcerative colitis, Crohn’s disease, or steatorrhea, either sex
1,000 IU30 days13
Vitamin D Repletion in Kidney Stone Formers: A Randomized Controlled Trial
2017 · 50,000 IU weekly · Patients with a history of calcium stones and vitamin D deficiency (less than 30 ng/ml)
7,143 IU6 weeks13
High-dose vitamin D in Addison's disease regulates T-cells and monocytes: A pilot trial
2018 · cholecalciferol treatment · Patients with Addison's disease; age and sex not specified
4,000 IU90 days13
The influence of vitamin D supplementation on local and systemic inflammatory markers in periodontitis patients: A pilot study
2019 · vitamin D group · Dark-skinned adults aged 18 years or older with generalized chronic moderate-to-severe periodontitis; participants were not initially vitamin D deficient
4,000 IU16 weeks13
Disassociation of Vitamin D's Calcemic Activity and Non-calcemic Genomic Activity and Individual Responsiveness: A Randomized Controlled Double-Blind Clinical Trial
2019 · 4000 IU/d · Healthy young adult Black and White adults with BMI <30 and serum 25(OH)D below 30 ng/mL; men and non-pregnant women
4,000 IU24 weeks13
Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women
2006 · 250 microg/day vitamin D(2) group · Postmenopausal women with osteopenia or osteoporosis; median age 61.5 years
250 mcg90 days12
The effect of high-dose vitamin D supplementation on serum vitamin D levels and milk calcium concentration in lactating women and their infants
2006 · 2000 IU/day vitamin D group · Fully breastfeeding mothers, randomized at 1 month postpartum; age not reported
2,000 IU90 days12
Short-Term Vitamin D3 Supplementation in Children with Neurodisabilities: Comparison of Two Delivery Methods
2017 · Vitamin D3 buccal spray · Children aged 5–17 years with neurodisabilities and vitamin D deficiency (25(OH)D ≤20 ng/mL)
800 IU90 days12
Short-Term Vitamin D3 Supplementation in Children with Neurodisabilities: Comparison of Two Delivery Methods
2017 · Vitamin D3 oral drops · Children aged 5–17 years with neurodisabilities and vitamin D deficiency (25(OH)D ≤20 ng/mL)
750 IU90 days12
Vitamin D Vitamers Affect Vitamin D Status Differently in Young Healthy Males
2017 · vitD3 treatment · Healthy men aged 20–30 years
10 mcg6 weeks12
Vitamin D Vitamers Affect Vitamin D Status Differently in Young Healthy Males
2017 · vitD2 treatment · Healthy men aged 20–30 years
10 mcg6 weeks12
Vitamin D Vitamers Affect Vitamin D Status Differently in Young Healthy Males
2017 · 25OH-D3 treatment · Healthy men aged 20–30 years
10 mcg6 weeks12
Plasma 25-hydroxyvitamin D responses of younger and older men to three weeks of supplementation with 1800 IU/day of vitamin D
1999 · Vitamin D2 supplementation group · Men aged 22–73 years with self-reported vitamin D intakes below 200 IU/day
1,800 IU3 weeks11
Influence of a single oral dose of vitamin D(2) on serum 25-hydroxyvitamin D concentrations in tuberculosis patients
2009 · vitamin D(2) group · Tuberculosis patients with hypovitaminosis D; age and sex not reported
2.5 mg1 day11
Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma
2023 · Cohort D · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL
600 IU16 weeks11
The bioavailability of vitamin D from fortified cheeses and supplements is equivalent in adults
2008 · fortified low-fat cheese (DLF) · Adults; age range, sex, and health condition not specified
4,000 IU8 weeks10
The bioavailability of vitamin D from fortified cheeses and supplements is equivalent in adults
2008 · liquid vitamin D supplement taken without food (DS-) · Adults; age range, sex, and health condition not specified
4,000 IU8 weeks10
Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial
2015 · 200,000 IU cholecalciferol group · Adults aged 18 years or older with severe sepsis or septic shock
200,000 IU1 day10
Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial
2015 · 400,000 IU cholecalciferol group · Adults aged 18 years or older with severe sepsis or septic shock
400,000 IU1 day10
The Effect of Vitamin D Supplementation on Metabolic Phenotypes in Thais with Prediabetes
2015 · vitamin D₃ · Thai adults with impaired fasting glucose and/or impaired glucose tolerance
2,143 IU90 days10
Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma
2023 · Cohort C · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL
6,000 IU16 weeks10
Vitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial
2024 · Cohort C (part 1) · Children aged 6 to under 18 with physician-diagnosed asthma, BMI at or above the 85th percentile, and screening serum 25(OH)D of 10–30 ng/mL
6,000 IU16 weeks10
Prospective, Randomized, Double-Blind, Parallel-Group, Comparative Effectiveness Clinical Trial Comparing a Powder Vehicle Compound of Vitamin D With an Oil Vehicle Compound in Adults With Cystic Fibrosis
2017 · Oil group · Adults aged 18 or older with cystic fibrosis admitted to hospital for a pulmonary exacerbation
100,000 IU1 day9
Cholecalciferol Injections Are Effective in Hypovitaminosis D After Duodenal Switch: a Randomized Controlled Study
2018 · Control group · Adults with hypovitaminosis D after biliopancreatic diversion with duodenal switch (BPD/DS), despite oral vitamin D supplementation; age range not stated
1,400 IU26 weeks9
Disassociation of Vitamin D's Calcemic Activity and Non-calcemic Genomic Activity and Individual Responsiveness: A Randomized Controlled Double-Blind Clinical Trial
2019 · 600 IU/d · Healthy young adult Black and White adults with BMI <30 and serum 25(OH)D below 30 ng/mL; men and non-pregnant women
600 IU24 weeks9
Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly
2005 · Vitamin D2-fortified cheese feeding · Younger adults aged 23 to 50 years and older adults aged 72 to 84 years
5,880 IU1 day8
Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly
2005 · Vitamin D2-fortified water feeding · Younger adults aged 23 to 50 years and older adults aged 72 to 84 years
32,750 IU1 day8
Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly
2008 · Ergocalciferol oral · Women aged 66–97 years with vitamin D deficiency
300,000 IU1 day8
Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly
2008 · Cholecalciferol oral · Women aged 66–97 years with vitamin D deficiency
300,000 IU1 day8
[Is daily supplementation with vitamin D2 equivalent to daily supplementation with vitamin D3 in the elderly?]
2012 · GD3 · Ambulatory postmenopausal women, mean age 77.1 years; most had deficient baseline 25OHD levels
800 IU45 days8
Vitamin D Repletion in Kidney Stone Formers: A Randomized Controlled Trial
2017 · 1,000 IU daily · Patients with a history of calcium stones and vitamin D deficiency (less than 30 ng/ml)
1,000 IU6 weeks8
Disassociation of Vitamin D's Calcemic Activity and Non-calcemic Genomic Activity and Individual Responsiveness: A Randomized Controlled Double-Blind Clinical Trial
2019 · 10,000 IU/d · Healthy young adult Black and White adults with BMI <30 and serum 25(OH)D below 30 ng/mL; men and non-pregnant women
10,000 IU24 weeks8
Effect of 12-Week BMI-Based Vitamin D(3) Supplementation in Parkinson's Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites
2023 · Vitamin D group, BMI 25 to 30 · Adults with Parkinson’s disease treated with deep brain stimulation, BMI between 25 and 30
5,000 IU12 weeks8
Exploration of smart adherence-monitoring methods in vitamin D-deficient patients: A pilot feasibility clinical study
2023 · App − only · Adults aged 19–64 years with serum 25(OH) vitamin D below 20 ng/mL; predominantly female
1,000 IU12 weeks8
Exploration of smart adherence-monitoring methods in vitamin D-deficient patients: A pilot feasibility clinical study
2023 · App + Watch · Adults aged 19–64 years with serum 25(OH) vitamin D below 20 ng/mL; predominantly female
1,000 IU12 weeks8
Impact of dietary and lifestyle on vitamin D in healthy student girls aged 11-15 years
2006 · vitamin D supplementation group · Girls aged 11–15 years with hypovitaminosis D
50,000 IU20 days7
Prospective, Randomized, Double-Blind, Parallel-Group, Comparative Effectiveness Clinical Trial Comparing a Powder Vehicle Compound of Vitamin D With an Oil Vehicle Compound in Adults With Cystic Fibrosis
2017 · Powder group · Adults aged 18 or older with cystic fibrosis admitted to hospital for a pulmonary exacerbation
100,000 IU1 day6
Pharmacokinetics of oral vitamin D(3) and calcifediol
2014 · single bolus calcifediol plus vitamin D(3) group · healthy females aged 50–70 years
280 mcg1 day5
Effect of 12-Week BMI-Based Vitamin D(3) Supplementation in Parkinson's Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites
2023 · Vitamin D group, BMI under 25 · Adults with Parkinson’s disease treated with deep brain stimulation, BMI under 25
4,000 IU12 weeks3
Effect of 12-Week BMI-Based Vitamin D(3) Supplementation in Parkinson's Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites
2023 · Vitamin D group, BMI over 30 · Adults with Parkinson’s disease treated with deep brain stimulation, BMI over 30
6,000 IU12 weeks2
Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin
2000 · vitamin D(3) · Postmenopausal women about 60 years old with normal or low bone mineral density
350 IU1 year—
Serum levels of 1,25-(OH)2-vitamin D are not altered by long-term supplementation with alphacalcidol (1-OH-vitamin D3). A double-blind, placebo-controlled study
1992 · alphacalcidol · non-vitamin D deficient subjects
1 mcg120 days—
Lack of effect of calcium intake on the 25-hydroxyvitamin d response to oral vitamin D3
2005 · Control group · Healthy older men and women
800 IU90 days—
Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly
2005 · Vitamin D3-fortified cheese group · Men and women aged 60 years or older
600 IU60 days—
Bread fortified with cholecalciferol increases the serum 25-hydroxyvitamin D concentration in women as effectively as a cholecalciferol supplement
2006 · fortified wheat bread · Healthy women aged 25–45 years with low baseline serum 25-hydroxyvitamin D concentrations
10 mcg3 weeks—
Bread fortified with cholecalciferol increases the serum 25-hydroxyvitamin D concentration in women as effectively as a cholecalciferol supplement
2006 · fortified rye bread · Healthy women aged 25–45 years with low baseline serum 25-hydroxyvitamin D concentrations
10 mcg3 weeks—
Bread fortified with cholecalciferol increases the serum 25-hydroxyvitamin D concentration in women as effectively as a cholecalciferol supplement
2006 · regular wheat bread and cholecalciferol supplement (vitamin D control) · Healthy women aged 25–45 years with low baseline serum 25-hydroxyvitamin D concentrations
10 mcg3 weeks—
How much vitamin D3 do the elderly need?
2006 · 5 microg vitamin D3 group · Women aged 65–85 years
5 mcg12 weeks—
How much vitamin D3 do the elderly need?
2006 · 10 microg vitamin D3 group · Women aged 65–85 years
10 mcg12 weeks—
Efficacy of daily and monthly high-dose calciferol in vitamin D-deficient nulliparous and lactating women
2007 · 2000 IU vitamin D2/d · Healthy vitamin D-deficient lactating and nulliparous women residing in the United Arab Emirates
2,000 IU90 days—
Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D
2008 · 1000 IU vitamin D3 · Healthy adults aged 18–84 years; 60% of the study population were vitamin D deficient at baseline
1,000 IU11 weeks—
Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D
2008 · 1000 IU vitamin D2 · Healthy adults aged 18–84 years; 60% of the study population were vitamin D deficient at baseline
1,000 IU11 weeks—
Effect of free vitamin D(2) drops on serum 25-hydroxyvitamin D in infants with immigrant origin: a cluster randomized controlled trial
2009 · intervention group · Healthy 6-week-old infants with Pakistani, Turkish or Somali background
10 mcg7 weeks—
Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children
2008 · short-term vitamin D3 group · Apparently healthy schoolchildren; age range and sex not reported
2,000 IU8 weeks—
Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children
2008 · long-term vitamin D3 group, 1,400 IU/wk · Apparently healthy schoolchildren; age range and sex not reported
200 IU1 year—
Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children
2008 · long-term vitamin D3 group, 14,000 IU/wk · Apparently healthy schoolchildren; age range and sex not reported
2,000 IU1 year—
Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients
2008 · daily group · Women, mean age 81 ± 8 years, who had undergone surgery to repair a hip fracture
1,500 IU60 days—
High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients
2008 · treated group (maintenance phase) · Haemodialysis patients who had received cholecalciferol during the replenishment phase
2,857 IU65 weeks—
Vitamin D deficiency and supplementation during pregnancy
2009 · single oral dose · Pregnant women from Indian Asian, Middle Eastern, Black and Caucasian backgrounds, recruited at 27 weeks’ gestation
200,000 IU1 day—
Vitamin D deficiency and supplementation during pregnancy
2009 · daily supplement · Pregnant women from Indian Asian, Middle Eastern, Black and Caucasian backgrounds, recruited at 27 weeks’ gestation
800 IU——
Finding the optimal dose of vitamin D following Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial
2009 · 800-IU group · Patients undergoing Roux-en-Y gastric bypass; age and sex not reported
800 IU2 years—
Finding the optimal dose of vitamin D following Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial
2009 · 2,000-IU group · Patients undergoing Roux-en-Y gastric bypass; age and sex not reported
2,000 IU2 years—
Finding the optimal dose of vitamin D following Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial
2009 · 5,000-IU group · Patients undergoing Roux-en-Y gastric bypass; age and sex not reported
5,000 IU2 years—
Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease
2008 · 5,000 IU/week cholecalciferol group · Adults with chronic kidney disease stages 2–4; mean age 66 years; 33 men and 54 women across the trial
714 IU1 year—
Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease
2008 · 20,000 IU/week cholecalciferol group · Adults with chronic kidney disease stages 2–4; mean age 66 years; 33 men and 54 women across the trial
2,857 IU1 year—
Wintertime vitamin D supplementation inhibits seasonal variation of calcitropic hormones and maintains bone turnover in healthy men
2009 · 10 microg (400 IU) group · Healthy white men aged 21–49 years
10 mcg26 weeks—
Vitamin D insufficiency prior to bariatric surgery: risk factors and a pilot treatment study
2009 · ergocalciferol group · Men and women aged 18–65 with 25OHD below 62 nmol/l who were severely obese and awaiting bariatric surgery
7,143 IU8 weeks—
Vitamin D insufficiency prior to bariatric surgery: risk factors and a pilot treatment study
2009 · cholecalciferol group · Men and women aged 18–65 with 25OHD below 62 nmol/l who were severely obese and awaiting bariatric surgery
1,143 IU8 weeks—
Estimation of the dietary requirement for vitamin D in healthy adults
2008 · 5 microg/d vitamin D3 · Men and women aged 20–40 years; healthy adults
5 mcg22 weeks—
Estimation of the dietary requirement for vitamin D in healthy adults
2008 · 10 microg/d vitamin D3 · Men and women aged 20–40 years; healthy adults
10 mcg22 weeks—
High-dose oral vitamin D3 supplementation in the elderly
2009 · Loading · Elderly participants; described as frail elderly, with no age range or condition specified
500,000 IU——
How much vitamin D for neonates?
1991 · 10 micrograms/d (400 IU/d) vitamin D · Neonates, including low-birth-weight and full-term well infants
10 mcg16 weeks—
How much vitamin D for neonates?
1991 · 0.85 micrograms/d 25-hydroxyvitamin D3 · Low-birth-weight and full-term well neonates
0.85 mcg16 weeks—
How much vitamin D for neonates?
1991 · 1.5 micrograms/d 25-hydroxyvitamin D3 · Low-birth-weight and full-term well neonates
1.5 mcg16 weeks—
Estimation of the dietary requirement for vitamin D in free-living adults >=64 y of age
2009 · 5 microg vitamin D(3)/d · men and women aged ≥64 years
5 mcg22 weeks—
Estimation of the dietary requirement for vitamin D in free-living adults >=64 y of age
2009 · 10 microg vitamin D(3)/d · men and women aged ≥64 years
10 mcg22 weeks—
Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light
2009 · D3 · Adults with cystic fibrosis and vitamin D insufficiency
7,143 IU12 weeks—
Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light
2009 · D2 · Adults with cystic fibrosis and vitamin D insufficiency
7,143 IU12 weeks—
Does vitamin D supplementation of healthy Danish Caucasian girls affect bone turnover and bone mineralization?
2010 · 5 microg/day vitamin D(3) · Healthy Danish Caucasian girls aged 11–12 years
5 mcg1 year—
Does vitamin D supplementation of healthy Danish Caucasian girls affect bone turnover and bone mineralization?
2010 · 10 microg/day vitamin D(3) · Healthy Danish Caucasian girls aged 11–12 years
10 mcg1 year—
Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults
2010 · Young adults, 5 microg/day · Healthy adults aged 20–40 years
5 mcg——
Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults
2010 · Young adults, 10 microg/day · Healthy adults aged 20–40 years
10 mcg——
Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults
2010 · Elderly adults, 5 microg/day · Healthy adults aged 64 years or older
5 mcg——
Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults
2010 · Elderly adults, 10 microg/day · Healthy adults aged 64 years or older
10 mcg——
Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention
2010 · VD group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D
10 mcg1 year—
Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults
2010 · vitamin D(3)-fortified orange juice · Healthy adults aged 18–84 years; vitamin D deficiency was present in 64% of participants at baseline.
1,000 IU11 weeks—
Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults
2010 · vitamin D(2)-fortified orange juice · Healthy adults aged 18–84 years; vitamin D deficiency was present in 64% of participants at baseline.
1,000 IU11 weeks—
Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults
2010 · vitamin D(3) capsule · Healthy adults aged 18–84 years; vitamin D deficiency was present in 64% of participants at baseline.
1,000 IU11 weeks—
Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults
2010 · vitamin D(2) capsule · Healthy adults aged 18–84 years; vitamin D deficiency was present in 64% of participants at baseline.
1,000 IU11 weeks—
Milk fortified with the current adequate intake for vitamin D (5 microg) increases serum 25-hydroxyvitamin D compared to control milk but is not sufficient to prevent a seasonal decline in young women
2010 · fortified milk group · Non-pregnant women aged 18–47 years living in Dunedin, New Zealand
5 mcg12 weeks—
Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States
2009 · 800 IU vitamin D daily · Adults aged 30–74 with a history of at least one pathologically confirmed adenomatous colonic polyp within the previous 36 months
800 IU26 weeks—
Combination of bolus dose vitamin D with routine vaccination in infants: a randomised trial
2010 · 200 IU daily · Healthy breastfed infants, assessed at six months of age
200 IU26 weeks—
Combination of bolus dose vitamin D with routine vaccination in infants: a randomised trial
2010 · 400 IU daily · Healthy breastfed infants, assessed at six months of age
400 IU26 weeks—
Heterogeneity in serum 25-hydroxy-vitamin D response to cholecalciferol in elderly women with secondary hyperparathyroidism and vitamin D deficiency
2010 · daily D(3) group · Women aged 65 and older with secondary hyperparathyroidism and vitamin D deficiency
1,000 IU26 weeks—
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol
2011 · Calcitriol alone · Healthy volunteers aged 19–45 years
1 mcg3 days—
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol
2011 · Calcitriol with lanthanum carbonate · Healthy volunteers aged 19–45 years
1 mcg3 days—
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol
2011 · Calcitriol with sevelamer carbonate · Healthy volunteers aged 19–45 years
1 mcg3 days—
Vitamin D(3) is more potent than vitamin D(2) in humans
2011 · D2-treated group · Healthy adults; age and sex not specified
7,143 IU12 weeks—
Vitamin D(3) is more potent than vitamin D(2) in humans
2011 · D3-treated group · Healthy adults; age and sex not specified
7,143 IU12 weeks—
Estimation of the dietary requirement for vitamin D in healthy adolescent white girls
2011 · 5 μg/d vitamin D3 group · Healthy white girls, mean age 11.3 years, in Denmark and Finland
5 mcg1 year—
Estimation of the dietary requirement for vitamin D in healthy adolescent white girls
2011 · 10 μg/d vitamin D3 group · Healthy white girls, mean age 11.3 years, in Denmark and Finland
10 mcg1 year—
Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults
2011 · daily D(2) · Community-dwelling adults aged 65 years and older
1,600 IU1 year—
Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults
2011 · daily D(3) · Community-dwelling adults aged 65 years and older
1,600 IU1 year—
Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis
2011 · RSD+ · Adults with osteoporosis; sex and age range not specified
800 IU16 weeks—
Randomized trial of fortified milk and supplements to raise 25-hydroxyvitamin D concentrations in schoolchildren in Mongolia
2011 · one-time seasonal supplement · Children aged 9–11 years in Mongolia with very low baseline 25(OH)D concentrations
13,700 IU——
Randomized trial of fortified milk and supplements to raise 25-hydroxyvitamin D concentrations in schoolchildren in Mongolia
2011 · daily supplements · Children aged 9–11 years in Mongolia with very low baseline 25(OH)D concentrations
300 IU——
Randomized trial of fortified milk and supplements to raise 25-hydroxyvitamin D concentrations in schoolchildren in Mongolia
2011 · fortified ultra-high-temperature pasteurized milk from the United States · Children aged 9–11 years in Mongolia with very low baseline 25(OH)D concentrations
300 IU——
Randomized trial of fortified milk and supplements to raise 25-hydroxyvitamin D concentrations in schoolchildren in Mongolia
2011 · fortified pasteurized Mongolian milk · Children aged 9–11 years in Mongolia with very low baseline 25(OH)D concentrations
300 IU——
Vitamin D-fortified milk achieves the targeted serum 25-hydroxyvitamin D concentration without affecting that of parathyroid hormone in New Zealand toddlers
2011 · Fortified toddler milk group(s) · Healthy toddlers aged 12–20 months
3.7 mcg20 weeks—
Oral cholecalciferol versus ultraviolet radiation B: effect on vitamin D metabolites in patients with chronic pancreatitis and fat malabsorption - a randomized clinical trial
2011 · vitamin D supplement · Patients with chronic pancreatitis and fat malabsorption
1,520 IU10 weeks—
Vitamin D status and associations in newborn formula-fed infants during initial hospitalization
2011 · supplemented group · Hospitalized formula-fed infants born at less than 32 weeks' gestational age
400 IU——
Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults
2012 · 7 μg 25-hydroxyvitamin D3 group · Adults aged 50 years or older, apparently healthy
7 mcg10 weeks—
Stability and bioavailability of vitamin D nanoencapsulated in casein micelles
2012 · Aqueous Tween-80-emulsified vitamin D3 supplement · Human volunteers; age, sex, and health status not specified
50,000 IU1 day—
Efficacy and safety of high dose intramuscular or oral cholecalciferol in vitamin D deficient/insufficient elderly
2012 · Oral group · Ambulatory nursing-home residents aged 65 years or older with vitamin D deficiency or insufficiency (25(OH)D <30 ng/ml)
600,000 IU12 weeks—
Fortified malted milk drinks containing low-dose ergocalciferol and cholecalciferol do not differ in their capacity to raise serum 25-hydroxyvitamin D concentrations in healthy men and women not exposed to UV-B
2012 · D2 at 5 μg/d · Healthy men and women
5 mcg4 weeks—
Fortified malted milk drinks containing low-dose ergocalciferol and cholecalciferol do not differ in their capacity to raise serum 25-hydroxyvitamin D concentrations in healthy men and women not exposed to UV-B
2012 · D2 at 10 μg/d · Healthy men and women
10 mcg4 weeks—
Fortified malted milk drinks containing low-dose ergocalciferol and cholecalciferol do not differ in their capacity to raise serum 25-hydroxyvitamin D concentrations in healthy men and women not exposed to UV-B
2012 · D3 at 5 μg/d · Healthy men and women
5 mcg4 weeks—
Fortified malted milk drinks containing low-dose ergocalciferol and cholecalciferol do not differ in their capacity to raise serum 25-hydroxyvitamin D concentrations in healthy men and women not exposed to UV-B
2012 · D3 at 10 μg/d · Healthy men and women
10 mcg4 weeks—
25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis
2012 · cholecalciferol treatment group · Adults with stage 5 CKD receiving maintenance hemodialysis; age and sex not specified
1,476 IU15 weeks—
High-dose vitamin d intervention in infants--effects on vitamin d status, calcium homeostasis, and bone strength
2012 · 10 μg group · Infants receiving supplementation from age 2 weeks to 3 months
10 mcg10 weeks—
Assessment of vitamin D concentration in non-supplemented professional athletes and healthy adults during the winter months in the UK: implications for skeletal muscle function
2013 · vitamin D group · Professional athletes; age and sex not specified
5,000 IU8 weeks—
Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial
2013 · vitamin D3 · Obese adolescents with low vitamin D status; mean age 14.1 years
4,000 IU26 weeks—
Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients
2013 · 400 IU/d vitamin D3 group · Prostate cancer patients with Gleason score 6 or 7 undergoing radical prostatectomy
400 IU——
Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients
2013 · 10 000 IU/d vitamin D3 group · Prostate cancer patients with Gleason score 6 or 7 undergoing radical prostatectomy
10,000 IU——
Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients
2013 · 40 000 IU/d vitamin D3 group · Prostate cancer patients with Gleason score 6 or 7 undergoing radical prostatectomy
40,000 IU——
Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial
2013 · Vitamin D supplementation phase · Healthy volunteers
2,000 IU30 days—
Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency
2013 · 400 IU/d group · Arab women with pregnancy, randomized at 12–16 weeks of gestation in a population with endemic vitamin D deficiency
400 IU——
Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency
2013 · 2000 IU/d group · Arab women with pregnancy, randomized at 12–16 weeks of gestation in a population with endemic vitamin D deficiency
2,000 IU——
Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency
2013 · 4000 IU/d group · Arab women with pregnancy, randomized at 12–16 weeks of gestation in a population with endemic vitamin D deficiency
4,000 IU——
The effect of high-dose vitamin D supplementation on calciotropic hormones and bone mineral density in obese subjects with low levels of circulating 25-hydroxyvitamin d: results from a randomized controlled study
2013 · cholecalciferol group · healthy obese men and women aged 18–50 years with plasma 25-hydroxyvitamin D below 50 nmol/L
7,000 IU26 weeks—
A randomized clinical trial of vitamin D supplementation in healthy adolescents
2013 · 200 IU group · Healthy adolescents aged 11–19 years with baseline vitamin D sufficiency
200 IU11 weeks—
A randomized clinical trial of vitamin D supplementation in healthy adolescents
2013 · 1000 IU group · Healthy adolescents aged 11–19 years with baseline vitamin D sufficiency
1,000 IU11 weeks—
Vitamin D favorably alters the cancer promoting prostaglandin cascade
2013 · 2,000 IU vitamin D-3 plus 400 mg celecoxib · Healthy women; age range and other characteristics not specified
2,000 IU30 days—
25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults
2013 · 1000 IU/d group · Obese adults
1,000 IU21 weeks—
25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults
2013 · 5000 IU/d group · Obese adults
5,000 IU21 weeks—
25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults
2013 · 10,000 IU/d group · Obese adults
10,000 IU21 weeks—
Vitamin D3 dose requirement to raise 25-hydroxyvitamin D to desirable levels in adolescents: results from a randomized controlled trial
2014 · low-dose group · Lebanese adolescents aged 13 ± 2 years
200 IU1 year—
Vitamin D3 dose requirement to raise 25-hydroxyvitamin D to desirable levels in adolescents: results from a randomized controlled trial
2014 · high-dose group · Lebanese adolescents aged 13 ± 2 years
2,000 IU1 year—
Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial
2014 · 1000 IU vitamin D₃/d · African American adults in Boston; ages and health condition not stated
1,000 IU90 days—
Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial
2014 · 2000 IU vitamin D₃/d · African American adults in Boston; ages and health condition not stated
2,000 IU90 days—
Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial
2014 · 4000 IU vitamin D₃/d · African American adults in Boston; ages and health condition not stated
4,000 IU90 days—
25-Hydroxyvitamin D concentrations in children with Crohn's disease supplemented with either 2000 or 400 IU daily for 6 months: a randomized controlled study
2014 · 400 IU group · Children aged 8–18 years with quiescent Crohn's disease
400 IU26 weeks—
25-Hydroxyvitamin D concentrations in children with Crohn's disease supplemented with either 2000 or 400 IU daily for 6 months: a randomized controlled study
2014 · 2000 IU group · Children aged 8–18 years with quiescent Crohn's disease
2,000 IU26 weeks—
Obstetric and neonatal outcomes of maternal vitamin D supplementation: results of an open-label, randomized controlled trial of antenatal vitamin D supplementation in Pakistani women
2014 · Group B (vitamin D supplementation) · Pregnant women in Karachi, Pakistan; age range and vitamin D status not specified
4,000 IU——
Impact of vitamin D3 dietary supplement matrix on clinical response
2014 · chewable tablet (TAB) · Healthy adults with serum 25(OH)D <33 ng/mL
10,000 IU12 weeks—
Impact of vitamin D3 dietary supplement matrix on clinical response
2014 · oil-emulsified drop (DROP) · Healthy adults with serum 25(OH)D <33 ng/mL
10,000 IU12 weeks—
Impact of vitamin D3 dietary supplement matrix on clinical response
2014 · encapsulated powder (CAP) · Healthy adults with serum 25(OH)D <33 ng/mL
10,000 IU12 weeks—
Vitamin D-binding protein levels do not influence the effect of vitamin D repletion on serum PTH and calcium: data from a randomized, controlled trial
2014 · vitamin D3 · Vitamin D-deficient adults with serum 25(OH)D <20 ng/mL
7,143 IU8 weeks—
Effect of fat on serum 25-hydroxyvitamin D levels after a single oral dose of vitamin D in young healthy adults: a double-blind randomized placebo-controlled study
2015 · Group 1 (0 g fat) · Healthy medical residents or students; age and sex not specified
50,000 IU2 weeks—
Effect of fat on serum 25-hydroxyvitamin D levels after a single oral dose of vitamin D in young healthy adults: a double-blind randomized placebo-controlled study
2015 · Group 2 (15 g fat) · Healthy medical residents or students; age and sex not specified
50,000 IU2 weeks—
Effect of fat on serum 25-hydroxyvitamin D levels after a single oral dose of vitamin D in young healthy adults: a double-blind randomized placebo-controlled study
2015 · Group 3 (30 g fat) · Healthy medical residents or students; age and sex not specified
50,000 IU2 weeks—
Iron stores of breastfed infants during the first year of life
2014 · 200 IU/day Vitamin D · Full-term breastfed infants, enrolled at 1 month of age
200 IU243 days—
Iron stores of breastfed infants during the first year of life
2014 · 400 IU/day Vitamin D · Full-term breastfed infants, enrolled at 1 month of age
400 IU243 days—
Iron stores of breastfed infants during the first year of life
2014 · 600 IU/day Vitamin D · Full-term breastfed infants, enrolled at 1 month of age
600 IU243 days—
Iron stores of breastfed infants during the first year of life
2014 · 800 IU/day Vitamin D · Full-term breastfed infants, enrolled at 1 month of age
800 IU243 days—
Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial
2014 · Cholecalciferol group · Adults receiving maintenance hemodialysis with 25(OH)D levels below 30 ng/mL
3,571 IU13 weeks—
Vitamin D supplementation of breastfed infants: a randomized dose-response trial
2014 · 200 IU/day vitamin D group · Term, exclusively breastfed infants enrolled at 1 month of age
200 IU36 weeks—
Vitamin D supplementation of breastfed infants: a randomized dose-response trial
2014 · 400 IU/day vitamin D group · Term, exclusively breastfed infants enrolled at 1 month of age
400 IU36 weeks—
Vitamin D supplementation of breastfed infants: a randomized dose-response trial
2014 · 600 IU/day vitamin D group · Term, exclusively breastfed infants enrolled at 1 month of age
600 IU36 weeks—
Vitamin D supplementation of breastfed infants: a randomized dose-response trial
2014 · 800 IU/day vitamin D group · Term, exclusively breastfed infants enrolled at 1 month of age
800 IU36 weeks—
Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial
2014 · vitamin D3 · Healthy non-Hispanic white adults aged 45–75 years
1,000 IU1 year—
Dietary fat increases vitamin D-3 absorption
2015 · Fat-free meal group · Healthy older men and women
50,000 IU1 day—
Dietary fat increases vitamin D-3 absorption
2015 · Low MUFA:PUFA meal group (1:4) · Healthy older men and women
50,000 IU1 day—
Dietary fat increases vitamin D-3 absorption
2015 · High MUFA:PUFA meal group (4:1) · Healthy older men and women
50,000 IU1 day—
Single high-dose vitamin D at birth corrects vitamin D deficiency in infants in Mexico
2015 · vitamin D3 group · Healthy term newborn infants enrolled within 24 hours after birth; infants were not selected for a diagnosed condition
50,000 IU1 day—
A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial
2016 · 400 IU/d vitamin D3 · Healthy Chinese adults
400 IU16 weeks—
A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial
2016 · 800 IU/d vitamin D3 · Healthy Chinese adults
800 IU16 weeks—
A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial
2016 · 1200 IU/d vitamin D3 · Healthy Chinese adults
1,200 IU16 weeks—
A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial
2016 · 2000 IU/d vitamin D3 · Healthy Chinese adults
2,000 IU16 weeks—
Large Individual Differences in Serum 25-Hydroxyvitamin D Response to Vitamin D Supplementation: Effects of Genetic Factors, Body Mass Index, and Baseline Concentration. Results from a Randomized Controlled Trial
2016 · vitamin D3 group · People with prediabetes; age and sex not specified
2,857 IU1 year—
Effects of vitamin D-fortified low fat yogurt on glycemic status, anthropometric indexes, inflammation, and bone turnover in diabetic postmenopausal women: A randomised controlled clinical trial
2016 · fortified yogurt (FY) · Postmenopausal women with type 2 diabetes; age range not reported
2,000 IU12 weeks—
Safety and Efficacy of High-dose Daily Vitamin D3 Supplementation in Children and Young Adults With Sickle Cell Disease
2015 · 4,000 IU/day vitamin D3 — SCD-SS group · African-American children and young adults aged 5–20 years with sickle cell disease, homozygous SS
4,000 IU12 weeks—
Safety and Efficacy of High-dose Daily Vitamin D3 Supplementation in Children and Young Adults With Sickle Cell Disease
2015 · 7,000 IU/day vitamin D3 — SCD-SS group · African-American children and young adults aged 5–20 years with sickle cell disease, homozygous SS
7,000 IU12 weeks—
Safety and Efficacy of High-dose Daily Vitamin D3 Supplementation in Children and Young Adults With Sickle Cell Disease
2015 · 4,000 IU/day vitamin D3 — healthy control group · African-American healthy children and young adults aged 5–20 years
4,000 IU12 weeks—
Safety and Efficacy of High-dose Daily Vitamin D3 Supplementation in Children and Young Adults With Sickle Cell Disease
2015 · 7,000 IU/day vitamin D3 — healthy control group · African-American healthy children and young adults aged 5–20 years
7,000 IU12 weeks—
Response of vitamin D binding protein and free vitamin D concentrations to vitamin D supplementation in hospitalized premature infants
2015 · 400 IU/day vitamin D3 group · Premature infants born before 32 weeks' gestation
400 IU8 weeks—
Response of vitamin D binding protein and free vitamin D concentrations to vitamin D supplementation in hospitalized premature infants
2015 · 800 IU/day vitamin D3 group · Premature infants born before 32 weeks' gestation
800 IU8 weeks—
Effect of Vitamin D3 Supplementation in Black and in White Children: A Randomized, Placebo-Controlled Trial
2015 · vitamin D3 group · Healthy Black and White children aged 8–14 years; mean baseline 25(OH)D was below 20 ng/mL
1,000 IU26 weeks—
Maternal vitamin D₃ supplementation at 50 μg/d protects against low serum 25-hydroxyvitamin D in infants at 8 wk of age: a randomized controlled trial of 3 doses of vitamin D beginning in gestation and continued in lactation
2015 · 10 μg vitamin D₃/d group · Pregnant women, supplementation begun during gestation and continued through 8 weeks postpartum; breastfed infants received no supplementation
10 mcg——
Vitamin D metabolism in the premature newborn: A randomized trial
2016 · 400 IU/day vitamin D3 · Premature infants born at less than 32 weeks’ gestation
400 IU8 weeks—
Vitamin D metabolism in the premature newborn: A randomized trial
2016 · 800 IU/day vitamin D3 · Premature infants born at less than 32 weeks’ gestation
800 IU8 weeks—
Free 25(OH)D and Calcium Absorption, PTH, and Markers of Bone Turnover
2015 · 4000-IU dose arm · Adults; age, sex, and health condition are not specified in the abstract.
4,000 IU10 weeks—
Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial
2015 · 400 IU maternal group · Exclusively lactating women 4 to 6 weeks postpartum
400 IU26 weeks—
Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial
2015 · 6400 IU maternal group · Exclusively lactating women 4 to 6 weeks postpartum
6,400 IU26 weeks—
Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial
2015 · Infant 400 IU group · Breastfeeding infants of lactating women assigned to the 400 IU maternal group
400 IU26 weeks—
[Effect of supplementation with a single dose of vitamin D in children with cerebral palsy. Preliminary randomised controlled study]
2015 · supplemented (S) group · Children with cerebral palsy; median age 9.9 years (range 6.2–13.5); both sexes
100,000 IU8 weeks—
Dietary vitamin D dose-response in healthy children 2 to 8 y of age: a 12-wk randomized controlled trial using fortified foods
2016 · EAR: 400 IU/d · Children aged 2–8 years
400 IU12 weeks—
Dietary vitamin D dose-response in healthy children 2 to 8 y of age: a 12-wk randomized controlled trial using fortified foods
2016 · RDA: 600 IU/d · Children aged 2–8 years
600 IU12 weeks—
Vitamin D activity of breast milk in women randomly assigned to vitamin D3 supplementation during pregnancy
2016 · 1000-IU group · Pregnant women enrolled at 27 weeks of gestation who were breastfeeding postpartum
1,000 IU——
Vitamin D activity of breast milk in women randomly assigned to vitamin D3 supplementation during pregnancy
2016 · 2000-IU group · Pregnant women enrolled at 27 weeks of gestation who were breastfeeding postpartum
2,000 IU——
Treatment of Vitamin D Deficiency in Predominantly Hispanic and Black Adolescents: A Randomized Clinical Trial
2016 · 50,000 IU/week · Adolescents aged 13–20 years with vitamin D deficiency; predominantly Hispanic and Black
7,143 IU8 weeks—
Treatment of Vitamin D Deficiency in Predominantly Hispanic and Black Adolescents: A Randomized Clinical Trial
2016 · 5,000 IU/day · Adolescents aged 13–20 years with vitamin D deficiency; predominantly Hispanic and Black
5,000 IU8 weeks—
Treatment of Vitamin D Deficiency in Predominantly Hispanic and Black Adolescents: A Randomized Clinical Trial
2016 · 1,000 IU/day · Adolescents aged 13–20 years with vitamin D deficiency; predominantly Hispanic and Black
1,000 IU8 weeks—
Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis
2016 · high-dose group · Adults with relapsing-remitting multiple sclerosis; age and sex not reported
10,400 IU26 weeks—
Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis
2016 · low-dose group · Adults with relapsing-remitting multiple sclerosis; age and sex not reported
800 IU26 weeks—
Effect of weekly high-dose vitamin D3 supplementation on serum cholecalciferol concentrations in pregnant women
2016 · Vitamin D3 (VitD) · Pregnant women enrolled at 26–29 weeks’ gestation in Dhaka, Bangladesh
5,000 IU8 weeks—
Vitamin D Dosing Strategies Among Jordanians With Hypovitaminosis D
2017 · group A · Volunteers with hypovitaminosis D; age and sex not reported
7,143 IU26 weeks—
Vitamin D Dosing Strategies Among Jordanians With Hypovitaminosis D
2017 · group B · Volunteers with hypovitaminosis D; age and sex not reported
7,000 IU26 weeks—
Vitamin D3 for uncontrolled childhood asthma: A pilot study
2016 · vitamin D3 group · Children with asthma; age and sex not specified
2,000 IU15 weeks—
Vitamin D treatment in Somali women living in Sweden - Two randomized, placebo-controlled studies
2016 · 800 IU/day cholecalciferol · Somali women living in Sweden, mean age 34; most were vitamin D-deficient
800 IU12 weeks—
Vitamin D treatment in Somali women living in Sweden - Two randomized, placebo-controlled studies
2016 · 1600 IU/day cholecalciferol · Somali women living in Sweden, mean age 34; most were vitamin D-deficient
1,600 IU12 weeks—
Short-term Administration of Alphacalcidol is Associated with More Significant Improvement of Muscular Performance in Women with Vitamin D Deficiency Compared to Native Vitamin D
2016 · cholecalciferol · Women with vitamin D deficiency
1,000 IU26 weeks—
Short-term Administration of Alphacalcidol is Associated with More Significant Improvement of Muscular Performance in Women with Vitamin D Deficiency Compared to Native Vitamin D
2016 · alphacalcidol · Women with vitamin D deficiency
1 mcg26 weeks—
Effect of vitamin D supplementation, directly or via breast milk for term infants, on serum 25 hydroxyvitamin D and related biochemistry, and propensity to infection: a randomised placebo-controlled trial
2016 · group B · Term newborn infants
10 mcg39 weeks—
Vitamin D status of black and white Americans and changes in vitamin D metabolites after varied doses of vitamin D supplementation
2016 · 2000 IU cholecalciferol group · Adults with prediabetes or well-controlled diabetes; mean age 59.1 years
2,000 IU16 weeks—
Vitamin D status of black and white Americans and changes in vitamin D metabolites after varied doses of vitamin D supplementation
2016 · 4000 IU cholecalciferol group · Adults with prediabetes or well-controlled diabetes; mean age 59.1 years
4,000 IU16 weeks—
Effect of high-dose vitamin D supplementation on cardiometabolic risk factors in subjects with metabolic syndrome: a randomized controlled double-blind clinical trial
2016 · vitamin D intervention group · Adults with metabolic syndrome; mean age 40.49 years, 49% male; all intervention participants were vitamin D deficient or insufficient
7,143 IU16 weeks—
The impact of 1-year vitamin D supplementation on vitamin D status in athletes: a dose-response study
2016 · 400 IU vitamin D3 per day · Male and female athletes aged 18–32 with deficient or insufficient baseline 25(OH)D concentrations
400 IU1 year—
The impact of 1-year vitamin D supplementation on vitamin D status in athletes: a dose-response study
2016 · 1100 IU vitamin D3 per day · Male and female athletes aged 18–32 with deficient or insufficient baseline 25(OH)D concentrations
1,100 IU1 year—
The impact of 1-year vitamin D supplementation on vitamin D status in athletes: a dose-response study
2016 · 2200 IU vitamin D3 per day · Male and female athletes aged 18–32 with deficient or insufficient baseline 25(OH)D concentrations
2,200 IU1 year—
CYP2R1 polymorphisms are important modulators of circulating 25-hydroxyvitamin D levels in elderly females with vitamin insufficiency, but not of the response to vitamin D supplementation
2017 · 600 IU daily · Lebanese elderly overweight adults; mean age 71 years; men and women, with vitamin D insufficiency
600 IU1 year—
CYP2R1 polymorphisms are important modulators of circulating 25-hydroxyvitamin D levels in elderly females with vitamin insufficiency, but not of the response to vitamin D supplementation
2017 · dose equivalent to 3750 IU daily · Lebanese elderly overweight adults; mean age 71 years; men and women, with vitamin D insufficiency
3,750 IU1 year—
The relationship between maternal self-efficacy, compliance and outcome in a trial of vitamin D supplementation in pregnancy
2017 · cholecalciferol group · Pregnant women aged over 18 years with a singleton pregnancy, recruited before 17 weeks’ gestation and with baseline 25(OH)D of 25–100 nmol/L
1,000 IU——
Estimation of the dietary requirement for vitamin D in adolescents aged 14-18 y: a dose-response, double-blind, randomized placebo-controlled trial
2016 · 10 μg/d group · White male and female adolescents aged 14–18 years in the United Kingdom during winter
10 mcg20 weeks—
Daily Cholecalciferol Supplementation during Pregnancy Alters Markers of Regulatory Immunity, Inflammation, and Clinical Outcomes in a Randomized Controlled Trial
2016 · 400 IU/d group · Pregnant women; supplementation began before 20 weeks of pregnancy and continued to delivery
400 IU——
Daily Cholecalciferol Supplementation during Pregnancy Alters Markers of Regulatory Immunity, Inflammation, and Clinical Outcomes in a Randomized Controlled Trial
2016 · 2000 IU/d group · Pregnant women; supplementation began before 20 weeks of pregnancy and continued to delivery
2,000 IU——
Vitamin D Improves Selected Metabolic Parameters but Not Neuropsychological or Quality of Life Indices in OSA: A Pilot Study
2017 · D3 group · Caucasian adults with obstructive sleep apnea; mean age 55 years
4,000 IU15 weeks—
Randomized clinical trial to comparing efficacy of daily, weekly and monthly administration of vitamin D(3)
2017 · group A · adult subjects with vitamin D deficiency
1,000 IU90 days—
Randomized clinical trial to comparing efficacy of daily, weekly and monthly administration of vitamin D(3)
2017 · group B · adult subjects with vitamin D deficiency
1,000 IU90 days—
Vitamin D3 supplementation in healthy adults: a comparison between capsule and oral spray solution as a method of delivery in a wintertime, randomised, open-label, cross-over study
2016 · Vitamin D3 liquid capsule · Healthy adults; age range and sex not specified
3,000 IU4 weeks—
Vitamin D3 supplementation in healthy adults: a comparison between capsule and oral spray solution as a method of delivery in a wintertime, randomised, open-label, cross-over study
2016 · Oral spray vitamin D3 · Healthy adults; age range and sex not specified
3,000 IU4 weeks—
Estimation of the dietary requirement for vitamin D in white children aged 4-8 y: a randomized, controlled, dose-response trial
2016 · 10 μg vitamin D3/d supplementation · White Danish children aged 4–8 years
10 mcg20 weeks—
Effects of Genetic and Nongenetic Factors on Total and Bioavailable 25(OH)D Responses to Vitamin D Supplementation
2017 · vitamin D3 group · Chinese participants with vitamin D deficiency; age and sex not specified
2,000 IU20 weeks—
Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial
2017 · vitamin D2 · People with cystic fibrosis; age range and sex not reported
15,650 IU90 days—
Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial
2017 · vitamin D3 · People with cystic fibrosis; age range and sex not reported
8,184 IU90 days—
Effect of Two Different Multimicronutrient Supplements on Vitamin D Status in Women of Childbearing Age: A Randomized Trial
2017 · 200 IU group (Elevit gynvital) · Apparently healthy women aged 18–45 years
200 IU8 weeks—
Effect of Two Different Multimicronutrient Supplements on Vitamin D Status in Women of Childbearing Age: A Randomized Trial
2017 · 800 IU group (Femibion 1) · Apparently healthy women aged 18–45 years
800 IU8 weeks—
DOES VITAMIN D METABOLITE MEASUREMENT HELP PREDICT 25(OH)D CHANGE FOLLOWING VITAMIN D SUPPLEMENTATION?
2017 · daily vitamin D3 · postmenopausal women
1,800 IU120 days—
Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone
2017 · D3 group · Adults aged 18 years or older with 25-hydroxyvitamin D levels below 20 ng/mL
2,400 IU16 weeks—
Changes in pro-inflammatory markers and leucine concentrations in response to Nordic Walking training combined with vitamin D supplementation in elderly women
2017 · 800 IU/day vitamin D3 group · Elderly women, mean age 67 ± 8 years; subgroup sizes and age ranges not reported
800 IU12 weeks—
Changes in pro-inflammatory markers and leucine concentrations in response to Nordic Walking training combined with vitamin D supplementation in elderly women
2017 · 4000 IU/day vitamin D3 group · Elderly women, mean age 67 ± 8 years; subgroup sizes and age ranges not reported
4,000 IU12 weeks—
Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults
2018 · 5 μg calcifediol group · Men and women aged 65 years or older; no condition specified
5 mcg24 weeks—
Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults
2018 · 10 μg calcifediol group · Men and women aged 65 years or older; no condition specified
10 mcg24 weeks—
The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial
2017 · vitamin D · People with metabolic syndrome; age and sex not specified
7,143 IU16 weeks—
Impact of high-dose vitamin D(3) on plasma free 25-hydroxyvitamin D concentrations and antimicrobial peptides in critically ill mechanically ventilated adults
2017 · 50,000 IU vitamin D3 group · Adults older than 18 years with respiratory failure requiring mechanical ventilation, critically ill in the ICU
50,000 IU5 days—
Impact of high-dose vitamin D(3) on plasma free 25-hydroxyvitamin D concentrations and antimicrobial peptides in critically ill mechanically ventilated adults
2017 · 100,000 IU vitamin D3 group · Adults older than 18 years with respiratory failure requiring mechanical ventilation, critically ill in the ICU
100,000 IU5 days—
Increased vitamin D intake differentiated according to skin color is needed to meet requirements in young Swedish children during winter: a double-blind randomized clinical trial
2017 · 10 μg/d vitamin D3 group · Children aged 5–7 years in Sweden with fair or dark skin
10 mcg90 days—
Multi-dose vitamin d supplementation in stable very preterm infants: Prospective randomized trial response to three different vitamin D supplementation doses
2017 · 400 IU/d group · Preterm infants born at 24–32 weeks’ gestation
400 IU——
Multi-dose vitamin d supplementation in stable very preterm infants: Prospective randomized trial response to three different vitamin D supplementation doses
2017 · 800 IU/d group · Preterm infants born at 24–32 weeks’ gestation
800 IU——
Multi-dose vitamin d supplementation in stable very preterm infants: Prospective randomized trial response to three different vitamin D supplementation doses
2017 · 1000 IU/d group · Preterm infants born at 24–32 weeks’ gestation
1,000 IU——
Longevity of daily oral vitamin D3 supplementation: differences in 25OHD and 24,25(OH)2D observed 2 years after cessation of a 1-year randomised controlled trial (VICtORy RECALL)
2017 · 400 IU daily vitamin D3 group · Caucasian, non-smoking postmenopausal women
400 IU1 year—
Longevity of daily oral vitamin D3 supplementation: differences in 25OHD and 24,25(OH)2D observed 2 years after cessation of a 1-year randomised controlled trial (VICtORy RECALL)
2017 · 1000 IU daily vitamin D3 group · Caucasian, non-smoking postmenopausal women
1,000 IU1 year—
Oral Supplementation of Parturient Mothers with Vitamin D and Its Effect on 25OHD Status of Exclusively Breastfed Infants at 6 Months of Age: A Double-Blind Randomized Placebo Controlled Trial
2017 · Intervention (A) · Exclusively breastfeeding term mothers in the early postpartum period
60,000 IU10 days—
Impact of Three Doses of Vitamin D3 on Serum 25(OH)D Deficiency and Insufficiency in At-Risk Schoolchildren
2017 · 600 IU/d group · Schoolchildren at risk for vitamin D deficiency; age and sex not specified
600 IU26 weeks—
Impact of Three Doses of Vitamin D3 on Serum 25(OH)D Deficiency and Insufficiency in At-Risk Schoolchildren
2017 · 1000 IU/d group · Schoolchildren at risk for vitamin D deficiency; age and sex not specified
1,000 IU26 weeks—
Impact of Three Doses of Vitamin D3 on Serum 25(OH)D Deficiency and Insufficiency in At-Risk Schoolchildren
2017 · 2000 IU/d group · Schoolchildren at risk for vitamin D deficiency; age and sex not specified
2,000 IU26 weeks—
The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial
2018 · weight-loss intervention + vitamin D3 · Overweight or obese women of reproductive age with PCOS and vitamin D insufficiency
7,143 IU12 weeks—
Vitamin D status and functional health outcomes in children aged 2-8 y: a 6-mo vitamin D randomized controlled trial
2018 · intervention group · Healthy children aged 2–8 y
400 IU26 weeks—
Vitamin D Status and Immune Health Outcomes in a Cross-Sectional Study and a Randomized Trial of Healthy Young Children
2018 · 400 IU/day (EAR) · Healthy, prepubertal children aged 2–8 years
400 IU12 weeks—
Vitamin D Status and Immune Health Outcomes in a Cross-Sectional Study and a Randomized Trial of Healthy Young Children
2018 · 600 IU/day (RDA) · Healthy, prepubertal children aged 2–8 years
600 IU12 weeks—
A Randomized Study to Compare a Monthly to a Daily Administration of Vitamin D₃ Supplementation
2018 · daily regimen treatment group · Caucasian men and women aged 18–55 with vitamin D deficiency and BMI 18–25 kg/m²
2,000 IU75 days—
Winter Cholecalciferol Supplementation at 55°N Has No Effect on Markers of Cardiometabolic Risk in Healthy Children Aged 4-8 Years
2018 · 10 µg/d vitamin D3 group · Healthy white Danish children aged 4–8 years
10 mcg20 weeks—
Correlation of 25-Hydroxyvitamin D Levels in Serum vs. Breastmilk in Vitamin D-Supplementation Breastfeeding Women during Lactation: Randomized Double Blinded Control Trial
2017 · vitamin D group · Thai breastfeeding women with maternal 25-hydroxyvitamin D levels of 10–30 ng/mL
1,800 IU6 weeks—
The Effect of Nordic Walking Training Combined with Vitamin D Supplementation on Postural Control and Muscle Strength in Elderly People-A Randomized Controlled Trial
2018 · HI-NW low-dose vitamin D subgroup · Women aged 69.02 ± 5.57 years on average with insufficient 25(OH)D levels, assigned to high-intensity interval Nordic Walking training
800 IU12 weeks—
The Effect of Nordic Walking Training Combined with Vitamin D Supplementation on Postural Control and Muscle Strength in Elderly People-A Randomized Controlled Trial
2018 · HI-NW high-dose vitamin D subgroup · Women aged 69.02 ± 5.57 years on average with insufficient 25(OH)D levels, assigned to high-intensity interval Nordic Walking training
4,000 IU12 weeks—
The Effect of Nordic Walking Training Combined with Vitamin D Supplementation on Postural Control and Muscle Strength in Elderly People-A Randomized Controlled Trial
2018 · MI-NW low-dose vitamin D subgroup · Women aged 69.02 ± 5.57 years on average with insufficient 25(OH)D levels, assigned to moderate-intensity continuous Nordic Walking training
800 IU12 weeks—
The Effect of Nordic Walking Training Combined with Vitamin D Supplementation on Postural Control and Muscle Strength in Elderly People-A Randomized Controlled Trial
2018 · MI-NW high-dose vitamin D subgroup · Women aged 69.02 ± 5.57 years on average with insufficient 25(OH)D levels, assigned to moderate-intensity continuous Nordic Walking training
4,000 IU12 weeks—
Effects of sunlight exposure and vitamin D supplementation on vitamin D levels in postmenopausal women in rural Thailand: A randomized controlled trial
2018 · sunlight exposure with vitamin D supplementation group · Postmenopausal women aged 50–70 years in rural Thailand
2,857 IU12 weeks—
Effect of vitamin D supplementation along with weight loss diet on meta-inflammation and fat mass in obese subjects with vitamin D deficiency: A double-blind placebo-controlled randomized clinical trial
2019 · vitamin D group · obese subjects with vitamin D deficiency (25OHD < 50 nmol/L); age and sex not stated
7,143 IU12 weeks—
Sunshine is an Important Determinant of Vitamin D Status Even Among High-dose Supplement Users: Secondary Analysis of a Randomized Controlled Trial in Crohn's Disease Patients
2019 · vitamin D3 group · Adults with Crohn's disease in remission; median age 44 years, 49% female
2,000 IU1 year—
A randomized double-blinded placebo controlled trial of ergocalciferol 40,000 versus 100,000 IU per week for vitamin D inadequacy in institutionalized postmenopausal women
2020 · standard dose group · Institutionalized postmenopausal women with baseline 25(OH)D levels below 30 ng/mL
5,714 IU12 weeks—
A randomized double-blinded placebo controlled trial of ergocalciferol 40,000 versus 100,000 IU per week for vitamin D inadequacy in institutionalized postmenopausal women
2020 · high dose group · Institutionalized postmenopausal women with baseline 25(OH)D levels below 30 ng/mL
14,286 IU12 weeks—
Can Supplementation with Vitamin D Modify Thyroid Autoantibodies (Anti-TPO Ab, Anti-Tg Ab) and Thyroid Profile (T3, T4, TSH) in Hashimoto's Thyroiditis? A Double Blind, Randomized Clinical Trial
2019 · vitamin D group · Women with Hashimoto's thyroiditis
7,143 IU90 days—
Efficacy of two different doses of oral vitamin D supplementation on inflammatory biomarkers and maternal and neonatal outcomes
2019 · 1,000 IU/d group · Pregnant women; age and condition details beyond pregnancy not stated
1,000 IU——
Efficacy of two different doses of oral vitamin D supplementation on inflammatory biomarkers and maternal and neonatal outcomes
2019 · 2,000 IU/d group · Pregnant women; age and condition details beyond pregnancy not stated
2,000 IU——
The Effect of High-Dose Postpartum Maternal Vitamin D Supplementation Alone Compared with Maternal Plus Infant Vitamin D Supplementation in Breastfeeding Infants in a High-Risk Population. A Randomized Controlled Trial
2019 · High-dose maternal supplementation: mother received 6000 IU/day vitamin D3 and infant received placebo · Arab breastfeeding mothers enrolled within four weeks postpartum and their term infants, in Doha and Al-Wakra, Qatar
6,000 IU26 weeks—
Genetic Variation of the Vitamin D Binding Protein Affects Vitamin D Status and Response to Supplementation in Infants
2019 · 10 μg/d vitamin D3 group · Healthy term infants
10 mcg716 days—
Effect of Oral Versus Intramuscular Vitamin D Replacement on Oxidative Stress and Outcomes in Traumatic Mechanical Ventilated Patients Admitted to Intensive Care Unit
2020 · oral vitamin D group · Patients with traumatic injury and vitamin D deficiency requiring mechanical ventilation; age and sex not reported
50,000 IU6 days—
Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults
2020 · 25(OH)D3 10 µg group · Older adults, mean age 63.3 ± 7.9 years; no specific condition stated
10 mcg26 weeks—
Rate of change of circulating 25-hydroxyvitamin D following sublingual and capsular vitamin D preparations
2019 · capsule · healthy volunteers
3,000 IU6 weeks—
Rate of change of circulating 25-hydroxyvitamin D following sublingual and capsular vitamin D preparations
2019 · sublingual spray · healthy volunteers
3,000 IU6 weeks—
Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients
2019 · vitamin D group · Patients with non-alcoholic fatty liver disease diagnosed by abdominal ultrasound and liver enzymes; age and sex not reported
7,143 IU12 weeks—
The Effect of Vitamin D Supplementation on its Metabolism and the Vitamin D Metabolite Ratio
2019 · vitamin-D-treated group · Adults over 18 with hypertension and 25(OH)D levels below 75 nmol/L
2,800 IU8 weeks—
Epigenetics Predicts Serum 25-Hydroxyvitamin D Response to Vitamin D(3) Supplementation in African Americans
2020 · 600 IU/day vitamin D3 · African Americans; age and sex not specified; no condition stated
600 IU16 weeks—
Epigenetics Predicts Serum 25-Hydroxyvitamin D Response to Vitamin D(3) Supplementation in African Americans
2020 · 2000 IU/day vitamin D3 · African Americans; age and sex not specified; no condition stated
2,000 IU16 weeks—
Epigenetics Predicts Serum 25-Hydroxyvitamin D Response to Vitamin D(3) Supplementation in African Americans
2020 · 4000 IU/day vitamin D3 · African Americans; age and sex not specified; no condition stated
4,000 IU16 weeks—
Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment
2019 · vitamin D treatment group · Men aged 50 years and older and women aged 55 years and older
2,000 IU1 year—
Effectiveness of vitamin D supplementation in Swedish children may be negatively impacted by BMI and serum fructose
2020 · 10 μg vitamin D group · children aged 5–7 years in northern and southern Sweden; no condition stated
10 mcg90 days—
Effects of Weekly Supplementation of Cholecalciferol and Calcifediol Among the Oldest-Old People: Findings From a Randomized Pragmatic Clinical Trial
2019 · Group A (25D3) · Community-dwelling women and men aged over 75 years, hospitalized in a geriatric acute-care ward; many had vitamin D deficiency or insufficiency
21.4 mcg30 weeks—
Effects of Weekly Supplementation of Cholecalciferol and Calcifediol Among the Oldest-Old People: Findings From a Randomized Pragmatic Clinical Trial
2019 · Group B (D3) · Community-dwelling women and men aged over 75 years, hospitalized in a geriatric acute-care ward; many had vitamin D deficiency or insufficiency
21.4 mcg30 weeks—
The impact of active vitamin D administration on the clinical outcomes of acne vulgaris
2021 · study group · Patients with acne vulgaris; age and sex not reported
0.25 mcg90 days—
Effects of vitamin D3 supplementation for 12 weeks on serum levels of anabolic hormones, anaerobic power, and aerobic performance in active male subjects: A randomized, double-blind, placebo-controlled trial
2020 · vitamin D3 supplement (VDS) · Active males
2,000 IU12 weeks—
Effects of vitamin D supplementation on circulating concentrations of growth factors and immune-mediators in healthy women during pregnancy
2021 · 400 IU vitamin D3/day · Pregnant women of Hispanic, African-American, or Caucasian ethnicity; age range not reported
400 IU——
Effects of vitamin D supplementation on circulating concentrations of growth factors and immune-mediators in healthy women during pregnancy
2021 · 4400 IU vitamin D3/day · Pregnant women of Hispanic, African-American, or Caucasian ethnicity; age range not reported
4,400 IU——
Efficacy and safety of active vitamin D supplementation in chronic spontaneous urticaria patients
2022 · study group · Patients with chronic spontaneous urticaria (age and sex not reported)
0.25 mcg12 weeks—
Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation
2020 · 2000 IU per day group · Patients with inflammatory bowel disease (IBD)
2,000 IU12 weeks—
Safety Aspects of a Randomized Clinical Trial of Maternal and Infant Vitamin D Supplementation by Feeding Type Through 7 Months Postpartum
2020 · 6,400 IU/day group · Postpartum mothers aged not reported, breastfeeding or formula-feeding
6,400 IU26 weeks—
Oral Vitamin D supplementation impacts gene expression in granulosa cells in women undergoing IVF
2021 · Vitamin D group · Women aged 18–39 with vitamin D deficiency undergoing IVF, normal BMI (18–25 kg/m²), and fewer than 3 previous IVF cycles
600,000 IU12 weeks—
Daily vitamin D(3) in overweight and obese children and adolescents: a randomized controlled trial
2021 · 600 IU vitamin D3 group · Children and adolescents aged 6–13 years who were overweight or obese
600 IU1 year—
Daily vitamin D(3) in overweight and obese children and adolescents: a randomized controlled trial
2021 · 1000 IU vitamin D3 group · Children and adolescents aged 6–13 years who were overweight or obese
1,000 IU1 year—
Daily vitamin D(3) in overweight and obese children and adolescents: a randomized controlled trial
2021 · 2000 IU vitamin D3 group · Children and adolescents aged 6–13 years who were overweight or obese
2,000 IU1 year—
Effect of low-fat dairy products fortified with 1500IU nano encapsulated vitamin D(3) on cardiometabolic indicators in adults with abdominal obesity: a total blinded randomized controlled trial
2021 · fortified low-fat yogurt (FY) · Adults with abdominal obesity
1,500 IU10 weeks—
Effect of low-fat dairy products fortified with 1500IU nano encapsulated vitamin D(3) on cardiometabolic indicators in adults with abdominal obesity: a total blinded randomized controlled trial
2021 · fortified low-fat milk (FM) · Adults with abdominal obesity
1,500 IU10 weeks—
25-OHD response to vitamin D supplementation in children: effect of dose but not GC haplotype
2021 · standard dose group · Healthy urban-dwelling children aged 7 months to 10 years, largely from a Hispanic/LatinX community
400 IU26 weeks—
25-OHD response to vitamin D supplementation in children: effect of dose but not GC haplotype
2021 · higher dose group · Healthy urban-dwelling children aged 7 months to 10 years, largely from a Hispanic/LatinX community
1,000 IU26 weeks—
Vitamin D(3) supplementation reduces serum markers of bone resorption and muscle damage in female basketball players with vitamin D inadequacy
2022 · vitamin D group · Female basketball players aged 15–30 with inadequate vitamin D status
4,000 IU6 weeks—
Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD
2022 · vitamin D3 supplementation · Adults with type 2 diabetes; mean age 70 ± 6 years; 66% male
2,000 IU2 years—
Vitamin D supplementation and cardiometabolic risk factors among diverse schoolchildren: a randomized clinical trial
2022 · 600 IU/d group · Racially diverse schoolchildren aged 8–15 years at risk of vitamin D deficiency
600 IU26 weeks—
Vitamin D supplementation and cardiometabolic risk factors among diverse schoolchildren: a randomized clinical trial
2022 · 1000 IU/d group · Racially diverse schoolchildren aged 8–15 years at risk of vitamin D deficiency
1,000 IU26 weeks—
Vitamin D supplementation and cardiometabolic risk factors among diverse schoolchildren: a randomized clinical trial
2022 · 2000 IU/d group · Racially diverse schoolchildren aged 8–15 years at risk of vitamin D deficiency
2,000 IU26 weeks—
Effectiveness of three Vitamin D dosing protocols on raising and maintaining blood serum levels of 25-hydroxyvitamin D over a three-month period: a randomized, prospective study
2023 · Group 2 · Patients with baseline total 25-hydroxyvitamin D below 30.0 ng/mL; age and sex not reported
14,286 IU12 weeks—
The effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled trial
2022 · vitamin D only (VitD) · Overweight or obese participants; age and sex not reported
3,000 IU12 weeks—
800 IU versus 400 IU per day of vitamin D(3) in term breastfed infants: a randomized controlled trial from an LMIC
2022 · 800 IU/day vitamin D3 · Healthy term breastfed infants, supplemented from the first week of life until 14 weeks of age
800 IU14 weeks—
800 IU versus 400 IU per day of vitamin D(3) in term breastfed infants: a randomized controlled trial from an LMIC
2022 · 400 IU/day vitamin D3 · Healthy term breastfed infants, supplemented from the first week of life until 14 weeks of age
400 IU14 weeks—
Safety and Efficacy of Early Vitamin D Supplementation in Critically Ill Extremely Preterm Infants: An Ancillary Study of a Randomized Trial
2023 · 200 IU group · Extremely preterm infants born at ≤28 weeks' gestation
200 IU4 weeks—
Safety and Efficacy of Early Vitamin D Supplementation in Critically Ill Extremely Preterm Infants: An Ancillary Study of a Randomized Trial
2023 · 800 IU group · Extremely preterm infants born at ≤28 weeks' gestation
800 IU4 weeks—
Vitamin D Supplementation and Its Relationship with Loss of Visceral Adiposity
2022 · G1 (800 IU/day) · Patients who underwent bariatric surgery; age and sex not specified
800 IU1 year—
Vitamin D Supplementation and Its Relationship with Loss of Visceral Adiposity
2022 · G2 (1800 IU/day) · Patients who underwent bariatric surgery; age and sex not specified
1,800 IU1 year—
The Effect of a Single High Dose of Vitamin D on Serum Levels of Its Metabolites in the Elderly
2022 · Vitamin D3 group · Adults aged 61–96 years; no specific condition reported
120,000 IU1 day—
[Vitamin D level in umbilical cord blood of late preterm infants and the effect of vitamin D(3) supplementation on the behavioral development of infants and young children: a prospective randomized controlled study]
2022 · Sufficiency group, subgroup A · Late preterm infants with sufficient umbilical-cord-blood 25(OH)D
800 IU——
[Vitamin D level in umbilical cord blood of late preterm infants and the effect of vitamin D(3) supplementation on the behavioral development of infants and young children: a prospective randomized controlled study]
2022 · Insufficiency group, subgroup A · Late preterm infants with insufficient umbilical-cord-blood 25(OH)D
800 IU——
[Vitamin D level in umbilical cord blood of late preterm infants and the effect of vitamin D(3) supplementation on the behavioral development of infants and young children: a prospective randomized controlled study]
2022 · Deficiency group, subgroup A · Late preterm infants with deficient umbilical-cord-blood 25(OH)D
800 IU——
Association of Body Weight With Response to Vitamin D Supplementation and Metabolism
2023 · Vitamin D3 (cholecalciferol) · Men aged 50 years or older and women aged 55 years or older, free of cancer and cardiovascular disease at baseline
2,000 IU2 years—
Vitamin D Status of Infants of Mothers with Gestational Diabetes: Status at Birth and a Randomized Controlled Trial of Vitamin D Supplementation across Infancy
2022 · 400 IU/d vitamin D group · Infants born to mothers with gestational diabetes and serum 25(OH)D below 50 nmol/L
400 IU1 year—
Vitamin D Status of Infants of Mothers with Gestational Diabetes: Status at Birth and a Randomized Controlled Trial of Vitamin D Supplementation across Infancy
2022 · 1000 IU/d vitamin D group · Infants born to mothers with gestational diabetes and serum 25(OH)D below 50 nmol/L
1,000 IU1 year—
Increased Serum Total and Free 25-Hydroxyvitamin D with Daily Intake of Cholecalciferol-Fortified Skim Milk: A Randomized Controlled Trial in Colombian Adolescents
2023 · cholecalciferol-fortified skim milk · Colombian adolescents aged 12–14.5 years and their mothers
2,400 IU6 weeks—
Effects of an Individualized vs. Standardized Vitamin D Supplementation on the 25(OH)D Level in Athletes
2023 · individualized supplementation (INDV) · Athletes aged 18–50 with insufficient vitamin D status (25(OH)D3 <30 ng/mL), exercising at least five hours per week
4,000 IU10 weeks—
Effects of an Individualized vs. Standardized Vitamin D Supplementation on the 25(OH)D Level in Athletes
2023 · standardized supplementation (STAD) · Athletes aged 18–50 with insufficient vitamin D status (25(OH)D3 <30 ng/mL), exercising at least five hours per week
2,000 IU10 weeks—
The Effect of Vitamin D Supplementation in Pregnant Women with Overweight and Obesity: A Randomised Controlled Trial
2023 · Control group · Pregnant women aged 21–45 years with pre-pregnancy BMI ≥25 kg/m², recruited at up to 16 weeks’ gestation
400 IU——
An 8-Week Vitamin D3-Fortified Fruit Drink Supplementation Increases Serum Ferritin Concentration: A Randomized Controlled Trial in Malaysian Women With Low Iron Stores
2024 · vitamin D3-fortified fruit drink · Nonpregnant, nonlactating women aged 18–40 years with low iron stores (serum ferritin <20 μg/L)
4,000 IU8 weeks—
Effect of Antenatal Oral Vitamin D Supplementation on Serum 25(OH)D Concentration in Exclusively Breastfed Infants at 6 Months of age - A Randomized Double-Blind Placebo-Controlled Trial
2024 · Vitamin D3 group · Pregnant women recruited at 30–32 weeks gestation who intended to exclusively breastfeed their infants for 6 months
8,571 IU5 weeks—
A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D(3) Oral Supplementation in a Randomized, Double-Blind Human Pilot Study
2024 · STD1000 (regular/standard Vitamin D3 1000 IU) · Healthy adults aged 21–65 years; men and women
1,000 IU30 days—
A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D(3) Oral Supplementation in a Randomized, Double-Blind Human Pilot Study
2024 · LMD1000 (LipoMicel Vitamin D3 1000 IU) · Healthy adults aged 21–65 years; men and women
1,000 IU30 days—
A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D(3) Oral Supplementation in a Randomized, Double-Blind Human Pilot Study
2024 · STD2500 (regular/standard Vitamin D3 2500 IU) · Healthy adults aged 21–65 years; men and women
2,500 IU30 days—
A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D(3) Oral Supplementation in a Randomized, Double-Blind Human Pilot Study
2024 · LMD2500 (LipoMicel Vitamin D3 2500 IU) · Healthy adults aged 21–65 years; men and women
2,500 IU30 days—
Effects of High-Dose Vitamin D Supplementation on Placental Vitamin D Metabolism and Neonatal Vitamin D Status
2024 · 10 µg vitamin D group · Pregnant women enrolled at gestational weeks 11–16; no specific pregnancy complication required
10 mcg26 weeks—
Oral vs. injected: which vitamin D boost works best for low levels?
2024 · Group A · Adults aged 18–60 with initial serum vitamin D levels below 30 ng/mL
800 IU12 weeks—
Oral vs. injected: which vitamin D boost works best for low levels?
2024 · Group B · Adults aged 18–60 with initial serum vitamin D levels below 30 ng/mL
8,571 IU12 weeks—
Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial
2024 · calcifediol 75 µg group · Adults aged 18 years or older with vitamin D deficiency, serum 25(OH)D >10 and <20 ng/mL; males and females
10.7 mcg52 weeks—
Cutoff levels of serum 25-OH-D for defining vitamin D deficiency in early infancy
2025 · 800 IU/day · Healthy, term, breastfed infants from 48 hours after birth to 14 weeks of age
800 IU14 weeks—
Cutoff levels of serum 25-OH-D for defining vitamin D deficiency in early infancy
2025 · 400 IU/day · Healthy, term, breastfed infants from 48 hours after birth to 14 weeks of age
400 IU14 weeks—
Effect of CYP2R1 and GC gene polymorphisms on serum 25(OH)D response to vitamin D(3) supplementation in prediabetes
2025 · Vitamin D3 group · Adults with prediabetes; age and sex not specified
1,600 IU24 weeks—
Relationship between Circulating Vitamin D Concentration and the Maternal Gut Microbiota during Early Pregnancy in Japanese Women: Results of a Pilot Study of Antenatal Vitamin D(3) Supplementation
2025 · low-dose group · Pregnant Japanese women, starting in the first trimester; participants were predominantly vitamin D-deficient
200 IU8 weeks—
Relationship between Circulating Vitamin D Concentration and the Maternal Gut Microbiota during Early Pregnancy in Japanese Women: Results of a Pilot Study of Antenatal Vitamin D(3) Supplementation
2025 · medium-dose group · Pregnant Japanese women, starting in the first trimester; participants were predominantly vitamin D-deficient
400 IU8 weeks—
Relationship between Circulating Vitamin D Concentration and the Maternal Gut Microbiota during Early Pregnancy in Japanese Women: Results of a Pilot Study of Antenatal Vitamin D(3) Supplementation
2025 · high-dose group · Pregnant Japanese women, starting in the first trimester; participants were predominantly vitamin D-deficient
1,000 IU8 weeks—
Impact of almond milk fortified with vitamin D3-loaded soy protein nanoparticles on serum 25(OH)D3 concentrations in adults with CKD: a pilot double-blind randomized controlled trial
2025 · Intervention group · Adults with advanced-stage chronic kidney disease; age range and sex not reported
4,000 IU3 weeks—
Effects of weekly cholecalciferol supplementation of lactating mothers on vitamin D status, and infant growth and gross motor development: a randomized controlled trial in rural Ethiopia
2025 · weekly cholecalciferol group · Lactating mothers in rural Ethiopia; age not reported
2,143 IU1 year—
Differences in the bioavailability of dihydrotachysterol preparations
1994 · Capsule preparation 1 · Healthy volunteers; age and sex not reported
1 mg1 day—
Differences in the bioavailability of dihydrotachysterol preparations
1994 · Capsule preparation 2 · Healthy volunteers; age and sex not reported
1 mg1 day—
Differences in the bioavailability of dihydrotachysterol preparations
1994 · Oral solution preparation 1 · Healthy volunteers; age and sex not reported
1 mg1 day—
Differences in the bioavailability of dihydrotachysterol preparations
1994 · A.T.10 oral solution · Healthy volunteers; age and sex not reported
1 mg1 day—
Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males
1996 · A · Normal males aged 21–54 years
2 mcg7 days—
Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males
1996 · B · Normal males aged 21–54 years
1 mcg7 days—
Effect of UVB phototherapy and oral calcitriol (1,25-dihydroxyvitamin D3) on vitamin D photosynthesis in patients with psoriasis
1996 · calcitriol · Patients with psoriasis; age and sex not reported
0.5 mcg8 weeks—
Ultraviolet irradiation corrects vitamin D deficiency and suppresses secondary hyperparathyroidism in the elderly
1998 · VIT-D · Female psychogeriatric nursing-home patients, mean age 85 years, predominantly with low serum 25-hydroxyvitamin D
400 IU12 weeks—
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men
1998 · vitamin D3 1250 micrograms/day · healthy men, mean age 28 years
1.25 mg8 weeks—
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men
1998 · 25(OH)D3 10 micrograms/day · healthy men, mean age 28 years
10 mcg4 weeks—
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men
1998 · 1,25(OH)2D3 0.5 microgram/day · healthy men, mean age 28 years
0.5 mcg2 weeks—
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men
1998 · 1,25(OH)2D3 1.0 microgram/day (first group) · healthy men, mean age 28 years
1 mcg2 weeks—
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men
1998 · 1,25(OH)2D3 1.0 microgram/day (second group) · healthy men, mean age 28 years
1 mcg2 weeks—
Effects of vitamin D, omega-3 and a simple strength exercise programme in cardiovascular disease prevention: The DO-HEALTH randomized controlled trial
2024 · Vitamin D3 · Community-dwelling adults aged 70 years and older, generally healthy and active, without major chronic conditions
2,000 IU3 years1,076
High Dose Supplementation of Vitamin D Affects Measures of Systemic Inflammation: Reductions in High Sensitivity C-Reactive Protein Level and Neutrophil to Lymphocyte Ratio (NLR) Distribution
2017 · Vitamin D supplementation · Adolescent girls
7,143 IU9 weeks580
Clinical and biomarker modifiers of vitamin D treatment response: the Multi-Ethnic Study of Atherosclerosis
2022 · vitamin D3 · Older adults in MESA; mean age 72 years; 53% female; no specific disease stated
2,000 IU16 weeks499
Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial
2025 · Vitamin D group · Generally healthy, community-dwelling adults aged 70 years and older; Swiss subgroup with DNA methylation measures at baseline and 3 years
2,000 IU3 years397
Process evaluation of a randomised controlled trial aimed at improving health behaviours and vitamin D status during pregnancy: Implementation of the SPRING trial
2025 · Vitamin D supplementation group · Pregnant women aged over 18 years with a singleton pregnancy of less than 17 weeks’ gestation
1,000 IU—321
Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial
2020 · Vitamin D · Pregnant women enrolled at pregnancy week 24; age range and health condition not specified
2,400 IU17 weeks294
Phosphate Concentrations and Modifying Factors in Healthy Children From 12 to 24 Months of Age
2021 · Group10 · Healthy infants; sex not specified for this arm; no stated condition
10 mcg670 days257
Vitamin D Supplementation Regulates Postoperative Serum Levels of PD-L1 in Patients with Digestive Tract Cancer and Improves Survivals in the Highest Quintile of PD-L1: A Post Hoc Analysis of the AMATERASU Randomized Controlled Trial
2021 · vitamin D group · Adults with stage I–III digestive tract cancer (esophageal, gastric, small intestinal, or colorectal) who underwent curative surgery; median age 66 years; both sexes
2,000 IU1 year251
Gestational Vitamin D Supplementation Leads to Reduced Perinatal RXRA DNA Methylation: Results From the MAVIDOS Trial
2019 · Cholecalciferol 1000 IU/day · Pregnant women aged over 18 years with singleton pregnancies, enrolled before 17 weeks’ gestation and eligible serum 25(OH)D status of 25–100 nmol/L
1,000 IU—225
Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial
2020 · vitamin D · Adults with non-alcoholic fatty liver disease (NAFLD)
1,000 IU360 days201
Healthcare Costs and Healthcare Utilization Outcomes of Vitamin D3 Supplementation at 5000 IU Daily during a 10.9 Month Observation Period within a Pragmatic Randomized Clinical Trial
2023 · intervention group · Adults aged 18 years or older who were employees of an inner-city university hospital; no specific condition stated
5,000 IU39 weeks196
Bone turnover in pregnancy, measured by urinary CTX, is influenced by vitamin D supplementation and is associated with maternal bone health: findings from the Maternal Vitamin D Osteoporosis Study (MAVIDOS) trial
2021 · cholecalciferol · Pregnant women receiving supplementation from 14 weeks of gestation to birth
1,000 IU—184
The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial
2021 · Vitamin D · Premenopausal women aged 22–59 with breast density of at least 25%
2,000 IU1 year140
Effect of vitamin D(3) on antiphospholipid antibodies in hospitalized patients with moderate to severe COVID-19
2024 · vitamin D3 group · Adults aged 18 or older hospitalized with moderate to severe COVID-19
200,000 IU1 day120
Effects of vitamin D supplementation on metabolic and endocrine parameters in PCOS: a randomized-controlled trial
2019 · Vitamin D · Premenopausal women aged 18 years or older with PCOS and serum 25(OH)D below 75 nmol/L
2,857 IU24 weeks119
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial
2012 · paricalcitol group · Patients with chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved left ventricular ejection fraction; estimated GFR 15 to 60 mL/min/1.73 m²
2 mcg48 weeks115
Effect of Vitamin D3 Supplementation in Combination with Weight Loss on Inflammatory Biomarkers in Postmenopausal Women: A Randomized Controlled Trial
2015 · Vitamin D · Postmenopausal women aged 50–75 with overweight or obesity and insufficient serum 25(OH)D (≥10 to <32 ng/mL)
2,000 IU1 year109
Effects of vitamin D supplementation during weight loss on sex hormones in postmenopausal women
2016 · Vitamin D · Postmenopausal women aged 50–75 with BMI ≥25 kg/m² and serum 25(OH)D ≥10 and <32 ng/mL, participating in a lifestyle-based weight-loss program
2,000 IU1 year109
Antiproteinuric effect of oral paricalcitol in chronic kidney disease
2005 · oral paricalcitol · Patients with CKD stage 3 or 4 and secondary hyperparathyroidism
1.36 mcg24 weeks107
Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial
2018 · 2000 IU vitamin D · Community-dwelling, ambulatory adults aged 65 years or older
2,000 IU1 year102
Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial
2018 · 4000 IU vitamin D · Community-dwelling, ambulatory adults aged 65 years or older
4,000 IU1 year102
Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial
2025 · 4000 IU vitamin D3 · Community-dwelling men and women aged 65 years and older; generally healthy older adults
4,000 IU1 year102
Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial
2025 · 2000 IU vitamin D3 · Community-dwelling men and women aged 65 years and older; generally healthy older adults
2,000 IU1 year102
Effects of Vitamin D Supplementation on Bone Turnover and Bone Mineral Density in Healthy Men: A Post-Hoc Analysis of a Randomized Controlled Trial
2019 · vitamin D group · Men aged 18 to under 70 years with serum 25(OH)D below 75 nmol/L; described as healthy
2,857 IU12 weeks100
Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study
2013 · Paricalcitol 2 μg/day · Men and women aged 20 years or older with type 2 diabetes, diabetic nephropathy, CKD stages 2–4, and PTH concentrations of 35–500 pg/mL
2 mcg24 weeks95
Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study
2013 · Paricalcitol 1 μg/day · Men and women aged 20 years or older with type 2 diabetes, diabetic nephropathy, CKD stages 2–4, and PTH concentrations of 35–500 pg/mL
1 mcg24 weeks93
The effect of cholecalciferol supplementation on allograft function in incident kidney transplant recipients: A randomized controlled study
2021 · Cholecalciferol · Adults aged 20–80 who were 1 month after living kidney transplantation; incident kidney transplant recipients
4,000 IU335 days92
Vitamin D supplementation and the effects on glucose metabolism during pregnancy: a randomized controlled trial
2014 · low-dose (LD) · Pregnant women with plasma 25-hydroxyvitamin D levels below 32 ng/mL before 20 weeks' gestation
400 IU—90
Effects of vitamin D supplementation on FGF23: a randomized-controlled trial
2019 · Vitamin D · Adults aged 18 years or older with arterial hypertension and serum 25(OH)D below 30 ng/mL
2,800 IU8 weeks90
Vitamin D supplementation and the effects on glucose metabolism during pregnancy: a randomized controlled trial
2014 · high-dose (HD) · Pregnant women with plasma 25-hydroxyvitamin D levels below 32 ng/mL before 20 weeks' gestation
5,000 IU—89
Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study
2017 · rhPTH(1–84) group · Adults aged 18–85 with hypoparathyroidism
400 IU24 weeks84
Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial
2018 · paricalcitol · Kidney transplant recipients with urinary protein-to-creatinine ratio ≥20 mg/mmol despite optimized RAAS blockade
2 mcg24 weeks83
Isolated vitamin D supplementation improves the immune-inflammatory biomarkers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial
2018 · VitD group · Postmenopausal women aged 50 to 65 years with amenorrhea for at least 12 months
1,000 IU39 weeks80
Impact of vitamin D supplementation on modulating heat-shock proteins in postmenopausal women: a randomized, double-blind, placebo-controlled study
2023 · VitD group · Postmenopausal women aged 45 to 65 years with amenorrhea for 12 months or more
1,000 IU304 days80
The Cardioprotective Effect of Vitamin D in Breast Cancer Patients Receiving Adjuvant Doxorubicin Based Chemotherapy
2022 · Vit D group · Women with newly diagnosed breast cancer receiving adjuvant doxorubicin-based chemotherapy
0.5 mcg12 weeks75
The effects of low-fat dairy products fortified with 1500 IU vitamin D(3) on serum liver function biomarkers in adults with abdominal obesity: a randomized controlled trial
2023 · fortified milk (FM) · Adults aged 30–50 years with abdominal obesity; men and women
1,500 IU10 weeks73
Positive effect of low dose vitamin D supplementation on growth of fetal bones: A randomized prospective study
2019 · intervention group · Pregnant patients; age and pregnancy-stage ranges not reported
1,000 IU—70
Vitamin D status and cardiometabolic risk markers in young Swedish children: a double-blind randomized clinical trial comparing different doses of vitamin D supplements
2020 · 10 µg group · Healthy children aged 5–7 years, including fair- and dark-skinned children
10 mcg90 days70
The effects of low-fat dairy products fortified with 1500 IU vitamin D(3) on serum liver function biomarkers in adults with abdominal obesity: a randomized controlled trial
2023 · fortified yogurt (FY) · Adults aged 30–50 years with abdominal obesity; men and women
1,500 IU10 weeks69
Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study
2005 · daily group · Maintenance hemodialysis patients of both sexes with secondary hyperparathyroidism and intact parathyroid hormone (iPTH) above 200 pg/mL
0.5 mcg20 weeks67
The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism
2021 · Calcitriol group · Adults aged 18–60 with non-alcoholic fatty liver disease and below-20 ng/ml baseline vitamin D; men and women
0.25 mcg17 weeks64
Impact of treatment with active vitamin D calcitriol on bone turnover markers in people with type 2 diabetes and stage 3 chronic kidney disease
2023 · calcitriol · People with type 2 diabetes and stage 3 chronic kidney disease with intact parathyroid hormone >30 pg/ml; median age 67 years
0.25 mcg48 weeks64
Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial
2025 · calcitriol · Adults aged 18–70 with type 2 diabetes and early diabetic kidney disease
0.25 mcg26 weeks60
Association of Vitamin D Level and Maternal Gut Microbiome during Pregnancy: Findings from a Randomized Controlled Trial of Antenatal Vitamin D Supplementation
2023 · high-dose treatment group · Pregnant women enrolled at 10–18 weeks of gestation
4,400 IU—59
Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans
2015 · placebo group · African American male veterans aged 35–85 with dysglycemia and hypovitaminosis D
400 IU1 year55
Association of Vitamin D Level and Maternal Gut Microbiome during Pregnancy: Findings from a Randomized Controlled Trial of Antenatal Vitamin D Supplementation
2023 · placebo group (400 IU daily cholecalciferol) · Pregnant women enrolled at 10–18 weeks of gestation
400 IU—55
Vitamin D Supplementation Modestly Reduces Serum Iron Indices of Healthy Arab Adolescents
2018 · tablet group · Saudi boys and girls aged 13–17 years with vitamin D deficiency at baseline; participants with severe deficiency were excluded from the analysis
1,000 IU26 weeks53
The effect of vitamin D supplementation on serum lipids in postmenopausal women with diabetes: A randomized controlled trial
2015 · vitamin D group · Postmenopausal women with type 2 diabetes
4,000 IU26 weeks52
Effect of vitamin D adjuvant therapy on the proportion of regulatory T cells in peripheral blood and pregnancy outcome of patients with recurrent miscarriage
2025 · Vitamin D group (VDG) · Women aged 22–35 with recurrent miscarriage and singleton pregnancy
800 IU12 weeks52
Effect of vitamin D adjuvant therapy on the proportion of regulatory T cells in peripheral blood and pregnancy outcome of patients with recurrent miscarriage
2025 · Vitamin D group (VDG) · Women aged 22–35 with recurrent miscarriage and singleton pregnancy
800 IU12 weeks52
Vitamin D(3) prevents cardiovascular diseases by lowering serum total homocysteine concentrations in overweight reproductive women: A randomized, placebo-controlled clinical trial
2018 · treatment group · Overweight women of reproductive age
7,143 IU60 days50
A Randomized Double-Blind Placebo-Controlled Trial Evaluating the Efficacy of Oral Cholecalciferol in Improving Renal and Vascular Functions in Vitamin D-Deficient Patients With Type 2 Diabetes Mellitus
2023 · Group A · Adults aged 18–65 with type 2 diabetes, stage IIIA or IIIB chronic kidney disease, and hypovitaminosis D
8,571 IU8 weeks50
Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease
2016 · calcitriol · Patients with type 2 diabetes and albuminuria treated with RAAS inhibitors
0.25 mcg24 weeks48
Vitamin D Supplementation Reduces Both Oxidative DNA Damage and Insulin Resistance in the Elderly with Metabolic Disorders
2019 · intervention group · Adults older than 45 years with serum vitamin D below 30 ng/mL; participants included people with and without type 2 diabetes
2,000 IU90 days48
Changes in the human transcriptome upon vitamin D supplementation
2017 · vitamin D3 · Adults; sex and age range not specified, with no condition stated
2,857 IU5 years47
High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study
2018 · cholecalciferol group · Adults aged 18–85 with CKD stages 3–4, secondary hyperparathyroidism, and 25(OH)D below 75 nmol/L
8,000 IU12 weeks47
Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial
2023 · Vit.D3 group · Jordanian participants with vitamin D deficiency and no other medical conditions; age and sex not specified
7,143 IU8 weeks47
Vitamin D supplementation in obese type 2 diabetes subjects in Ajman, UAE: a randomized controlled double-blinded clinical trial
2015 · Vitamin D-group, phase 1 · UAE-national men and women aged 30–60 with obesity (BMI ≥30 kg/m²), type 2 diabetes, and serum 25(OH)D <50 nmol/L
6,000 IU90 days45
Vitamin D supplementation in obese type 2 diabetes subjects in Ajman, UAE: a randomized controlled double-blinded clinical trial
2015 · Vitamin D-group, phase 2 · UAE-national men and women aged 30–60 with obesity (BMI ≥30 kg/m²), type 2 diabetes, and serum 25(OH)D <50 nmol/L
3,000 IU90 days45
Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial
2015 · Vitamin D group · Vitamin D-deficient women with PCOS who were not pregnant or taking exogenous hormones
7,143 IU8 weeks45
Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease
2021 · VD group (experimental group) · Adults over 18 years with confirmed mild-to-moderate COVID-19 and hypovitaminosis D (serum vitamin D below 30 ng/mL); men and women
60,000 IU10 days44
Vitamin D supplementation reduces serum lipids of children with hypertriacylglycerolemia: A randomized, triple-masked, placebo-controlled crossover trial
2021 · supplemented group · Children aged 4–11 years with hypertriacylglycerolemia
1,000 IU12 weeks44
The Effects of Cholecalciferol Supplementation on FGF23 and α-Klotho in Hemodialysis Patients With Hypovitaminosis D: A Randomized, Double-Blind, Placebo-Controlled Trial
2022 · cholecalciferol group · Patients with hypovitaminosis D requiring hemodialysis
7,143 IU12 weeks43
Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial
2014 · vitamin D supplementation · Patients with chronic HCV genotype 1b
1,000 IU—42
The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease
2023 · Cholecalciferol · Adults aged 18–85 with CKD stages G3–G4 and secondary hyperparathyroidism, with 25(OH)D below 75 nmol/L
8,000 IU12 weeks42
Insulin resistance via modification of PGC1α function identifying a possible preventive role of vitamin D analogues in chronic inflammatory state of obesity. A double blind clinical trial study
2014 · intervention group (alfacalcidol) · Obese participants (BMI ≥30); age and sex not specified
1 mcg8 weeks40
Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D
2014 · VD group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 22.1 years
400 IU1 year40
Prenatal high-dose vitamin D3 supplementation has balanced effects on cord blood Th1 and Th2 responses
2016 · vitD group · Pregnant women aged 18 to under 35 years, enrolled at 26–29 weeks of gestation in Dhaka
5,000 IU—40
Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study
2017 · Placebo group · Adults aged 18–85 with hypoparathyroidism
400 IU24 weeks40
Calcitriol Reduces Albuminuria and Urinary Angiotensinogen Level in Renal Transplant Recipients
2018 · calcitriol group · Renal transplant recipients with low 25-(OH)D levels; nondiabetic
0.25 mcg1 year40
Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial
2019 · calcitriol group · Adults aged 18–68 years with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma in complete remission after autologous peripheral blood hematopoietic stem cell transplantation
0.75 mcg30 days40
Calcitriol supplementation before parathyroidectomy and calcium level after surgery in parathyroid adenoma patients: a randomized controlled trial
2023 · intervention group · Adults with primary hyperparathyroidism undergoing parathyroidectomy
0.25 mcg7 days40
Effect of vitamin D on endothelial and ventricular function in chronic heart failure patients: A prospective, randomized, placebo-controlled trial
2022 · vitamin D group · Adults with vitamin D-deficient, stable chronic heart failure; mean age about 66 years; both sexes
4,000 IU26 weeks39
Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients
2011 · treatment group · Adults with treatment-naïve chronic hepatitis C genotype 1 infection
2,000 IU—36
Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth
2008 · daily orally calcitriol (DO group) · Adults receiving haemodialysis for more than 6 months with secondary hyperparathyroidism and intact PTH 100–300 pg/ml
0.25 mcg1 year35
A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men
2009 · supplemented group · Men aged 35 years or older who were apparently healthy and centrally obese
60,000 IU6 weeks35
1,25-Dihydroxyvitamin D3 stimulation test and the effect of a prostaglandin synthesis inhibitor (piroxicam) in young adults
1991 · 1,25(OH)2 vitamin D3 (Rocaltrol) stimulation test · Healthy young adult men
4 mcg4 days34
Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study
2013 · Cinacalcet group · Adults aged 18–70 receiving peritoneal dialysis with secondary hyperparathyroidism
0.13 mcg16 weeks33
Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study
2013 · Control group · Adults aged 18–70 receiving peritoneal dialysis with secondary hyperparathyroidism
0.27 mcg16 weeks33
Vitamin D to Prevent Lung Injury Following Esophagectomy-A Randomized, Placebo-Controlled Trial
2018 · cholecalciferol arm · Adults undergoing planned esophagectomy for malignancy; men aged 18 or older and women aged 55 or older or more than 2 years post-menopause
300,000 IU1 day33
Vitamin D supplementation in obese Sri Lankan children: a randomized controlled trial
2020 · Supplementation Group · Children aged 5–15 years with obesity and vitamin D deficiency
357 IU24 weeks33
Supplementation with 1000 IU vitamin D/d leads to parathyroid hormone suppression, but not increased fractional calcium absorption, in 4-8-y-old children: a double-blind randomized controlled trial
2013 · 1000 IU vitamin D(3)/d · Healthy prepubertal children aged 4–8 years
1,000 IU8 weeks32
Vitamin D supplementation in obese Sri Lankan children: a randomized controlled trial
2020 · Treatment Group · Children aged 5–15 years with obesity and vitamin D deficiency
7,143 IU24 weeks32
Impact of high-dose vitamin D supplementation initiated shortly after diagnosis on residual beta cell function and partial remission rates in children with type 1 diabetes
2025 · Cases · Children aged 2–12 years with newly diagnosed type 1 diabetes
4,286 IU26 weeks32
High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients
2020 · Group I · Men and women aged 18–65 years with type 2 diabetes mellitus and diabetic peripheral neuropathy; most had vitamin D deficiency or insufficiency
714 IU24 weeks31
High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients
2020 · Group II · Men and women aged 18–65 years with type 2 diabetes mellitus and diabetic peripheral neuropathy; most had vitamin D deficiency or insufficiency
5,714 IU24 weeks31
Low-Dose Vitamin D(3) Supplementation Does Not Affect Natural Regulatory T Cell Population but Attenuates Seasonal Changes in T Cell-Produced IFN-γ: Results From the D-SIRe2 Randomized Controlled Trial
2021 · VitD3 group · Healthy adults older than 18 years
400 IU43 weeks31
Oral vitamin D supplementation on the prevention of peritoneal dialysis-related peritonitis: A pilot randomised controlled trial
2024 · Vitamin D group · Patients receiving peritoneal dialysis who had recovered from a recent episode of peritonitis; age and sex not stated
2,000 IU1 year31
Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial
2014 · paricalcitol · Adults with stages 3–5 chronic kidney disease and left ventricular hypertrophy
1 mcg52 weeks30
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial
2015 · Group Paricalcitol · Adults over 18 with stage 3b–5 chronic kidney disease and hemoglobin levels of 10–12.5 g/dL
1 mcg26 weeks30
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial
2015 · Group Calcitriol · Adults over 18 with stage 3b–5 chronic kidney disease and hemoglobin levels of 10–12.5 g/dL
0.25 mcg26 weeks30
Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients
2016 · Paricalcitol plus cholecalciferol (study group) · Adults aged 18 years or older receiving hemodialysis, with stage 5D chronic kidney disease, secondary hyperparathyroidism and low serum 25(OH)D3
714 IU16 weeks30
Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
2017 · 4 000 IU vitamin D group · Insulin-resistant patients with PCOS aged 18–40 years
4,000 IU12 weeks30
Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
2017 · 1 000 IU vitamin D group · Insulin-resistant patients with PCOS aged 18–40 years
1,000 IU12 weeks30
Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
2018 · CCC (study group) · Adults over 18 years receiving maintenance hemodialysis with severe secondary hyperparathyroidism
5,000 IU24 weeks30
Effects of active vitamin D on insulin resistance and islet β-cell function in non-diabetic chronic kidney disease patients: a randomized controlled study
2022 · Non-dialysis experimental group · Adults with non-diabetic chronic kidney disease receiving non-dialysis treatment; mean age 53.45 years in the non-dialysis group
0.5 mcg26 weeks30
Vitamin D Supplementation Modulates Platelet-Mediated Inflammation in Subjects With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
2022 · vitamin D3 group · Adults aged 35–65 with vitamin-D-deficient, uncontrolled type 2 diabetes
8,571 IU26 weeks30
The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial
2025 · UDCA + VitD group · Adults aged 18 years or older with treatment-naive primary biliary cholangitis; 70% female in the initial group
1,200 IU2 years30
Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial
2009 · paricalcitol group · Patients with proteinuric chronic kidney disease and eGFR of 15 to 90 mL/min/1.73 m²
1 mcg26 weeks28
Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: A randomized placebo-controlled trial
2015 · vitamin D · Patients with hypercholesterolemia receiving statin treatment
2,000 IU26 weeks28
Effects of 1α-Calcidol (Alfacalcidol) on Microvascular Endothelial Function, Arterial Stiffness, and Blood Pressure in Type II Diabetic Nephropathy Patients
2016 · alfacalcidol group · Patients with type II diabetic nephropathy; age and sex not reported
0.25 mcg26 weeks28
Effect of two vitamin D repletion protocols on 24-h urine calcium in patients with recurrent calcium kidney stones and vitamin D deficiency: a randomized clinical trial
2023 · 2000 IU/daily · Adults aged 18–70 with recurrent calcium kidney stones and vitamin D deficiency (25(OH)D 10–20 ng/mL)
2,000 IU12 weeks28
The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients
2015 · vitamin D3 supplementation group · Adults with multiple sclerosis; some had deficient or insufficient 25-hydroxyvitamin D levels
7,143 IU26 weeks27
Vitamin D binding protein is not affected by high-dose vitamin D supplementation: a post hoc analysis of a randomised, placebo-controlled study
2018 · vitamin D treated group · Persistent MRSA carriers; age and sex not stated; generally healthy
4,000 IU1 year27
Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial
2013 · paricalcitol · Adults with stage III-IV chronic kidney disease and micro- or macroalbuminuria; age >18 years
2 mcg6 weeks26
Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial
2015 · Group B · Overweight, vitamin D-deficient women aged 18–40 years with PCOS
7,143 IU8 weeks26
Vitamin D supplementation during pregnancy: Effect on the neonatal immune system in a randomized controlled trial
2018 · 4400 IU/d vitamin D3 · Pregnant women; age and pregnancy condition details beyond pregnancy are not reported.
4,400 IU—26
Alfacalcidol vs Calcitriol in the Management of Patient With Hypoparathyroidism: A Randomized Controlled Trial
2021 · Calcitriol (switched from alfacalcidol) · Patients with idiopathic hypoparathyroidism who had optimal calcemic control on alfacalcidol
0.75 mcg26 weeks25
The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes
2021 · D-yogurt drink (DY) · Adults aged 30–60 years with confirmed type 2 diabetes
1,000 IU12 weeks25
Vitamin D supplementation affects serum high-sensitivity C-reactive protein, insulin resistance, and biomarkers of oxidative stress in pregnant women
2013 · vitamin D group · Pregnant women aged 18–40 years at 25 weeks of gestation; described as healthy
400 IU9 weeks24
Acute Supplementation with High Dose Vitamin D3 Increases Serum Anti-Müllerian Hormone in Young Women
2017 · Vitamin D3 group · Women aged 19–25 years with regular menstrual cycles and no known ovarian conditions
50,000 IU7 days24
Effects of vitamin D supplements on frequency of CD4(+) T-cell subsets in women with Hashimoto's thyroiditis: a double-blind placebo-controlled study
2019 · vitamin D group · Women with Hashimoto's thyroiditis
7,143 IU90 days24
Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial
1994 · continuous calcitriol group · Dialysis patients with elevated 1,84-iPTH levels
0.75 mcg12 weeks24
Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial
2009 · 800 IU vitamin D3 supplementation · Adults aged 30–75 in generally good health with at least one pathology-confirmed sporadic colon or rectal adenoma in the previous 36 months
800 IU26 weeks23
Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial
2009 · vitamin D supplementation group · Adults aged 30–75 in general good health with a history of at least one pathology-confirmed colorectal adenoma within the past 36 months
800 IU26 weeks23
Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients
2010 · 800 IU vitamin D3 supplementation group · Adults aged 30–75 with a history of at least one adenomatous colonic or rectal polyp within the past 36 months
800 IU26 weeks23
A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients
2011 · vitamin D3 group · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp in the preceding 36 months
800 IU180 days23
Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial
2011 · 800 IU vitamin D3 group · Adults aged 30–75 with a history of sporadic colorectal adenoma
800 IU26 weeks23
A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients
2012 · 800 IU vitamin D3 supplementation · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp within the past 36 months
800 IU26 weeks23
Effects of calcium and vitamin D3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: a randomized controlled trial
2015 · vitamin D3 group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp within the past 36 months; both sexes
800 IU26 weeks23
Vitamin D inhibits pro-inflammatory cytokines in the airways of cystic fibrosis patients infected by Pseudomonas aeruginosa- pilot study
2019 · calcitriol group · Children and adolescents aged 6–19 years with cystic fibrosis and chronic Pseudomonas aeruginosa infection
0.5 mcg90 days23
Vitamin D inhibits pro-inflammatory cytokines in the airways of cystic fibrosis patients infected by Pseudomonas aeruginosa- pilot study
2019 · cholecalciferol group · Children and adolescents aged 6–19 years with cystic fibrosis and chronic Pseudomonas aeruginosa infection
1,000 IU90 days23
The effects of chromium and vitamin D(3) co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial
2020 · vitamin D3 supplement · patients with type 2 diabetes mellitus; age and sex not stated
7,143 IU120 days23
The effect of vitamin D supplementation on flow-mediated dilatation, oxidized LDL and intracellular adhesion molecule 1 on type 2 diabetic patients with hypertension: A randomized, placebo-controlled, double-blind trial
2021 · vitamin D group · Patients with type 2 diabetes and hypertension; age and sex not reported
2,000 IU12 weeks23
Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia
2006 · Group 1 · Patients undergoing total thyroidectomy; age and sex not reported
1.5 mcg7 days22
A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease
2010 · cholecalciferol · Adults with vitamin D-deficient stage 3 or 4 chronic kidney disease and parathyroid hormone values above the Kidney Disease Outcomes Quality Initiative target
4,000 IU90 days22
No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes
2010 · 1,25(OH)2D3 treatment group · Adults with recent-onset type 1 diabetes; randomized efficacy phase participants
0.25 mcg39 weeks22
Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial
2014 · Cholecalciferol group · Healthy men and women older than 18 years with vitamin D insufficiency (serum 25(OH)vitamin D ≤50 nmol/L)
3,000 IU16 weeks22
Acute Effects of Single Doses of Bonito Fish Peptides and Vitamin D on Whole Blood Gene Expression Levels: A Randomized Controlled Trial
2019 · VitD3 · Overweight or obese adults aged 18–65 years, without metabolic disorders requiring treatment
1,000 IU1 day22
Effect of high-dose vitamin D supplementation in combination with weight loss diet on glucose homeostasis, insulin resistance, and matrix metalloproteinases in obese subjects with vitamin D deficiency: a double-blind, placebo-controlled, randomized clinical trial
2020 · Vitamin D group · Obese participants with vitamin D deficiency, BMI 30–40 kg/m² and serum 25(OH)D ≤50 nmol/L; age and sex not specified
7,143 IU12 weeks22
Effects of cholecalciferol supplementation on serum angiogenic biomarkers in breast cancer patients treated with tamoxifen: A controlled randomized clinical trial
2020 · cholecalciferol intervention group · Women with breast cancer treated with tamoxifen; age range and menopausal status not specified
7,143 IU8 weeks22
Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial
2025 · Vit D 1000 (D1) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m²
1,000 IU8 weeks22
Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial
2025 · Vit D 5000 (D5) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m²
5,000 IU8 weeks22
Effect of vitamins on the lipid profile of patients on regular hemodialysis
2000 · vitamin D3 · hemodialysis patients; age and sex not reported
50,000 IU90 days21
Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial
1994 · intermittent calcitriol group · Dialysis patients with elevated 1,84-iPTH levels
0.75 mcg12 weeks21
[Treatment of secondary hyperparathyroidism with vitamin D metabolites]
1994 · 1-alpha-OHD3 plus placebo · Adults aged 19–67 with secondary hyperparathyroidism receiving chronic haemodialysis
0.25 mcg13 weeks20
The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial
2010 · 200,000 IU vitamin D(3) · Patients with type 2 diabetes and baseline 25-hydroxyvitamin D levels <100 nmol/l
200,000 IU1 day20
Vitamin D(3) repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial
2017 · Vitamin D3 treatment · Adults aged 18 years or older with NYHA class II or III heart failure and baseline 25(OH)D ≤32 ng/ml
10,000 IU26 weeks20
A randomized double-blind placebo-controlled trial of vitamin D supplementation in juvenile-onset systemic lupus erythematosus: positive effect on trabecular microarchitecture using HR-pQCT
2018 · JoSLE-VitD · Female patients with juvenile-onset systemic lupus erythematosus
7,143 IU24 weeks20
Vitamin D3 supplementation improves serum SFRP5 and Wnt5a levels in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial
2018 · Vitamin D group · Adults with type 2 diabetes; 16 women and 24 men across the trial; age range not reported
4,000 IU8 weeks20
Vitamin D Supplementation and T Cell Regulation in Preterm Infants: A Randomized Controlled Trial
2019 · 400 IU/day vitamin D3 group · Preterm infants born at 28–33 weeks’ gestation
400 IU4 weeks20
Vitamin D Supplementation and T Cell Regulation in Preterm Infants: A Randomized Controlled Trial
2019 · 800 IU/day vitamin D3 group · Preterm infants born at 28–33 weeks’ gestation
800 IU4 weeks20
Alfacalcidol vs Calcitriol in the Management of Patient With Hypoparathyroidism: A Randomized Controlled Trial
2021 · Alfacalcidol (continued same treatment) · Patients with idiopathic hypoparathyroidism who had optimal calcemic control on alfacalcidol
2 mcg26 weeks20
Vitamin D supplementation during pregnancy inhibits the activation of fetal membrane NF-κB pathway
2022 · Group 1 · Pregnant women with vitamin D insufficiency (serum vitamin D 20–30 ng/mL), supplemented from week 14 of pregnancy until delivery
500 IU—20
Vitamin D supplementation during pregnancy inhibits the activation of fetal membrane NF-κB pathway
2022 · Group 2 · Pregnant women with vitamin D insufficiency (serum vitamin D 20–30 ng/mL), supplemented from week 14 of pregnancy until delivery
1,000 IU—20
The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial
2010 · 100,000 IU vitamin D(3) · Patients with type 2 diabetes and baseline 25-hydroxyvitamin D levels <100 nmol/l
100,000 IU1 day19
Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients
2018 · Vitamin D (2-arm randomization) · Women aged 45–75 with a removed histologically verified colorectal adenoma who declined to forego calcium supplementation
1,000 IU1 year19
Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study
2020 · Group C · Patients with latent autoimmune diabetes in adults (LADA)
2,000 IU1 year19
Effects of active vitamin D on insulin resistance and islet β-cell function in non-diabetic chronic kidney disease patients: a randomized controlled study
2022 · Peritoneal dialysis experimental group · Adults with non-diabetic chronic kidney disease receiving peritoneal dialysis; mean age 49.95 years in the peritoneal dialysis group
0.5 mcg26 weeks19
A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome
2019 · vitamin D group · Women aged 18–45 with PCOS who were overweight or obese and vitamin D deficient
3,200 IU90 days18
Effects of active vitamin D on insulin resistance and islet β-cell function in non-diabetic chronic kidney disease patients: a randomized controlled study
2022 · Hemodialysis experimental group · Adults with non-diabetic chronic kidney disease receiving hemodialysis; mean age 48.75 years in the hemodialysis group
0.5 mcg26 weeks18
Effect of Ergocalciferol on β-Cell Function in New-Onset Type 1 Diabetes: A Secondary Analysis of a Randomized Clinical Trial
2024 · Ergocalciferol · Youths aged 10–21 years with newly diagnosed type 1 diabetes
7,143 IU1 year18
Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial
2017 · intervention group · Children and young people aged 1 to under 21 years with stage 2–5 non-dialysis chronic kidney disease
4,000 IU12 weeks17
Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial
2017 · control group · Children and young people aged 1 to under 21 years with stage 2–5 non-dialysis chronic kidney disease
400 IU12 weeks17
Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients
2018 · Vitamin D (4-arm randomization) · Adults aged 45–75 with a removed histologically verified colorectal adenoma; men and women
1,000 IU1 year17
Effect of Vitamin D Supplementation on Faecal Microbiota: A Randomised Clinical Trial
2019 · vitamin D group · Adults aged 18–60 with vitamin D deficiency and overweight or obesity
4,000 IU16 weeks17
Effect of 1,25 (OH)2D3 treatment on glucose intolerance in uraemia
1992 · oral calcitriol · Adults receiving haemodialysis with uraemia
0.5 mcg8 weeks16
Effects of 1,25 (OH)2D3 treatment on lipid levels in uremic hemodialysis patients
1992 · calcitriol treatment · Uremic hemodialysis patients
0.5 mcg8 weeks16
Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma
2010 · 1,25(OH)2D3-treated patients · Adults aged 45–92 with newly diagnosed head and neck squamous cell carcinoma scheduled for surgery
4 mcg3 weeks16
Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients
2011 · calcitriol group · Haemodialysis patients with secondary hyperparathyroidism and intact parathyroid hormone >32 pmol/L
0.586 mcg24 weeks16
Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients
2011 · alfacalcidol group · Haemodialysis patients with secondary hyperparathyroidism and intact parathyroid hormone >32 pmol/L
0.986 mcg24 weeks16
Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)
2022 · intervention group · Vitamin D-deficient adults with asymptomatic or mildly symptomatic SARS-CoV-2 infection; age and sex not reported
60,000 IU7 days16
Single High-Dose Vitamin D Supplementation as an Approach for Reducing Ultramarathon-Induced Inflammation: A Double-Blind Randomized Controlled Trial
2021 · supplementation group (S) · Healthy male semi-professional ultramarathon runners aged 30 years or older
150,000 IU1 day16
Effects of Endurance Exercise and Vitamin D Supplementation on Insulin Resistance and Plasma Lipidome in Middle-Aged Adults with Type 2 Diabetes
2023 · EX + VD group · Middle-aged adults with type 2 diabetes mellitus, not receiving insulin treatment
1,000 IU12 weeks16
Effects of Endurance Exercise and Vitamin D Supplementation on Insulin Resistance and Plasma Lipidome in Middle-Aged Adults with Type 2 Diabetes
2023 · VD group · Middle-aged adults with type 2 diabetes mellitus, not receiving insulin treatment
1,000 IU12 weeks16
Vitamin D Supplementation Influences Ultramarathon-Induced Changes in Serum Amino Acid Levels, Tryptophan/Branched-Chain Amino Acid Ratio, and Arginine/Asymmetric Dimethylarginine Ratio
2023 · experimental (supplemented, S) group · Semi-professional male ultramarathon runners with previous ultramarathon experience (at least 5 starts); age range not reported
150,000 IU1 day16
Effect of Single High-Dose Vitamin D(3) Supplementation on Post-Ultra Mountain Running Heart Damage and Iron Metabolism Changes: A Double-Blind Randomized Controlled Trial
2024 · supplementation group (S) · Healthy semi-professional male ultramarathon runners aged 30 years or older with at least five previous ultramarathon finishes
150,000 IU1 day16
Plasma Lipidomic Profiles Improve upon Traditional Risk Factors for the Prediction of Arterial Stiffness Among Patients with Type 2 Diabetes Mellitum: A Randomized, Placebo-Controlled Trial
2024 · EX + VD group · Adults aged 33–65 with type 2 diabetes, not treated with insulin
1,000 IU12 weeks16
Plasma Lipidomic Profiles Improve upon Traditional Risk Factors for the Prediction of Arterial Stiffness Among Patients with Type 2 Diabetes Mellitum: A Randomized, Placebo-Controlled Trial
2024 · VD group · Adults aged 33–65 with type 2 diabetes, not treated with insulin
1,000 IU12 weeks16
Single high-dose vitamin D supplementation impacts ultramarathon-induced changes in serum levels of bone turnover markers: a double-blind randomized controlled trial
2025 · supplemented group · Semiprofessional male ultramarathon runners who intended to complete a 240 km ultramarathon; ages 42.40 ± 7.59 years in the supplemented group
150,000 IU1 day16
The effect of 1,25(OH)2 vitamin D3 on CD4+/CD8+ subsets of T lymphocytes in postmenopausal women
1997 · Group one (1 ug/day) · Postmenopausal women
1 mcg2 weeks16
Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure
1998 · Treatment A · Adults with predialytic chronic renal failure and secondary hyperparathyroidism
0.5 mcg90 days16
Effect of Vitamin D Supplementation on Muscle Status in Old Patients Recovering from COVID-19 Infection
2021 · vitamin D (VD) group · Older male patients recovering from recent PCR-confirmed COVID-19 infection, without stated comorbidities
2,000 IU6 weeks15
Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease
1997 · Group B · Patients with untreated Graves' disease; age and sex not stated
1.5 mcg24 weeks15
Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study
2014 · ACD group · Hemodialysis patients with mild secondary hyperparathyroidism whose intact PTH had decreased to the target range
0.5 mcg12 weeks14
High-dose vitamin D(3) reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults
2017 · vitamin D group · Healthy adults aged 18–65; most were vitamin D deficient at baseline
250,000 IU1 day14
The effect of 1,25(OH)2 vitamin D3 on CD4+/CD8+ subsets of T lymphocytes in postmenopausal women
1997 · Group two (2 ug/day) · Postmenopausal women
2 mcg2 weeks14
Vitamin D2 supplementation amplifies eccentric exercise-induced muscle damage in NASCAR pit crew athletes
2013 · Vitamin D group · Adult NASCAR pit crew athletes; sex not stated; not selected for a diagnosed condition or vitamin D deficiency
3,800 IU6 weeks13
The effect of short-term vitamin D on the antioxidant capacity following exhaustive aerobic exercise
2023 · Experimental (Exp) · Men aged 20–30 with vitamin D deficiency, without underlying disease; non-athletes
2,000 IU6 weeks13
Effect of 24,25-dihydroxycholecalciferol on intestinal absorption of calcium and phosphate and on parathyroid hormone secretion in chronic renal failure
1992 · 24,25-dihydroxycholecalciferol treatment · Patients with chronic renal failure requiring dialysis; 7 of the 12 were hypercalcaemic
10 mcg90 days12
Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease
2017 · Stage 3/4 CKD Part 1 paricalcitol · Children aged 10–16 years with stage 3 or 4 chronic kidney disease
3 mcg1 day12
Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease - a randomized trial
2017 · Paricalcitol 1 μg · Adults over 20 years with moderate chronic kidney disease (eGFR 15–59 mL/min/1.73 m²)
1 mcg12 weeks12
Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease - a randomized trial
2017 · Paricalcitol 2 μg · Adults over 20 years with moderate chronic kidney disease (eGFR 15–59 mL/min/1.73 m²)
2 mcg12 weeks12
Oxidative stress in critically ill ventilated adults: effects of vitamin D(3) and associations with alveolar macrophage function
2018 · 50,000 IU vitamin D3 group · Adults older than 18 years with critical illness and respiratory failure requiring mechanical ventilation
50,000 IU5 days12
Oxidative stress in critically ill ventilated adults: effects of vitamin D(3) and associations with alveolar macrophage function
2018 · 100,000 IU vitamin D3 group · Adults older than 18 years with critical illness and respiratory failure requiring mechanical ventilation
100,000 IU5 days12
Effect of Vitamin D(3) on the Postprandial Lipid Profile in Obese Patients: A Non-Targeted Lipidomics Study
2019 · low-dose cholecalciferol group · Obese, pre-menopausal, vitamin D-deficient women
75,000 IU7 days12
Effect of Vitamin D(3) on the Postprandial Lipid Profile in Obese Patients: A Non-Targeted Lipidomics Study
2019 · high-dose cholecalciferol group · Obese, pre-menopausal, vitamin D-deficient women
300,000 IU7 days12
Effect of vitamin D(3) vs. calcifediol on VDR concentration and fiber size in skeletal muscle
2023 · VD3 group · Postmenopausal women; mean age 61 ± 4 years
3,200 IU26 weeks12
Randomized controlled trial of vitamin d supplementation on toll-like receptor-2 (tlr-2) and toll-like receptor-4 (tlr-4) in tuberculosis spondylitis patients
2023 · 10,000 IU/day group · Patients aged 19–50 with tuberculosis spondylitis
10,000 IU8 weeks12
Randomized controlled trial of vitamin d supplementation on toll-like receptor-2 (tlr-2) and toll-like receptor-4 (tlr-4) in tuberculosis spondylitis patients
2023 · 5,000 IU/day group · Patients aged 19–50 with tuberculosis spondylitis
5,000 IU8 weeks12
Randomized controlled trial of vitamin d supplementation on toll-like receptor-2 (tlr-2) and toll-like receptor-4 (tlr-4) in tuberculosis spondylitis patients
2023 · 400 IU/day group · Patients aged 19–50 with tuberculosis spondylitis
400 IU8 weeks12
Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial
2025 · Pilot cohort · Infertile men; mean age 33.4 years
25 mcg270 days12
Effects of Resistance Training Combined with Vitamin D Supplementation on Health-Related Variables in the Elderly: Muscle Strength, Body Composition, and Inflammatory Status
2025 · experimental group (EG) · Men and women aged 60 or older without a stated diagnosed condition; participants had adequate vitamin D levels
2,000 IU12 weeks12
Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone
1995 · Group A · Adults with chronic renal insufficiency who were not receiving dialysis
0.55 mcg39 weeks12
1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells
2009 · 1,25(OH)2D3-treated patients · Adults aged 42–77 with newly diagnosed stage II–IV head and neck squamous cell carcinoma scheduled for surgery
4 mcg3 weeks11
Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial
2012 · Group-1: alphacalcidol first · Adults aged 18 years or older with chronic kidney disease stage 3b
0.25 mcg2 weeks11
Maternal pregnancy vitamin D supplementation increases offspring bone formation in response to mechanical loading: Findings from a MAVIDOS Trial sub-study
2020 · Intervention group (children whose mothers received antenatal vitamin D) · Pregnant women with baseline 25(OH)D of 25–100 nmol/L at 11–14 weeks’ gestation; their offspring were aged 4–5 years at the sub-study
1,000 IU—11
Alterations of liver enzymes and lipid profile in response to exhaustive eccentric exercise: vitamin D supplementation trial in overweight females with non-alcoholic fatty liver disease
2022 · experimental group · Women aged 20–40 years with overweight and ultrasound-diagnosed non-alcoholic fatty liver disease
2,000 IU6 weeks11
Vitamin D3 supplementation in COVID-19 patients with cardiovascular disease and gut dysbiosis
2024 · vitamin D3 group · Adults hospitalized with mild COVID-19 and a history of cardiovascular disease
10,000 IU—11
Calcitriol per os once, twice or three times a week: effect of different schedules of administration in hemodialysis patients
2000 · Group A · Patients on hemodialysis with secondary hyperparathyroidism; age and sex not reported
0.0000114 mg/kg60 days10
Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis
2003 · Adults with cystic fibrosis · Adults with cystic fibrosis
1 mcg2 weeks10
Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis
2003 · Age-, sex- and BMI-matched controls · Adult age-, sex- and BMI-matched controls without stated cystic fibrosis
1 mcg2 weeks10
Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial
2012 · Group-2: sevelamer carbonate first · Adults aged 18 years or older with chronic kidney disease stage 3b
0.25 mcg2 weeks10
Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis
2018 · Plain vitamin D3 treatment · Post-menopausal women with osteoporosis, approximately 73 years old
800 IU27 days10
Home-based aerobic training and vitamin D improve neurotrophins and inflammatory biomarkers in MS patients
2022 · AT+Vit D · Females aged 20–40 with multiple sclerosis (EDSS 3–5) and BMI 25–30 kg/m²
7,143 IU8 weeks10
Concurrent alteration in inflammatory biomarker gene expression and oxidative stress: how aerobic training and vitamin D improve T2DM
2022 · AT+Vit D · Males aged 35–50 years with type 2 diabetes mellitus
7,143 IU8 weeks10
Concurrent alteration in inflammatory biomarker gene expression and oxidative stress: how aerobic training and vitamin D improve T2DM
2022 · Vit D · Males aged 35–50 years with type 2 diabetes mellitus
7,143 IU8 weeks10
Decreased inflammatory gene expression accompanies the improvement of liver enzyme and lipid profile following aerobic training and vitamin D supplementation in T2DM patients
2022 · AT+Vit D · Men aged 35–50 with type 2 diabetes mellitus
7,143 IU8 weeks10
Decreased inflammatory gene expression accompanies the improvement of liver enzyme and lipid profile following aerobic training and vitamin D supplementation in T2DM patients
2022 · Vit D · Men aged 35–50 with type 2 diabetes mellitus
7,143 IU8 weeks10
[Effect of 1 alpha-OH-D3 on the bone metabolism after high tibial osteotomy]
1993 · 1 alpha-OH-D3 treated group · Female patients with gonarthrosis undergoing high tibial osteotomy
1 mcg—10
Changes in 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D are associated with maturation of regulatory T lymphocytes in patients with chronic pancreatitis: a randomized controlled trial
2012 · group B · Patients with chronic pancreatitis and fat malabsorption; age and sex not reported
1,520 IU10 weeks9
Effects of 1,25-dihydroxyvitamin D3 and vitamin D3 on the expression of the vitamin d receptor in human skeletal muscle cells
2015 · vitamin D3-supplemented women · Women aged 65 years and older with mobility limitations and moderately low baseline 25OHD
4,000 IU16 weeks9
Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis
2018 · ELD treatment · Post-menopausal women with osteoporosis, approximately 74 years old
0.75 mcg27 days9
Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis
2018 · ALF treatment · Post-menopausal women with osteoporosis, approximately 75 years old
1 mcg27 days9
Home-based aerobic training and vitamin D improve neurotrophins and inflammatory biomarkers in MS patients
2022 · Vit D · Females aged 20–40 with multiple sclerosis (EDSS 3–5) and BMI 25–30 kg/m²
7,143 IU8 weeks9
Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism
1995 · intermittent oral calcitriol · Adults with secondary hyperparathyroidism receiving chronic haemodialysis
0.0000064 mg/kg10 weeks8
Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial
1998 · daily · CAPD patients with mild to moderate secondary hyperparathyroidism
0.75 mcg85 days8
Adipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients
2021 · ASC + VIT D group · Patients aged 16–35 years with recent-onset type 1 diabetes (<4 months) and positive GADA; both sexes
2,000 IU26 weeks7
Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism
1995 · daily oral calcitriol · Adults with secondary hyperparathyroidism receiving chronic haemodialysis
0.0000064 mg/kg10 weeks7
Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial
2013 · Group II (2,000 IU/d) · Healthy adults aged 18 or older, men and women; included participants with vitamin D deficiency and participants with insufficient or sufficient status
2,000 IU8 weeks5
Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial
2013 · Group I (400 IU/d) · Healthy adults aged 18 or older, men and women; included participants with vitamin D deficiency and participants with insufficient or sufficient status
400 IU8 weeks3
Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy
2004 · calcitriol · Patients with histologically confirmed prostate adenocarcinoma scheduled for radical prostatectomy; age and sex range not reported
0.0000714 mg/kg4 weeks—
Calcemic response to magnesium or 1-alpha-hydroxycholecalciferol treatment in intestinal hypomagnesemia
1991 · Group II (1-alpha-hydroxycholecalciferol) · Gastroenterological patients with intestinal hypomagnesemia; age and sex not reported
1 mcg7 days—
A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease
2006 · continuous group · Patients with end-stage renal disease on hemodialysis and secondary hyperparathyroidism
1 mcg12 weeks—
A single dose of vitamin D enhances immunity to mycobacteria
2007 · vitamin D · Healthy adult tuberculosis contacts in London, United Kingdom
2.5 mg1 day—
Combined calcium and vitamin D supplementation is not superior to calcium supplementation alone in improving disturbed bone metabolism in patients with congestive heart failure
2008 · CaD group · Ambulatory men with congestive heart failure, low vitamin D status, and insufficient dietary calcium intake
50 mcg270 days—
Calcium balance during calcitriol and paricalcitol administration in healthy humans
2008 · paricalcitol · Healthy individuals with normal renal function; age and sex not reported
1.5 mcg6 days—
Calcium balance during calcitriol and paricalcitol administration in healthy humans
2008 · calcitriol · Healthy individuals with normal renal function; age and sex not reported
0.5 mcg6 days—
Reduction in serum alkaline phosphatase levels by treatment with active vitamin D (alphacalcidol) in primary and secondary hyperparathyroidism and in euparathyroid individuals
1991 · Oral alphacalcidol group · People with mild primary hyperparathyroidism
1 mcg26 weeks—
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women
2010 · D group · Postmenopausal Japanese women aged 49–81 years with osteoporosis or osteopenia
1 mcg1 year—
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women
2010 · D + R group · Postmenopausal Japanese women aged 49–81 years with osteoporosis or osteopenia
1 mcg1 year—
Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial
2010 · vitamin D supplementation group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp
800 IU26 weeks—
Effects of 25-hydroxyvitamin D level and its change on parathyroid hormone in premenopausal Chinese women
2010 · vitamin D3 dairy product group · Premenopausal Chinese women aged 28.0±4.4 years
200 IU90 days—
Efficient tetanus toxoid immunization on vitamin D supplementation
2011 · vitamin D group · 32 individuals; age, sex, and health condition not specified
2,000 IU10 weeks—
Maintenance of wintertime vitamin D status with cholecalciferol supplementation is not associated with alterations in serum cytokine concentrations among apparently healthy younger or older adults
2011 · 5 μg/d cholecalciferol (D3) group · Apparently healthy younger adults aged 20–40 years and older adults aged ≥64 years
5 mcg22 weeks—
Maintenance of wintertime vitamin D status with cholecalciferol supplementation is not associated with alterations in serum cytokine concentrations among apparently healthy younger or older adults
2011 · 10 μg/d cholecalciferol (D3) group · Apparently healthy younger adults aged 20–40 years and older adults aged ≥64 years
10 mcg22 weeks—
Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women
2011 · alendronate plus vitamin D3 (ALN + D) · Postmenopausal women with low bone mineral density and 25(OH)D concentrations of 25 ng/mL or less
400 IU30 days—
The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation
2011 · vitamin D3-treated subjects · Trial participants; age, sex, and health condition are not specified in the abstract.
4,000 IU6 weeks—
Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus patients
2011 · calcitriol group · Adults aged 30–75 years with type 2 diabetes
0.5 mcg12 weeks—
Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23
2012 · ergocalciferol treatment · Adults aged 18–45 with vitamin D deficiency (25-hydroxyvitamin D ≤20 ng/ml)
7,143 IU12 weeks—
Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus
2012 · cholecalciferol group · Patients with new-onset type 1 diabetes mellitus and fasting serum C-peptide levels ≥0.6 ng/mL
2,000 IU540 days—
High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial
2012 · vitamin D group · Adults with early chronic kidney disease, stages 2–3; age and sex not specified
7,143 IU52 weeks—
Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects
2012 · 40,000 IU vitamin D per week · Overweight and obese subjects; age and sex not specified
5,714 IU1 year—
Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects
2012 · 20,000 IU vitamin D per week · Overweight and obese subjects; age and sex not specified
2,857 IU1 year—
Blood lead concentration is not altered by high-dose vitamin D supplementation in children and young adults with HIV
2013 · 4000 IU/day group · Children and young adults aged 8–24 years with HIV
4,000 IU12 weeks—
Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects
2013 · 40,000 IU cholecalciferol per week · Middle-aged overweight and obese subjects
5,714 IU1 year—
Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects
2013 · 20,000 IU cholecalciferol per week · Middle-aged overweight and obese subjects
2,857 IU1 year—
The effect of different doses of vitamin D supplementation on insulin resistance during pregnancy
2013 · Group A · Pregnant women enrolled before 12 weeks of gestation
200 IU——
A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes
2013 · intervention group · Children aged 8–15 with newly diagnosed type 1 diabetes of less than 8 weeks’ duration
0.5 mcg26 weeks—
Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue
2013 · 400 IU/day group · Men aged 42–67 with prostate cancer undergoing radical prostatectomy
400 IU8 weeks—
Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue
2013 · 10,000 IU/day group · Men aged 42–67 with prostate cancer undergoing radical prostatectomy
10,000 IU8 weeks—
Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue
2013 · 40,000 IU/day group · Men aged 42–67 with prostate cancer undergoing radical prostatectomy
40,000 IU8 weeks—
Effect of vitamin D administration in vitamin D-deficient pregnant women on maternal and neonatal serum calcium and vitamin D concentrations: a randomised clinical trial
2013 · Treatment group · Vitamin D-deficient pregnant women recruited at 26–28 weeks of pregnancy
7,143 IU8 weeks—
A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis
2014 · Vitamin D3, atopic dermatitis subjects · Adults with moderate-to-severe atopic dermatitis; mean age 31.2 years
4,000 IU3 weeks—
A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis
2014 · Vitamin D3, non-atopic control subjects · Non-atopic adults; mean age 31.9 years
4,000 IU3 weeks—
A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis
2014 · Vitamin D3, psoriasis subjects · Adults with mild psoriasis; mean age 38.8 years
4,000 IU3 weeks—
Effect of vitamin D replacement on hip structural geometry in adolescents: a randomized controlled trial
2013 · 1400 IU vitamin D3 group · Adolescent girls and boys; mean age 13.1 years for girls and 12.7 years for boys
200 IU1 year—
Effect of vitamin D replacement on hip structural geometry in adolescents: a randomized controlled trial
2013 · 14,000 IU vitamin D3 group · Adolescent girls and boys; mean age 13.1 years for girls and 12.7 years for boys
2,000 IU1 year—
Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial)
2013 · VitD3 treatment group · Adults with stable chronic heart failure and reduced left ventricular ejection fraction; mean age 64 years, 93% male
2,000 IU6 weeks—
Vitamin D favorably alters the cancer promoting prostaglandin cascade
2013 · 2,000 IU vitamin D-3 · Healthy women; age range and other characteristics not specified
2,000 IU30 days—
Serum IL-18 and hsCRP correlate with insulin resistance without effect of calcitriol treatment on type 2 diabetes
2013 · Calcitriol group · Adults with type 2 diabetes
0.5 mcg12 weeks—
A randomized study on the effect of vitamin D₃ supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women
2013 · vitamin D (VD) · Women aged 65 years or older with mobility limitations and serum 25-hydroxyvitamin D levels of 22.5 to 60 nmol/L
4,000 IU120 days—
A Randomized controlled trial on safety and efficacy of single intramuscular versus staggered oral dose of 600 000IU Vitamin D in treatment of nutritional rickets
2014 · 60 000 IU oral vitamin D once a week for 10 weeks · Children aged 0.5–5 years with nutritional rickets
8,571 IU10 weeks—
Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23
2014 · cholecalciferol · Patients with chronic kidney disease, stages 1–5; age and sex not specified
5,714 IU8 weeks—
Vitamin D and fetal-neonatal calcium homeostasis: findings from a randomized controlled trial of high-dose antenatal vitamin D supplementation
2014 · oral vitamin D3 · Pregnant women in Bangladesh, enrolled at 26–29 weeks of gestation
5,000 IU——
Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: a randomized controlled clinical trial
2014 · vitamin D group · Adults with vitamin D insufficiency and type 2 diabetes; age and sex range not stated
7,143 IU8 weeks—
Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model
2015 · 400 IU/day vitamin D3 group · Men with prostate cancer scheduled for radical prostatectomy
400 IU8 weeks—
Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model
2015 · 10,000 IU/day vitamin D3 group · Men with prostate cancer scheduled for radical prostatectomy
10,000 IU8 weeks—
Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model
2015 · 40,000 IU/day vitamin D3 group · Men with prostate cancer scheduled for radical prostatectomy
40,000 IU8 weeks—
Calcium supplementation increases blood creatinine concentration in a randomized controlled trial
2014 · Vitamin D3 alone · Adults aged 45–75 in generally good health with a previously removed large bowel adenoma; predominantly male
1,000 IU5 years—
[Effects of vitamin D supplementation on insulin resistance in patients with type 2 diabetes mellitus]
2014 · intervention group · Adults aged 30–75 years with type 2 diabetes mellitus
0.5 mcg12 weeks—
Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: Potential benefits of calcitriol
2015 · calcitriol · Adults with steroid-resistant asthma
0.5 mcg4 weeks—
Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta
2015 · cholecalciferol 20,000 IU/week · Patients with relapsing-remitting multiple sclerosis, all using IFN-beta-1b; age and sex not specified
2,857 IU1 year—
Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C
2015 · Cholecalciferol group · Patients with genotype 1b chronic hepatitis C and serum HCV-RNA levels greater than 5 Log IU/mL
2,000 IU76 weeks—
Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C
2015 · Alfacalcidol group · Patients with genotype 1b chronic hepatitis C and serum HCV-RNA levels greater than 5 Log IU/mL
0.5 mcg76 weeks—
The effect of 14 weeks of vitamin D3 supplementation on antimicrobial peptides and proteins in athletes
2016 · vitamin D3 supplement · Healthy male athletes during a winter training period
5,000 IU14 weeks—
Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial
2015 · low-dose vitamin D arm · Postmenopausal women with vitamin D insufficiency (serum 25(OH)D >14 and ≤27 ng/mL); women with osteoporosis were excluded.
800 IU1 year—
Short-term effect of high-dose vitamin D on the level of interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial
2015 · intervention group · Patients with relapsing-remitting multiple sclerosis
10,000 IU90 days—
Effects of vitamin D supplementation as an adjuvant therapy in coronary artery disease patients
2016 · vitamin D supplementation group · Adults with stable coronary artery disease residing in Beijing
0.5 mcg26 weeks—
High-Dose versus Low-Dose Vitamin D Supplementation and Arterial Stiffness among Individuals with Prehypertension and Vitamin D Deficiency
2015 · low-dose vitamin D group · Adults aged 18–50 with prehypertension or elevated untreated blood pressure and vitamin D deficiency
400 IU26 weeks—
High-Dose versus Low-Dose Vitamin D Supplementation and Arterial Stiffness among Individuals with Prehypertension and Vitamin D Deficiency
2015 · high-dose vitamin D group · Adults aged 18–50 with prehypertension or elevated untreated blood pressure and vitamin D deficiency
4,000 IU26 weeks—
Vitamin D Supplementation Modulates T Cell-Mediated Immunity in Humans: Results from a Randomized Control Trial
2016 · high-dose vitamin D3 · Adults with vitamin D deficiency and untreated pre- or early stage I hypertension
4,000 IU26 weeks—
Vitamin D Supplementation Modulates T Cell-Mediated Immunity in Humans: Results from a Randomized Control Trial
2016 · low-dose vitamin D3 · Adults with vitamin D deficiency and untreated pre- or early stage I hypertension
400 IU26 weeks—
A Vitamin D-Calcium-Fortified Yogurt Drink Decreased Serum PTH but did not Affect Osteocalcin in Subjects with Type 2 Diabetes
2015 · Group 2 (DD) · Women and men aged 30–50 years with type 2 diabetes
1,000 IU12 weeks—
Persistent Effect of Vitamin D Supplementation on Musculoskeletal Parameters in Adolescents One Year After Trial Completion
2016 · 200 IU/day vitamin D group · Adolescents, mean age 13.9 ± 2 years; girls and boys
200 IU1 year—
Persistent Effect of Vitamin D Supplementation on Musculoskeletal Parameters in Adolescents One Year After Trial Completion
2016 · 2000 IU/day vitamin D group · Adolescents, mean age 13.9 ± 2 years; girls and boys
2,000 IU1 year—
Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial
2016 · cholecalciferol group · Pregnant women aged over 18 years with singleton pregnancies, recruited before 17 weeks’ gestation; eligible maternal serum 25(OH)D was 25–100 nmol/L.
1,000 IU——
Effects of supplemental calcium and vitamin D on the APC/β-catenin pathway in the normal colorectal mucosa of colorectal adenoma patients
2017 · 1,000 IU/day vitamin D3 supplementation · Adults aged 45–75 with a history of colorectal adenomas
1,000 IU1 year—
Assessment of Adequacy of Supplementation of Vitamin D in Very Low Birth Weight Preterm Neonates: A Randomized Controlled Trial
2016 · Group 1 · Very low birth weight preterm neonates
400 IU6 weeks—
Assessment of Adequacy of Supplementation of Vitamin D in Very Low Birth Weight Preterm Neonates: A Randomized Controlled Trial
2016 · Group 2 · Very low birth weight preterm neonates
1,000 IU6 weeks—
Effects of vitamin D supplementation on glycated haemoglobin and fasting glucose levels in hypertensive patients: a randomized controlled trial
2016 · vitamin D group · Adults with arterial hypertension and 25(OH)D concentrations below 30 ng/mL
2,800 IU8 weeks—
T-lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: A randomized controlled trial with sequential crossover
2017 · cholecalciferol followed by placebo sequence · Adults with type 1 diabetes; sex breakdown was 19 women and 20 men
4,000 IU90 days—
Vitamin D supplementation reduces insulin resistance in Japanese adults: a secondary analysis of a double-blind, randomized, placebo-controlled trial
2016 · vitamin D3 group · Healthy Japanese adults; age range and sex not reported
420 IU1 year—
Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D(3) administration
2017 · vitamin D3 treatment group · Adults aged 18 years or older with cystic fibrosis hospitalized for an acute pulmonary exacerbation
250,000 IU7 days—
Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial
2017 · vitamin D group · Adults aged 18 or older with arterial hypertension and low serum 25(OH)D
2,800 IU8 weeks—
Effect of Cholecalciferol therapy on serum FGF(23) in vitamin D deficient patients: a randomized clinical trial
2018 · Cholecalciferol treatment group · Vitamin D deficient patients; age and sex not specified
7,143 IU12 weeks—
Bolus Weekly Vitamin D3 Supplementation Impacts Gut and Airway Microbiota in Adults With Cystic Fibrosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
2018 · vitamin D3 · Adults with cystic fibrosis and vitamin D insufficiency (25-hydroxyvitamin D < 30 ng/mL)
7,143 IU12 weeks—
Expression and shedding of CD44 in the endometrium of women with endometriosis and modulating effects of vitamin D: A randomized exploratory trial
2018 · Vitamin D alongside routine protocol · Women with endometriosis; age and sex beyond the stated population not reported
7,143 IU13 weeks—
The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: a randomized placebo-controlled trial
2018 · intervention group · Women aged 20–38 years with PCOS and plasma 25OHD <20 ng/mL
7,143 IU8 weeks—
Effectiveness of vitamin D therapy in improving metabolomic biomarkers in obesity phenotypes: Two randomized clinical trials
2018 · MHO vitamin D group · Adults with metabolically healthy obesity and sub-optimal vitamin D levels
4,000 IU120 days—
Effectiveness of vitamin D therapy in improving metabolomic biomarkers in obesity phenotypes: Two randomized clinical trials
2018 · MUHO vitamin D group · Adults with metabolically unhealthy obesity and sub-optimal vitamin D levels
4,000 IU120 days—
Cholecalciferol Supplementation Promotes Bone Turnover in Chinese Adults with Vitamin D Deficiency
2018 · cholecalciferol · Chinese adults with vitamin D deficiency; mean age 31.9 years, 69% women
2,000 IU20 weeks—
Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males
2018 · 0.5-μg group · Healthy Chinese adult males
0.5 mcg1 day—
Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males
2018 · 0.75-μg group · Healthy Chinese adult males
0.75 mcg1 day—
Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial
2019 · 600 IU/d vitamin D3 · Overweight or obese African American adults with serum 25(OH)D below 50 nmol/L; mean age 26.1 years in the analysed sample, 16% male
600 IU16 weeks—
Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial
2019 · 2,000 IU/d vitamin D3 · Overweight or obese African American adults with serum 25(OH)D below 50 nmol/L; mean age 26.1 years in the analysed sample, 16% male
2,000 IU16 weeks—
Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial
2019 · 4,000 IU/d vitamin D3 · Overweight or obese African American adults with serum 25(OH)D below 50 nmol/L; mean age 26.1 years in the analysed sample, 16% male
4,000 IU16 weeks—
Effects of vitamin D and calcium on expression of MSH2 and transforming growth factors in normal-appearing colorectal mucosa of sporadic colorectal adenoma patients: A randomized clinical trial
2019 · vitamin D3 group · People with sporadic colorectal adenomas; age and sex not specified
1,000 IU1 year—
Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol
2018 · calcitriol group · Postmenopausal women with osteopenia or osteoporosis and low bone mass; ages not specified
0.5 mcg12 weeks—
The effects of vitamin D(3) supplementation on some metabolic and inflammatory markers in diabetic nephropathy patients with marginal status of vitamin D: A randomized double blind placebo controlled clinical trial
2019 · intervention group · Patients with diabetic nephropathy and marginal vitamin D status; age and sex not reported
7,143 IU8 weeks—
Effects of supplemental calcium and vitamin D on tight-junction proteins and mucin-12 expression in the normal rectal mucosa of colorectal adenoma patients
2019 · vitamin D supplementation · Adults aged 45–75 with a removed colorectal adenoma and no remaining polyps after colonoscopy; patients at increased risk for colorectal neoplasms
1,000 IU1 year—
Local In Vivo Measures of Muscle Lipid and Oxygen Consumption Change in Response to Combined Vitamin D Repletion and Aerobic Training in Older Adults
2019 · vitamin D repletion alone (D) · Adults aged 60–80 years with serum 25(OH)D ≤32 ng/mL and BMI 18.5–34.9 kg/m²
10,000 IU13 weeks—
Local In Vivo Measures of Muscle Lipid and Oxygen Consumption Change in Response to Combined Vitamin D Repletion and Aerobic Training in Older Adults
2019 · vitamin D repletion plus aerobic training (DAT) · Adults aged 60–80 years with serum 25(OH)D ≤32 ng/mL and BMI 18.5–34.9 kg/m²
10,000 IU13 weeks—
Randomized Study of the Effect of Vitamin D and Omega-3 Fatty Acids Cosupplementation as Adjuvant Chemotherapy on Inflammation and Nutritional Status in Colorectal Cancer Patients
2020 · vitamin D group · Colorectal cancer patients
7,143 IU8 weeks—
Changes in microparticle profiles by vitamin D receptor activation in chronic kidney disease - a randomized trial
2019 · 1 μg paricalcitol daily · Adults older than 20 years with stage 3–4 chronic kidney disease (eGFR 15–59 mL/min/1.73 m²)
1 mcg12 weeks—
Changes in microparticle profiles by vitamin D receptor activation in chronic kidney disease - a randomized trial
2019 · 2 μg paricalcitol daily · Adults older than 20 years with stage 3–4 chronic kidney disease (eGFR 15–59 mL/min/1.73 m²)
2 mcg12 weeks—
Effect of vitamin D3 supplementation on vascular and metabolic health of vitamin D-deficient overweight and obese children: a randomized clinical trial
2020 · 600-IU group · Vitamin D-deficient overweight or obese children aged 10–18 years
600 IU26 weeks—
Effect of vitamin D3 supplementation on vascular and metabolic health of vitamin D-deficient overweight and obese children: a randomized clinical trial
2020 · 1000-IU group · Vitamin D-deficient overweight or obese children aged 10–18 years
1,000 IU26 weeks—
Effect of vitamin D3 supplementation on vascular and metabolic health of vitamin D-deficient overweight and obese children: a randomized clinical trial
2020 · 2000-IU group · Vitamin D-deficient overweight or obese children aged 10–18 years
2,000 IU26 weeks—
Inflammatory biomarkers response to two dosages of vitamin D supplementation in patients with ulcerative colitis: A randomized, double-blind, placebo-controlled pilot study
2020 · 2000 IU/day vitamin D group · Patients with mild to moderate active ulcerative colitis; age and sex not reported
2,000 IU12 weeks—
Inflammatory biomarkers response to two dosages of vitamin D supplementation in patients with ulcerative colitis: A randomized, double-blind, placebo-controlled pilot study
2020 · 1000 IU/day vitamin D group · Patients with mild to moderate active ulcerative colitis; age and sex not reported
1,000 IU12 weeks—
In infants with sufficient vitamin D status at birth, vitamin D supplementation does not impact immune development
2020 · vitamin D supplementation · Infants sufficient in vitamin D at birth
400 IU26 weeks—
Vitamin D(3) Supplementation Increases Long-Chain Ceramide Levels in Overweight/Obese African Americans: A Post-Hoc Analysis of a Randomized Controlled Trial
2020 · 18,000 IU/month (~600 IU/day) vitamin D3 · African-American participants aged 13–45 years with overweight or obesity and vitamin D insufficiency
600 IU16 weeks—
Vitamin D(3) Supplementation Increases Long-Chain Ceramide Levels in Overweight/Obese African Americans: A Post-Hoc Analysis of a Randomized Controlled Trial
2020 · 60,000 IU/month (~2000 IU/day) vitamin D3 · African-American participants aged 13–45 years with overweight or obesity and vitamin D insufficiency
2,000 IU16 weeks—
Vitamin D(3) Supplementation Increases Long-Chain Ceramide Levels in Overweight/Obese African Americans: A Post-Hoc Analysis of a Randomized Controlled Trial
2020 · 120,000 IU/month (~4000 IU/day) vitamin D3 · African-American participants aged 13–45 years with overweight or obesity and vitamin D insufficiency
4,000 IU16 weeks—
Vitamin D Treatment Attenuates Heart Apoptosis After Coronary Artery Bypass Surgery: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
2020 · Vitamin D group · Patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass
150,000 IU3 days—
Effects of Vitamin D and Omega-3 Fatty Acids Co-Supplementation on Inflammatory Factors and Tumor Marker CEA in Colorectal Cancer Patients Undergoing Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
2020 · vitamin D · Patients with stage II or III colorectal cancer undergoing chemotherapy
7,143 IU8 weeks—
Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS
2020 · high-dose arm · Adults aged 18–65 with relapsing-remitting multiple sclerosis on stable IFNβ-1b treatment
10,200 IU547 days—
Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS
2020 · low-dose arm · Adults aged 18–65 with relapsing-remitting multiple sclerosis on stable IFNβ-1b treatment
200 IU547 days—
Seasonal Antimicrobial Activity of the Airway: Post-Hoc Analysis of a Randomized Placebo-Controlled Double-Blind Trial
2020 · vitamin D3 group · Adults aged 18–60 years recruited from the community, without the listed exclusionary illnesses; winter–spring participants had generally suboptimal vitamin D levels
1,000 IU90 days—
Safety Aspects of a Randomized Clinical Trial of Maternal and Infant Vitamin D Supplementation by Feeding Type Through 7 Months Postpartum
2020 · 400 IU/day group · Postpartum mothers aged not reported, breastfeeding or formula-feeding; breastfeeding infants in this group also received vitamin D
400 IU26 weeks—
Safety Aspects of a Randomized Clinical Trial of Maternal and Infant Vitamin D Supplementation by Feeding Type Through 7 Months Postpartum
2020 · 2,400 IU/day group · Postpartum mothers aged not reported, breastfeeding or formula-feeding
2,400 IU26 weeks—
Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial
2021 · vitamin D group · Adults aged 45–75 with a histologically verified colorectal adenoma
1,000 IU1 year—
Fibroblast growth factor 23 concentrations and modifying factors in children from age 12 to 24 months
2020 · 10 μg/day vitamin D3 group · Healthy infants, enrolled at approximately 2 weeks of age and followed to 24 months
10 mcg——
Improving the endothelial dysfunction in type 2 diabetes with chromium and vitamin D(3) byreducing homocysteine and oxidative stress: A randomized placebo-controlled trial
2020 · group II: D 3 · People with type 2 diabetes mellitus; age and sex not stated
7,143 IU120 days—
Changes in Bone Turnover, Inflammatory, Oxidative Stress, and Metabolic Markers in Women Consuming Iron plus Vitamin D Supplements: a Randomized Clinical Trial
2021 · D-P · Women aged 18–45 years with hemoglobin ≤12.7 g/dL and 25OHD ≤29 ng/mL
1,000 IU12 weeks—
The modulating effects of vitamin D on the activity of β-catenin in the endometrium of women with endometriosis: a randomized exploratory trial
2021 · treatment group · Infertile women with stage III or IV endometriosis
7,143 IU13 weeks—
A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease
2021 · calcitriol · Patients with non-alcoholic fatty liver disease and vitamin D deficiency or insufficiency
1 mcg8 weeks—
A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease
2021 · cholecalciferol · Patients with non-alcoholic fatty liver disease and vitamin D deficiency or insufficiency
7,143 IU8 weeks—
The effect of vitamin D supplementation on circulating osteoprogenitor cells: A pilot randomized controlled trial
2021 · 1000 IU supplement alone · Healthy older adults, stratified by baseline vitamin D level into deficient and non-deficient groups
1,000 IU6 weeks—
Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial
2022 · treatment group · Children with biopsy-proven nonalcoholic fatty liver disease (NAFLD)
2,000 IU26 weeks—
The Effects of Vitamin D Supplementation on Metabolic and Oxidative Stress Markers in Patients With Type 2 Diabetes: A 6-Month Follow Up Randomized Controlled Study
2021 · Vitamin D3 group, participants with baseline 25(OH)D ≤ 50 nmol/L · Adults aged 30 years or older with type 2 diabetes treated with metformin and baseline 25(OH)D ≤ 50 nmol/L
7,143 IU26 weeks—
The Effects of Vitamin D Supplementation on Metabolic and Oxidative Stress Markers in Patients With Type 2 Diabetes: A 6-Month Follow Up Randomized Controlled Study
2021 · Vitamin D3 group, participants with baseline 25(OH)D > 50 nmol/L · Adults aged 30 years or older with type 2 diabetes treated with metformin and baseline 25(OH)D > 50 nmol/L
2,000 IU26 weeks—
Efficacy of low-fat milk and yogurt fortified with vitamin D(3) on systemic inflammation in adults with abdominal obesity
2022 · Fortified low-fat milk · Adults aged 30–50 years with abdominal obesity
1,500 IU10 weeks—
Efficacy of low-fat milk and yogurt fortified with vitamin D(3) on systemic inflammation in adults with abdominal obesity
2022 · Fortified low-fat yogurt · Adults aged 30–50 years with abdominal obesity
1,500 IU10 weeks—
Maternal Vitamin D Status Correlates to Leukocyte Antigenic Responses in Breastfeeding Infants
2022 · control group · Exclusively breastfeeding mothers and their 1-month-old infants
400 IU90 days—
Maternal Vitamin D Status Correlates to Leukocyte Antigenic Responses in Breastfeeding Infants
2022 · treatment group · Exclusively breastfeeding mothers and their 1-month-old infants
6,400 IU90 days—
An Open-Label, Randomized Pharmacokinetic Study of 2 Formulations of Eldecalcitol Capsules Following Single Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions
2022 · Test formulation · Healthy Chinese male and female volunteers under fasting and fed conditions
0.75 mcg1 day—
An Open-Label, Randomized Pharmacokinetic Study of 2 Formulations of Eldecalcitol Capsules Following Single Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions
2022 · Reference formulation · Healthy Chinese male and female volunteers under fasting and fed conditions
0.75 mcg1 day—
Effect of Vitamin D and/or Calcium Supplementation on Pancreatic β-Cell Function in Subjects with Prediabetes: A Randomized, Controlled Trial
2023 · vitamin D group · Chinese adults with prediabetes
1,600 IU24 weeks—
Effects of Vitamin D(3) and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
2022 · Vitamin D3 active group · Men aged 50 years or older and women aged 55 years or older, without a history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke, transient ischemic attack, or coronary revascularization
2,000 IU1935 days—
Vitamin D3 and deconvoluting a rash
2023 · VitD(+) group · Healthy adults; exact age range and sex distribution not stated
200,000 IU1 day—
Does maternal vitamin D status influence placental weight or vascular and inflammatory pathology? Secondary analysis from the Kellogg Pregnancy Study
2023 · daily placebo group · Women aged 18–45 with singleton pregnancies, enrolled at 10–14 weeks’ gestation; generally healthy, with a sub-cohort with specified chronic conditions
400 IU——
Low-grade inflammation from prenatal period to age 6-8 years in a Vitamin D trial
2024 · group 10 · Healthy full-term infants, from age 2 weeks to 2 years
10 mcg2 years—
Racial differences in measures of glycemia in the Vitamin D and Type 2 Diabetes (D2d) Study: a secondary analysis of a randomized trial
2024 · vitamin D group · Adults aged 30 years or older (25 years or older for specified Indigenous and Pacific Islander groups), at high risk of diabetes with prediabetes
4,000 IU913 days—
Effects of Vitamin D-3 Supplementation During Pregnancy and Lactation on Maternal and Infant Biomarkers of Environmental Enteric Dysfunction, Systemic Inflammation, and Growth: A Secondary Analysis of a Randomized Controlled Trial
2024 · vitamin D-3 group · Pregnant and lactating women living with HIV in Dar es Salaam, Tanzania
3,000 IU——
Calcium plus vitamin D supplementation during pregnancy has no impact on postpartum transient longitudinal changes in hip geometry in adolescent mothers: a secondary analysis of a randomised controlled trial
2024 · calcium plus vitamin D · Pregnant adolescents aged 14–19 years with low daily calcium intake (approximately 600 mg/day); lactating postpartum adolescents were assessed
200 mcg——
The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial
2025 · vitamin D (VitD) group · Women newly diagnosed with breast cancer receiving chemotherapy; age range not reported
7,143 IU9 weeks—
High-dose vitamin D supplementation in pregnancy ameliorates obesity-induced increase in maternal IL-1β level without affecting obesity-induced increase in IL-6 and MCP
2025 · 400 IU/day group · Pregnant women, with results analysed by pre-pregnancy BMI
400 IU——
High-dose vitamin D supplementation in pregnancy ameliorates obesity-induced increase in maternal IL-1β level without affecting obesity-induced increase in IL-6 and MCP
2025 · 3600 IU/day group · Pregnant women, with results analysed by pre-pregnancy BMI
3,600 IU——
Vitamin D(3) and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial
2025 · Vitamin D3 only · Females aged 55 years or older and males aged 50 years or older; no specific condition stated
2,000 IU5 years—
Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients
1994 · oral calcitriol (ORC) · 10 hemodialysis patients with secondary hyperparathyroidism; age and sex not reported
0.69 mcg12 weeks—
Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial
1994 · cholecalciferol group · Healthy men and women aged 63–76 years
2.5 mg1 day—
Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)
1995 · Calcitriol · Adults with mild to moderate renal failure and elevated 1,84 iPTH
0.125 mcg1 year—
A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures
1996 · alfacalcidol treatment · Elderly women aged 64–79 years with radiological evidence of vertebral fractures
0.5 mcg26 weeks—
Effects of calcitriol on eosinophil activity and antibody responses in patients with schistosomiasis
1997 · calcitriol alone · Patients with Schistosoma haematobium infection; age and sex not reported
1 mcg5 days—
Effects of calcitriol on eosinophil activity and antibody responses in patients with schistosomiasis
1997 · praziquantel plus calcitriol · Patients with Schistosoma haematobium infection; age and sex not reported
1 mcg5 days—
Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men
1998 · prednisolone and calcitriol · Healthy men aged 21–54 years
2 mcg7 days—
Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men
1998 · calcitriol · Healthy men aged 21–54 years
2 mg7 days—
SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial
2017 · D&Cancer Ca + D group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health
2,000 IU1 year915
Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients
2014 · strontium ranelate 2 g/vitamin D₃ 1000 IU daily · Men and postmenopausal women aged 50 years or older with primary osteoporosis and serum 25(OH)D >22.5 nmol/l
1,000 IU26 weeks413
Factors predicting vitamin D response variation in non-Hispanic white postmenopausal women
2012 · calcium and vitamin D supplementation · Non-Hispanic white postmenopausal women
1,100 IU4 years392
A randomized clinical trial comparing 3 different replacement regimens of vitamin D in clinically asymptomatic pediatrics and adolescents with vitamin D insufficiency
2016 · Group 2 · Children and adolescents aged 2–18 years with inadequate vitamin D, clinically asymptomatic
6,829 IU1 year247
Does Vitamin D3 Supplementation Improve Depression Scores among Rural Adolescents? A Randomized Controlled Trial
2024 · calcium intervention arm · Rural adolescent boys and girls aged 14–19 years with any form of depression
250 IU9 weeks216
SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial
2017 · CaMEWS Ca + D group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health
1,100 IU1 year203
Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study
2002 · calcium-vitamin D3 fixed combination group · Ambulatory institutionalized women; mean age 85.2 years; vitamin D insufficiency and low calcium intake described in the study population
800 IU2 years199
A randomized clinical trial comparing 3 different replacement regimens of vitamin D in clinically asymptomatic pediatrics and adolescents with vitamin D insufficiency
2016 · Group 3 · Children and adolescents aged 2–18 years with inadequate vitamin D, clinically asymptomatic
3,000 IU1 year194
Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study
2002 · calcium plus vitamin D3 separate combination group · Ambulatory institutionalized women; mean age 85.2 years; vitamin D insufficiency and low calcium intake described in the study population
800 IU2 years190
Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial
2014 · ALN/D5600 group · Postmenopausal women with osteoporosis and serum 25(OH)D ≥9 ng/mL
800 IU16 weeks173
Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation
2011 · active treatment arm · Healthy men and women aged 65 and older
700 IU2 years152
Impact of Maternal Daily Oral Low-Dose Vitamin A Supplementation on the Mother-Infant Pair: A Randomised Placebo-Controlled Trial in China
2021 · supplementation group · Lactating mothers aged 20–40 years, 30–45 days postpartum, breastfeeding healthy full-term singleton infants
600 IU60 days144
Vitamin D Receptor Fok-I polymorphism modulates diabetic host response to vitamin D intake: need for a nutrigenetic approach
2013 · vitamin D–fortified doogh group · Adults aged 29–67 with type 2 diabetes
1,000 IU12 weeks140
Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older adults
2008 · calcium-vitamin D supplementation treatment group · Men and women aged 65 years or older; healthy and ambulatory
700 IU3 years132
Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial
2020 · vitamin D3 4 000 IU/day · Healthy adults aged 55–70 years with serum 25-hydroxyvitamin D of 30–125 nmol/L
4,000 IU3 years125
Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial
2020 · vitamin D3 400 IU/day · Healthy adults aged 55–70 years with serum 25-hydroxyvitamin D of 30–125 nmol/L
400 IU3 years124
Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial
2020 · vitamin D3 10 000 IU/day · Healthy adults aged 55–70 years with serum 25-hydroxyvitamin D of 30–125 nmol/L
10,000 IU3 years124
Randomized trial of three doses of vitamin D to reduce deficiency in pregnant Mongolian women
2019 · 2000 IU · Women aged 18 years or older, pregnant at 12–16 weeks’ gestation, in Mongolia; no stated disease requirement
2,000 IU—121
Time out: should vitamin D dosing be based on patient's body mass index (BMI): a prospective controlled study
2021 · Group A (2000 IU) · Women with vitamin D deficiency and BMI ≥30 kg/m²; mean age 50 years; treated in orthopaedic, obstetrics and gynaecology clinics
2,000 IU90 days121
Randomized trial of three doses of vitamin D to reduce deficiency in pregnant Mongolian women
2019 · 4000 IU · Women aged 18 years or older, pregnant at 12–16 weeks’ gestation, in Mongolia; no stated disease requirement
4,000 IU—120
Randomized trial of three doses of vitamin D to reduce deficiency in pregnant Mongolian women
2019 · 600 IU · Women aged 18 years or older, pregnant at 12–16 weeks’ gestation, in Mongolia; no stated disease requirement
600 IU—119
Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D(3) combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal
2018 · ALN/D5600 · Postmenopausal women in China aged over 55 with postmenopausal osteoporosis
800 IU1 year111
Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly
2021 · Low dose (600 IU/day) · Lebanese women and men aged 65 years or older who were overweight or obese and had baseline serum 25(OH)D of 10–30 ng/mL
600 IU1 year111
Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly
2021 · High dose (3750 IU/day) · Lebanese women and men aged 65 years or older who were overweight or obese and had baseline serum 25(OH)D of 10–30 ng/mL
3,750 IU1 year110
A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D Deficiency
2025 · calcifediol 125 µg · Adults aged 18 years or older with severe vitamin D deficiency (serum 25(OH)D ≤10 ng/mL), male or female
17.9 mcg52 weeks110
Response of serum 25(OH)D to Vitamin D and calcium supplementation in school-children from a semi-rural setting in India
2018 · Daily vitamin D and calcium supplementation · Schoolchildren aged 6–12 years, boys and girls, from a semi-rural setting in India; baseline vitamin D status varied
1,000 IU26 weeks106
Dose response to vitamin D supplementation among postmenopausal African American women
2007 · Vitamin D group, 20 μg/day phase · Healthy postmenopausal African American women not receiving hormone replacement therapy
20 mcg2 years104
Dose response to vitamin D supplementation among postmenopausal African American women
2007 · Vitamin D group, 50 μg/day phase · Healthy postmenopausal African American women not receiving hormone replacement therapy
50 mcg1 year104
A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D Deficiency
2025 · calcifediol 100 µg · Adults aged 18 years or older with severe vitamin D deficiency (serum 25(OH)D ≤10 ng/mL), male or female
800 IU52 weeks104
REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients
2023 · extended-release calcifediol (ERC) · Adults aged 18 years or older with mild to moderate symptomatic COVID-19
3.12 mg4 weeks80
High-dose versus low-dose ergocalciferol for correcting hypovitaminosis D after fragility hip fracture: a randomized controlled trial
2021 · Low-dose vitamin D group · Adults older than 50 years with fragility hip fracture and hypovitaminosis D; mean age in the study was 78.9 years overall
2,857 IU12 weeks70
High-dose versus low-dose ergocalciferol for correcting hypovitaminosis D after fragility hip fracture: a randomized controlled trial
2021 · High-dose vitamin D group · Adults older than 50 years with fragility hip fracture and hypovitaminosis D; mean age in the study was 78.9 years overall
8,571 IU12 weeks70
A randomized, double-blind, placebo-controlled trial of vitamin D supplementation with or without calcium in community-dwelling vitamin D deficient subjects
2022 · Vitamin D3 + Calcium · Adults aged 18 years and over, men and women, with vitamin D deficiency; apparently healthy community-dwelling UAE residents and expatriates
2,000 IU26 weeks68
Impact of vitamin D supplementation during lactation on vitamin D status and body composition of mother-infant pairs: a MAVID randomized controlled trial
2014 · 400 IU/d group · Caucasian lactating mothers who delivered a healthy term infant and intended to breastfeed for 6 months
400 IU26 weeks67
Effects of a Novel Dispersible Supplement Containing 2500 IU of Vitamin D and 1000 µg of B12 in Restoring Vitamin D and B12 Insufficiency: A Multicenter, Randomized Controlled Trial
2025 · Group A · Adults aged over 20 and under 80 with vitamin D concentration below 20 ng/mL and vitamin B12 concentration below 250 ng/L
2,500 IU12 weeks62
Effects of a Novel Dispersible Supplement Containing 2500 IU of Vitamin D and 1000 µg of B12 in Restoring Vitamin D and B12 Insufficiency: A Multicenter, Randomized Controlled Trial
2025 · Group B · Adults aged over 20 and under 80 with vitamin D concentration below 20 ng/mL and vitamin B12 concentration below 250 ng/L
2,000 IU12 weeks62
Changes in blood pressure and lipid levels in young women consuming a vitamin D-fortified skimmed milk: a randomised controlled trial
2013 · D-fortified · Women aged 18–35 with low iron stores; healthy, non-pregnant, and non-breast-feeding
200 IU16 weeks55
Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial
2011 · vitamin D3-fortified doogh (FYD) · Adults aged 29–67 years with type 2 diabetes; 57 women and 43 men overall
1,000 IU12 weeks50
Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes
2012 · vitamin D3-fortified doogh (FD) · People with type 2 diabetes
1,000 IU12 weeks50
Daily vs. monthly oral vitamin D(3) for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial
2023 · Daily (D) group · Infants with symptomatic vitamin D deficiency
2,000 IU90 days46
Evaluation of a new solid formulation of calcium and vitamin D in institutionalized elderly subjects. A randomized comparative trial versus separate administration of both constituents
1995 · G1 · Institutionalized elderly subjects, mean age 83.1 years, with vitamin D deficiency and without severe renal failure
800 IU26 weeks46
Efficacy of daily 4,000 International Units (IU) versus 6,000 IU of oral vitamin D(3) in vitamin D deficient children with overweight and obesity: An open-label randomized controlled trial
2025 · Group A · Children aged 5–18 years with overweight or obesity and vitamin D deficiency
4,000 IU12 weeks45
Efficacy of daily 4,000 International Units (IU) versus 6,000 IU of oral vitamin D(3) in vitamin D deficient children with overweight and obesity: An open-label randomized controlled trial
2025 · Group B · Children aged 5–18 years with overweight or obesity and vitamin D deficiency
6,000 IU12 weeks45
Evaluation of a new solid formulation of calcium and vitamin D in institutionalized elderly subjects. A randomized comparative trial versus separate administration of both constituents
1995 · G2 · Institutionalized elderly subjects, mean age 83.1 years, with vitamin D deficiency and without severe renal failure
800 IU26 weeks45
Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma
2023 · Cohort E · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL
58,000 IU16 weeks43
Vitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial
2024 · Cohort E (part 2, replacement dose) · Children aged 6 to under 18 with physician-diagnosed asthma, BMI at or above the 85th percentile, and screening serum 25(OH)D of 10–30 ng/mL
8,000 IU16 weeks43
Effect of Vitamin D and Docosahexaenoic Acid Co-Supplementation on Vitamin D Status, Body Composition, and Metabolic Markers in Obese Children: A Randomized, Double Blind, Controlled Study
2022 · GROUP II (vitamin D + wheat germ oil) · Children aged 6–14 years with obesity and vitamin D deficiency
1,200 IU26 weeks41
Daily versus fortnightly oral vitamin D(3) in treatment of symptomatic vitamin D deficiency in children aged 1-10 years: An open labelled randomized controlled trial
2024 · group daily (D) · Children aged 1–10 years with symptomatic vitamin D deficiency
4,000 IU12 weeks40
25 hydroxy vitamin D is higher when a renal multivitamin is given with cholecalciferol at hemodialysis
2016 · multivitamin with vitamin D (MVD) group · Adults receiving hemodialysis; age and sex not specified
1,714 IU20 weeks39
Loading dose vitamin D3 improves vitamin D insufficiency in adults undergoing hematopoietic stem cell transplantation: A randomized controlled trial
2023 · High vitamin D (intervention) group · Adults aged 18 or older undergoing allogeneic hematopoietic stem cell transplantation
102,000 IU100 days39
Efficacy and Safety of a Personalized Vitamin D(3) Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial
2022 · vitamin D3 arm · Adults aged 18 years or older with nonmetastatic colorectal cancer, recent tumor surgery, and vitamin D insufficiency (25(OH)D <50 nmol/L)
2,000 IU12 weeks38
Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial
2017 · D2/D3 daily · Healthy adults aged 18–60 years with serum 25(OH)D of 20–50 nmol/L
2,000 IU20 weeks35
Effect of Vitamin D and Docosahexaenoic Acid Co-Supplementation on Vitamin D Status, Body Composition, and Metabolic Markers in Obese Children: A Randomized, Double Blind, Controlled Study
2022 · GROUP I (vitamin D + DHA) · Children aged 6–14 years with obesity and vitamin D deficiency
1,200 IU26 weeks33
Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial
2009 · group 1 · Morbidly obese women with vitamin D depletion after Roux-en-Y gastric bypass
7,943 IU1 year30
Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial
2009 · group 2 · Morbidly obese women with vitamin D depletion after Roux-en-Y gastric bypass
800 IU1 year30
Effects of Vitamin D3 Supplementation and Resistance Training on 25-Hydroxyvitamin D Status and Functional Performance of Older Adults: A Randomized Placebo-Controlled Trial
2021 · vitamin D3 daily group (VDD) · Adults aged 65–85 years, community-dwelling, with low-to-moderate baseline vitamin D levels; independent lifestyle
800 IU14 weeks30
Influence of food matrix delivery system on the bioavailability of vitamin D(3): A randomized crossover trial in postmenopausal women
2023 · Apple juice with whey protein isolate (WPI) · Postmenopausal women aged 60–80 years with vitamin D insufficiency
200 mcg1 day30
A randomised comparison of increase in serum 25-hydroxyvitamin D concentration after 4 weeks of daily oral intake of 10 microg cholecalciferol from multivitamin tablets or fish oil capsules in healthy young adults
2007 · multivitamin tablets · Healthy adults aged 19–49 years
10 mcg4 weeks28
Fortification of Yogurts with Vitamin D and Calcium Enhances the Inhibition of Serum Parathyroid Hormone and Bone Resorption Markers: A Double Blind Randomized Controlled Trial in Women over 60 Living in a Community Dwelling Home
2015 · Fortified Yogurt (FY) · Women aged 61–90 with serum 25OHD ≤20 ng/mL, living in community sheltered accommodation
10 mcg12 weeks28
A randomised comparison of increase in serum 25-hydroxyvitamin D concentration after 4 weeks of daily oral intake of 10 microg cholecalciferol from multivitamin tablets or fish oil capsules in healthy young adults
2007 · fish oil capsules · Healthy adults aged 19–49 years
10 mcg4 weeks27
Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome
2015 · 1000 mg calcium/d + 50,000 IU/wk vitamin D · Overweight and obese vitamin D deficient women diagnosed with PCOS
7,143 IU8 weeks26
Vitamin D(3) Loading Is Superior to Conventional Supplementation After Weight Loss Surgery in Vitamin D-Deficient Morbidly Obese Patients: a Double-Blind Randomized Placebo-Controlled Trial
2017 · intervention group · Men and women aged 18–100 years with vitamin D deficiency (serum 25(OH)D <75 nmol/L), morbid obesity, and planned omega-loop gastric bypass surgery
3,420 IU26 weeks25
Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study
2020 · Group A · Healthy vitamin D-deficient Caucasian men and women aged 18–60 years
11,000 IU12 weeks25
A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: no advantage of loading doses over daily supplementation
2011 · 50,000 IU vitamin D2 loading dose · Men and women over age 50 with an acute fragility hip fracture
51,000 IU90 days22
A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: no advantage of loading doses over daily supplementation
2011 · 100,000 IU vitamin D2 loading dose · Men and women over age 50 with an acute fragility hip fracture
101,000 IU90 days22
Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial
2013 · weight loss and placebo · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight loss
10 mcg6 weeks22
Effects of vitamin D3 and calcium supplementation on serum levels of tocopherols, retinol, and specific vitamin D metabolites
2012 · calcium plus vitamin D3 · Adults aged 30–75 in general health with a history of at least one pathology-confirmed adenomatous colorectal polyp within the previous 36 months
800 IU26 weeks21
Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial
2013 · weight maintenance and placebo · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight maintenance
10 mcg6 weeks21
Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial
2013 · weight maintenance and vitamin D3-supplementation (WM-D) · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight maintenance
63.6 mcg6 weeks20
Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation
2013 · Vitamin D3 group · Healthy adults aged 15–70 years, both sexes; some had vitamin D deficiency
400 IU90 days20
Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial
2013 · weight loss and vitamin D3-supplementation (WL-D) · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight loss
63.6 mcg6 weeks19
Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation
2013 · Vitamin D2 group · Healthy adults aged 15–70 years, both sexes; some had vitamin D deficiency
400 IU90 days19
Treatment Effect of Ergocalciferol on Bone Metabolism Indexes and Parathyroid Hormone in Hemodialysis Patients
2018 · Intervention · Hemodialysis patients with vitamin D deficiency; ages and sex not reported
7,143 IU90 days19
Oral vitamin D supplemental therapy to attain a desired serum 25-hydroxyvitamin D concentration in essential healthcare teams
2022 · Intervention · Healthcare workers aged 18–69 working in settings with high risk of contact with people with COVID-19; adults, predominantly female, with most participants below the study’s vitamin D sufficiency threshold at baseline
1,429 IU10 weeks19
Comparison of two vitamin D supplementation strategies in children with sickle cell disease: a randomized controlled trial
2021 · Vitamin D3 bolus · Children aged 5–17 years with sickle cell disease, all genotypes; the study notes many children with SCD were vitamin D-deficient
301,000 IU90 days18
Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women
2006 · vitamin K2 plus vitamin D3 · Postmenopausal women, mean age 53, with osteopenia or osteoporosis and BMD below 0.809 g/cm2
0.75 mcg2 years17
Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation
2025 · VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase
4,000 IU6 weeks17
Narrowband ultraviolet B three times per week is more effective in treating vitamin D deficiency than 1600 IU oral vitamin D₃ per day: a randomized clinical trial
2012 · oral vitamin D(3) and calcium group · Participants with vitamin D deficiency (25(OH)D(3) ≤ 25 nmol L(-1)); age and sex not reported
1,600 IU6 weeks16
Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma
2023 · Cohort A · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL
56,000 IU16 weeks12
Influence of daily 10-85 μg vitamin D supplements during pregnancy and lactation on maternal vitamin D status and mature milk antirachitic activity
2019 · 35 µg vitamin D3/d · Healthy pregnant women, from 20 gestational weeks through 4 weeks postpartum
35 mcg—11
Influence of daily 10-85 μg vitamin D supplements during pregnancy and lactation on maternal vitamin D status and mature milk antirachitic activity
2019 · 60 µg vitamin D3/d · Healthy pregnant women, from 20 gestational weeks through 4 weeks postpartum
60 mcg—11
Influence of daily 10-85 μg vitamin D supplements during pregnancy and lactation on maternal vitamin D status and mature milk antirachitic activity
2019 · 85 µg vitamin D3/d · Healthy pregnant women, from 20 gestational weeks through 4 weeks postpartum
85 mcg—11
Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma
2023 · Cohort B · Children aged 6–17 years with overweight or obesity, asthma, and baseline 25(OH)D of 10 to <30 ng/mL
60,000 IU16 weeks11
Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study
2010 · Silicon-rich Water (SW) · Postmenopausal women within 5 years of menopause with reduced bone density but no osteopenia or osteoporosis by DEXA
800 IU14 weeks10
Calcium and vitamin D intakes in children: a randomized controlled trial
2013 · Group 1 (dietary counseling plus Ca and Vitamin D supplementation) · Children aged 9.7–11.4 years with dietary calcium and vitamin D intake below 70% of the recommended intake
400 IU120 days10
Influence of daily 10-85 μg vitamin D supplements during pregnancy and lactation on maternal vitamin D status and mature milk antirachitic activity
2019 · 10 µg vitamin D3/d · Healthy pregnant women, from 20 gestational weeks through 4 weeks postpartum
10 mcg—10
Vitamin A and D Absorption in Adults with Metabolic Syndrome versus Healthy Controls: A Pilot Study Utilizing Targeted and Untargeted LC-MS Lipidomics
2021 · MetS adults · Adults aged 24–40 with metabolic syndrome; 5 men and 5 women
119 IU1 day10
Vitamin A and D Absorption in Adults with Metabolic Syndrome versus Healthy Controls: A Pilot Study Utilizing Targeted and Untargeted LC-MS Lipidomics
2021 · Healthy controls · Healthy adults aged 24–40; 5 men and 5 women
119 IU1 day10
Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study
2010 · Purified Water (PW) · Postmenopausal women within 5 years of menopause with reduced bone density but no osteopenia or osteoporosis by DEXA
800 IU14 weeks9
The effects of omega-3 fatty acid on vitamin D activation in hemodialysis patients: a pilot study
2015 · Cholecalciferol with omega-3 FA group · Hemodialysis patients with baseline 25(OH)D levels below 30 ng/mL; mean age 62.1 years; 33.3% men
7,143 IU12 weeks8
Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin
2000 · vitamins K(1)+D(3) · Postmenopausal women about 60 years old with normal or low bone mineral density
350 IU1 year—
Lack of effect of calcium intake on the 25-hydroxyvitamin d response to oral vitamin D3
2005 · Calcium group · Healthy older men and women
800 IU90 days—
Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant
2004 · 1600 IU vitamin D2 and 400 IU vitamin D3 (prenatal vitamin) · Fully lactating women enrolled 1 month after birth
2,000 IU90 days—
Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant
2004 · 3600 IU vitamin D2 and 400 IU vitamin D3 · Fully lactating women enrolled 1 month after birth
4,000 IU90 days—
Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults
2006 · vitamin D group · Healthy university students aged 18–27 years, male and female
15 mcg8 weeks—
Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women
2007 · 200 microg phylloquinone/d · Postmenopausal women
10 mcg6 weeks—
Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women
2007 · 500 microg phylloquinone/d · Postmenopausal women
10 mcg6 weeks—
High-dose vitamin D3 supplementation in a cohort of breastfeeding mothers and their infants: a 6-month follow-up pilot study
2006 · High-dose group · Fully breastfeeding women enrolled at 1 month postpartum and their infants
6,000 IU26 weeks—
Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients
2008 · Group II (400 IU cholecalciferol per day) · Long-term inpatients aged over 65 years who were chronically bedridden; vitamin D deficiency was prevalent
400 IU26 weeks—
Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients
2008 · Group III (1200 IU cholecalciferol per day) · Long-term inpatients aged over 65 years who were chronically bedridden; vitamin D deficiency was prevalent
1,200 IU26 weeks—
Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D
2008 · 500 IU vitamin D2 plus 500 IU vitamin D3 · Healthy adults aged 18–84 years; 60% of the study population were vitamin D deficient at baseline
1,000 IU11 weeks—
Treatment of hypovitaminosis D in infants and toddlers
2008 · Vitamin D2 daily · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported
2,000 IU6 weeks—
Treatment of hypovitaminosis D in infants and toddlers
2008 · Vitamin D2 weekly · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported
7,143 IU6 weeks—
Treatment of hypovitaminosis D in infants and toddlers
2008 · Vitamin D3 daily · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported
2,000 IU6 weeks—
The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit
2008 · group 1 · Adults aged 65–102 years with secondary hyperparathyroidism and normal or reduced serum calcium, living in a low-income housing unit
300,000 IU39 weeks—
The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit
2008 · group 2 · Adults aged 65–102 years with secondary hyperparathyroidism and normal or reduced serum calcium, living in a low-income housing unit
800 IU39 weeks—
High-dose oral vitamin D3 supplementation in the elderly
2009 · Loading + Monthly · Elderly participants; described as frail elderly, with no age range or condition specified
500,000 IU——
Effect of combined maternal and infant vitamin D supplementation on vitamin D status of exclusively breastfed infants
2009 · group 1 · Healthy breastfeeding mothers and their exclusively breastfed infants
2,400 IU90 days—
Effect of combined maternal and infant vitamin D supplementation on vitamin D status of exclusively breastfed infants
2009 · group 2 · Healthy breastfeeding mothers and their exclusively breastfed infants
400 IU90 days—
Effect of vitamin D supplementation in the institutionalized elderly
2009 · group (B) · Institutionalized elderly with low baseline vitamin D status
5 mcg30 days—
The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function
2010 · D group · Women aged 69.3–78.8 years
800 IU1 year—
Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol
2009 · Ergocalciferol group · Hip fracture inpatients with vitamin D insufficiency
1,000 IU90 days—
Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol
2009 · Cholecalciferol group · Hip fracture inpatients with vitamin D insufficiency
1,000 IU90 days—
Is a lower dose of vitamin D supplementation enough to increase 25(OH)D status in a sunny country?
2010 · supplement group · Postmenopausal women with osteoporosis, mean age 62 ± 8 years
400 IU90 days—
Improvement of vitamin D status in Japanese institutionalized elderly by supplementation with 800 IU of vitamin D(3)
2009 · Ca+VD group · Institutionalized elderly; age and sex not specified; baseline serum 25-hydroxyvitamin D was in the hypovitaminosis D range
800 IU30 days—
Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention
2010 · VD and Ca (VD-Ca) group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D
10 mcg1 year—
Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention
2010 · Multiple micronutrient and Ca (MMN-Ca) group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D
10 mcg1 year—
Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States
2009 · 2,000 mg calcium plus 800 IU vitamin D daily · Adults aged 30–74 with a history of at least one pathologically confirmed adenomatous colonic polyp within the previous 36 months
800 IU26 weeks—
Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting
2010 · high-dose regimen · Vitamin D-deficient inpatients with serum 25(OH)D ≤ 50 nmol/L
50,000 IU10 days—
Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting
2010 · continuous low-dose regimen · Vitamin D-deficient inpatients with serum 25(OH)D ≤ 50 nmol/L
4,000 IU90 days—
Is a daily supplementation with 40 microgram vitamin D3 sufficient? A randomised controlled trial
2012 · vitamin D(3) plus calcium group · Community-dwelling adults aged 55–84 years
40 mcg1 year—
Dose response to vitamin D supplementation in postmenopausal women: a randomized trial
2012 · Vitamin D(3) 400 IU once daily · Postmenopausal white women with vitamin D insufficiency
400 IU1 year—
Dose response to vitamin D supplementation in postmenopausal women: a randomized trial
2012 · Vitamin D(3) 800 IU once daily · Postmenopausal white women with vitamin D insufficiency
800 IU1 year—
Dose response to vitamin D supplementation in postmenopausal women: a randomized trial
2012 · Vitamin D(3) 1600 IU once daily · Postmenopausal white women with vitamin D insufficiency
1,600 IU1 year—
Dose response to vitamin D supplementation in postmenopausal women: a randomized trial
2012 · Vitamin D(3) 2400 IU once daily · Postmenopausal white women with vitamin D insufficiency
2,400 IU1 year—
Dose response to vitamin D supplementation in postmenopausal women: a randomized trial
2012 · Vitamin D(3) 3200 IU once daily · Postmenopausal white women with vitamin D insufficiency
3,200 IU1 year—
Dose response to vitamin D supplementation in postmenopausal women: a randomized trial
2012 · Vitamin D(3) 4000 IU once daily · Postmenopausal white women with vitamin D insufficiency
4,000 IU1 year—
Dose response to vitamin D supplementation in postmenopausal women: a randomized trial
2012 · Vitamin D(3) 4800 IU once daily · Postmenopausal white women with vitamin D insufficiency
4,800 IU1 year—
Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens
2012 · Arm A · Children and adolescents aged 5–21 with inflammatory bowel disease and serum 25OHD below 20 ng/ml
2,000 IU6 weeks—
Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens
2012 · Arm B · Children and adolescents aged 5–21 with inflammatory bowel disease and serum 25OHD below 20 ng/ml
2,000 IU6 weeks—
Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens
2012 · Arm C · Children and adolescents aged 5–21 with inflammatory bowel disease and serum 25OHD below 20 ng/ml
7,143 IU6 weeks—
Stability and bioavailability of vitamin D nanoencapsulated in casein micelles
2012 · Vitamin D3 encapsulated in re-assembled casein micelles · Human volunteers; age, sex, and health status not specified
50,000 IU1 day—
The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women
2013 · 400 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL)
400 IU1 year—
The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women
2013 · 800 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL)
800 IU1 year—
The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women
2013 · 1600 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL)
1,600 IU1 year—
The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women
2013 · 2400 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL)
2,400 IU1 year—
The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women
2013 · 3200 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL)
3,200 IU1 year—
The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women
2013 · 4000 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL)
4,000 IU1 year—
The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women
2013 · 4800 IU vitamin D3 per day · Caucasian women aged 57–90 years with vitamin D insufficiency (serum 25OHD ≤20 ng/mL)
4,800 IU1 year—
Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis
2013 · Group 1 (G1) · Adults receiving haemodialysis with chronic kidney disease and secondary hyperparathyroidism; age and sex not reported
1 mcg26 weeks—
Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis
2013 · Group 2 (G2) · Adults receiving haemodialysis with chronic kidney disease and secondary hyperparathyroidism; age and sex not reported
38 mcg26 weeks—
Effects of vitamin D supplementation in older African American women
2013 · Vitamin D3 400 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL
400 IU1 year—
Effects of vitamin D supplementation in older African American women
2013 · Vitamin D3 800 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL
800 IU1 year—
Effects of vitamin D supplementation in older African American women
2013 · Vitamin D3 1600 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL
1,600 IU1 year—
Effects of vitamin D supplementation in older African American women
2013 · Vitamin D3 2400 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL
2,400 IU1 year—
Effects of vitamin D supplementation in older African American women
2013 · Vitamin D3 3200 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL
3,200 IU1 year—
Effects of vitamin D supplementation in older African American women
2013 · Vitamin D3 4000 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL
4,000 IU1 year—
Effects of vitamin D supplementation in older African American women
2013 · Vitamin D3 4800 IU daily · Healthy older African American women with serum 25OHD ≤20 ng/mL
4,800 IU1 year—
A 250 μg/week dose of vitamin D was as effective as a 50 μg/d dose in healthy adults, but a regimen of four weekly followed by monthly doses of 1250 μg raised the risk of hypercalciuria
2013 · 1250 μg/week for 4 weeks, then 1250 μg/month for 2 months · Healthy adults
179 mcg90 days—
Vitamin D supplementation in young White and African American women
2014 · 400 IU vitamin D3 daily · Women aged 25–45 with vitamin D insufficiency (serum 25OHD ≤20 ng/mL), healthy; White and African American
400 IU1 year—
Vitamin D supplementation in young White and African American women
2014 · 800 IU vitamin D3 daily · Women aged 25–45 with vitamin D insufficiency (serum 25OHD ≤20 ng/mL), healthy; White and African American
800 IU1 year—
Vitamin D supplementation in young White and African American women
2014 · 1600 IU vitamin D3 daily · Women aged 25–45 with vitamin D insufficiency (serum 25OHD ≤20 ng/mL), healthy; White and African American
1,600 IU1 year—
Vitamin D supplementation in young White and African American women
2014 · 2400 IU vitamin D3 daily · Women aged 25–45 with vitamin D insufficiency (serum 25OHD ≤20 ng/mL), healthy; White and African American
2,400 IU1 year—
The necessity and safety of calcium and vitamin D in the elderly
1990 · Treatment group, independently living elderly women · Independently living elderly women
45 mcg11 weeks—
The necessity and safety of calcium and vitamin D in the elderly
1990 · Treatment group, institutionalized elderly women · Institutionalized elderly women
45 mcg11 weeks—
Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial
2014 · CaD · Children aged approximately 8 years
200 IU12 weeks—
Calcium-vitamin D-fortified milk is as effective on circulating bone biomarkers as fortified juice and supplement but has less acceptance: a randomised controlled school-based trial
2014 · supplement · Children aged 9–12 years, both sexes, in Tehran
200 IU12 weeks—
Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women
2014 · vitamin D3 400 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency
400 IU1 year—
Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women
2014 · vitamin D3 800 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency
800 IU1 year—
Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women
2014 · vitamin D3 1600 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency
1,600 IU1 year—
Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women
2014 · vitamin D3 2400 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency
2,400 IU1 year—
Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women
2014 · vitamin D3 3200 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency
3,200 IU1 year—
Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women
2014 · vitamin D3 4000 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency
4,000 IU1 year—
Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women
2014 · vitamin D3 4800 IU/d · Postmenopausal women aged 57–90 with vitamin D insufficiency
4,800 IU1 year—
Association Between Single Gene Polymorphisms and Bone Biomarkers and Response to Calcium and Vitamin D Supplementation in Young Adults Undergoing Military Training
2017 · calcium and vitamin D · Young adults undergoing Army or Air Force initial military training
1,000 IU9 weeks—
A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia
2017 · Initial daily Vitamin D3 + calcium citrate formulation · Adolescents aged 10–21 years with newly diagnosed B-ALL or T-ALL and Vitamin D insufficiency or deficiency
2,000 IU——
The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome
2017 · treatment group · children with steroid-sensitive nephrotic syndrome, after achieving remission
8,571 IU90 days—
Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation
2017 · VitD/Ca arm · HIV-infected, ART-naive participants with 25-(OH)D ≥10 and <75 ng/mL, CrCl ≥60 mL/min, and serum calcium <10.5 mg/dL; age and sex not specified
4,000 IU48 weeks—
A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS
2019 · D3 2,000 IU daily · Adults aged 25–85 years with 25(OH)D below 30 ng/mL
2,000 IU1 year—
A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS
2019 · D3 3,000 IU daily · Adults aged 25–85 years with 25(OH)D below 30 ng/mL
3,000 IU1 year—
A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS
2019 · D2 50,000 IU weekly · Adults aged 25–85 years with 25(OH)D below 30 ng/mL
7,143 IU1 year—
A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS
2019 · D2 50,000 IU twice weekly · Adults aged 25–85 years with 25(OH)D below 30 ng/mL
7,143 IU1 year—
Effect of 6-Month Vitamin D Supplementation on Plasma Matrix Gla Protein in Older Adults
2019 · Vitamin D3 group · Adults aged 60–80 with low serum 25(OH)D, clinically relevant depressive symptoms, and at least one functional limitation
1,200 IU26 weeks—
Calcium and vitamin D supplementation and bone health in Marine recruits: Effect of season
2019 · Ca + D fortified snack bars · Male and female Marine recruits, mean age 18.9 years, undergoing 12 weeks of initial military training
1,000 IU12 weeks—
The Effect of High-Dose Postpartum Maternal Vitamin D Supplementation Alone Compared with Maternal Plus Infant Vitamin D Supplementation in Breastfeeding Infants in a High-Risk Population. A Randomized Controlled Trial
2019 · Maternal plus infant supplementation: mother received 600 IU/day vitamin D3 and infant received 400 IU/day vitamin D3 · Arab breastfeeding mothers enrolled within four weeks postpartum and their term infants, in Doha and Al-Wakra, Qatar
1,000 IU26 weeks—
Total, Bioavailable, and Free 25(OH)D Relationship with Indices of Bone Health in Elderly: A Randomized Controlled Trial
2021 · 600 IU/day vitamin D3 group · Adults older than 65 years who were overweight and had baseline serum 25(OH)D of 10–30 ng/mL
600 IU1 year—
Total, Bioavailable, and Free 25(OH)D Relationship with Indices of Bone Health in Elderly: A Randomized Controlled Trial
2021 · 3750 IU/day vitamin D3 group · Adults older than 65 years who were overweight and had baseline serum 25(OH)D of 10–30 ng/mL
3,750 IU1 year—
Effectiveness of three Vitamin D dosing protocols on raising and maintaining blood serum levels of 25-hydroxyvitamin D over a three-month period: a randomized, prospective study
2023 · Group 3 · Patients with baseline total 25-hydroxyvitamin D below 30.0 ng/mL; age and sex not reported
52,000 IU12 weeks—
The effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled trial
2022 · magnesium + vitamin D (MagD) · Overweight or obese participants; age and sex not reported
3,000 IU12 weeks—
Vitamin D-A Risk Factor for Bone Fractures in Children: A Population-Based Prospective Case-Control Randomized Cross-Sectional Study
2023 · study group · Children aged 2–17 years with fractures; supplementation was given when serum 25-OH-vitamin D was below 30 ng/mL.
2,000 IU26 weeks—
High-dose cholecalciferol supplementation to obese infertile men is sufficient to reach adequate vitamin D status
2024 · active group · Infertile men, including men with normal weight, overweight, and obesity
301 g150 days—
The Effect of Vitamin D Supplementation in Pregnant Women with Overweight and Obesity: A Randomised Controlled Trial
2023 · Intervention group · Pregnant women aged 21–45 years with pre-pregnancy BMI ≥25 kg/m², recruited at up to 16 weeks’ gestation
800 IU——
Prophylactic effect of low dose vitamin D in osteopenia of prematurity: a clinical trial study
2014 · group one · Preterm newborns with birth weight under 2000 g and gestational age under 37 weeks
200 IU8 weeks30
Prophylactic effect of low dose vitamin D in osteopenia of prematurity: a clinical trial study
2014 · group two · Preterm newborns with birth weight under 2000 g and gestational age under 37 weeks
400 IU8 weeks30
Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial
2023 · Vitamin D3 only · Generally healthy, robust, community-dwelling adults aged 70 years or older
2,000 IU3 years—
Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial
2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception
10 mcg—870
Antenatal Multiple Micronutrient Supplementation Compared to Iron-Folic Acid Affects Micronutrient Status but Does Not Eliminate Deficiencies in a Randomized Controlled Trial Among Pregnant Women of Rural Bangladesh
2019 · MM · Pregnant women aged 12–45 years in rural Bangladesh
5 mcg165 days749
Effects of Oral Nutritional Supplement with β-Hydroxy-β-methylbutyrate (HMB) on Biochemical and Hematological Indices in Community-Dwelling Older Adults at Risk of Malnutrition: Findings from the SHIELD Study
2024 · specialized ONS · Community-dwelling men and women aged 65 years or older in Singapore, at medium or high risk of malnutrition
15.5 mcg180 days401
Enhancement of vitamin A combined vitamin D supplementation on immune response to Bacille Calmette-Guérin vaccine revaccinated in Chinese infants
2014 · supplementation group · Chinese infants who were revaccinated with BCG; age range and sex distribution not specified
500 IU90 days307
Thirteen weeks of supplementation of vitamin D and leucine-enriched whey protein nutritional supplement attenuates chronic low-grade inflammation in sarcopenic older adults: the PROVIDE study
2019 · active group · Adults aged 65 years or older with mild to moderate physical-function limitations and class I or II sarcopenia
1,600 IU13 weeks184
Newborn micronutrient status biomarkers in a cluster-randomized trial of antenatal multiple micronutrient compared with iron folic acid supplementation in rural Bangladesh
2020 · MM · Pregnant women in rural Bangladesh; age range not specified; no disease condition specified
5 mcg—176
Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study
2017 · vitamin D group · Adult critically ill ICU patients with serum 25(OH)D levels ≤20 ng/ml; ages and sex not restricted
540,000 IU26 weeks153
Vitamin D Supplementation Improves Fasting Insulin Levels and HDL Cholesterol in Infertile Men
2022 · Vitamin D and calcium group · Infertile men; age not stated
1,400 IU150 days151
Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism
2020 · high dose vitamin D3 arm · Adults aged 65 years or older, overweight, ambulatory, with serum 25(OH)D of 10–30 ng/ml
3,750 IU1 year129
Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism
2020 · low dose vitamin D3 arm · Adults aged 65 years or older, overweight, ambulatory, with serum 25(OH)D of 10–30 ng/ml
600 IU1 year128
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis
2007 · PTH group · Postmenopausal women with low bone mineral density and osteoporosis
400 IU1 year119
Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy
2005 · Group B · Patients after total thyroidectomy
2 mcg—111
Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy
2005 · Group A · Patients after total thyroidectomy
1 mcg—104
A Combined Nutrition and Exercise Intervention Influences Serum Vitamin B-12 and 25-Hydroxyvitamin D and Bone Turnover of Healthy Chinese Middle-Aged and Older Adults
2020 · intervention group · Chinese men and women aged 50 years or older, apparently healthy and community-dwelling
30 mcg24 weeks80
The DALI vitamin D randomized controlled trial for gestational diabetes mellitus prevention: No major benefit shown besides vitamin D sufficiency
2020 · Vitamin D intervention arm · Pregnant women with prepregnancy BMI ≥29 kg/m², without gestational diabetes mellitus, enrolled by 19+6 weeks of gestation; overweight or obese
1,600 IU—79
Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover
2004 · Calcitonin group · Women older than 65 with high bone turnover, at high risk of osteoporosis
200 IU26 weeks75
Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study
2013 · D+ group · Adults with primary hyperparathyroidism after parathyroidectomy
1,600 IU1 year75
Consumption of a calcium and vitamin D-fortified food product does not affect iron status during initial military training: a randomised, double-blind, placebo-controlled trial
2016 · Ca/vitamin D group · Young adult male and female volunteers enrolled in US Army basic combat training
25 mcg9 weeks75
Effects of vitamin D supplementation on salivary immune responses during Marine Corps basic training
2019 · Vitamin D3 + calcium group · Male and female US Marine Corps recruits entering basic training; ages and vitamin D status not specified
1,000 IU12 weeks73
Impact of vitamin D supplementation during lactation on vitamin D status and body composition of mother-infant pairs: a MAVID randomized controlled trial
2014 · 1200 IU/d group · Caucasian lactating mothers who delivered a healthy term infant and intended to breastfeed for 6 months
800 IU26 weeks70
Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial
2003 · mid-dose · Postmenopausal Chinese women aged 48–62 years
125 IU1 year68
Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial
2003 · high dose · Postmenopausal Chinese women aged 48–62 years
125 IU1 year68
Obesity and efficacy of vitamin D(3) supplementation in healthy black adults
2020 · 1000 IU/day vitamin D3 · African American men and women aged 30–80; healthy adults, including participants with and without obesity
1,000 IU90 days65
Obesity and efficacy of vitamin D(3) supplementation in healthy black adults
2020 · 4000 IU/day vitamin D3 · African American men and women aged 30–80; healthy adults, including participants with and without obesity
4,000 IU90 days63
Vitamin D Supplementation in Overweight/obese Asian Indian Women with Prediabetes Reduces Glycemic Measures and Truncal Subcutaneous Fat: A 78 Weeks Randomized Placebo-Controlled Trial (PREVENT-WIN Trial)
2020 · Group A (vitamin D supplementation) · Overweight/obese Asian Indian women aged 20–60 years with prediabetes and vitamin D deficiency
8,571 IU78 weeks61
Obesity and efficacy of vitamin D(3) supplementation in healthy black adults
2020 · 2000 IU/day vitamin D3 · African American men and women aged 30–80; healthy adults, including participants with and without obesity
2,000 IU90 days61
Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans
2015 · vitamin D2 group · African American male veterans aged 35–85 with dysglycemia and hypovitaminosis D
7,543 IU1 year60
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients
2019 · treated · Adults aged 18–80 with histologically diagnosed nonalcoholic fatty liver disease (NAFLD)
20 mg26 weeks60
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis
2007 · PTH/alendronate combination group · Postmenopausal women with low bone mineral density and osteoporosis
400 IU1 year59
Low iron status as a factor of increased bone resorption and effects of an iron and vitamin D-fortified skimmed milk on bone remodelling in young Spanish women
2014 · Fe+D group · Young iron-deficient women
5 mcg16 weeks55
Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method
2005 · CaCO(3) + cholecalciferol · Healthy younger women and older women and men; median ages 30 and 66, respectively
1,200 IU4 weeks53
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
2008 · ALN add TPTD · Postmenopausal women with osteoporosis previously treated with alendronate
400 IU26 weeks52
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
2008 · ALN switch TPTD · Postmenopausal women with osteoporosis previously treated with alendronate
400 IU26 weeks50
Consumption of vitamin D-fortified yogurt drink increased leptin and ghrelin levels but reduced leptin to ghrelin ratio in type 2 diabetes patients: a single blind randomized controlled trial
2017 · Vitamin D3-fortified doogh (FD) · Adults with type 2 diabetes; age and sex not specified
1,000 IU12 weeks50
Once daily calcium (1000 mg) and vitamin D (1000 IU) supplementation during military training prevents increases in biochemical markers of bone resorption but does not affect tibial microarchitecture in Army recruits
2022 · Ca + D fortified food bar · Male and female Army recruits undergoing basic combat training; mean age 21.8 years
1,000 IU8 weeks50
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
2008 · RLX switch TPTD · Postmenopausal women with osteoporosis previously treated with raloxifene
400 IU26 weeks49
Limosilactobacillus reuteri DSM 17938 supplementation and SARS-CoV-2 specific antibody response in healthy adults: a randomized, triple-blinded, placebo-controlled trial
2023 · active treatment (probiotic) · Healthy adults aged 18–60 years without prior SARS-CoV-2 infection or seropositivity
20 mcg26 weeks48
Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]
2004 · Control group · Postmenopausal women aged 45–65 with active rheumatoid arthritis
400 IU2 years47
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
2008 · RLX add TPTD · Postmenopausal women with osteoporosis previously treated with raloxifene
400 IU26 weeks47
Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial
2023 · D+ group · Jordanian participants with vitamin D deficiency and no other medical conditions; age and sex not specified
7,143 IU8 weeks47
Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease
2014 · 1000 μg vitamin K/d plus calcium and vitamin D3 group (main RCT) · Adults with Crohn's disease, currently in remission
10 mcg1 year43
Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]
2004 · HRT group · Postmenopausal women aged 45–65 with active rheumatoid arthritis
400 IU2 years41
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study
2009 · Group 1 · Postmenopausal women with osteoporosis
400 IU1 year41
Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D
2014 · VD-Ca group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 23.0 years
400 IU1 year41
The effect of high-dose vitamin D supplementation on insulin resistance and arterial stiffness in patients with type 2 diabetes
2014 · vitamin D group · Adults aged 30–69 with vitamin D-deficient type 2 diabetes
2,000 IU24 weeks40
Changes in biochemical indices of bone metabolism in post-menopausal women following a dietary intervention with fortified dairy products
2009 · dairy intervention group (IG) · Post-menopausal women
7.5 mcg150 days39
Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin
2011 · First group · Postmenopausal women with osteoporosis
400 IU26 weeks37
Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D
2014 · MMN-VD-Ca group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 22.4 years
400 IU1 year37
The effects of fish oil plus vitamin D(3) intervention on non-alcoholic fatty liver disease: a randomized controlled trial
2022 · FO + D group · Adults aged 56.0 ± 15.9 years with non-alcoholic fatty liver disease
1,680 IU90 days37
Consumption of vitamin D-and calcium-fortified soft white cheese lowers the biochemical marker of bone resorption TRAP 5b in postmenopausal women at moderate risk of osteoporosis fracture
2012 · treated · Healthy postmenopausal women aged 56.6 ± 3.9 years with low spontaneous calcium and vitamin D intake
2.5 mcg6 weeks36
Role of vitamin D-calcium supplementation on metabolic profile and oxidative stress in gestational diabetes mellitus: A randomized controlled trial
2021 · group B · Women diagnosed with gestational diabetes mellitus at 24–28 weeks of gestation, controlled on a diabetic diet
250 IU6 weeks36
Multiple Micronutrients, Lutein, and Docosahexaenoic Acid Supplementation during Lactation: A Randomized Controlled Trial
2020 · MMS group · Healthy breastfeeding women, aged 18–45 years, beginning supplementation 4–6 weeks after delivery
600 IU12 weeks35
Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin
2011 · Second group · Postmenopausal women with osteoporosis
400 IU26 weeks34
Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China
2020 · low VitD experimental group · Postmenopausal women with osteoporosis and serum 25(OH)D <10 ng/mL
0.25 mcg26 weeks34
Role of vitamin D-calcium supplementation on metabolic profile and oxidative stress in gestational diabetes mellitus: A randomized controlled trial
2021 · group A · Women diagnosed with gestational diabetes mellitus at 24–28 weeks of gestation, controlled on a diabetic diet
1,000 IU6 weeks34
Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial
2008 · ch-OSA 3 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy
20 mcg1 year33
Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial
2008 · ch-OSA 6 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy
20 mcg1 year33
Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial
2008 · ch-OSA 12 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy
20 mcg1 year33
The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD
2016 · vitamin D, vitamin K and calcium supplements · Overweight patients with type 2 diabetes and CHD; age and sex not specified
10 mcg12 weeks33
Vitamin D and the hepatitis B vaccine response: a prospective cohort study and a randomized, placebo-controlled oral vitamin D(3) and simulated sunlight supplementation trial in healthy adults
2021 · oral vitamin D3 (ORAL) · Healthy men aged 17 years or older entering the British Army Combat Infantryman’s Course; vitamin D status varied, with many below sufficiency at baseline.
1,400 IU12 weeks32
Between-meal risedronate does not alter bone turnover in nursing home residents
2006 · Risedronate group · Skilled nursing-home residents, mean age 76 years; 46 men and 14 women overall, with hypovitaminosis D common at baseline
400 IU12 weeks31
The effect of vitamin d on aldosterone and health status in patients with heart failure
2014 · vitamin D3 group · Adults aged 50 years or older with NYHA class II–IV heart failure and serum 25OHD ≤37.5 ng/ml
7,143 IU26 weeks31
Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial
2016 · HD/HK · Postmenopausal women aged 50–65 years
16.3 mcg12 weeks31
Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial
2016 · HD/LK · Postmenopausal women aged 50–65 years
15 mcg12 weeks31
A pilot intervention to increase calcium intake in female collegiate athletes
2004 · treatment group · Female collegiate athletes with regular menstrual cycles; age not reported
400 IU16 weeks30
Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D
2014 · vitamin D-fortified doogh (DD) · Adults aged 30–50 of both sexes with type 2 diabetes
1,000 IU12 weeks30
Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D
2014 · calcium-vitamin D-fortified doogh (CDD) · Adults aged 30–50 of both sexes with type 2 diabetes
1,000 IU12 weeks30
The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inflammation, and Oxidative Stress Biomarkers in Vitamin D-Deficient Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
2016 · vitamin D-K-calcium co-supplementation group · Vitamin D-deficient women aged 18–40 years with polycystic ovary syndrome
400 IU8 weeks30
Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial
2016 · LD/HK · Postmenopausal women aged 50–65 years
3.86 mcg12 weeks30
Vitamin D and probiotic co-supplementation affects mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome
2019 · vitamin D plus probiotic supplements · Women aged 18–40 with polycystic ovary syndrome
3,571 IU12 weeks30
Between-meal risedronate does not alter bone turnover in nursing home residents
2006 · Placebo group · Skilled nursing-home residents, mean age 76 years; 46 men and 14 women overall, with hypovitaminosis D common at baseline
400 IU12 weeks29
Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women
2013 · vitamin D- and calcium-fortified yogurt (FY) · Institutionalized women, mean age 85.5 years, at high risk for vitamin D deficiency and osteoporotic fracture
10 mcg8 weeks29
The Effects of Calcium, Vitamins D and K co-Supplementation on Markers of Insulin Metabolism and Lipid Profiles in Vitamin D-Deficient Women with Polycystic Ovary Syndrome
2017 · calcium, vitamin D and vitamin K group · Women aged 18–40 years with vitamin D deficiency and polycystic ovary syndrome
400 IU8 weeks28
Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial
2022 · 600 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline.
600 IU16 weeks28
Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins
2017 · vitamin D arm · Participants; age, sex, and health condition not specified
1,200 IU1 year27
Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia
2020 · Group B (control) · Postmenopausal women with osteopenia
400 IU90 days27
Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations
2020 · Nutrient supplement phase, healthy participants · Healthy adults aged 20–65 years
1,000 IU4 weeks27
Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial
2015 · Group C · Overweight, vitamin D-deficient women aged 18–40 years with PCOS
7,143 IU8 weeks26
Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial
2022 · 1200 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline.
1,200 IU16 weeks26
Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial
2022 · 4000 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline.
4,000 IU16 weeks26
Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women
2000 · calcium carbonate plus calcitriol · Thai postmenopausal women with osteoporosis, more than 10 years postmenopausal
0.5 mcg90 days25
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis
2010 · Treatment group · Patients with multiple sclerosis; age and sex not specified
40,000 IU52 weeks25
Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China
2020 · high VitD experimental group · Postmenopausal women with osteoporosis and serum 25(OH)D ≥10 ng/mL
0.25 mcg26 weeks25
The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes
2021 · Ca+D-yogurt drink (CDY) · Adults aged 30–60 years with confirmed type 2 diabetes
1,000 IU12 weeks25
Effect of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia: a randomized placebo-controlled trial
2012 · calcium-vitamin D supplements · Pregnant women aged 18–35 in the third trimester, primigravida, with singleton pregnancies and at risk for pre-eclampsia
200 IU9 weeks24
Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia
2020 · Group A · Postmenopausal women with osteopenia
400 IU90 days24
Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations
2020 · Nutrient supplement phase, participants with Crohn's disease · Adults aged 20–65 years with Crohn’s disease in remission
1,000 IU6 weeks24
Alfacalcidol (alpha D3) and calcium in osteoporosis
1994 · treatment group · Postmenopausal women with osteoporosis; mean age 67 years
0.5 mcg3 years24
Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover
2004 · Calcium and vitamin D control group · Women older than 65 with high bone turnover, at high risk of osteoporosis
200 IU26 weeks23
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis
2004 · No-alendronate group (controls) · HIV-infected men and women on stable HAART with osteopenia or osteoporosis
500 IU52 weeks23
[Treatment of secondary hyperparathyroidism with vitamin D metabolites]
1994 · 1-alpha-OHD3 plus 24,25(OH)2D3 · Adults aged 19–67 with secondary hyperparathyroidism receiving chronic haemodialysis
10.3 mcg13 weeks23
Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial
2009 · 2.0 g elemental calcium plus 800 IU vitamin D3 · Adults aged 30–75 in generally good health with at least one pathology-confirmed sporadic colon or rectal adenoma in the previous 36 months
800 IU26 weeks23
Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial
2009 · calcium plus vitamin D supplementation group · Adults aged 30–75 in general good health with a history of at least one pathology-confirmed colorectal adenoma within the past 36 months
800 IU26 weeks23
Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients
2010 · calcium plus vitamin D3 supplementation group · Adults aged 30–75 with a history of at least one adenomatous colonic or rectal polyp within the past 36 months
800 IU26 weeks23
A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients
2011 · calcium plus vitamin D3 group · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp in the preceding 36 months
800 IU180 days23
Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial
2011 · 2.0 g elemental calcium plus 800 IU vitamin D3 group · Adults aged 30–75 with a history of sporadic colorectal adenoma
800 IU26 weeks23
A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients
2012 · 2.0 g elemental calcium plus 800 IU vitamin D3 supplementation · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp within the past 36 months
800 IU26 weeks23
Effects of calcium and vitamin D3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: a randomized controlled trial
2015 · calcium plus vitamin D3 group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp within the past 36 months; both sexes
800 IU26 weeks23
The effects of chromium and vitamin D(3) co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial
2020 · both vitamin D3 and CrPic · patients with type 2 diabetes mellitus; age and sex not stated
7,143 IU120 days23
Acute Effects of Single Doses of Bonito Fish Peptides and Vitamin D on Whole Blood Gene Expression Levels: A Randomized Controlled Trial
2019 · VitD3 + BPH · Overweight or obese adults aged 18–65 years, without metabolic disorders requiring treatment
1,000 IU1 day22
Investigation of the Effect of Nutritional Supplementation with Whey Protein and Vitamin D on Muscle Mass and Muscle Quality in Subacute Post-Stroke Rehabilitation Patients: A Randomized, Single-Blinded, Placebo-Controlled Trial
2022 · HP group · Adults aged 40 years or older with ischemic or hemorrhagic stroke in subacute rehabilitation
40 mcg16 weeks22
Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial
2025 · Vit D 1000 + NAC (D1N) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m²
1,000 IU8 weeks22
Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial
2025 · Vit D 5000 + NAC (D5N) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m²
5,000 IU8 weeks22
Nutritional approach for inhibiting bone resorption in institutionalized elderly women with vitamin D insufficiency and high prevalence of fracture
2011 · Soft plain cheese consumption period · Institutionalized women aged 65 years or older with vitamin D insufficiency and low calcium intake
2.5 mcg6 weeks21
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves' Disease Hyperthyroidism During Methimazole Treatment
2022 · MMI+Se+VitD (intervention group) · Adults aged 18–70 with newly diagnosed Graves’ disease and low or suboptimal selenium and vitamin D levels
1,000 IU270 days21
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study
2009 · Group 2 (control group) · Postmenopausal women with osteoporosis
400 IU1 year20
Calcium and vitamin-D supplementation on bone structural properties in peripubertal female identical twins: a randomised controlled trial
2011 · calcium-supplemented group · Peripubertal girls aged 9 to 13 years
400 IU26 weeks20
Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial
2016 · Treatment arm · Children and adolescents aged 4–16 years with biopsy-proven NAFLD and serum vitamin D deficiency
800 IU24 weeks20
Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study
2018 · K citrate group · Postmenopausal women with osteopenia, more than 5 years post-menopause
400 IU26 weeks20
Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study
2018 · Placebo group with background supplements · Postmenopausal women with osteopenia, more than 5 years post-menopause
400 IU26 weeks20
Bioavailability of calcium supplements and the effect of Vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D
1996 · three tablets containing 1000 mg CaCO3 plus 5 micrograms (200 IU) vitamin D/d · Healthy women aged 28–59 years
5 mcg3 days20
The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1-infected males: results of a clinical trial
2013 · A · HIV-1-infected males
1,200 IU16 weeks19
Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation
2025 · ω-3VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase
4,000 IU6 weeks19
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis
2004 · Alendronate-treatment group · HIV-infected men and women on stable HAART with osteopenia or osteoporosis
500 IU52 weeks18
Fortified breakfast cereal consumed daily for 12 wk leads to a significant improvement in micronutrient intake and micronutrient status in adolescent girls: a randomised controlled trial
2016 · Fortified cereal, morning · Females aged 16–19 years who regularly skipped breakfast and had low riboflavin status and haemoglobin; no diagnosed illness
4.15 mcg12 weeks18
Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients
2018 · Calcium + Vitamin D (4-arm randomization) · Adults aged 45–75 with a removed histologically verified colorectal adenoma; men and women
1,000 IU1 year17
Fortified breakfast cereal consumed daily for 12 wk leads to a significant improvement in micronutrient intake and micronutrient status in adolescent girls: a randomised controlled trial
2016 · Fortified cereal, evening · Females aged 16–19 years who regularly skipped breakfast and had low riboflavin status and haemoglobin; no diagnosed illness
4.15 mcg12 weeks16
Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial
2025 · ERC plus adjunctive doxercalciferol · Adults with non-dialysis chronic kidney disease, mild to moderate secondary hyperparathyroidism, and elevated iPTH; mean age 65.8 years in the combined adjunctive-AVD arm
0.5 mcg52 weeks14
Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial
2025 · ERC plus adjunctive paricalcitol · Adults with non-dialysis chronic kidney disease, mild to moderate secondary hyperparathyroidism, and elevated iPTH; mean age 65.8 years in the combined adjunctive-AVD arm
1 mcg52 weeks14
Effect of vitamin D and calcium supplementation on bone turnover in institutionalized adults with Down's Syndrome
2006 · supplementation group · Adults with Down's syndrome living in an institution
800 IU1 year12
[Treatment of postmenopausal osteoporosis with 1-alpha(OH)D3]
1995 · 1-alpha(OH) vitamin D3 group · Postmenopausal women with osteoporosis
0.5 mcg26 weeks12
The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners
2021 · ω-3 PUFA group · Healthy physically active male recreational marathon runners, with no stated disease; age range not reported
30 mcg3 weeks12
Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial
2025 · ERC plus adjunctive calcitriol · Adults with non-dialysis chronic kidney disease, mild to moderate secondary hyperparathyroidism, and elevated iPTH; mean age 65.8 years in the combined adjunctive-AVD arm
0.25 mcg52 weeks12
Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone
1995 · Group B · Adults with chronic renal insufficiency who were not receiving dialysis
0.55 mcg39 weeks12
Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa
2006 · calcium plus vitamin D treatment group · Adults with adenomatous polyps; age and sex not stated
400 IU26 weeks11
Systemic vitamin D supplementation and local bone formation after maxillary sinus augmentation - a randomized, double-blind, placebo-controlled clinical investigation
2016 · vitamin D3 + calcium group · Adults undergoing maxillary sinus augmentation; age and sex not stated
5,000 IU213 days10
SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE?
2015 · Calcium citrate group (Group 1 in Methods) · Adults who underwent Roux-en-Y gastric bypass and had mainly abnormal alkaline phosphatase, vitamin D and PTH levels; ages 25–55
800 IU60 days10
SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE?
2015 · Calcium carbonate group (Group 2 in Methods) · Adults who underwent Roux-en-Y gastric bypass and had mainly abnormal alkaline phosphatase, vitamin D and PTH levels; ages 25–68
800 IU60 days10
Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3
1994 · group 1 · Adults aged 26–72 years receiving hemodialysis with secondary hyperparathyroidism resistant to long-term low-dose 1-alpha-OHD3 therapy
10 mcg24 weeks10
A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis
1993 · Study group: 2.5 mEq/L calcium dialysate with oral calcitriol · Patients on peritoneal dialysis
0.25 mcg8 weeks9
Tibial bone responses to 6-month calcium and vitamin D supplementation in young male jockeys: A randomised controlled trial
2015 · Supplemented group · Apprentice male jockeys, mean age 20.2 ± 3.2 years, engaged in caloric restriction and high volumes of physical activity
400 IU26 weeks8
The effect of calcium and vitamin D supplementation on bone health of male Jockeys
2017 · calcium and vitamin D group · Apprentice male jockeys; mean age 20.18 ± 3.23 years
400 IU26 weeks8
Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion
2001 · Two doses of Orocal D3 at a 6-hour interval · Healthy male volunteers; age not stated
800 IU1 day—
Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion
2001 · One morning dose of Cacit vitamin D3 · Healthy male volunteers; age not stated
880 IU1 day—
Absorbability and cost effectiveness in calcium supplementation
2001 · marketed calcium carbonate · Postmenopausal women
10 mcg7 days—
Absorbability and cost effectiveness in calcium supplementation
2001 · encapsulated calcium carbonate · Postmenopausal women
10 mcg7 days—
Absorbability and cost effectiveness in calcium supplementation
2001 · marketed calcium citrate · Postmenopausal women
10 mcg7 days—
Alendronate prevents further bone loss in renal transplant recipients
2001 · Group A · Adults aged 44.2 ± 11.6 years with a kidney transplant at least 6 months earlier
0.5 mcg1 year—
Alendronate prevents further bone loss in renal transplant recipients
2001 · Group B · Adults aged 44.2 ± 11.6 years with a kidney transplant at least 6 months earlier
0.5 mcg1 year—
Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion
2002 · Two doses of Orocal D3 · Healthy volunteers; age and sex not specified
800 IU1 day—
Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion
2002 · Single morning dose of Cacit D3 · Healthy volunteers; age and sex not specified
880 IU1 day—
Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels
2002 · calcium-vitamin D (CaD) group · postmenopausal women with serum 25(OH)vitamin D levels below 18 ng/mL
200 IU90 days—
Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women
2004 · calcium citrate · Older postmenopausal women
900 IU12 weeks—
Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women
2004 · calcium carbonate · Older postmenopausal women
900 IU12 weeks—
Mineral water fortified with folic acid, vitamins B6, B12, D and calcium improves folate status and decreases plasma homocysteine concentration in men and women
2004 · Fortified mineral water · Free-living men and women without folate deficiency or elevated homocysteine
0.6 mcg8 weeks—
Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis
2004 · group D · Elderly women with osteoporosis; mean age 77.4 years
1 mcg26 weeks—
Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial
2005 · group A · Postmenopausal women aged 49–71 years; healthy
5.7 mcg26 weeks—
Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial
2005 · group B · Postmenopausal women aged 49–71 years; healthy
5.7 mcg26 weeks—
Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake
2005 · High-calcium mineral water plus vitamin D · Postmenopausal women with dietary calcium intake below 700 mg/day; mean age 70.1 years
400 IU26 weeks—
Calcemic response to magnesium or 1-alpha-hydroxycholecalciferol treatment in intestinal hypomagnesemia
1991 · Combined 1-alpha-hydroxycholecalciferol and magnesium chloride treatment · Gastroenterological patients with intestinal hypomagnesemia; age and sex not reported
1 mcg7 days—
Dietary acid-base balance, bone resorption, and calcium excretion
2006 · Cereal (acidogenic) diet group · Healthy older men and women
400 IU60 days—
Dietary acid-base balance, bone resorption, and calcium excretion
2006 · Fruit and vegetable (alkalinogenic) diet group · Healthy older men and women
400 IU60 days—
Effect of calcium, vitamins K1 and D3 on bone in galactosemia
2006 · calcium, vitamins K1 and D3 supplementation · Children aged 3–17 years with classical galactosemia
10 mcg2 years—
The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults
2007 · calcium and vitamin D supplementation · Caucasian adults aged 65 years or older without diabetes; baseline fasting glucose was normal or impaired
700 IU3 years—
Biochemical short-term changes produced by hormonal replacement therapy
1991 · calcium · White postmenopausal women, 6 months to 6 years after menopause
400 IU60 days—
Biochemical short-term changes produced by hormonal replacement therapy
1991 · cyclic estrogen-progestin plus calcium · White postmenopausal women, 6 months to 6 years after menopause
400 IU60 days—
Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss
2008 · Placebo group · Postmenopausal Korean women aged 50–65 with moderate bone loss
400 IU12 weeks—
Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss
2008 · Alendronate group · Postmenopausal Korean women aged 50–65 with moderate bone loss
400 IU12 weeks—
Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women
2009 · placebo · Men and women aged 50 and older; described as healthy older adults
525 IU90 days—
Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women
2009 · potassium bicarbonate group · Men and women aged 50 and older; described as healthy older adults
525 IU90 days—
Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women
2009 · sodium bicarbonate group · Men and women aged 50 and older; described as healthy older adults
525 IU90 days—
Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women
2009 · potassium chloride group · Men and women aged 50 and older; described as healthy older adults
525 IU90 days—
The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD
2009 · calcium-vitamin D(3) fixed combination · Elderly white women; the analysis focused on participants with moderate chronic kidney disease
800 IU26 weeks—
The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD
2009 · calcium plus vitamin D(3) separate combination · Elderly white women; the analysis focused on participants with moderate chronic kidney disease
800 IU26 weeks—
Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial
2010 · calcium plus vitamin D supplementation group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp
800 IU26 weeks—
Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D
2010 · group 1 · postmenopausal volunteers with initial serum 25OHD below 60 nmol/L
1,000 IU8 weeks—
Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D
2010 · group 2 · postmenopausal volunteers with initial serum 25OHD below 60 nmol/L
1,000 IU8 weeks—
The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design
2010 · vitamin D3 and calcium · Healthy men and women aged 20–80 years
100 mcg90 days—
Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial
2011 · vitamin D-fortified yogurt drink (DY) · people with type 2 diabetes; age and sex not stated
1,000 IU12 weeks—
Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial
2011 · vitamin D + calcium-fortified yogurt drink (DCY) · people with type 2 diabetes; age and sex not stated
1,000 IU12 weeks—
Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness
2012 · ibandronate group · Postmenopausal women with chronic critical illness
2,000 IU11 days—
Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness
2012 · placebo group · Postmenopausal women with chronic critical illness
2,000 IU11 days—
Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50+ years: an 18-month randomized controlled trial
2011 · PRT + fortified milk supplement · Healthy men aged 50–79 years
800 IU548 days—
Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50+ years: an 18-month randomized controlled trial
2011 · Fortified milk supplement · Healthy men aged 50–79 years
800 IU548 days—
Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes
2012 · vitamin D-fortified doogh (DD) · Adults aged 30–60 of both sexes with type 2 diabetes
1,000 IU12 weeks—
Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes
2012 · calcium + vitamin D3-fortified doogh (CDD) · Adults aged 30–60 of both sexes with type 2 diabetes
1,000 IU12 weeks—
Blood lead concentration is not altered by high-dose vitamin D supplementation in children and young adults with HIV
2013 · 7000 IU/day group · Children and young adults aged 8–24 years with HIV
7,000 IU12 weeks—
One year B and D vitamins supplementation improves metabolic bone markers
2013 · group B · Healthy adults older than 54 years
1,200 IU1 year—
Regular consumption of both vitamin D- and calcium- and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial
2013 · vitamin D-fortified doogh (DD) · Men and women aged 30–60 years with type 2 diabetes
1,000 IU12 weeks—
Regular consumption of both vitamin D- and calcium- and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial
2013 · calcium- and vitamin D-fortified doogh (CDD) · Men and women aged 30–60 years with type 2 diabetes
1,000 IU12 weeks—
Calcium and vitamin d supplementation in postmenopausal women
2013 · vitamin D3 and calcium · healthy postmenopausal white women
100 mcg26 weeks—
Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial
2014 · CaDEA · Children aged approximately 8 years
200 IU12 weeks—
Vitamin D does not increase calcium absorption in young women: a randomized clinical trial
2014 · vitamin D3 400 IU group · White and African American women aged 25 to 45 years with vitamin D insufficiency
400 IU1 year—
Vitamin D does not increase calcium absorption in young women: a randomized clinical trial
2014 · vitamin D3 800 IU group · White and African American women aged 25 to 45 years with vitamin D insufficiency
800 IU1 year—
Vitamin D does not increase calcium absorption in young women: a randomized clinical trial
2014 · vitamin D3 1600 IU group · White and African American women aged 25 to 45 years with vitamin D insufficiency
1,600 IU1 year—
Vitamin D does not increase calcium absorption in young women: a randomized clinical trial
2014 · vitamin D3 2400 IU group · White and African American women aged 25 to 45 years with vitamin D insufficiency
2,400 IU1 year—
Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial
2014 · 1,000 IU/day vitamin D3 · Black adults aged 30–80 years from a community-based healthy population
1,000 IU90 days—
Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial
2014 · 2,000 IU/day vitamin D3 · Black adults aged 30–80 years from a community-based healthy population
2,000 IU90 days—
Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial
2014 · 4,000 IU/day vitamin D3 · Black adults aged 30–80 years from a community-based healthy population
4,000 IU90 days—
Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study
2014 · intervention group (IG) · Steroid-naïve pre-pubertal children with new-onset nephrotic syndrome treated with glucocorticoids; boys and girls
1,000 IU12 weeks—
Calcium and vitamin D supplementation maintains parathyroid hormone and improves bone density during initial military training: a randomized, double-blind, placebo controlled trial
2014 · Ca+Vit D · Men and women undergoing Army initial military training (basic combat training); ages and health conditions not specified
1,000 IU9 weeks—
Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: a randomized controlled clinical trial
2014 · joint calcium-vitamin D group · Adults with vitamin D insufficiency and type 2 diabetes; age and sex range not stated
7,143 IU8 weeks—
Calcium supplementation increases blood creatinine concentration in a randomized controlled trial
2014 · Calcium plus vitamin D · Adults aged 45–75 in generally good health with a previously removed large bowel adenoma; predominantly male
1,000 IU5 years—
Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months
2015 · 1,000 IU/day · African-American adults aged 30–80 who were overweight or obese
1,000 IU90 days—
Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months
2015 · 2,000 IU/day · African-American adults aged 30–80 who were overweight or obese
2,000 IU90 days—
Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months
2015 · 4,000 IU/day · African-American adults aged 30–80 who were overweight or obese
4,000 IU90 days—
A Vitamin D-Calcium-Fortified Yogurt Drink Decreased Serum PTH but did not Affect Osteocalcin in Subjects with Type 2 Diabetes
2015 · Group 3 (CDD) · Women and men aged 30–50 years with type 2 diabetes
1,000 IU12 weeks—
Vitamin D and Evening Primrose Oil Administration Improve Glycemia and Lipid Profiles in Women with Gestational Diabetes
2016 · Vitamin D and EPO group · Pregnant women with gestational diabetes mellitus
1,000 IU6 weeks—
Vitamin D supplementation during pregnancy and infancy reduces aeroallergen sensitization: a randomized controlled trial
2016 · 1000 IU/400 IU · Pregnant women from 27 weeks’ gestation and their infants from birth to 6 months
1,400 IU——
Vitamin D supplementation during pregnancy and infancy reduces aeroallergen sensitization: a randomized controlled trial
2016 · 2000 IU/800 IU · Pregnant women from 27 weeks’ gestation and their infants from birth to 6 months
2,800 IU——
Effects of supplemental calcium and vitamin D on the APC/β-catenin pathway in the normal colorectal mucosa of colorectal adenoma patients
2017 · 1,200 mg/day elemental calcium plus 1,000 IU/day vitamin D3 supplementation · Adults aged 45–75 with a history of colorectal adenomas
1,000 IU1 year—
One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation
2017 · group B · Adults older than 54 years; no specific condition stated
1,200 IU1 year—
Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial
2017 · Calcium + vitamin D alone · Postmenopausal women aged 50–79 in the WHI hormone therapy trials
400 IU5 years—
Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial
2017 · Calcium + vitamin D plus hormone therapy · Postmenopausal women aged 50–79 in the WHI hormone therapy trials
400 IU5 years—
Maternal vitamin D sufficiency and reduced placental gene expression in angiogenic biomarkers related to comorbidities of pregnancy
2017 · 4000 IU/day vitamin D3 group · Pregnant women aged 18–45 with singleton pregnancies, enrolled at 8–14 weeks’ gestation
4,400 IU——
Vitamin D(3) supplementation decreases a unique circulating monocyte cholesterol pool in patients with type 2 diabetes
2018 · vitamin D3 group · Adults aged 25–80 with type 2 diabetes, hypertension, and serum 25(OH)D below 25 ng/mL
4,000 IU120 days—
Nutritional Supplementation With Physical Activity Improves Muscle Composition in Mobility-Limited Older Adults, The VIVE2 Study: A Randomized, Double-Blind, Placebo-Controlled Trial
2017 · daily nutritional supplement · Mobility-limited, vitamin D-insufficient older adults; mean age 78.5 years, 46.3% female
800 IU26 weeks—
Effects of Vitamin D Supplementation on Semen Quality, Reproductive Hormones, and Live Birth Rate: A Randomized Clinical Trial
2018 · active group · Infertile men with serum 25-hydroxyvitamin-D levels ≤50 nmol/L
1,400 IU150 days—
Safety of calcium and vitamin D supplements, a randomized controlled trial
2018 · CaCO3 1200 mg/day with 10 000 IU vitamin D3/day · Healthy, white postmenopausal women
10,000 IU1 year—
Safety of calcium and vitamin D supplements, a randomized controlled trial
2018 · CaCO3 1200 mg/day with 600 IU vitamin D3/day · Healthy, white postmenopausal women
600 IU1 year—
Effects of vitamin D and calcium on expression of MSH2 and transforming growth factors in normal-appearing colorectal mucosa of sporadic colorectal adenoma patients: A randomized clinical trial
2019 · vitamin D3 plus calcium group · People with sporadic colorectal adenomas; age and sex not specified
1,000 IU1 year—
Effects of supplemental calcium and vitamin D on tight-junction proteins and mucin-12 expression in the normal rectal mucosa of colorectal adenoma patients
2019 · calcium plus vitamin D supplementation · Adults aged 45–75 with a removed colorectal adenoma and no remaining polyps after colonoscopy; patients at increased risk for colorectal neoplasms
1,000 IU1 year—
Randomized Study of the Effect of Vitamin D and Omega-3 Fatty Acids Cosupplementation as Adjuvant Chemotherapy on Inflammation and Nutritional Status in Colorectal Cancer Patients
2020 · cosupplementation group · Colorectal cancer patients
7,143 IU8 weeks—
Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial
2020 · n-3 LCPUFA plus vitamin D · Pregnant women enrolled at pregnancy week 24; age range and health condition not specified
2,400 IU17 weeks—
Effects of Maternal Vitamin D3 Supplementation on Offspring Epigenetic Clock of Gestational Age at Birth: A Post-hoc Analysis of a Randomized Controlled Trial
2020 · Vitamin D3 supplementation · Pregnant women; mean age 29.6 ± 4.8 years; multiethnic population
4,400 IU——
Effects of Vitamin D and Omega-3 Fatty Acids Co-Supplementation on Inflammatory Factors and Tumor Marker CEA in Colorectal Cancer Patients Undergoing Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
2020 · co-supplementation · Patients with stage II or III colorectal cancer undergoing chemotherapy
7,143 IU8 weeks—
Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial
2021 · calcium plus vitamin D group · Adults aged 45–75 with a histologically verified colorectal adenoma
1,000 IU1 year—
Improving the endothelial dysfunction in type 2 diabetes with chromium and vitamin D(3) byreducing homocysteine and oxidative stress: A randomized placebo-controlled trial
2020 · group IV: vitamin D3 and CrPic · People with type 2 diabetes mellitus; age and sex not stated
7,143 IU120 days—
Changes in Bone Turnover, Inflammatory, Oxidative Stress, and Metabolic Markers in Women Consuming Iron plus Vitamin D Supplements: a Randomized Clinical Trial
2021 · D-Fe · Women aged 18–45 years with hemoglobin ≤12.7 g/dL and 25OHD ≤29 ng/mL
1,000 IU12 weeks—
Differential regulation of a placental SAM68 and sFLT1 gene pathway and the relevance to maternal vitamin D sufficiency
2020 · 4000 IU/day vitamin D3 plus standard prenatal vitamin · Pregnant women aged 18–45 years; placental samples were from term pregnancies
4,400 IU——
Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab
2020 · Infliximab and vitamin D (Ifx + VitD) · Adults aged 18–80 with active colonic and/or ileocecal Crohn’s disease
20,000 IU7 weeks—
Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab
2020 · Placebo infliximab and vitamin D (placeboIfx + VitD) · Adults aged 18–80 with active colonic and/or ileocecal Crohn’s disease
20,000 IU7 weeks—
Vitamin K2 (menaquinone-7) increases plasma adiponectin but does not affect insulin sensitivity in postmenopausal women: a randomized controlled trial
2021 · MK-7 group · Postmenopausal women; the abstract describes them as healthy
38 mcg1 year—
The effect of vitamin D supplementation on circulating osteoprogenitor cells: A pilot randomized controlled trial
2021 · 50,000 IU bolus dose plus 1000 IU daily supplement · Healthy older adults, stratified by baseline vitamin D level into deficient and non-deficient groups
51,000 IU6 weeks—
The effect of combined supplementation with vitamin D and omega-3 fatty acids on blood glucose and blood lipid levels in patients with gestational diabetes
2021 · test group · Women aged 18–40 with gestational diabetes
80,000 IU6 weeks—
Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial
2022 · MK-7 plus vitamin D · Elderly men with an aortic valve calcification score >300 AU
25 mcg2 years—
Small-Scale Randomized Controlled Trial to Explore the Impact of β-Hydroxy-β-Methylbutyrate Plus Vitamin D(3) on Skeletal Muscle Health in Middle Aged Women
2022 · SED HMB + D · Women aged 45–60 years, apparently healthy, assigned to sedentary control; vitamin D status varied at baseline
2,000 IU12 weeks—
Small-Scale Randomized Controlled Trial to Explore the Impact of β-Hydroxy-β-Methylbutyrate Plus Vitamin D(3) on Skeletal Muscle Health in Middle Aged Women
2022 · RET HMB + D · Women aged 45–60 years, apparently healthy, assigned to resistance exercise training; vitamin D status varied at baseline
2,000 IU12 weeks—
Effect of Vitamin D and/or Calcium Supplementation on Pancreatic β-Cell Function in Subjects with Prediabetes: A Randomized, Controlled Trial
2023 · vitamin D plus calcium group · Chinese adults with prediabetes; the reported disposition-index result was for vitamin D-insufficient individuals
1,600 IU24 weeks—
Effects of Vitamin D(3) and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
2022 · Vitamin D3 and marine n-3 fatty acids active group · Men aged 50 years or older and women aged 55 years or older, without a history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke, transient ischemic attack, or coronary revascularization
2,000 IU1935 days—
Changes in bone turnover after high-dose vitamin D supplementation during acute pulmonary exacerbation in cystic fibrosis
2023 · Vitamin D3 · Adults aged 16 years or older with cystic fibrosis admitted to hospital for an acute pulmonary exacerbation
250,000 IU1 year—
Does maternal vitamin D status influence placental weight or vascular and inflammatory pathology? Secondary analysis from the Kellogg Pregnancy Study
2023 · 4000 IU vitamin D3 group · Women aged 18–45 with singleton pregnancies, enrolled at 10–14 weeks’ gestation; generally healthy, with a sub-cohort with specified chronic conditions
4,000 IU——
Effects of dietary supplementation of fish oil plus vitamin D(3) on gut microbiota and fecal metabolites, and their correlation with nonalcoholic fatty liver disease risk factors: a randomized controlled trial
2024 · FO + D group · Subjects studied in relation to nonalcoholic fatty liver disease risk factors; age and sex not reported
1,680 IU90 days—
Vitamin D(3) and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial
2025 · Vitamin D3 plus marine n-3 fatty acids · Females aged 55 years or older and males aged 50 years or older; no specific condition stated
2,000 IU5 years—
Effects of vitamin K2 and D3 supplementation on epicardial adipose tissue and systemic inflammation: A substudy of the AVADEC trial
2025 · vitamin K2 and D3 group · Men aged 65–74 at cardiovascular risk
25 mcg2 years—
Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3
1998 · cholecalciferol group · Inpatients with hypovitaminosis D and secondary hyperparathyroidism
800 IU26 weeks—
Low dose estrogen and calcium have an additive effect on bone resorption in older women
1999 · Calcium plus vitamin D (Ca+D) · Healthy women over 70 years of age
800 IU12 weeks—
Low dose estrogen and calcium have an additive effect on bone resorption in older women
1999 · Combination Ca+D and E2 · Healthy women over 70 years of age
800 IU12 weeks—
Safety and tolerability of 6-month supplementation with a vitamin D, calcium and leucine-enriched whey protein medical nutrition drink in sarcopenic older adults
2020 · One-serving WP-MND group during the open-label extension · Adults aged 65 years or older with sarcopenia who continued from the RCT
800 IU13 weeks133
Effects of combined nutritional supplementation and exercise on proxy measures of muscle mass, strength, and function in older adults with sarcopenia: a 12-week multicentre RCT
2025 · intervention group · Adults aged 65 years or older with sarcopenia or possible sarcopenia; men and women
400 IU12 weeks55
Change in Micronutrient Intake among People with Relapsing-Remitting Multiple Sclerosis Adapting the Swank and Wahls Diets: An Analysis of Weighed Food Records
2021 · Wahls (modified Paleolithic elimination diet) group · Adults with relapsing-remitting multiple sclerosis and moderate to severe fatigue; age and sex range not specified
5,000 IU12 weeks39
Change in Micronutrient Intake among People with Relapsing-Remitting Multiple Sclerosis Adapting the Swank and Wahls Diets: An Analysis of Weighed Food Records
2021 · Swank (low-saturated fat diet) group · Adults with relapsing-remitting multiple sclerosis and moderate to severe fatigue; age and sex range not specified
5,000 IU12 weeks38
A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome
2017 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS)
400 IU12 weeks30
The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes
2019 · Magnesium-zinc-calcium-vitamin D group · Women aged 18–40 with gestational diabetes mellitus, at 24–28 weeks’ gestation at diagnosis
400 IU6 weeks30
Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome
2011 · intervention arm · Postmenopausal women with metabolic syndrome
1,000 IU14 weeks25
Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins
2017 · vitamin D + B arm · Participants; age, sex, and health condition not specified
1,200 IU1 year25
Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial
2010 · treatment arm · Healthy postmenopausal women
1,000 IU14 weeks16
Characterizing gut microbial dysbiosis and exploring the effect of prebiotic fiber supplementation in patients with COPD
2025 · nutritional supplement group · Adults with moderate to very severe, clinically stable COPD (GOLD II–IV); ages reported as 69.3 ± 7.4 years
20 mcg90 days16
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover
2004 · 0.15 mg daily sCT · Healthy postmenopausal women aged 55–85 years
400 IU90 days—
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover
2004 · 0.4 mg daily sCT · Healthy postmenopausal women aged 55–85 years
400 IU90 days—
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover
2004 · 1.0 mg daily sCT · Healthy postmenopausal women aged 55–85 years
400 IU90 days—
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover
2004 · 2.5 mg daily sCT · Healthy postmenopausal women aged 55–85 years
400 IU90 days—
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover
2004 · 1.0 mg intermittent sCT (every other day) · Healthy postmenopausal women aged 55–85 years
400 IU90 days—
Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women
2005 · KBC 30 mmol/d · Postmenopausal women
400 IU3 years—
Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women
2005 · KBC 60 mmol/d · Postmenopausal women
400 IU3 years—
Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women
2005 · KBC 90 mmol/d · Postmenopausal women
400 IU3 years—
One year B and D vitamins supplementation improves metabolic bone markers
2013 · group A · Healthy adults older than 54 years
1,200 IU1 year—
Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women
2016 · Intervention (Int), premenopausal women · Premenopausal women, mean age 41 years; no specific condition stated
15 mcg12 weeks—
Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women
2016 · Intervention (Int), postmenopausal women · Postmenopausal women, mean age 59 years; no specific condition stated
15 mcg12 weeks—
One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation
2017 · group A · Adults older than 54 years; no specific condition stated
1,200 IU1 year—
A Simplified Regimen Compared with WHO Guidelines Decreases Antenatal Calcium Supplement Intake for Prevention of Preeclampsia in a Cluster-Randomized Noninferiority Trial in Rural Kenya
2017 · standard regimen · Pregnant women enrolled between 16 and 30 weeks of gestation
200 IU8 weeks—
A Simplified Regimen Compared with WHO Guidelines Decreases Antenatal Calcium Supplement Intake for Prevention of Preeclampsia in a Cluster-Randomized Noninferiority Trial in Rural Kenya
2017 · low-dose regimen · Pregnant women enrolled between 16 and 30 weeks of gestation
200 IU8 weeks—
Multimicronutrient and omega-3 fatty acid supplementation reduces low-grade inflammation in older participants: An exploratory study
2025 · multimicronutrient and n-3 PUFA supplementation · Healthy, physically active older adults; mean age 75.6 ± 3.9 years; sex not specified
50 mcg12 weeks—
Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial
2023 · Vitamin D3 plus marine omega-3s · Generally healthy, robust, community-dwelling adults aged 70 years or older
2,000 IU3 years—
Predicting comorbidities of pregnancy: A comparison between total and free 25(OH)D and their associations with parathyroid hormone
2023 · prenatal plus extra supplementation · Pregnant women with singleton pregnancies
4,400 IU—196
Predicting comorbidities of pregnancy: A comparison between total and free 25(OH)D and their associations with parathyroid hormone
2023 · group receiving a daily prenatal · Pregnant women with singleton pregnancies
400 IU—191
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
2016 · placebo · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate
400 IU1 year88
Standard versus distal Roux-en-Y gastric bypass in patients with BMI 50-60 kg/m2: 5-year outcomes of a double-blind, randomized clinical trial
2021 · Standard RYGB · Adults aged 20–60 years with BMI 50–60 kg/m² referred for bariatric surgery
800 IU5 years57
Standard versus distal Roux-en-Y gastric bypass in patients with BMI 50-60 kg/m2: 5-year outcomes of a double-blind, randomized clinical trial
2021 · Distal RYGB · Adults aged 20–60 years with BMI 50–60 kg/m² referred for bariatric surgery
800 IU5 years56
Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial
2025 · Randomized trial, placebo group · Infertile men; mean age approximately 34 years
25 mcg160 days49
The impact of supplemental n-3 long chain polyunsaturated fatty acids and dietary antioxidants on physical performance in postmenopausal women
2013 · Placebo group (background supplements) · Postmenopausal women over age 65 without the listed bone, cancer or liver diseases; most were prefrail or frail.
1,000 IU180 days41
Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome
2015 · 50,000 IU/wk vitamin D + calcium placebo · Overweight and obese vitamin D deficient women diagnosed with PCOS
7,143 IU8 weeks26
Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol
2008 · group 1 (alfacalcidol) · Kidney transplant recipients with low bone mineral density; 22 women and 42 men were recruited overall, but the arm's sex and age distribution are not reported.
0.5 mcg1 year25
Vitamin D supplementation during pregnancy: Effect on the neonatal immune system in a randomized controlled trial
2018 · 400 IU/d vitamin D3 · Pregnant women; age and pregnancy condition details beyond pregnancy are not reported.
400 IU—25
Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial
2017 · placebo group · Postmenopausal women aged 50–72 years with osteopenia
200 IU26 weeks25
Effects of 12 Weeks of Whole-Body Vibration Training and Vitamin D Supplementation on Bone Density and Muscle Quality in the Aged with Osteosarcopenia: A Randomized Controlled Trial
2025 · control group · Older adults with osteosarcopenia; age range and sex not specified
0.25 mcg90 days24
The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1-infected males: results of a clinical trial
2013 · B · HIV-1-infected males
1,200 IU16 weeks17
Biochemical short-term changes produced by hormonal replacement therapy
1991 · placebo · White postmenopausal women, 6 months to 6 years after menopause
400 IU60 days—
Vitamin D supplementation for nonspecific musculoskeletal pain in non-Western immigrants: a randomized controlled trial
2012 · Original placebo group switched to vitamin D at week 6 · Vitamin D-deficient non-Western immigrants with nonspecific persistent musculoskeletal pain
150,000 IU6 weeks—
Vitamin D favorably alters the cancer promoting prostaglandin cascade
2013 · 400 IU vitamin D-3 · Healthy women; age range and other characteristics not specified
400 IU30 days—
Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial
2014 · vitamin D3 and calcium carbonate · Healthy non-Hispanic white adults aged 45–75 years
1,000 IU1 year—
Free 25(OH)D and Calcium Absorption, PTH, and Markers of Bone Turnover
2015 · 800-IU dose arm · Adults; age, sex, and health condition are not specified in the abstract.
800 IU10 weeks—
Free 25(OH)D and Calcium Absorption, PTH, and Markers of Bone Turnover
2015 · 2000-IU dose arm · Adults; age, sex, and health condition are not specified in the abstract.
2,000 IU10 weeks—
Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial
2015 · 2400 IU maternal group · Exclusively lactating women 4 to 6 weeks postpartum
2,400 IU26 weeks—
microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma
2017 · 400 IU/day group · Men with prostate cancer scheduled for prostatectomy; age not reported
400 IU8 weeks—
microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma
2017 · 10,000 IU/day group · Men with prostate cancer scheduled for prostatectomy; age not reported
10,000 IU8 weeks—
microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma
2017 · 40,000 IU/day group · Men with prostate cancer scheduled for prostatectomy; age not reported
40,000 IU8 weeks—
Maternal Obesity, 25-Hydroxy Vitamin D Concentration, and Bone Density in Breastfeeding Dyads
2017 · control group · Exclusively breastfeeding mother-infant dyads recruited 4–6 weeks postpartum; maternal age and infant age range not reported
800 IU——
Maternal Obesity, 25-Hydroxy Vitamin D Concentration, and Bone Density in Breastfeeding Dyads
2017 · intervention group · Exclusively breastfeeding mother-infant dyads recruited 4–6 weeks postpartum; maternal age and infant age range not reported
6,400 IU——
Body mass index, calcium supplementation and risk of colorectal adenomas
2019 · VCPPS vitamin D3 · People with a recently removed colorectal adenoma; sex and age range not specified
1,000 IU1303 days—
Body mass index, calcium supplementation and risk of colorectal adenomas
2019 · VCPPS calcium carbonate plus vitamin D3 · People with a recently removed colorectal adenoma; sex and age range not specified
1,000 IU1303 days—
A high weekly dose of cholecalciferol and calcium supplement enhances weight loss and improves health biomarkers in obese women
2018 · vitamin D3 (Diet/D) · Obese women with vitamin D deficiency
7,143 IU90 days—
Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia
2022 · Group B · Postmenopausal women with osteopenia
400 IU1 year—
Association of Body Weight With Response to Vitamin D Supplementation and Metabolism
2023 · Vitamin D3 plus marine omega-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, free of cancer and cardiovascular disease at baseline
2,000 IU2 years—
Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial
2024 · vitamin D · Men aged 50 years or older and women aged 55 years or older, free of cardiovascular disease and cancer at baseline
2,000 IU1935 days—
Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial
1998 · Control group · Postmenopausal women with osteoporosis, at least one prevalent vertebral fracture, and low bone mineral density; mean age 68.4 years
400 IU1 year—